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« Nothing in the world can take the place of Persistence. 
Talent will not; nothing is more common than unsuccessful men with talent. 
Genius will not; unrewarded genius is almost a proverb. 
Education will not; the world is full of educated derelicts. 
Persistence and determination alone are omnipotent. » 
 
Calvin Coolidge 
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INTRODUCTION 
Autoimmune diseases cumulatively affect 5% to 10% of the general population and are a 
significant cause of morbidity and mortality worldwide.  The economic burden of autoimmune 
diseases is enormous.  For example, the National Institutes of Health estimate that over 23 million 
United States residents have an autoimmune disease, which accounts for yearly direct costs of 
approximately $100 billion.  As a comparison, direct costs related to cancer and vascular diseases 
are $57 and $200 billion, respectively [1].  At the level of the individual patient, autoimmune 
diseases often have a negative impact on quality of life and are associated with high healthcare costs 
and significant productivity loss [2-5]. These socioeconomic facts reflect the complexity of 
autoimmunity and the often mysterious etiologies of autoimmune diseases, which are the result of 
immune responses against antigens of the host (self-antigens).  Indeed, autoimmunity is very 
seldom set off by a single cause but is triggered by a variety of agents and dysfunction of multiple 
molecular and cellular pathways.  As with a genetic predisposition to cancer, inherited defects in 
self-tolerance genes typically precipitate autoimmune diseases stochastically after a latent phase.  
Multiple mutations, both inherited and somatic, may be required for a self-reactive clone to 
circumvent sequential tolerance checkpoints. In addition, environmental factors such as toxins, viral 
infections and traumatic injury may synergize with accumulated mutations to tip the balance from 
tolerance to autoimmunity [6,7].   
In organ-specific autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, ulcerative 
colitis and type I diabetes, the autoantigens are mostly confined to the affected organ.  In systemic 
autoimmunity, however, the autoantigens typically are ubiquitous intracellular proteins.  A 
prototypic systemic autoimmune inflammatory condition is systemic lupus erythematosus or SLE, 
in which genetic, epigenetic, hormonal and environmental factors result in the dysregulation of all 
the key components of the immune system, culminating in the production of pathogenic 
autoantibodies against intracellular and mostly intranuclear proteins and nucleic acids [8,9].  The 
formation and deposition of immune complexes (ICs) in various tissues result in the activation of 
complement and ultimately lead to acute and chronic inflammation.  Consistent with the systemic 
nature of SLE autoantigens, auto-immune tissue injury can extend to nearly any organ system and 
the common clinical presentations of SLE range from fatigue, rash and arthritis, through anemia and 
thrombocytopenia to serositis, nephritis, seizures and psychosis, with fluctuating intensity and 
severity within and between patients [10,11]. 
World-wide, prevalences of SLE range from 20 to 70 per 100 000, whereas incidence rates vary 
from approximately 1 to 10 per 100 000 person-years [12].  Since around 90% of SLE patients are 
women, gender is obviously the strongest risk factor for SLE.  An increased risk among 
reproductive age women is clearly seen in African Americans, whereas in other populations the 
highest age-specific incidence rates occur in women after the age of 40 years. Disease frequency 
and severity are two to four times higher among nonwhite populations around the world, and 
disease tends to be more severe in men and in pediatric and late-onset SLE.  The life expectancy of 
SLE patients has improved from a survival of less than 50% at 5 years (after diagnosis) in the 1950s 
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to a current survival of 85% at 10 years and 75% at 20 years.  Hence, SLE is characterized by a 
bimodal pattern of mortality, with early mortality mainly caused by SLE pathology or by 
immunodepression-induced infections, whereas patients with SLE who live longer develop new 
disease- and therapy-induced comorbidities such as accumulation of organ damage, osteonecrosis 
and coronary heart disease [11,13].  A less favorable survival prognosis is often observed for ethnic 
minorities, which is possibly partly related to socioeconomic status rather than to ethnicity per se, 
and adequate social support has been shown to be a general protective factor in SLE patients [12]. 
SLE is a polygenic disease and the genetic influences on SLE development generally result from 
the combined effects of a large number of genes, with each allele contributing only mildly and the 
requirement of accumulation of several genes to contribute significantly to an increased risk of SLE 
[14-17].  However, in some rare cases (e.g. C1q), disease may be caused by deficiencies in a single 
gene [18].  Besides the genetic component, the contribution of environmental factors to the 
generation of additional immune dysfunctions in SLE is undeniable.  Indeed, the concordance rate 
for SLE is only 24-57% among monozygotic twins and approximately 2-5% among dizygotic twins 
[14].  Epigenetic changes such as the observed DNA hypomethylation in SLE T and B cells may be 
caused by drugs such as hydralazine and procainamide.  Exposure to ultraviolet light is a known 
risk factor for relapses in clinical disease, and various environmental toxins, such as silica, 
pesticides, mercury and smoking may increase the risk of SLE [10,11].  Finally, viral infection may 
trigger systemic autoimmunity by the induction of type I interferons and by molecular mimicry, 
which is the cross-reaction of T cells, B cells or antibodies against viral, bacterial or parasitic 
epitopes with self-antigens [19,20]. 
Despite the identification of multiple genetic and environmental risk factors, the etiology and 
pathogenesis of SLE are incompletely understood and current therapies rely largely on the use of 
immunosuppressive corticosteroids and cytotoxic anti-proliferative drugs, which have limited 
efficacy and carry significant risks of toxicity and development of the above-mentioned 
comorbidities.  During the past decade, however, studies of the key components of the immune 
system in multiple animal models of SLE and in patients have provided important new insights into 
underlying disease mechanisms and have led to an etiopathogenesis model in which aberrant 
clearance of and immune reaction to apoptotic and necrotic debris play a central role in the breaking 
of systemic tolerance and  promotion of autoimmune tissue injury (Figure 1) [21-27]. 
Apoptosis, the most common type of programmed cell death, plays a pivotal role in 
embryogenesis, development and homeostasis of multicellular organisms [28].  In higher 
organisms, billions of apoptotic cells generated during the maintenance of homeostasis are rapidly 
and efficiently removed by professional phagocytes in an immunologicaly silent way [29].  
Apoptotic cells actively secrete ‘find me’ signals (e.g. lysophosphatidylcholine (LPC), nucleotides, 
apoptotic blebs), which stimulate a chemotactic response in macrophages, but repel neutrophils 
[27,29].  Macrophages identify their prey by ‘eat me’ signals such as externalized 
phosphatidylserine, which is bound by engulfment receptors (e.g. Mer tyrosine kinase, CD14) or 
indirectly by bridging molecules (e.g. milk-fat globule epidermal growth factor (EGF)-factor 
I N T R O D U C T I O N  
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(MFG-E8), growth arrest-specific 6 (Gas6)), triggering the internalization of the apoptotic cell.  
Upon ingestion of the apoptotic prey, macrophages produce anti-inflammatory ‘tolerate me’ 
cytokines, including transforming growth factor-β (TGF-β) and interleukin (IL)-10 [27,29].   
If this efficient clearance process fails, apoptotic cells will progress to secondary necrosis, 
release pro-inflammatory danger signals and lose their membrane integrity with consequent spilling 
of the intracellular contents into the extracellular milieu (cf. Figure 1).  In SLE patients, many 
defects were found with respect to the clearance of apoptotic cells and necrotic cell remnants, such 
as decreased C-reactive protein (CRP) levels, complement deficiencies, reduced serum DNase I 
activity and various phagocytic defects [18,23,27,30].  In addition, lymphocytes of SLE patients 
show increased apoptosis rates [22,30-32].  Hence, upon exposure to apoptotic triggers such as 
ultraviolet light, toxins, drugs, trauma and infections, an overload of circulating apoptotic cells and 
uncleared secondary necrotic material will be generated in SLE patients.   
These apoptotic and necrotic debris, also called secondary necrotic cell-derived material or 
SNEC, accumulate in germinal centers of SLE patients, where their uptake by tingible body 
macrophages is impaired, and associate with follicular dendritic cells (FDCs) [33].  Presentation of 
SNEC by FDCs to autoreactive B cells that were generated during the random process of somatic 
mutation may provide survival signals for these self-reactive cells that normally undergo apoptosis 
and rapid removal by tingible body macrophages.  The positively selected SNEC-reactive B cells 
leave the germinal centre and migrate into the mantle zone where they may receive further 
costimulation by interaction with CD4+ T cells and differentiate into autoantibody-secreting plasma 
cells or self-specific memory cells (cf. Figure 1) [23,27].  Alternatively, these autoreactive B cells 
may encounter their cognate autoantigen bound to DNA or RNA (e.g. histones, small nuclear 
ribonucleic particles (snRNPs) such as U1snRNP and Smith antigen, Ro/Sjögren’s syndrome 
antigen A (SSA), La/SSB).  The first activation signal is then provided by binding and 
internalization of the autoantigen by the B cell receptor (BCR).  In the endosomal compartment 
DNA may interact with toll-like receptor-9 (TLR9) and RNA with TLR7, producing the second 
activation signal for the autoreactive B cell and leading to autoantibody secretion [34-36].  
Under homeostatic conditions, the removal of apoptotic cells by macrophages and dendritic cells 
is tolerogenic.  However, in the presence of danger signals (e.g. high mobility group box 1 protein 
(HMGB1) and uric acid) released by necrotic cells in SLE, dendritic cells may become activated 
instead of tolerogenic.  Activated DCs then produce increased amounts of pro-inflammatory 
cytokines (e.g. IL-6 and interferon-α (IFN-α) and break tolerance by the immunogenic (instead of 
tolerogenic) presentation of SNEC to autoreactive T cells (cf. Figure 1) [37,38].  Activated 
autoreactive T cells will then provide help to autoreactive B cells, which will also result in the 
production of autoantibodies.   
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Figure 1.  Etiopathogenesis model of SLE.  Enhanced apoptosis rates and defective clearance of apoptotic cells are 
central deficiencies in SLE. Hence, upon exposure to apoptotic triggers such as ultraviolet light (UVB), toxins, drugs, 
trauma and viral infections, an overload of circulating apoptotic cells and uncleared secondary necrotic cell-derived 
material (SNEC) accumulates in germinal centers of SLE patients.  Follicular dendritic cells (FDCs) present SNEC to 
autoreactive B cells, which differentiate into autoantibody-secreting plasma cells after costimulation by autoreactive 
CD4+ T cells.  Alternatively, autoreactive B cells may encounter their cognate autoantigen bound to nucleic acid and 
become activated by binding and internalization of the autoantigen by the B cell receptor (BCR), and interaction of the 
bound DNA/RNA with toll-like receptor-9 (TLR9)/TLR7 in the endosomal compartment.  The presence of danger 
signals released by necrotic cells leads to secretion of IL-6 and IFN-α by mature dendritic cells (mDCs) and 
immunogenic presentation of SNEC to autoreactive T cells, which subsequently provide help to autoreactive B cells, 
resulting in autoantibody production.   
I N T R O D U C T I O N  
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After the initiation phase, in which tolerance to self is broken by the above-mentioned 
mechanisms, systemic autoimmunity will be further propagated by the clearance deficiency in the 
periphery. Indeed, secreted SNEC-reactive autoantibodies will encounter autoantigens that are 
continuously supplied by the clearance deficiency in the periphery and form immune complexes 
(ICs).  Deposition of ICs in the tissues causes direct inflammation and tissue injury, which result in 
additional supply of necrotic material (NEC).  Alternatively, IC may activate plasmacytoid dendritic 
cells (pDCs) by their binding and uptake via Fcγ receptor(R)IIa and concomitant interaction of 
HMGB1 with the receptor for advanced glycation end-products (RAGE) or other innate immune 
receptors.  Intracellular activation of TLR7 and TLR9 by nucleic acid-containing ICs, results in 
massive production of IFN-α [34,35], which was recently discovered to play central roles in SLE.  
IFN-α induces increased expression of autoantigens, maturation and activation of DCs, with 
increased expression of costimulatory molecules, chemokine receptors and the B lymphocyte 
stimulator (Blys)/B cell activating factor (BAFF), which promotes efficient autoantigen 
presentation to CD4+ T helper cells.  Furthermore, IFN-α stimulates cytotoxic CD8+ T cells and 
impairs regulatory T cell (Treg) function in SLE, leading to additional tissue injury.  IFN-α 
stimulates B cell activation, differentiation, antibody production and immunoglobulin (Ig) isotype 
switching.  Hence, the increased IFN-α levels in SLE patients result in a potent amplification of 
systemic autoimmune reactions [39].   
 
 
 
 
 
 
 
Figure 1. Continued.  After tolerance to self is broken in the initiation phase, systemic autoimmune responses are 
further propagated by the clearance deficiency in the periphery, which produces a continuous supply of SNEC.  
Deposition of ICs in the tissues causes inflammation and tissue injury, which result in additional supply of necrotic 
material (NEC). Alternatively, ICs may activate plasmacytoid dendritic cells (pDCs) by their binding and uptake via 
Fcγ receptor(R)IIa and concomitant interaction of the danger signal high mobility group box 1 protein (HMGB1) with 
the receptor for advanced glycation end-products (RAGE) or other innate immune receptors.  Intracellular activation of 
TLR7 and TLR9 by nucleic acid-containing ICs, results in massive production of IFN-α, which induces maturation and 
activation of DCs and efficient autoantigen presentation to CD4+ T helper cells. IFN-α also stimulates cytotoxic CD8+ T 
cells and impairs regulatory T cell (Treg) function in SLE, leading to additional tissue injury. IFN-α stimulates B cell 
activation, differentiation, antibody production and immunoglobulin (Ig) isotype switching. Alternatively, anti-nucleic 
acid ICs may directly activate autoreactive B cells by BCR/TLR coengagement, which leads to B cell proliferation, 
differentiation and Ig class switching independently of T cell help.  Since a single B cell can present different 
autoantigen epitopes to T cells, various autoreactive T cells may be activated, which in turn promote the activation of 
additional autoreactive B cells, leading to epitope spreading. FcγR-mediated phagocytosis of autoantibody-coated dying 
cells results in the precipitation of inflammation, which further contributes to chronic inflammation and multiple organ 
damage in SLE.  IL-6, interleukin-6; IFN-α, interferon-α; MHC II, major histocompatibility complex Class II; TCR, T 
cell receptor. 
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As discussed above, anti-nucleic acid ICs may directly activate autoreactive B cells by 
BCR/TLR coengagement, which leads to B cell proliferation, differentiation and Ig class switching 
independently of T cell help [34-36].  Besides their role in autoantibody production, B cells also 
have multiple autoantibody-independent roles in SLE.  B cells can efficiently present antigen and 
activate T cells, they can augment T cell activation through costimulatory interactions and they can 
produce many cytokines that affect inflammation, lymphogenesis and immune regulation [40].  In 
addition, since a single B cell can present different autoantigen epitopes to T cells, various 
autoreactive T cells may be activated, which in turn promote the activation of additional 
autoreactive B cells, leading to epitope spreading (cf. Figure 1) [36].  An additional pathogenic 
effect of autoantibodies lies in the opsonization of dying cells. Whereas clearance of apoptotic cells 
by engulfment receptors is considered a neutral or even anti-inflammatory process, favoring the 
induction of tolerance, FcγR-mediated phagocytosis of autoantibody-coated dying cells results in 
the precipitation of inflammation, which further contributes to the chronicity and multiple organ 
damage of SLE [27,41]. 
The clearance hypothesis in SLE was nicely confirmed by murine studies, in which genetic 
deficiency of various molecules that promote the clearance of apoptotic remnants induced systemic 
autoimmunity (e.g. C1q, DNase I, serum amyloid protein (SAP), Mer, MFG-E8) [16,17].  However, 
other mouse models with defective removal of dying cells (e.g. mannose binding lectin (MBL)- and 
CD14-knockout mice) failed to develop autoimmunity, suggesting that compensatory mechanisms 
may exist in healthy individuals [27]. Hence, the amount of self-antigen may only be sufficient to 
drive systemic autoimmunity on a susceptible genetic background.  Indeed, severe tissue trauma, 
which also results in an overload of intracellular debris, only triggers autoimmunity in mice and 
patients with a certain genetic predisposition [42,43].  Studies in mice and men have shown that 
SLE is associated with dysfunctions throughout the entire immune system, as well as epigenetic 
alterations, which may act synergistically with the described clearance deficiencies to induce a full-
blown autoreactive response [15-17,24].  For example, in healthy persons the immunogenicity of 
self-DNA is minimized by CpG suppression, CpG methylation, and inhibitory motifs that act 
together with the inaccessibility to TLRs, which are sequestered within the endosomal 
compartment.  In SLE, the immunogenicity of self-DNA/RNA is not only enhanced by the 
increased release from necrotic cells, but also by a higher frequency of CpG dinucleotides, as well 
as by hypomethylation and oxidative modification [35].  In addition, IFN-α may decrease the 
selectivity of B cells for CpG-rich DNA and allow stimulation by even non-CpG DNA [44].  
Hyperactivated SLE T cells provide excessive help to B cells and mount inflammatory responses, 
while failing to produce sufficient IL-2.  This is caused by various defects in signal transduction 
(e.g. diminished expression of the CD3ζ chain), by abnormal gene transcription (e.g. increased 
expression of the costimulatory molecule CD40 ligand (CD40L) and the adhesion molecule CD44) 
and by hypomethylation of T cell DNA.  Decreased IL-2 production may contribute to the defective 
Treg function, the defective CD8+ T cell cytotoxic capacity and the decreased activation-induced cell 
death in SLE patients [15].  Patients with SLE contain abnormally high levels of serum IL-17, 
which together with BAFF controls the survival and proliferation of B cells and their differentiation 
into Ig-secreting cells [45]. A high fraction of CD4+ and CD3+B220+CD4-CD8- double negative 
I N T R O D U C T I O N  
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(DN) T cells in these patients produce IL-17 [46,47].  DN T cells only represent 1% to 2% of 
peripheral T lymphocytes in healthy persons [48], but are expanded in the peripheral blood of SLE 
patients.  In addition, SLE DN T cells are characterized by increased levels of activation markers 
[49], production of IL-4 [50], and induction of Ig and pathogenic anti-DNA autoantibodies [51].  
IL-17-producing DN T cells were found in kidney biopsies of patients with lupus nephritis and were 
shown to induce nephritis in a non-autoimmune mouse model [46,52].  Similar to T cells, a marked 
increase of hyperactivated and memory B cells is observed in SLE [24,25].  Finally, post-
translational modifications such as phosphorylation, transglutamination, deamidation, methylation 
and caspase- and granzyme B-mediated proteolysis were proposed to generate neo-epitopes that 
may initiate or exacerbate systemic autoimmunity [53-55].  
In conclusion, SLE is a complex multifactorial disease, in which multiple clearance 
deficiencies and immune system aberrations accumulate and synergize in the breaking of systemic 
immune tolerance and in the amplification of systemic autoimmune responses, culminating in 
multisystem tissue injury and end-organ damage. 
 
Matrix metalloproteinases are Zn2+-dependent endopeptidases with homeostatic roles in 
development, reproduction and wound healing.  However, dysregulation of MMP activity 
contributes to multiple pathologic conditions such as cancer, vascular and neurodegenerative 
diseases, uncontrolled inflammation and autoimmune diseases [56-60].  Gelatinase B/MMP-9 is 
mainly produced by neutrophils and macrophages during inflammation and may influence immune 
function by the proteolysis of cytokines and chemokines [61,62].  In addition, MMP-9 releases 
immunodominant T cell epitopes from myelin basic protein and αB-crystallin in multiple sclerosis 
[63,64], from collagen type II in rheumatoid arthritis [65] and from insulin in type I diabetes [66], 
which may explain why MMP-9-deficient mice are less susceptible to develop disease symptoms in 
these organ-specific autoimmune diseases [67-70].  The integration of balances between pro- and 
anti-inflammatory cytokines, and between proteases and protease inhibitors in the generation of 
remnant epitopes for T cells was formulated as the REGA (Remnant Epitopes Generate 
Autoimmunity) model for autoimmunity [69]. This model explained how proteinase-generated 
linear peptide epitopes contribute to activation of T lymphocytes. 
Hence, the parallel was drawn to a possible role of MMP-9 in the modulation of systemic 
autoantigens. On the one hand, MMP-9 may play an exacerbating role by the release of neo-
epitopes that stimulate autoreactive T cells, as was observed in organ-specific autoimmune diseases. 
On the other hand, MMP-9 may contribute to extracellular (or intracellular) degradation of 
autoantigens during apoptosis and secondary necrosis, and have protective effects by the destruction 
of immunogenic epitopes for T and B cells. In the latter case, lack of MMP-9-mediated proteolysis 
would engender an additional clearance defect in SLE. In addition, MMP-9 deficiency was shown 
to enhance proliferation of alloreactive T cells [71,72], suggesting that MMP-9 may play a role in 
lymphocyte homeostasis.  Hence, investigating the influence of MMP-9 in a disorder with 
dysregulated adaptive immunity, such as SLE, may yield novel insights on the role of matrix 
metalloproteinases in lymphocyte homeostasis.  
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AIMS 
The primary objectives of the present doctoral research were to evaluate the roles of MMP-9 in the 
proteolysis of systemic autoantigens and in the development of systemic autoimmunity.  To this 
end, three main research paths were followed, which are summarized below. 
Characterization  of  the  physiopathological  roles  of MMPs  in  cell  surface 
proteolysis 
MMPs were initially identified as extracellular matrix (ECM)-consuming enzymes [73].  However, 
soon thereafter compelling evidence emerged showing that these proteases not only degrade 
structural molecules but also a whole assortment of soluble proteins with very diverse biological 
functions [56,74,75].  On the route from extracellular to intracellular substrates, an evident 
intermediate station was the analysis of MMP substrates at the boundary between the extracellular 
and intracellular milieu.  Since a comprehensive (re)view on the cleavage of cell surface-associated 
substrates by MMPs was lacking, the first aim of this doctoral research was to generate a systematic 
survey of all membrane-associated MMP substrates, or more specifically of all proteins tethered to 
the cell surface by a transmembrane domain that were described to be modified by MMPs in a 
particular physiopathological context (Chapter 1).   
 
Systematic  identification  of  intracellular  proteins  as  substrates  for  
MMP(­9) 
In order to define whether MMPs, and MMP-9 in particular, were capable of modulating 
(intracellular) systemic autoantigens, a systematic search for intracellular MMP-9 substrates was 
undertaken using a one-dimensional degradomics approach (Chapter 2) and by developing and 
applying multidimensional degradomics methods (Chapter 3).  By cataloguing the biological 
functions of identified intracellular candidate substrates, an overview of the intracellular MMP-9 
degradome was generated to clarify potential roles of MMPs in intracellular protein proteolysis in 
general, and in systemic autoantigen cleavage in particular. 
 
Characterization of  the  role(s) of MMP­9  in  the development of  systemic 
autoimmunity in vivo 
Since little was known on the functions of MMP-9 in systemic autoimmune models, mice were 
generated with both MMP-9 deficiency and the lpr (lymphoproliferative) loss-of-function mutation 
in the apoptosis-inducing receptor Fas on a C57Bl/6 background (Chapter 4).  C57Bl/6 mice 
lacking functional Fas develop moderate lymphoproliferation and late-onset systemic 
autoimmunity.  Hence, besides the influence of MMP-9 on systemic autoimmunity, this model 
permitted to study the role of MMP-9 in the (dys)regulation of lymphocyte homeostasis. 
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ABSTRACT Matrix metalloproteinases (MMPs) constitute a family of more
than 20 endopeptidases. Identification of specific matrix and non-matrix com-
ponents as MMP substrates showed that, aside from their initial role as ex-
tracellular matrix modifiers, MMPs play significant roles in highly complex
processes such as the regulation of cell behavior, cell-cell communication, and
tumor progression. Thanks to the comprehensive examination of the expanded
MMP action radius, the initial view of proteases acting in the soluble phase
has evolved into a kaleidoscope of proteolytic reactions connected to the cell
surface. Important classes of cell surface molecules include adhesion molecules,
mediators of apoptosis, receptors, chemokines, cytokines, growth factors, pro-
teases, intercellular junction proteins, and structural molecules. Proteolysis of
cell surface proteins by MMPs may have extremely diverse biological implica-
tions, ranging from maturation and activation, to inactivation or degradation
of substrates. In this way, modification of membrane-associated proteins by
MMPs is crucial for communication between cells and the extracellular milieu,
and determines cell fate and the integrity of tissues. Hence, insights into the
processing of cell surface proteins by MMPs and the concomitant effects on
physiological processes as well as on disease onset and evolution, leads the way
to innovative therapeutic approaches for cancer, as well as degenerative and
inflammatory diseases.
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INTRODUCTION
Matrix metalloproteinases (MMPs) constitute a family
of over 20 different endopeptidases characterized by
a conserved Zn2+-binding motif HEXXHXXGXXH in
the catalytic domain and a number of conserved protein
domains. The three histidines in this motif are respon-
sible for binding the catalytic Zn2+ ion (Figure 1) (Na-
gase and Woessner, 1999; Brinckerhoff and Matrisian,
2002). Expression of most MMPs is under transcrip-
tional regulation, e.g., by growth factors, hormones, cy-
tokines and oncogenic transformation. MMPs are neu-
tral endopeptidases produced as secreted or membrane-
bound pro-enzymes or zymogens, which become ac-
tivated by removal of the NH2-terminal propeptide.
The interaction of a conserved cysteine in the propep-
tide with the catalytic Zn2+ ion seals the catalytic site
and results in the latency of the pro-enzyme (Figure 1)
(Visse and Nagase, 2003). Removal of the propeptide,
for example by proteolysis, alters this coordination with
Zn2+. Due to the subsequent conformational change,
the Zn2+ ion becomes available for the binding of a
hydrolytic water molecule and of the substrate. There-
fore, the MMP activation mechanism was named the
‘cysteine switch mechanism’ (Van Wart and Birkedal-
Hansen, 1990). This activation can be mediated by pro-
teases and other MMPs, or chemically by means of
organomercurials, urea, some detergents and also by
reactive oxygen species. In addition, some MMPs are
activated intracellularly by furins (Nagase and Woess-
ner, 1999).
Examples of ‘archetypical’ MMPs are the collagenases,
which are active against fibrillar collagens, and the
stromelysins, which cleave non-collagen components of
the extracellular matrix (ECM) (Folgueras et al., 2004).
They contain a COOH-terminal hemopexin domain
(Figure 1), which contributes to substrate specificity,
and to interactions with endogenous inhibitors and
cargo receptors (Piccard et al., 2007). This hemopexin
domain is absent in the smallest MMPs, the matrilysins.
In addition, the gelatinases, active on denaturated col-
lagens, incorporate three fibronectin type II repeats for
the binding of gelatin, and MMP-9 is the only MMP
to possess a Ser/Thr/Pro-rich O-glycosylated domain,
which forms an attachment site for multiple O-linked
sugars (Van den Steen et al., 2006). In addition to the
secreted MMPs, six human membrane-bound MMPs
(MT-MMPs) exist. These are linked to the cell surface
through a COOH-terminal transmembrane domain
(MT1-, MT2-, MT3- and MT5-MMP) or a glycosyl
phosphatidylinositol (GPI) anchor (MT4- and MT6-
MMP) (Visse and Nagase, 2003).
Once switched on, MMP proteolytic activity is under
tight control by specific inhibitors, primarily the
tissue inhibitors of metalloproteinases (TIMPs) (Brew
et al., 2000). In plasma, the general protease inhibitor,
α2-macroglobulin, is the predominant MMP inhibitor
(Baker et al., 2002), whereas the TIMPs are considered
to be the key inhibitors in tissue. In humans, four differ-
ent TIMPs (TIMP-1 to -4) have been characterized that
form non-covalent 1:1 complexes with MMPs. TIMP-
1, TIMP-2, and TIMP-4 are present in the extracellular
environment in a soluble form, whereas TIMP-3 is in-
soluble, sequestered by the ECM (Gomez et al., 1997).
Although TIMPs bind tightly to most MMPs, some
important differences exist in the inhibition profile
(Table 1). For instance, TIMP-1 is known to inhibit
most soluble MMPs, but it is a poor inhibitor for
MT1-MMP, MT2-MMP, MT3-MMP, MT5-MMP, and
MMP-19. Binding affinity to MMP-9 is high for TIMP-
1, but low for TIMP-2 and TIMP-3, whereas TIMP-2,
TIMP-3, and TIMP-4 bind with high affinity to
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FIGURE 1 Domain structure of the human MMPs. An archetypal MMP contains a signal peptide for secretion, a propeptide, a catalytic
domain with a conserved Zn2+-binding motif and a COOH-terminal domain. The hemopexin domain is absent in the smallest MMPs, the
matrilysins, whereas the gelatinases incorporate three fibronectin type II repeats for the binding of gelatin, and MMP-9 is the only MMP to
possess a Ser/Thr/Pro-rich O-glycosylated domain. Some MMPs are attached to the cell surface through a COOH-terminal transmembrane
domain or a GPI anchor. The interaction of a conserved cysteine in the propeptide with the catalytic Zn2+ ion seals the catalytic site and
results in the latency of the pro-enzyme. MMPs are activated according to the ‘cysteine switch mechamism’ in which removal of the
propeptide frees the catalytic Zn2+ ion, allowing it to bind a hydrolytic water ion and the substrate. CA-MMP, cysteine array-MMP; GPI,
glycosyl phosphatidylinositol; Ig, Immunoglobulin; RASI-1, rheumatoid arthritis synovial inflammation-1. Based on (Van den Steen et al.,
2002), (Folgueras et al., 2004) and (Nagase et al., 2006).
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TABLE 1 TIMP characteristics and inhibition profiles
TIMP-1 TIMP-2 TIMP-3 TIMP-4
Localization Soluble
Soluble/cell
surface ECM
Soluble/cell
surface
MW (kDa) 28 21 24/27 22
MMPs inhibited Most MMPs, best
inhibited:MMP-9
Many MMPs, best
inhibited: MMP-2
Many MMPs, best
inhibited: MMP-2
Many MMPs, best
inhibited: MMP-2
MMPs poorly inhibited MT1-MMP None None None
MT2-MMP
MT3-MMP
MT5-MMP
MMP-19
ADAMs inhibited ADAM-10 None ADAM-10 none
ADAM-12
ADAM-17
ADAM-19
ADAMTS-4
ADAMTS-5
MMP-2 (Gomez et al., 1997; Nagase et al., 2006). In ad-
dition, TIMP-3 inhibits members of the ‘a disentegrin
and metalloproteinase (ADAM)-family’, including
ADAM-10/Kuzbanian, ADAM-12, ADAM-17/tumor
necrosis factor-α (TNF-α)-converting enzyme (TACE)
and ADAM-19, as well as the aggrecan-degrading
enzymes ‘a disentegrin and metalloproteinase with
thrombospondin-like motif ’ (ADAMTS)-4 and
ADAMTS-5, and TIMP-1 inhibits ADAM-10 (Baker
et al., 2002). As a consequence, the TIMP inhibition
profile of a particular cleavage can already shed some
light on the identity of the protease in charge.
Thanks to their structural diversity and broad sub-
strate range, MMPs play a part in multiple physiolog-
ical and pathological processes (Sternlicht and Werb,
2001). As it is more challenging to study membrane-
bound molecules, the initial identification of MMP
substrates included mainly soluble proteins. However,
due to the fast development and fine-tuning of power-
ful biochemical techniques, insights into MMP cleav-
age of membrane-bound substrates grew in parallel with
the appreciation of its relative importance in physiology
as well as pathology. This review contains a survey of
known membrane-bound substrates of every MMP, or
more specifically of all proteins with a transmembrane
domain that have been shown to be the subject of mod-
ification by one or several MMPs. In addition, we will
discuss the cleavage of some important cell surface pro-
teins that do not contain a transmembrane domain but
are always attached to the cell surface by other means of
anchoring. The consequences of proteolysis of cell sur-
face proteins by MMPs will be stressed to generate, from
scattered information, a clear view on the importance of
this process. Consequently, the substrates are grouped
in functional classes in the context of the physiological
or pathological roles they play with or without proteol-
ysis. To facilitate comprehensive reading, all substrate
molecules are grouped in a master table which includes
the modifying MMPs, the context of cleavage, known
cleavage sites, the biological effect of proteolysis and
the physiopathological implications (Table 2). In many
instances, various names, abbreviations and acronyms
have been given to these substrates. For clarity, these
are provided once at the beginning of each section (see
also the list of abbreviations).
1. PROTEOLYTIC MODIFICATION OF
CELL SURFACE PROTEINS IN CANCER
DEVELOPMENT AND EVOLUTION
Tumorigenesis and cancer progression originate from at
least seven fundamental alterations in cellular physiol-
ogy: 1) production of autocrine growth signals; 2) un-
sensitivity to growth-inhibitory signals; 3) escape from
apoptosis; 4) loss of senescence; 5) sustained angio-
genesis; 6) tissue invasion; and 7) metastasis (Hana-
han and Weinberg, 2000). MMPs have an impact on
the microenvironment of tumors. Moreover, the ex-
pression and activity of specific MMPs is elevated in
almost every kind of cancer. Some MMPs are synthe-
sized principally by tumor cells (e.g., MMP-7), whereas
other MMPs (e.g., MMP-2 and -9) are rather produced
by stromal cells in the tumors, like fibroblasts, inflam-
matory cells, and endothelial cells (Egeblad and Werb,
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2002). In earlier studies, the MMPs were claimed to be
important in migration, invasion and metastasis mainly
by the degradation of basement membranes and struc-
tural components in the ECM. However, more recent
findings show that proteolysis of a panacea of essential
secreted and membrane-bound molecules, like growth
factor precursors and receptors, tyrosine kinase recep-
tors (TKRs), cytokines and chemokines, cell adhesion
molecules, and other proteases, modifies the tumor mi-
croenvironment. These modifications will affect tumor
progression at all levels (Nelson et al., 2000; McCaw-
ley and Matrisian, 2001). In this first part we will dis-
cuss proteolytic modifications of cell surface proteins
by MMPs and their concomitant effects on cancer evo-
lution (see Figure 2). Insight into the paradoxical conse-
quences of proteolysis of cell surface proteins by MMPs
might be of paramount importance in the design of new
cancer therapies based on MMP inhibition.
1.1 Promotion or Inhibition of Cancer
Cell Proliferation
MMPs stimulate tumor cell proliferation by catalysing
the release of growth factors from the ECM, by the
activation of membrane-bound growth factor receptors
or by cleavage of membrane-bound substrates, e.g., in-
tegrins, that assist in the induction of cell prolifera-
tion. Conversely, MMPs might also negatively regulate
cancer-cell growth by releasing pro-apoptotic molecules
like Fas ligand (FasL) and TNF-α, or by activating trans-
forming growth factor-β (TGF-β), which has a tumor
suppressing effect in early phases of oncogenesis (Ege-
blad and Werb, 2002).
1.1.1 Fibroblast Growth Factor Receptor-1
(FGFR-1)
The fibroblast growth factors (FGFs) constitute a family
of twenty structurally related polypeptides with a com-
mon high affinity to heparin. Their biological functions
are broad and range from the induction of cellular pro-
liferation to tissue regeneration, neurite outgrowth, and
angiogenesis (Powers et al., 2000). FGFs elicit their bio-
logical response by binding to four different cell surface
TKRs, which are typically composed of an extracellu-
lar part with three immunoglobulin (Ig)-like domains,
a single transmembrane domain and a bipartite TKR
domain. Regulation of FGF biological activity may be
achieved through several mechanisms, including bind-
ing to high and low affinity receptors on the cell surface,
release of FGF from the ECM by heparanases or other
proteases or binding to a carrier protein that can deliver
FGFs to their receptors. In addition, FGF activity might
be regulated by the release of the entire ectodomain of
the FGF receptor-1 (FGFR-1, basic fibroblast growth
factor receptor-1 (bFGF-R), fms-like tyrosine kinase 2,
c-fgr, CD331) into the circulation and the ECM (Levi
et al., 1996; Powers et al., 2000). MMP-2 is able to free
the entire FGFR-1 ectodomain from an immobilized
FGFR1 ectodomain-alkaline phosphatase (FRAP) fu-
sion protein in vitro by hydrolyzing the Val368-Met369
bond, eight amino acids upstream of the transmem-
brane domain (Figure 3). By this truncation, the lig-
and binding site is released as a soluble ectodomain re-
taining its FGF binding ability (Levi et al., 1996). FGFs
may stimulate tumor cell growth in at least one of the
following ways: 1) by acting as mitogens for the tu-
mor cells themselves; 2) by promoting angiogenesis for
the growing tumor and 3) by inhibiting apoptosis and
allowing tumor cells to keep growing beyond normal
constraints (Powers et al., 2000). In this regard, release
of the FGFR-1 ectodomain by MMP-2 would counter
these mechanisms in two ways. On the one hand, the
released FGFR-1 ectodomain might bind extracellular
FGF and in this manner diminish the biological avail-
ability and growth promoting activity of FGF. On the
other hand, treatment of FGFR-1 overexpressing cells
with MMP-2 clearly reduces binding of the FGF mi-
togen (Levi et al., 1996). Thus, investigating the release
of the FGFR-1 ectodomain by MMP-2 or by related
MMPs in vivo may provide new insights in tumor cell
growth inhibition.
1.1.2 Heparin-Binding Epidermal Growth
Factor-Like Growth Factor (HB-EGF)
The heparin-binding epidermal growth factor (EGF)-
like growth factor (HB-EGF, also called diphtheria toxin
receptor [DT-R]) is a member of the EGF family of
growth factors, which encompasses the receptor family
of a number of structurally homologous mitogens like
EGF, transforming growth factor-α (TGF-α) and am-
phiregulin (AR) (Raab and Klagsbrun, 1997; Iwamoto
and Mekada, 2000). HB-EGF binds to the EGF receptor
(EGFR/HER1/ErbB1) as well as to HER4/ErbB4, in-
ducing homo- or heterodimerisation of the monomeric
receptors with consequent tyrosine phosphorylation in
the cytoplasmic domains, resulting in the activation
of several signal tranduction pathways (Zwick et al.,
1999; Herbst, 2004). HB-EGF is synthesized as a trans-
membrane protein (mHB-EGF) with the ectodomain
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FIGURE 3 Cleavage of the human FGFR-1 ectodomain-AP fusion protein by MMP-2 and comparison with murine FGFR-1. MMP-2 cleaves
the FGFR-1 ectodomain from an immobilized FGFR1 ectodomain-alkaline phosphatase (FRAP) fusion protein in vitro at the Val368-Met369
bond, eight amino acids upstream of the transmembrane domain (A). This truncation releases a soluble ectodomain that retains FGF
binding ability, thus decreasing FGF binding sites on the tumor cell and competing with the remaining intact FGFR-1. Murine FGFR-1
is shown for comparison (B). Arrow, cleavage site of MMP-2; AP, alkaline phosphatase; Ig, immunoglobulin domain; TK, tyrosine kinase
domain; TM, transmembrane domain; R*, start of the AP. Adapted from (Levi et al., 1996).
containing a heparin-binding and an EGF-like domain.
mHB-EGF can be cleaved at the plasma membrane
to yield soluble HB-EGF (sHB-EGF) (Raab and Klags-
brun, 1997; Iwamoto and Mekada, 2000). mHB-EGF
is not only a precursor for sHB-EGF but is a bioactive
molecule itself, which inhibits growth of neighboring
cells. As a contrast, sHB-EGF is a potent mitogen for a
number of cells including smooth muscle cells, epithe-
lial cells and keratinocytes. Therefore, release of HB-
EGF causes the conversion of a juxtacrine growth in-
hibitor into a paracrine/autocrine growth factor, with an
opposite impact on cell growth (Iwamoto and Mekada,
2000; Higashiyama, 2004). mHB-EGF proteolysis is
probably mediated by metalloproteinases as it is pre-
vented by the broad spectrum metalloproteinase in-
hibitor batimastat (Prenzel et al., 1999). In cell cultures,
MMP-3 cleaves mHB-EGF in the juxtamembrane do-
main at the Glu151-Asn152 site (Suzuki et al., 1997;
Wu et al., 2004), whereas MMP-7, MMP-2 and MMP-9
and some proteases of the ADAM family [ADAM-9,
ADAM-10, ADAM-12, and ADAM-17/TACE] medi-
ate mHB-EGF cleavage in vivo under specific circum-
stances (Higashiyama, 2004; Hao et al., 2004).
HB-EGF plays an important role in a multitude of bi-
ological processes and diseases. According to the con-
cerned process, the mHB-EGF proteolysis is induced by
varying stimuli and mediated by different metallopro-
teinases. Release of sHB-EGF allows cross-talking be-
tween G protein-coupled receptors (GPCRs) and TKRs
in accordance with the triple membrane-passing signal
mechanism (TMPS) for the transactivation of TKRs
(Figure 4). In the TMPS, GPCRs are activated by an
extracellular ligand and subsequently induce the ac-
tivation of metalloproteinases through the initiation
of several signaling cascades. Finally, metalloproteinase
activity releases sHB-EGF that activates its TKR, the
EGFR (Higashiyama, 2004; Shah and Catt, 2004a). Sev-
eral studies showed enhanced HB-EGF gene expres-
sion in tumors compared to normal tissue (Raab and
Klagsbrun, 1997). sHB-EGF expression increased tu-
mor growth rate, colony-forming ability, and activa-
tion of the cyclin D1 promotor, as well as induction
of vascular endothelial growth factor (VEGF) in vitro.
In addition, sHB-EGF induced the expression and ac-
tivity of MMP-3 and MMP-9, leading to enhanced
cell migration. In vivo sHB-EGF enhanced tumorigen-
esis and angiogenesis. Hence, release of sHB-EGF by
MMPs may be an interesting step for therapeutical
intervention (Ongusaha et al., 2004; Miyamoto et al.,
2004).
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FIGURE 4 Release of sHB-EGF by MMPs allows cross-talking between G protein-coupled receptors (GPCRs) and tyrosine kinase
receptors (TKRs) in accordance with the triple membrane-passing signal mechanism (TMPS). In the TMPS, GPCRs are first activated
by an extracellular ligand (1) and subsequently induce the production of metalloproteinases through the initiation of several signaling
cascades (2). Finally, metalloproteinase activity releases sHB-EGF that activates its TKR, the EGFR, which induces signal transduction
to stimulate cell differentiation, growth and survival (3). Arrow, cleavage by an MMP. Adapted from (Shah and Catt, 2004a).
Besides stimulating tumor cell proliferation, sHB-EGF
induces proliferation of Mu¨ller glial cells, which is a
common feature of several diseases of the sensory retina.
During proliferative vitreoretinopathy (PVR), Mu¨ller
cells proliferate continuously, migrate onto retinal sur-
faces, and participate in the formation of periretinal
cellular membranes (Rentsch, 1973; Bringmann and Re-
ichenbach, 2001). Proliferation of Mu¨ller cells in PVR
seems to be stimulated by binding of ATP to P2Y purine
receptors (GPCRs) and requires the transactivation of
two TKRs. Activation of P2Y receptors by ATP leads
to an increase in intracellular Ca2+ concentration and
may cause a release of platelet-derived growth factor
(PDGF) from the cells. Released PDGF activates the
PDGF-α receptor (1st TKR), which causes MMP-9 pro-
duction. MMP-9 then releases sHB-EGF, which in turn
activates the EGFR (2nd TKR). Finally, the activated
EGFRs and PDGF-α receptors induce proliferative ac-
tivity in Mu¨ller cells by initiating several kinase sig-
naling pathways. As a neutralizing antibody against
MMP-9 reversed the mitogenic effect of ATP, inhibi-
tion of MMP-9 in the pathway may be a useful tool to
suppress uncontrolled intraocular proliferation in PVR
(Milenkovic et al., 2003; Shah and Catt, 2004a).
Besides the stimulating effects on tumor progression
and PVR, proteolysis of mHB-EGF by MMPs plays a
part in cardiovascular diseases (see Section 2.1.1) and re-
productive endocrinology (see Section 5.2), which will
be discussed in later chapters.
1.1.3 Tyrosine Kinase-Type Cell Surface
Receptor HER2
The EGFR family comprises four TKRs of which ty-
rosine kinase-type cell surface receptor HER2 (HER2,
receptor tyrosine-protein kinase erbB-2, p185erbB2, c-
ErbB2, NEU proto-oncogene [neu], MLN 19, CD340)
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is the most oncogenic, as it is active in the absence of a
stimulating ligand. In addition, HER2 in heterodimeric
receptors is highly mitogenic because it decelerates
growth factor dissociation from its partner receptor,
prolonging the duration of intracellular signaling. In
addition, endocytosis of HER2-containing complexes
is relatively slow and these complexes tend to recycle
back to the cell surface, rather than being degraded in
the lysosomes. HER2, a 185 kDa transmembrane gly-
coprotein receptor, underlies many altered functions
of tumor cells, including excessive growth, invasive be-
havior and attraction of blood vessels (Mosesson and
Yarden, 2004). It is overexpressed in 25% to 30% of
breast cancers, and it has been associated with high
risks of relapse and death (Slamon et al., 1987), although
the prognostic value of HER2 has been the matter of
some controversy (Ross et al., 2003). Blockage of HER2
with the humanized anti-HER2 monoclonal antibody
trastuzumab is an example of successful immunother-
apy for HER-2-positive breast cancer patients, as it has
been demonstrated to reduce the risk of recurrence by
roughly 50% in five randomized clinical trials (Piccart-
Gebhart, 2006).
The HER2 ectodomain is released and detected in the
serum of cancer patients. High serum levels of HER2
ectodomain correlate with a poor prognosis and de-
creased responsiveness to therapy in patients with ad-
vanced breast cancer. This may be due to the enhanced
signaling activity of the remaining cell-associated part
of HER2. The cleavage is inhibited by the metallopro-
teinase inhibitors batimastat and TNF-α protease in-
hibitor (TAPI), as well as by TIMP-1, which inhibits
soluble MMPs (Codony-Servat et al., 1999). In addi-
tion, trastuzumab inhibits basal and induced HER2
cleavage, preceding antibody-induced receptor down-
modulation (Molina et al., 2001). Further identification
of the metalloproteinase in charge could lead to new op-
tions for the therapy of patiens with breast cancer and
high levels of HER2 shedding, for example by combin-
ing MMP inhibition with trastuzumab therapy.
1.2 Survival of Cancer Cells or
Induction of Apoptosis
Evasion of apoptosis permits survival of tumor cells in
spite of genetic instability. Low levels of oxygen and nu-
trients, host defence against the tumor by the immune
system, anti-cancer treatments and local in vivo changes
in the ECM with effects on invasion and metastasis al-
ter the protease load in the tumor environment (Reed,
1999). Proteolysis by MMPs can have apoptotic as well
as anti-apoptotic effects.
1.2.1 Fas Ligand (FasL)
An important effector in apoptosis is the Fas/FasL
system, which is involved in three types of immune-
associated killing: 1) elimination of virally infected cells
and tumor cells by cytotoxic T cells (CTLs) and natural
killer (NK) cells; 2) maintenance of immune privilege
or survival of tumor cells; and 3) regulation of lym-
phocyte development and maintenance of peripheral
immune homeostasis. Fas ligand (FasL, tumor necrosis
factor ligand superfamily member 6, CD95 L, apoptosis
antigen ligand (APTL), APO-1 L, CD178) is a ∼40 kDa
type II transmembrane protein of the TNF family of
death factors. It is expressed on activated T lymphocytes
like CTLs and tumor infiltrating lymphocytes (TILs),
on macrophages and NK cells and on cells within im-
mune privileged tissues including the eye, testis, uterus,
and placenta (Linkermann et al., 2003). After trimeriza-
tion FasL induces apoptosis by binding to a trimer of
its receptor Fas (tumor necrosis factor receptor super-
family member 6, apoptosis-mediating surface antigen
FAS, APO-1, FASLG receptor, CD95). FasL can be re-
leased form the cell surface by MMP-3 and MMP-7.
However, the effects of soluble FasL (sFasL) on apop-
tosis and tumor progression seem to vary. Apoptosis
may be induced in epithelial cells through cleavage of
membrane-bound FasL to functional sFasL by MMP-
7. Furthermore, this cleavage turns out to be crucial
for apoptosis of prostate epithelium after castration, as
prostate involution is significantly reduced in MMP-
7 deficient mice (Powell et al., 1999). In contrast with
apoptosis induction in epithelial cells, FasL shedding
by MMP-7 has an anti-apoptotic effect in tumor cells,
protecting them from chemotherapeutic drug toxicity
(Mitsiades et al., 2001). This protection of tumor cells
may be explained by the fact that the ability of sFasL to
induce apoptosis is significantly lower than that of its
cell surface precursor (Tanaka et al., 1998). A possible
explanation for the paradoxical effects of FasL in both
cell types might be the higher sensivity of epithelial cells
to apoptotic signals, while FasL confers a kind of im-
mune privilege to tumors by inducing apoptosis in infil-
trating lymphocytes. Tumor cells indeed express lower
levels of Fas and increased levels of FasL, which allows
them to ‘counterattack’ Fas-bearing immune cells (Kim
et al., 2004). Acute overexpression of MMP-7 in vitro
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as well as in vivo induces apoptosis, whereas chronic
or repeated exposure to MMP-7 can select for tumor
cells that are less sensitive to death-inducing stimuli
(Fingleton et al., 2001; Vargo-Gogola et al., 2002b). An-
other potential explanation for the mentioned discrep-
ancies in sFasL activity came up after the identification
of novel MMP-7 cleavage sites in murine and human
FasL. Mutational analysis showed that MMP-7 cleaves
human and murine FasL at an ELAELR sequence, close
to the transmembrane domain (Figure 5), followed by
a secondary cleavage at the COOH-terminally located
SL sites. Strong indications exist that cleavage of hu-
man FasL also occurs at another ELR sequence in
the trimerization domain. As trimerization of FasL has
been shown to be important for its activity, cleavage
within the trimerization domain may play a signifi-
cant role in the regulation of sFasL function, releasing
less active FasL. Human sFasL peptides generated after
MMP-7 cleavage at ELAELR contain 13 or 16 addi-
tional amino acids compared to the peptides formed
after proteolysis at the SL site. The entire extracellu-
lar portion of FasL was shown to be pro-apoptotic in
vitro, whereas sFasL produced by cleavage at the SL
site was inactive in the same assay (Hohlbaum et al.,
2000). This implies that the amino acid sequence be-
tween the SL cleavage site and the transmembrane do-
main contributes to the pro-apoptotic activity of sFasL.
Therefore, truncation at the SL site might release inac-
tive sFasL peptides (Vargo-Gogola et al., 2002a). Differ-
ential FasL proteolysis by MMP-7 might thus lead to
the release of sFasL molecules with diverse biological
activities.
1.2.2 Fas
MMP-7 expression also contributes to another strategy
by which tumor cells can resist Fas-induced apopto-
sis. As a matter of fact, Fas too is cleaved by MMP-
7, between Glu19-Leu20 and Asn32-Leu33 (Figure 6)
(Strand et al., 2004). These cleavages remove 19 or 32
amino acids from the extracellular NH2-terminus of
the Fas molecule and delete part of a domain for
self-association termed ‘preligand assembly domain’
(PLAD). The PLAD domain has been shown to fa-
cilitate oligomerization of Fas receptors before ligand
binding. Preassembly of Fas receptors might be crucial
for the regulation of Fas signaling (Siegel et al., 2000).
Fas proteolysis by MMP-7 indeed results in attenuated
apoptosis induction (Strand et al., 2004). MMP-7 is pro-
duced by the tumor cells themselves at early stages of tu-
mor development. Therefore, the impact of this MMP
on apoptosis resistance provides a potential target for
new combination therapies in which MMP inhibition
may significantly augment the efficacy of conventional
chemotherapy (Poulaki et al., 2001).
1.3 Regulation of Angiogenesis
Oxygen and nutrients, provided by the vascular sys-
tem, are crucial for cell function and survival, obligat-
ing virtually all cells in a tissue to reside within 100
µm of a capillary blood vessel. Consequently, angio-
genesis or the formation of new blood vessels, is a pre-
requisite for the survival of proliferating cells and is
the result of subtle and often complex interactions be-
tween regulator and effector molecules (Hanahan and
Weinberg, 2000; Pepper, 2001; Bergers and Benjamin,
2003).
1.3.1 Urokinase-Type Plasminogen
Activator Receptor (uPAR)
The urokinase-type plasminogen activator receptor
(uPAR, monocyte activation antigen Mo3, CD87) is a
GPI-anchored receptor containing three homologous
domains (D1, D2, and D3) (Blasi and Carmeliet, 2002).
D1 is involved in the binding of the urokinase-type plas-
minogen activator (urokinase or u-PA) and enhances
the interaction with the ECM by binding the ECM
molecule vitronectin. D2 and D3 are also indispens-
able for high-affinity interactions (Hoyer-Hansen et al.,
1997a; Oda et al., 1998). uPAR regulates u-PA activity—
the activation of plasminogen to plasmin that degrades
fibrin (Blasi and Carmeliet, 2002)—on the cell surface
and is also important for the activation of signaling
pathways through the interaction with several integrins
(Reuning et al., 2003). Besides the membrane-anchored
uPAR, a soluble receptor (suPAR) is released after pro-
teolysis of the GPI anchor by cellular phospholipase
D (Figure 7) (Wilhelm et al., 1999). Both uPAR and
suPAR can be cleaved between the D1 and D2 do-
main, generating a D1-fragment and a D2D3-fragment
(Blasi and Carmeliet, 2002). The D1 domain can be
released by proteolytic activity of u-PA, directly or
indirectly through activation of plasminogen (Hoyer-
Hansen et al., 1997b), or by other proteases such as
chymotrypsin and elastase (Ploug and Ellis, 1994). The
specificty of the cleaving protease is crucial, as uPAR
fragments may or may not be chemotactically active on
different cell types in vitro, depending on the presence or
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FIGURE 5 Cleavage sites of MMP-7 in the ectodomain of human and murine FasL. MMP-7 cleaves human and murine FasL at an
ELAELR sequence, close to the transmembrane domain (TM), followed by a secondary cleavage at COOH-terminally located SL sites.
Human sFasL peptides generated after MMP-7 cleavage at ELAELR were shown to be pro-apoptotic in vitro. However, the peptides formed
after proteolysis at the S126-L127 site, which contain 13 or 16 amino acids less, were inactive in the same apoptosis assay. This might mean
that the amino acid sequence between the SL cleavage site and the transmembrane domain contributes to the pro-apoptotic activity of
sFasL. Cleavage of human FasL almost certainly occurs at an additional ELR sequence, E142-L143R, in the trimerization domain (TRIM).
As trimerization of FasL has been shown to be important for its activity, cleavage within the trimerization domain may release less active
FasL. Arrows indicate the cleavage sites of MMP-7. Adapted from (Vargo-Gogola et al., 2002a).
absence of a specific NH2-terminal peptide, SRSRY, on
the D2D3-fragment (Fazioli et al., 1997). Inhibition of
MMPs in a three-dimensional fibrin matrix, used as an
experimental angiogenesis model, caused enhanced for-
mation of capillary-like tubular structures and showed
that the cleavage between D1 and D2 can also be per-
formed by MMPs. The first MMP to be identified as
uPAR sheddase was MMP-12 (Koolwijk et al., 2001), but
also several other MMPs were able to release the D1
domain of suPAR in vitro: MMP-2, MMP-3, MMP-8,
MMP-9, MMP-13, MMP-19, MT1-MMP, and MT6-
FIGURE 6 MMP-7 cleaves the ‘preligand assembly domain’ (PLAD) in the Fas ectodomain. Fas is cleaved by MMP-7 between Glu19-
Leu20 and Asn32-Leu33. These cleavages remove 19 or 32 amino acids from the Fas NH2-terminus and delete part of a domain for
self-association termed ‘preligand assembly domain’ (PLAD). The PLAD domain facilitates oligomerization of Fas receptors before ligand
binding. Preassembly of Fas receptors may be crucial for the regulation of Fas signaling and proteolysis of the PLAD domain by MMP-7
indeed results in decreased sensitivity of tumor cells to Fas-mediated apoptosis. Arrows indicate the cleavage sites of MMP-7; CRD,
cysteine-rich domain; TM, transmembrane domain. Adapted from (Strand et al., 2004).
MMP (Andolfo et al., 2002). However, the most effi-
cient MMPs for uPAR cleavage were MMP-3, MMP-
12, MMP-19, and MT6-MMP. In particular, MMP-3,
MMP-12, and MT6-MMP show the same specificity
of cleavage having the Thr86-Tyr87 peptide bond as
major cleavage site, while MMP-19 cleaves suPAR pre-
dominantly at Tyr87-Ser88 (Figure 7). uPAR cleavage
by MMPs results in the exposure of the chemotactic
epitope SRSRY at the NH2-terminus of the generated
D2D3-fragment and may thus generate biologically ac-
tive fragments. Murine uPAR is cleaved by MMP-12
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FIGURE 7 Cleavage of uPAR and suPAR by MMPs releases the u-PA-binding domain D1. uPAR is a GPI-anchored receptor for u-PA
containing 3 homologous domains (D1, D2, and D3). In addition to the membrane-anchored uPAR, a soluble receptor (suPAR) is released
after cleavage of the GPI anchor by cellular phospholipase D. Both uPAR and suPAR can be cleaved between the D1 and D2 domains,
generating a D1-fragment and a D2D3-fragment. Release of the D1 domain can be mediated by MMPs, but also by serine proteases such
as u-PA, plasmin, chymotrypsin and elastase. The first MMP to be identified as uPAR sheddase was MMP-12 but also several other MMPs
release the D1 domain of suPAR in vitro. However, the MMPs most efficient at uPAR cleavage are MMP-3, MMP-12, MMP-19 and MT6-MMP.
In particular, MMP-3, MMP-12 and MT6-MMP show the same specificity of cleavage with the Thr86-Tyr87 peptide bond as major cleavage
site, whereas MMP-19 cleaves suPAR predominantly at Tyr87-Ser88. Loss of the D1 domain results in less cellular u-PA binding and,
consequently, in diminished formation of new capillary structures in an angiogenesis model.
as well (at the Pro89-Gln90 peptide bond), despite the
limited sequence homology between the linker regions
(Andolfo et al., 2002).
Unexpected enhanced angiogenesis through MMP in-
hibition might be caused by the higher availability of
functional uPAR at the cell surface, resulting in in-
creased u-PA binding and, subsequently, enhanced for-
mation of new capillary structures. As plasmin activates
several MMPs (for reviews, see: Collen, 2001; Pepper,
2001; Van den Steen et al., 2001), release of the D1 frag-
ment by an MMP might be a kind of feedback regula-
tion. Since angiogenesis in and growth of some tumors
are inhibited by competitors of uPAR, and taking into
account that some MMPs (such as MMP-9) exert pro-
angiogenic effects, the influence of MMP inhibition
on uPAR levels and on angiogenesis certainly requires
further examination.
Cleavage of uPAR by MMP-12 may also play a role in
the autoimmune disease systemic sclerosis. This will be
detailed in a subsequent paragraph (see Section 3.4.4).
1.3.2 Betaglycan
Betaglycan, also known as the TGF-β type III receptor,
is a membrane-anchored proteoglycan whose gly-
cosaminoglycan chains consist of heparan and chon-
droitin sulfate. Membrane-bound betaglycan is gener-
ally considered a positive regulator of TGF-β because
it increases the binding affinity of TGF-β for its recep-
tor II, enhancing cell responsiveness to TGF-β (Lopez-
Casillas et al., 1994). TGF-β controls many physiologi-
cal processes and has tumor-suppressing activity in the
early phases of carcinogenesis. In subsequent stages of
tumor progression, the increased secretion of TGF-β
by both tumor cells and stroma cells, is involved in the
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enhancement of tumor invasion and mestastasis, ac-
companied by immunosuppression (Kim et al., 2004).
TGF-β upregulates MMP-9 activity, which may also
amplify angiogenesis and tumor growth. Addition-
ally, MMP-9 is capable of activating latent TGF-β (Yu
and Stamenkovic, 2000; Bandyopadhyay et al., 2005),
thanks to the anchoring of MMP-9 and TGF-β to CD44
on the cell surface (see Section 1.4.7) (Yu and Sta-
menkovic, 1999).
Two soluble forms of betaglycan are relased by pro-
teolytic cleavage. In some cell types these cleavages are
induced by the tyrosine phosphatase inhibitor, pervana-
date, and generate a bigger fragment of 120 kDa (sBG-
120), which encompasses almost the entire extracellular
domain, and a smaller 90 kDa fragment (sBG-90). The
cleavage that generates sBG-90 is inhibited by TIMP-2,
but not by TIMP-1, which points to an MT-MMP as the
involved protease. Overexpression of MT1-MMP and
MT3-MMP, but not of the other MT-MMPs, indeed
releases the sBG-90 fragment. Surprisingly, MT2-MMP
overexpression decreases the levels of betaglycan and
of MT1-MMP (Velasco-Loyden et al., 2004). In con-
trast with membrane-bound betaglycan, recombinant
soluble betaglycan has been shown to inhibit TGF-β in
vitro (Lopez-Casillas et al., 1994). Therefore, betaglycan
might function as a dual modulator of TGF-β activity:
as a membrane-anchored protein it enhances TGF-β
activity, whereas its soluble form causes TGF-β inhi-
bition. TGF-β-promoted tumor-host interactions lead-
ing to enhanced angiogenesis have been shown to be
effectively attenuated by the systemic administration
of soluble betaglycan in a xenograft model of prostate
cancer. The inhibition of tumor angiogenesis and con-
sequently of tumor growth appears at least in part due
to the inhibition of TGF-β-induced MMP-9 upregula-
tion (Bandyopadhyay et al., 2005). Further investigation
will clarify if sBG-90 and sBG-120 have the same TGF-
β-inhibiting activities and if proteolysis of betaglycan
by MT1-MMP or MT3-MMP can reduce angiogenesis
and tumor growth.
1.3.3 Vascular Endothelial Cadherin
(VE-Cadherin)
Vascular endothelial-cadherin (VE-cadherin, cadherin-
5, 7B4 antigen, CD144) is a member of the large cad-
herin family that includes Ca2+-dependent cell-cell ad-
hesion molecules responsible for cell-to-cell recogni-
tion and adhesion in solid tissues. Cadherins dimerize
through the extracellular domain with other cadherin
molecules on adjacent cells (trans-interaction). In this
homotypic interaction, the intracellular domain inter-
acts with various catenin proteins to form the cytoplas-
mic cell-adhesion complex (CCC), which is crucial for
strong cell-cell adhesion and potent suppression of inva-
sion. Cadherins are expressed in several types of tissues
with some specificity: Epithelial (E)-cadherin is mostly
present in epithelial cells, Neuronal (N)-cadherin in the
nervous system, smooth muscle cells, fibroblasts and
endothelial cells, and VE-cadherin is specific for the en-
dothelium (Cavallaro and Christofori, 2004; Cavallaro
et al., 2006).
MMP-7 treatment of human umbilical endothelial cells
(HUVECs) accelerates HUVEC proliferation and de-
grades VE-cadherin on the cell surface, with concomi-
tant accumulation of β-catenin in the nucleus and an in-
crease of MMP-7 expression. These results suggest that
MMP-7-mediated cleavage of VE-cadherin releases β-
catenin from the VE-cadherin/catenin complex, allow-
ing it to translocate from the cytoplasm to the nucleus,
where it can activate T-cell factor DNA binding protein,
which accelerates cell proliferation and MMP-7 expres-
sion (Ichikawa et al., 2006). However, MMP-7 also has
another important role in angiogenesis as it cleaves plas-
minogen and converts it to angiostatin (Patterson and
Sang, 1997), which is one of the strongest inhibitors of
angiogenesis. In light of this, it is crucial to further ex-
amine the sometimes paradoxical effects of MMP-7 on
angiogenesis before targetting its activity in anti-cancer
therapy.
1.3.4 Semaphorin 4D
Semaphorins are secreted, transmembrane or GPI-
linked proteins, defined by cysteine-rich semaphorin
protein domains, that have essential roles in a variety of
tissues. Functionally, semaphorins were initially charac-
terized for their importance in the development of the
nervous system and in axonal guidance. More recently,
they have been found to play a role in a wide range of
processes, including tissue organization during devel-
opment, angiogenesis, immunoregulation, and tumor
progression. A common theme in the mechanisms of
semaphorin function is that they alter the cytoskele-
ton, i.e., the organization of actin filaments and the
microtubular network, through binding with their re-
ceptors. The best characterized semaphorin receptors
are members of the neurophilin and plexin families
(Yazdani and Terman, 2006). Plexin-1B is highly ex-
pressed in endothelial cells and promotes migration and
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tubulogenesis in vitro as well as in vivo when bound by
its ligand, semaphorin 4D (BB18, A8, GR3, CD100)
(Basile et al., 2004). Semaphorin 4D is highly expressed
in head and neck squamous cell carcinomas as well as
in some of the most prevalent solid tumors, including
breast, prostate, colon and lung cancer tissues (Basile
et al., 2006).
In order to exert its pro-angiogenic functions,
semaphorin 4D, a transmembrane protein, must be
processed and released into a soluble form to act in
a paracrine manner on endothelial cells. Semaphorin
4D is expressed on the cell surface as a homodimer
(see Figure 2), which is a prerequisite for its prote-
olytic release from the cell surface (Elhabazi et al.,
2001). The shedding process can be inhibited by the
metalloproteinase inhibitors EDTA, EGTA and Ilo-
mastat/GM6001, as well as by TIMP-2, but not by
TIMP-1 (Elhabazi et al., 2001; Basile et al., 2007). The
inhibitor profile, combined with the observation that
MT1-MMP, while not expressed in non-tumorigenic
epithelial cell lines, was present in several head and
neck squamous carcinoma cell lines, pointed to MT1-
MMP as the semaphorin 4D sheddase. Basile and
coworkers (2007) demonstrated that MT1-MMP was
required for processing and release of semaphorin 4D
from these cells, thereby inducing endothelial cell
chemotaxis in vitro and blood vessel growth in vivo.
As a consequence, MT1-MMP-dependent shedding of
semaphorin 4D may play a critical role in tumor-
induced angiogenesis, and therefore may represent
new fronts of attack in the anti-angiogenic therapy of
cancer.
1.4 Stimulation or Inhibition of
Migration, Invasion, and Metastasis
Much like tumorigenesis, the processes of invasion and
metastasis are highly complex. In its simplest form,
metastasis requires the tumor cell to detach from its
primary location, invade through stromal elements or
existing junctions between normal cells, enter and leave
blood vessels or lymphatics, and then establish a colony
at the metastatic site. These steps require molecular pro-
cesses at the cell surface in which contacts between the
invading tumor cell and surrounding cells and stroma
are repeatedly broken (anti-adhesion) and new contacts
established as the tumor cell moves forward (adhe-
sion). This alternation of adhesion and anti-adhesion
can be achieved through coordinated expression of pro-
teases and adhesion molecules (Chambers et al., 2002;
Hollingsworth and Swanson, 2004).
1.4.1 Mucin-1 (MUC1)
Mucin-1 (MUC1, polymorphic epithelial mucin [PEM,
PEMT], episialin, tumor-associated mucin, carcinoma-
associated mucin, tumor-associated epithelial mem-
brane antigen [EMA], H23AG, peanut-reactive urinary
mucin [PUM], breast carcinoma-associated antigen
DF3, CD227), a transmembrane mucin, plays a key
role in the inhibition of embryo implantation, in the
protection of mucosal surfaces against microbial and
proteolytic degradation, and in some aspects of tumor
progression. It is expressed on several epithelial surfaces
like uterine, lung and intestinal epithelia as well as on
tumor cells. The relatively short cytoplasmic tail asso-
ciates with cytoskeletal elements, cytosolic adaptor pro-
teins and/or participates in signal transduction. The ex-
tracellular domain can be released form the cell surface,
which might serve practical functions, such as the facil-
itation of rapid clearance of mucosa surface-associated
material, or cell mobility. The mechanism controling
this ectodomain release has not yet been elucidated,
even though it has been postulated that alterations
in pH, ionic concentration or hydration might trigger
proteolytic release by specific proteases (Hollingsworth
and Swanson, 2004). The major protease in this cleav-
age process is TACE (Thathiah et al., 2003). However,
according to the TIMP-inhibition profile (see Table
1), an additional MUC1 shedding activity belonging
to the MT-MMP family was identified in TACE defi-
cient cells. MT1-MMP is expressed on these cells and,
in addition, MT1-MMP overexpression or deficiency
causes increased or inhibited MUC1 shedding, respec-
tively. Furthermore, MT1-MMP indeed cleaves MUC1
in vitro and is colocalized with MUC1 in vivo in human
uterine epithelia (Thathiah and Carson, 2004). Cancer
cells, especially from adenocarcinomas, express aber-
rant forms and levels of mucins, which have an im-
pact on the biological properties of tumors in several
ways (Hollingsworth and Swanson, 2004). Evidences
are emerging that cell surface mucins contribute to the
regulation of differentiation and proliferation of tumor
cells, through ligand-receptor interactions and morpho-
genetic signal transduction. In addition, MUC1 ex-
pression on tumor cells causes anti-adhesion through
steric hindrance by forming multiple exposed glyco-
sylated rod-like structures and by the binding of re-
ceptors on the same cell (cis-interactions), preventing
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interaction of these receptors with other cells. This anti-
adhesion permits tumor cells to detach form the tumor
mass and to invade the surrounding stroma. Invasion
is subsequently enhanced, as MUC1 also has an adhe-
sive action by binding adhesion molecules on stroma
cells and endothelial cells (trans-interactions). Finally,
MUC1 also contributes to immune evasion by forming
a leukocyte-impermeable barrier around the tumor and
through immunosuppressive effects on T-cell prolifera-
tive responses. Since MT1-MMP is often expressed by
cancer cells, the cleavage of MUC1 may affect all these
processes.
1.4.2 Epithelial Cadherin (E-Cadherin)
Epithelial cadherin (E-cadherin, uvomorulin, cadherin-
1, CAM 120/80, CD324) is another member of the cad-
herin family and is expressed mostly in epithelial cells
(see Section 1.3.3). Loss of E-cadherin-mediated cell-cell
adhesion has been shown to be a prerequisite for tumor
cell invasion and metastasis (Birchmeier and Behrens,
1994). Proteolytic degradation of E-cadherin by MMPs
is one of the regulation mechanisms by which epithelial
cell-cell adhesion can be ablated. MMP-3 and MMP-7
both cleave the 120 kDa transmembrane E-cadherin,
releasing a 80 kDa soluble form (sE-cadherin) (Lochter
et al., 1997; Noe et al., 2001). Treatment of prostate
cancer cells with hepatocyte growth factor/scatter fac-
tor (HGF/SF) causes shedding of E-cadherin through
the induction of MMP-7, resulting in cell scattering
and a switch to a more invasive phenotype (Davies
et al., 2001). Released sE-cadherin induces invasion in
vitro and inhibits cell aggregation indicating that it dis-
turbs cell-bound E-cadherin functions in a paracrine
way (Noe et al., 2001). However, it is not clear whether
sE-cadherin induces invasion by perturbation of cell-
cell interaction and/or by engaging a signalling path-
way in which free β-catenin can act as a transcriptional
coactivator (Hecht and Kemler, 2000). An induction of
MMP-2, MMP-9, and MT1-MMP expression was ob-
served both at the mRNA and protein levels in the pres-
ence of sE-cadherin. ECM degradation by these MMPs
might be an extra mechanism by which E-cadherin
ectodomain shedding contributes to tumor invasion
and metastasis formation (Nawrocki-Raby et al., 2003).
Besides the influence on invasion and metastasis, pro-
teolysis of E-cadherin also plays a role in epithelial-
mesenchymal transition, a conversion to an altered
cellular phenotype which is associated with aggressive
malignant behaviour (Cavallaro and Christofori, 2004).
Induction of MMP-3 expression in mammary epithelial
cells results in E-cadherin cleavage and triggers a pro-
gressive phenotypic conversion cumulating in cells that
are unable to undergo lactogenic differentiation and
that become invasive (Lochter et al., 1997; Sternlicht
et al., 1999). Finally, during apoptosis, the cytoplasmic
tail of E-cadherin is truncated by caspase-3, whilst a 84
kDa ectodomain fragment is released by a metallopro-
teinase. This simultanous cleavage of intracellular and
extracellular domains might be a highly efficient mecha-
nism to disrupt E-cadherin-dependent cell-cell contacts
in apoptotic cells or tumor cells, which is a prerequisite
for cell rounding and exit from the epithelium (Stein-
husen et al., 2001).
In acute renal failure, E-cadherin degradation by MT1-
MMP leads to disruption of epithelial integrity and
epithelial cell shedding (see Section 2.2.3), whereas in
normal physiology, MMP-7-mediated shedding of E-
cadherin is required for the repair of injured lung ep-
ithelium (McGuire et al., 2003).
1.4.3 Integrin Subunit Precursors
Integrins are a diverse family of transmembrane glyco-
proteins that form heterodimeric receptors for ECM
molecules and membrane-associated molecules of the
Ig family. Every integrin is composed of a non-
covalently coupled α- and β-subunit. The 18 known
α-subunits and 8 β-subunits form at least 25 distinct
heterodimers in human, with each pair being specific
for a unique set of ligands. Integrins are crucial for cell
adhesion, migration and invasion, not only through the
direct physical adhesion to the ECM and to other cells,
but also because they send and receive molecular sig-
nals that are essential for these processes (inside-out and
outside-in signaling, respectively) (Hood and Cheresh,
2002).
The binding of integrins to ECM molecules is altered
by changes in integrin expression and affinity when can-
cer cells become metastatic, or when endothelial cells
enter the angiogenic state (Varner and Cheresh, 1996;
Demetriou and Cress, 2004). Maturation of some inte-
grin subunits requires a posttranslational cleavage of the
precursor chain. The exact role of this endoproteolyti-
cal modification in integrin function is unclear, but its
absence has important consequences for signal trans-
duction pathways and leads to alterations in integrin
functions such as cell adhesion to vitronectin (Berthet
et al., 2000). Proteolysis of pro-integrin chains is per-
formed by proprotein convertases (PC) of the subtilisin/
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FIGURE 8 Endoproteolytic cleavage of pro-αv-integrin by MT1-MMP and by a proprotein convertase. Proteolysis of pro-integrin chains
is performed by proprotein convertases, but also by MT1-MMP. MT1-MMP cleaves the pro-αv chain at two different positions between the
disulfide-connected Cys852 and Cys904. The first cleavage, between Asp891 and Leu892, generates a 125 kDa heavy α-chain, disulfide-
bound to a 25 kDa light chain that is one residu shorter at the N-terminus in comparison with the convertase-processed chain. The second
MT1-MMP cleavage removes an additional 10 kDa from the heavy α-chain and is situated downstream from the Cys852. These proteolytic
modifications do not affect ligand binding of the resultingαvβ3 integrin but enhance outside-in signal transduction, which results in more
efficient adhesion and migration on vitronectin. Adapted from (Ratnikov et al., 2002).
kexin-like family, but also by MT1-MMP. MT1-MMP
cleaves the pro-αv chain (integrin α-V precursor, vit-
ronectin receptor subunit α, CD51) at two differ-
ent positions between the disulfide-connected Cys852
and Cys904. The first cleavage, between Asp891 and
Leu892, generates the 125 kDa heavy chain, disulfide-
bound to a 25 kDa light chain that is one residu shorter
at the N-terminus in comparison with the PC-processed
chain (Figure 8). The putative second MT1-MMP cleav-
age site is situated downstream from the Cys852 and
produces a 115 kDa heavy α-chain (Ratnikov et al.,
2002). These proteolytic modifications do not affect
ligand binding of the resulting αvβ3 integrin but en-
hance outside-in signal transduction. As a result, cells
co-expressing MT1-MMP and αvβ3 integrin show more
efficient adhesion and migration on vitronectin, the
ECM ligand of αvβ3 (Deryugina et al., 2002).
In addition, the MT1-MMP-mediated cleavage seems
to regulate cross-talk between αvβ3 and α2β1 integrins.
In MT1-MMP deficient cells, the functional activity of
the collagen-binding α2β1-integrin, which is not cleaved
by MT1-MMP, is suppressed by the presence of αvβ3
integrin, resulting in diminished cell adhesion to colla-
gen type I. Co-expression of MT1-MMP and αvβ3 re-
stores the α2β1-mediated collagen binding. Expression
of both αvβ3 integrin and MT1-MMP is elevated in
malignant tumor cells and is correlated with increased
migration. Cross-talk between αvβ3 and α2β1 inte-
grins through MT1-MMP-mediated pro-αv-proteolysis
might thus contribute to efficient adhesion of aggres-
sive tumor cells to type I collagen, an important substra-
tum of the ECM (Baciu et al., 2003). In addition, MT1-
MMP modifies the β3-subunit (integrin β-3 precursor,
platelet membrane glycoprotein IIIa (GPIIIa), CD61)
of αvβ3 integrin from a 95 kDa to a 90 kDa chain, which
is also correlated with functional αvβ3 integrin activa-
tion and increased adhesion on vitronectin (Deryugina
et al., 2000). Moreover, after functional activation by
MT1-MMP, αvβ3 integrin shows a higher affinity for
the MMP-2 hemopexin domain, and binding to αvβ3
integrin concentrates MMP-2 at specific spots on the
cell surface, which may again contribute to cell migra-
tion through the ECM. Hence, functional regulation
of integrins by MT1-MMP plays an essential role in
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efficient adhesion and directional migration of tumor
cells. As a consequence, this pathway could be another
interesting target in therapeutic approaches aiming at
suppressing tumor cell spreading.
MT1-MMP also mediates maturation of the pro-α3
(integrin α-3 precursor, galactoprotein B3 (GAPB3),
VLA-3 α chain, FRP-2, CD49c) and pro-α5 (integrin
α-5 precursor, fibronectin receptor subunit α, integrin
α-F, VLA-5, CD49e) chains to the respective mature
disulfide-bound heavy and light α-chains (Baciu et al.,
2003). However, pro-α5 cleavage does not affect α5β1
integrin function. The consequences of pro-α3 cleavage
have not been investigated.
MMP-7 is another tumor-derived MMP capable of in-
tegrin subunit proteolysis. MMP-7 releases a 90 kDa
fragment of the 200 kDa β4-subunit precursor (integrin
β-4 precursor, GP150, CD104), possibly through cleav-
age of the Tyr106-Ile107 and Gly416-Leu417 peptide
bounds. The first putative cleavage site is very close to
the ligand-binding domain, and cleavage might thus
interfere with the binding of the α6β4 integrin to its lig-
and laminin (von Bredow et al., 1997). α6β4 integrin has
been most implicated in epithelial carcinogenesis (Watt,
2002). In epithelium-derived carcinoma, increased lev-
els of β4 integrin and loss of its polarized distribu-
tion to the basolateral membrane site of the cell have
been correlated with tumor aggressiveness (Rigot et al.,
1999). Adhesion of breast cancer cells to endothelial
cells through binding of α6β4 integrin to a specific lung-
endothelial cell adhesion molecule is critical for lung
metastasis, but is totally abolished after cleavage of the
β4 integrin ectodomain by MMP-7 (Abdel-Ghany et al.,
2001). Hence, in this case, MMP-mediated modifica-
tion of an integrin subunit reduces tumor cell adhesion
and migration.
Furthermore, integrins are important players in tumor
cell proliferation, apoptosis and angiogenesis, in leuko-
cyte migration and in a whole array of pathologies
(Wehrle-Haller and Imhof, 2003). As a consequence,
insight in the functional regulation of these bidirec-
tional signaling molecules by MMPs may generate new
possibilities for therapeutic intervention.
1.4.4 Tissue Transglutaminase (tTG)
Another adhesion and signaling receptor being
cleaved by MT-MMPs is the ubiquitously expressed
cell surface-associated tissue transglutaminase (tTG,
protein-glutamine γ -glutamyltransferase 2, TGase C
(TGC), transglutaminase-2, TGase-H). tTG catalyzes co-
valent cross-linking between reactive lysine and glu-
tamine residues of proteins and protein polymers. In
addition, tTG functions as a coreceptor for β1 and β3
integrins and promotes integrin-dependent adhesion
and cell spreading on fibronectin. Good functioning
of cell surface tTG is essential for regulation and main-
tenance of cell-matrix interactions, as well as for the
mobility of tumor and host cells. On the contrary,
deregulation of tTG activity is associated with multi-
ple human diseases (Griffin et al., 2002). Overexpres-
sion of MT1-MMP by glioma and fibrosarcoma cells
causes proteolytic degradation of tTG at the leading
edge of motile cancer cells, leading to specific sup-
pression of cell migration and adhesion on fibronectin
(Belkin et al., 2001). 80 kDa tTG degradation is me-
diated in vitro by MT1-MMP, MT2-MMP, and MT3-
MMP, but not MT4-MMP, and produces fragments of
∼53 kDa, ∼41 kDa and ∼32 kDa. MT1-MMP cleavage
at Arg458-Ala459 and His461-Leu462 generates the 53
and 32 kDa fragments, while cleavage at Pro375-Val376
splits the protein in half, providing the 41 kDa frag-
ments. Cleavage at any of these three sites abolishes
receptor and enzymatic activity by separating the NH2-
terminal fibronectin-binding domain and the COOH-
terminal integrin-binding domain, as well as by inactiva-
tion of the catalytic domain. tTG proteolysis suppresses
cell adhesion and migration on fibronectin. Recipro-
cally, fibronectin protects its surface receptor, tTG, from
MT1-MMP-mediated proteolysis, thereby supporting
cell adhesion and mobility. In contrast, cell migration
on collagen matrices is stimulated by tTG degradation.
This suggests that the composition of the surround-
ing ECM might control the proteolysis of adhesion
molecules colocalized with MT-MMPs on distinct areas
of the cell surface of migrating tumor cells (Belkin et al.,
2001).
Additional examination shows that MMP-2 supports
its activator MT1-MMP in tTG proteolysis. MMP-2
hydrolyzes cell-associated tTG very efficiently and as-
sociates predominantly with the catalytic core domain
II of tTG. Furthermore, in silico simulations show that
during the tTG-MMP-2 interaction, the catalytic site of
MMP-2 is probably in very close proximity of the MMP
cleavage sites. tTG, in turn, preferentially associates with
the activation intermediate of MMP-2, which reduces
MMP-2 activation and protects tTG against MMP-2
proteolysis (Belkin et al., 2004). Hence, MMP-2 is as im-
portant as MT1-MMP in the degradation of cell surface-
tTG, and the cooperation of both MMPs explains the
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extensive tTG proteolysis at the normal tissue/tumor
boundary. Loss of adhesive and enzymatic activities of
tTG at the interface between normal and tumor tissue
will reduce cell-matrix interactions and inhibit matrix
cross-linking, which might cause multiple pathological
alterations in host cell adhesion and mobility (Belkin
et al., 2004).
1.4.5 34/67 kDa Laminin Receptor (LR)
As mentioned before, the regulation of sequential tu-
mor cell adhesion and anti-adhesion to ECM compo-
nents is crucial in the complex process of tumor in-
vasion and metastasis. Besides the modulation of in-
tegrin binding to vitronectin and type I collagen, and
of tTG binding to fibronectin, MMPs also intervene
in cell adhesion to laminin by modification of a ma-
jor laminin binding molecule, the 34/67 kDa laminin
receptor (LR, 40S ribosomal protein SA, p40, colon car-
cinoma laminin-binding protein, NEM/1CHD4, mul-
tidrug resistance-associated protein, MGr1-Ag). Over-
expression of LR is strongly correlated with metastatic
and aggressive tumor cell phenotypes (Berno et al.,
2005). Using thyroid hormone-dependent Xenopus Lae-
vis metamorphosis as a model, the 37 kDa LR precur-
sor was identified as a potential physiological substrate
of Xenopus stromelysin-3 or XMMP-11 (Amano et al.,
2005b). The highly conserved 37 kDa protein is the pre-
cursor of the receptor but the exact manner by which
it configures its mature 67 kDa form is not clear. It
was suggested that acylation followed by homo- or het-
erodimerization of the 37 kDa precursor forms the ma-
ture 67 kDa laminin receptor. The heterodimer is likely
to be stabilized by strong intramolecular hydrophobic
interactions between fatty acids bound to the 37 kDa
precursor and to an unknown galectin-3 cross-reacting
molecule (Buto et al., 1998). The COOH-terminal two-
thirds of the LR is located extracellularly and contains a
six-amino-acid laminin-binding sequence, whereas the
NH2-terminal third faces the cytoplasm preceded by
a short transmembrane domain (see Figure 2). In vitro
incubation of Xpro-LR with other (human) MMPs
showed that all tested MMPs cleaved LR, with MMP-
2 being most efficient, MT1-MMP least efficient, and
MMP-3 and MMP-9 cleaving with intermediate ef-
ficiencies. However, the cleavage products generated
by these MMPs were distinct from those produced
by MMP-11. Whereas the cleavage sites of MMP-11,
Ala115-Phe116, and Pro133-Ile134, were located be-
tween the transmembrane domain and the laminin-
binding sequence, cleavage by all other MMPs occurred
COOH-terminally of the laminin-binding sequence. As
a consequence, only MMP-11 releases LR-fragments
that contain the laminin-binding site and may alter
cell-laminin interactions. In addition, human LR was
cleaved by MMP-11 at the two same sites as in Xenopus
LR, which means that LR is a conserved substrate for
MMP-11 in vertebrates (Amano et al., 2005b). Further
investigation using transgenic tadpoles overexpressing
MMP-11 showed that LR is cleaved in vivo by MMP-11
during intestinal metamorphosis (Amano et al., 2005a).
Besides its physiological role in Xenopus Laevis develop-
ment, MMP-11-mediated cleavage of LR is likely to be
involved in tumor developement and cancer progres-
sion.
MMP-11, similar to LR, is an active partner of invading
cancer cells (Rio, 2005). Thus, the coexistence of MMP-
11, which is expressed by the fibroblasts within the tu-
mors but not actually by the tumor cells themselves, and
LR in tumors may be expected to lead to the cleavage of
tumor cell surface LR. This may alter tumor cell-ECM
interaction to affect tumor development and cell mi-
gration. Peptide G, an LR peptide (residues 161 to 180)
containing the laminin-binding sequence (residues 173
to 178) indeed changes the conformation of laminin-1
and increases and stabilizes laminin-1 binding on tu-
mor cells (Magnifico et al., 1996). In addition, peptide
G-modified laminin signals tumor cells to change their
cytoskeleton to promote motility and invasion. It also
induces the expression of a number of proteases char-
acteristic of invasive cancer cells, and leads to increased
gelatinolytic activity by MMP-2. Invasiveness of tumor
cells conditioned by peptide G-modified laminin was
shown to be MMP-2-dependent as it was significantly
more inhibited by TIMP-2 than invasiveness induced
by native laminin (Berno et al., 2005). Full-length LR
shed from malignant cells also induced conformational
changes in laminin after binding. In addition, the shed
LR modified production of anti-angiogenic angiostatins
from plasmin in vitro, in this way promoting tumor-
associated neoangiogenesis (Moss et al., 2006). As LR-
fragments released by MMP-11 contain the laminin-
binding site, they might also modulate laminin con-
formation and enhance tumor cell invasiveness and
angiogenesis. Gaining insight into the malignant po-
tential of these soluble LR-fragments may thus be of
great interest to elucidate one of the mechanisms that
underlies the detrimental effect of MMP-11 in cancer
progression.
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1.4.6 Syndecan-1, -3, and -4
Syndecans are transmembrane heparan sulfate pro-
teoglycans expressed on all adherent cells (see Fig-
ure 2). They are important players in tissue morpho-
genesis by binding a variety of ECM components
such as fibronectin, thrombospondin, various collagens
and growth factors via their glycosaminoglycan chains
(Beauvais and Rapraeger, 2004). In addition, they can
interact with the cytoskeleton through their conserved
cytoplasmic domains. Syndecan expression can alter
cell adhesion, migration and morphology. The synde-
can family is composed of four strongly related pro-
teins (syndecan-1, -2, -3, and -4). The intact ectodomain
of each syndecan is constitutively shed from cultured
cells as part of normal cell surface heparan sulfate pro-
teoglycan turnover and this process seems to play a
role in various pathophysiological events such as host
defense, wound healing, arthritis and Alzheimer’s dis-
ease. How this shedding is regulated remains largely un-
known. The ectodomain release of syndecan-1 (CD138)
and syndecan-4 (amphiglycan, ryudocan core protein)
from NMuMG epithelial and SVEC4–10 endothelial
cells is accelerated by various physiological agents ac-
tivating several intracellular signal transduction path-
ways. The proteolytic activity responsible for this accel-
erated shedding is associated with the cell surface and
can be specifically inhibited by TIMP-3, pointing to
ADAMs as possible mediators (Fitzgerald et al., 2000).
However, as will be discussed in a later chapter, se-
creted MMP-7 also sheds the syndecan-1 ectodomain,
releasing a syndecan-1/chemokine KC complex from
the mucosal surface of injured lungs, in this way form-
ing a chemokine gradient that directs neutrophils to the
site of injury (Li et al., 2002; Shapiro, 2003). HT1080
fibrosarcoma cells also show constitutive shedding of
the syndecan-1 ectodomain, but here the shedding
activity is inhibited by TIMP-2 and batimastat, but
not by TIMP-1. Therefore, the MMP in charge here
is not MMP-7, but probably the endogenous MT1-
MMP. Recombinant syndecan-1 is cleaved in vitro by
MT1-MMP as well as by MT3-MMP preferentially at
the Gly245-Leu246 peptide bond (Endo et al., 2003).
Syndecan-1 expression is associated with inhibition of
invasion and reduced migration of HT1080 fibrosar-
coma cells. Treatment of these cells with MMP in-
hibitors increases cell surface syndecan-1 concentra-
tions concomitant with formation of actin stress fibers,
which results in further reduction of migration. In con-
trast, shedding of the syndecan-1 ectodomain by MT1-
MMP enhances cell motility on collagen (Endo et al.,
2003).
In addition, the shedding of syndecan-4, and to a lesser
extent that of syndecan-1, from HeLa cells and human
primary macrophages was reported to be accelerated
by the chemokine stromal cell-derived factor-1 (SDF-
1/CXCL12) and mediated by MMP-9. SDF-1 increases
MMP-9 mRNA and MMP-9 activity in HeLa cells,
whereas MMP-9 silencing by RNA interference strongly
decreases syndecan-1 and syndecan-4 ectodomain shed-
ding accelerated by SDF-1. Shedding of syndecan-4 and
syndecan-1 from human primary macrophages is accel-
erated by SDF-1 as well, and inhibited by anti-MMP-9
antibodies (Brule et al., 2006). As SDF-1 does not bind
to soluble syndecan ectodomains, this shedding process
by MMP-9 may be part of an autoregulatory/down-
regulation cycle: (1) SDF-1 binding to syndecan-4 facil-
itates its presentation to its receptor CXCR4; (2) SDF-1
activates MMP-9, which removes syndecan-1 and –4
from the cell surface; (3) decreased membrane expres-
sion of syndecans down-regulates SDF-1 binding to its
receptor (Charnaux et al., 2006). In addition, MMP-9
cleaves off the NH2-terminal tetrapeptide of SDF-1,
which also results in loss of binding to its receptor
CXCR4 (McQuibban et al., 2001). As syndecan-4 pro-
motes cell spreading in a β1-integrin-dependent fashion
(Thodeti et al., 2003), the role played by its MMP-9-
mediated ectodomain shedding in tumor cell migration
and metastasis certainly deserves further investigation.
Syndecan shedding has also been observed in phys-
iological systems. In vitro release of the syndecan-3
ectodomain from rat Schwann cells, the myelin-forming
cells of the peripheral nervous system, is also mediated
by an MMP. These Schwann cells transiently express
syndecan-3 during embryonic and early postnatal de-
velopment. Inhibition of syndecan-3 cleavage by sev-
eral MMP inhibitors such as batimastat/BB-94 and BB-
3103 significantly enhances Schwann cell adhesion to
the non-collagenous NH2-terminal domain of α4(V)
collagen, which binds syndecan-3 and mediates hep-
aran sulfate-dependent Schwann cell adhesion. MMP-
dependent syndecan-3 shedding was also observed in
vivo in the peripheral nerve tissue of newborn rats, dis-
appearing on day 10, the end of the myelin-forming
process in Schwann cells (Asundi et al., 2003). As a con-
sequence, syndecan ectodomain shedding is cell type-
specific and this illustrates the varying physiological
roles of these proteoglycans in different tissues. As syn-
decan ectodomain release has an impact on various
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pathophysiological processes, the identification of the
proteolytic activity in charge might be of great use in
the development of new diagnostic and therapeutic
strategies.
1.4.7 CD44
CD44 (phagocytic glycoprotein 1 [PGP-1]), HUTCH-
1, ECM receptor-III [ECMR-III], GP90 lympho-
cyte homing/adhesion receptor, hermes antigen,
hyaluronate receptor, heparan sulfate proteoglycan, epi-
can) is a ubiquitous multistructural and multifunctional
cell adhesion molecule involved in cell-cell and cell-
matrix interactions. This family of glycoproteins con-
sists of many isoforms generated by different use of
alternatively spliced exons and extensive glycosylation.
The most abundant form is the standard hematopoietic
type, CD44H, which does not have any variant inser-
tions (Naor et al., 1997). The ECM adhesion activity
of CD44 is located in the NH2-terminal globular do-
main that forms an important receptor for hyaluronic
acid, an abundant glycosaminoglycan that fills intersti-
tial spaces between different tissues and takes part in
embryonic development, healing processes, inflamma-
tion and tumor development (Toole, 2004). CD44 also
binds other ECM components such as type I collagen,
fibronectin, fibrin, laminin, and chondroitin sulfate.
CD44 has been shown to take part in many important
processes such as lymph node homing, T-cell activation,
presentation of chemokines and growth factors to trav-
eling cells, wound healing, angiogenesis, metastasis and
apoptosis (Naor et al., 1997). The NH2-terminal ligand-
binding domain is followed by a stem sequence, a trans-
membrane domain and a cytoplasmic tail. The cytoplas-
mic domain interacts with the actin cytoskeleton and is
important for the localization of CD44 at the ruffling
edge of migrating cells. MT1-MMP is co-expressed with
CD44 on migrating cells and metastatic tumor cells
(Seiki, 2002; Seiki, 2003; Itoh and Seiki, 2004). MT1-
MMP binds the extracellular portion of CD44H by its
hemopexin domain. Hence, CD44H has a major role in
ECM degradation, as it forms the connection between
MT1-MMP and the actin cytoskeleton, and anchors
MT1-MMP at the migrating front (Figure 9) (Mori et al.,
2002).
MT1-MMP, in turn, acts as a processing enzyme for
CD44H, which is critical for the stimulation of cell
motility, probably because it allows the cells to de-
tach from the ECM (Kajita et al., 2001). Co-expression
of MT1-MMP and CD44H increases shedding of the
commonly produced 65 to 70 kDa fragments of CD44
and generates two additional smaller fragments. Shed-
ding of the 65 to 70 kDa fragments occurs constitu-
tively and is inhibited by TIMP-3, but not by TIMP-
1 or TIMP-2, suggesting the proteolytic activity is an
ADAM-like protease, although this shedding is in-
creased by MT1-MMP expression. In contrast, release
of the two smaller fragments is abolished by TIMP-2
and TIMP-3, but not by TIMP-1, which is the inhi-
bition pattern of MT1-MMP. The cleavage sites (CS)
corresponding to the three major fragments are Ser249-
Gln250 (CS3) for the big fragment, and Gly192-Tyr193
(CS1) and Gly233-Ser234 (CS2) for the two smaller frag-
ments (Figure 9). These cleavage sites are also detected
in vivo. In normal tissues, more clipping of the frag-
ment at CS3 occurs than of those of the other sites,
whereas in carcinomas CS1 fragments are significantly
increased. Thus, CD44 shedding at CS1 and CS3 rep-
resents the normal physiological process, whereas in-
creased shedding at CS1 is associated with malignant
tumors (Nakamura et al., 2004).
Whereas MT1-MMPs displays the most potent CD44
H shedding activity, other MT-MMPs such as MT2-,
MT3-, and MT5-MMP, but not MT4- and MT6-MMP,
can also cleave CD44H in vitro at CS2, while cleavage
at CS1 was hardly detectable (Suenaga et al., 2005). The
interaction between the hemopexin domain and CD44
H is conserved in each MT-MMP, which suggests that
CD44 is more than a receptor for ECM molecules and
may also form a platform for the assembly of various
MMPs with their substrates, to modulate cell migra-
tion (Figure 9) (Seiki, 2002; Suenaga et al., 2005). Like
MT1-MMP, MMP-9 binds directly to CD44 (Yu and
Stamenkovic, 1999) and activates latent TGF-β, which
contributes to tumor-induced angiogenesis (Yu and Sta-
menkovic, 2000). In contrast, MMP-7 attaches indi-
rectly to the heparan sulfate chains of the CD44 isoform
with a variant exon 3, which also binds substrates of
MMP-7, namely mHB-EGF and osteopontin (Yu et al.,
2002; Seiki, 2002).
Furthermore, proteolysis of CD44 results in signal
transduction to the nucleus. Ectodomain shedding of
CD44 induces cleavage in the cytoplasmic portion,
which releases the intracellular domain, CD44ICD,
into the cytoplasm (Figure 9). CD44ICD migrates
to the nucleus where it activates transcription medi-
ated through the 12-O-tetradecanoylphorbol 13-acetate
(TPA)-responsive element (TRE). One of the potential
targets for transcriptional activation by CD44ICD is
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FIGURE 9 CD44 forms a platform for the assembly of various MMPs with their substrates, to modulate cell migration. The extracellular
portion of CD44 binds to the MT1-MMP hemopexin domain (thin line), while the CD44 cytoplasmic domain interacts with the actin cy-
toskeleton, in this way anchoring MT1-MMP on the ruffling edge of migrating tumor cells. MT1-MMP, in turn, acts as a processing enzyme
for CD44, which is critical for the stimulation of cell motility, probably because it allows the cells to detach from the ECM. Co-expression of
MT1-MMP and CD44 generates two soluble fragments, resulting from proteolysis at Gly192-Tyr193 (CS1) (shown in the figure) and Gly233-
Ser234 (CS2) (not shown). Furthermore, ectodomain shedding of CD44 by MT1-MMP (1) induces cleavage in the cytoplasmic portion (2),
which releases the intracellular domain, CD44ICD, into the cytoplasm. CD44ICD migrates to the nucleus where it activates transcription
mediated through the 12-O-tetradecanoylphorbol 13-acetate (TPA)-responsive element (TRE). One of the genes under control of TRE is
the CD44 gene itself, suggesting that CD44 ectodomain cleavage promotes the rapid turnover of CD44 that is required for efficient cell
migration. In addition, CD44 acts as a platform to assemble various MMPs with their substrates, clustering proteolytic events that regulate
cell migration. MMP-9 also interacts directly with CD44 (dotted line), whereas MMP-7 attaches indirectly to the heparan sulfate chains
(HS) of CD44. L, ligand-binding domain; S, stem sequence. Adapted from (Seiki, 2002).
the CD44 gene itself, suggesting that CD44 ectodomain
cleavage and the subsequent intracellular signaling pro-
mote the rapid turnover of CD44 that is required for
efficient cell migration (Okamoto et al., 2001). As a con-
sequence, disruption of the interaction between MT-
MMPs and CD44 might be another strategy to inhibit
metastasis of malignant tumors (Peterson et al., 2000;
Ueda et al., 2003).
1.4.8 Extracellular Matrix
Metalloproteinase Inducer (EMMPRIN)
A search for MMP inducing factors in tumor cells
led to the identification of EMMPRIN (Extracellular
matrix metalloproteinase inducer) with the numerous
synonyms: basigin, leukocyte activation antigen M6
(M6), tumor cell-derived collagenase stimulatory factor
(TCSF), neurothelin, OK blood group antigen, OX-47,
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gp42, CE9, 5A11, 5F7, HT7, and CD147. EMMPRIN is
composed of two Ig domains in the extracellular region,
a single transmembrane domain and a short cytoplas-
mic domain containing 39 amino acids (see Figure 2). It
is a highly glycosylated cell surface protein, with the dif-
ferent glycosylation patterns of the 28 kDa native pro-
tein accounting for a variable molecular weight, ranging
between 44 and 66 kDa. Depending on the cell system,
EMMPRIN can stimulate production of MMP-1, -2, -3,
-9, MT1-MMP, and MT2-MMP, and only glycosylated
EMMPRIN is able to induce these MMPs. The NH2-
terminal Ig domain is required for the MMP induction,
but also for the formation of homo-oligomers in a cis-
dependent manner in the plama membrane. The MMP-
inducing function of EMMPRIN in part involves the
molecule acting as a counter-receptor for itself, also re-
quiring the NH2-terminal Ig domain, but in this case
the interaction is in a trans manner (Gabison et al., 2005;
Yan et al., 2005).
EMMPRIN can be released from the cell surface in
at least two different ways. A significant amount is re-
leased via vesicular shedding, whereby EMMPRIN is
initially associated with microvesicles which are quickly
degraded upon release from the cells to discharge
full-length soluble EMMPRIN. The other pathway is
MMP-dependent proteolytic shedding (Gabison et al.,
2005). In addition to inducing MMPs, EMMPRIN is
cleaved and shed by MMPs or other MPs, because this
shedding is inhibited by Zn2+ chelators (EDTA and
1,10-phenanthroline) and by the broad-spectrum MMP
inhibitor GM6001 (Tang et al., 2004; Haug et al., 2004).
In addition, MMP-1 and MMP-2 cleave EMMPRIN
at the membrane-proximal region in vitro (Haug et al.,
2004). Besides release of the intact form, a new EMM-
PRIN fragment of 22 kDa was identified in the cul-
ture media of two tumor cell lines (HT1080 and A431),
the shedding of which was enhanced by phorbol 12-
myristate 13-acetate (PMA) while that of the intact form
was not (Egawa et al., 2006). The EMMPRIN sheddase
was hypothesized to be of the MT-MMP family, in view
of its expression and inhibition profiles. In addition,
HT1080 and A431 cells express MT1-MMP and EMM-
PRIN was co-purified from cell lysates with MT1-MMP.
Knockdown of MT1-MMP with siRNA indeed inhib-
ited the shedding substantially, although MT2-MMP
may also contribute to the shedding because knock-
down of both MT1- and MT2-MMP produced slightly
greater inhibition. The COOH-terminal amino acid of
the 22 kDa fragment was identified as Asn98, and MT1-
MMP also cleaved at this site in an in vitro digestion. Al-
though an additional cleavage site, between Pro93 and
Met94, was observed after in vitro incubation with MT1-
MMP, the corresponding fragment was not identified
in cell culture media (Egawa et al., 2006). The Asn98-
Ile99 cleavage site is located in the linker sequence con-
necting the two Ig-like domains (see Figure 2), which
means that the 22 kDa fragment contains the NH2-
terminal Ig domain that is crucial for MMP induction
and homophilic interactions. The purified 22 kDa frag-
ment indeed retained MMP-inducing activity. Thus, the
shedding may down-regulate the cellular functions me-
diated by EMMPRIN, because MT1-MMP cleaves off
the essential distal Ig domain. This regulation may be
particularly important at the ruffling edge of migrating
tumor cells, as both proteins co-localize there (Egawa
et al., 2006). At the same time, the released soluble 22
kDa active fragment may act on cells either in the local
tumor environment or diffuse away to act on distant
cells to further stimulate MMP and EMPRINN expres-
sion and augment the migration and invasion potential
of tumor cells.
The pathologic consequences of elevated EMMPRIN
expression in tumor growth and metastasis were directly
demonstrated using EMMPRIN-overexpressing cancer
cells. MDA-MB-436 human breast cancer cells are nor-
mally slow-growing cells when they are implanted into
nude mice. However, after EMMPRIN gene transfec-
tion, these cells adopted a more aggressive pheno-
type, exhibiting both accelerated growth and increased
invasiveness, and increased MMP-2 and MMP-9 ex-
pression (Zucker et al., 2001). In addition to stimulat-
ing MMP production, EMMPRIN also binds MMP-1
and retains it at the cell surface, an arrangement that
may promote turnover of pericellular collagen, thereby
also facilitating migration and metastasis. The role of
EMMPRIN in tumor cell invasion was confirmed, as
EMMPRIN function-blocking antibodies inhibited in-
vasion through a reconstituted basement membrane.
Besides its role in the stimulation of invasion, migra-
tion and metastasis, EMMPRIN induces angiogenesis
via stimulation of VEGF production and multidrug re-
sistance via upregulation of HER2-signaling and cell
survival pathway activities (Gabison et al., 2005; Yan
et al., 2005). Targeting the release of soluble EMM-
PRIN molecules by MMPs, may thus be of great inter-
est to limit the expansion and migration of the tumor
by restricting the diffusion of malignant EMMPRIN
actions.
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Besides the elevated EMMPRIN expression on tumor
cells, EMMPRIN was also shown to have a broader
tissue distribution, including activated T-cells, differ-
entiated macrophages and epithelia. The presence of
EMMPRIN in non-tumoral tissue suggests a role in
other physiological and/or pathological situations, such
as embryonic development, adult tissue homeostasis,
atherosclerosis (see Section 2.1.2), arthritis and ulcera-
tion (Gabison et al., 2005).
1.4.9 Low-Density Lipoprotein
Receptor-Related Protein (LRP)
The low-density lipoprotein receptor (LDL-R) family
consists of several related cargo transporters that also
inform the cell of changes in its environment by me-
diating signaling responses. Low-density lipoprotein
receptor-related protein 1 (LRP, α2-macroglobulin re-
ceptor (α2-MR), apolipoprotein E receptor (ApoE-R),
CD91) is a membrane-bound receptor which mediates
the endocytosis of a wide variety of ligands, including
lipoproteins, proteases, proteinase inhibitor complexes,
ECM components, bacterial toxins, viruses, intracellu-
lar proteins and growth factors. In addition to the four
clusters of ligand-binding repeats, LRP consists of a 85
kDa membrane-spanning light β-chain (LRP-85) that is
non-covalently associated with a 515 kDa large extra-
cellular α-chain (LRP-515) (Figure 10). The cytoplasmic
domain, containing 100 amino acids, plays a role in
signal transduction by interacting with the cytoplasmic
scaffold and adaptor proteins (Strickland et al., 2002;
Lillis et al., 2005). In view of its multiple interactions at
the cell surface, LRP is a strategic relay in the control of
cell behavior. Indeed, LRP not only mediates the endo-
cytic clearance of several major contributors of cancer
development, such as ECM components (fibronectin,
and thrombospondin-1 and -2) and various proteolytic
enzymes (tissue-type plasminogen activator [t-PA], u-
PA, MMP-2, MMP-9, and MMP-13), but it is also in-
volved in cell signalling that regulates cell migration
and possibly, survival and proliferation. Its own regula-
tion thus appears to be a crucial process, as suggested
by two opposite physiopathological examples, with, re-
spectively, enhanced and suppressed LRP expression:
the cycling human endometrium (see Section 5.1) and
cancer (Emonard et al., 2005).
Invasive cancer cells derived from human prostate or
breast tumors express lower levels of LRP, as com-
pared to their non-invasive counterparts. Similarly, LRP
expression decreases in late stages of melanocytic tu-
mour progression and in invasive endometrial carci-
noma (Emonard et al., 2005). In addition, MT1-MMP,
which is highly expressed by the most invasive tumor
cells (Seiki, 2003; Sato et al., 2005), has been shown to
efficiently degrade LRP (Rozanov et al., 2004a). LRP-
515 associates with the MT1-MMP catalytic domain
and is highly susceptible to MT1-MMP proteolysis in
vitro (Figure 10). In cells co-expressing LRP and MT1-
MMP, the levels of cellular LRP are decreased and the
NH2-terminal ligand-binding portion is released in the
extracellular milieu, thereby destroying the functional
activity of the receptor. Similar to MT1-MMP, MT2-
MMP, MT3-MMP, and MT4-MMP also degrade LRP
(Rozanov et al., 2004a), suggesting that LRP is likely to
be susceptible to proteolysis by several individual MT-
MMPs in many cancer cell types. LRP is directly in-
volved in the capture, internalization, and clearance of
MMP-2, MMP-9, and MMP-13 from the extracellular
milieu, and in the translocation into the cell compart-
ment for subsequent lysosomal degradation (Emonard
et al., 2005; Van den Steen et al., 2006). In malignant
cells, MT1-MMP activates MMP-2, and protects the ac-
tive enzyme from uptake and clearance by cleaving LRP
(Figure 10). Thus, LRP proteolysis by MT1-MMP con-
tributes to maintaining high levels of proteinases such
as MMP-2, MMP-9, u-PA, and t-PA in the extracellular
milieu, allowing for extensive degradation of the ECM
by aggressive migrating cells. In this context, inhibi-
tion of MT1-MMP would have a dual beneficial effect
in countering tumor invasion and metastasis; first by
reducing the activation of pro-MMP-2 and second by
enhancing LRP-mediated clearance of ECM-degrading
proteases.
1.4.10 MT1-MMP
MT1-MMP expression levels are closely associated with
invasiveness and malignancy of tumors, suggesting that
MT1-MMP is one of the critical factors for tumor inva-
sion and metastasis. Besides degrading multiple ECM
molecules, MT1-MMP contributes to the process of tu-
mor cell metastasis by cell surface proteolysis of various
biologically important molecules such as MUC1, tTG,
integrins, syndecan-1, CD44, and LRP, as discussed be-
fore. Furthermore, it activates pro-MMP-2 and concen-
trates its proteolytic activity on the cell surface, which
is an important step for cancer cells to invade into basal
lamina (Sato et al., 2005; Itoh and Seiki, 2006). MT1-
MMP is produced as an inactive ∼60 kDa zymogen that
is activated by furin-like convertases, which cleave at
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FIGURE 10 Degradation of LRP by MT1-MMP leads to reduced internalization of MMP-2. (A) When MT1-MMP activity is inhibited by TIMP-
2, no MMP-2 activation occurs. MMP-2 binds thrombospondin (T) and is cleared from the extracellular milieu after binding the scavenger
receptor LRP. (B) In malignant cells, which often over-express both MT1-MMP and pro-MMP-2, MT1-MMP activates MMP-2. In addition, the
515 kDa large extracellular α-chain of LRP (LRP-515), which associates with the MT1-MMP catalytic domain (dotted line), is cleaved by
MT1-MMP and the NH2-terminal ligand-binding portion is released in the extracellular milieu, thereby destroying the functional activity
of the receptor. Hence, active MMP-2 is protected from uptake and clearance by LRP and accumulates in the extracellular environment,
where it assists MT1-MMP in degrading the ECM in front of aggressive migrating cells. LRP-85, the 85 kDa membrane-spanning light
β-chain of LRP. Adapted from (Rozanov et al., 2004a).
the Arg108-Arg-Lys-Arg motif located between the pro-
peptide and the catalytic domain. Active MT1-MMP
(∼57 kDa), starting at Tyr112, is then transported to
the plasma membrane with the catalytic domain fac-
ing the extracellular space, where it cleaves pericellu-
lar substrates. In addition to being a sheddase, MT1-
MMP is regulated by ectodomain shedding itself. Ac-
tive MT1-MMP undergoes autocatalytic processing at
the cell surface, leading to the formation of an inac-
tive 44 kDa fragment and release of the entire catalytic
domain (Figure 11). First, MT1-MMP cleaves itself at
the Gly284-Gly285 peptide bond in the hinge region,
generating the inactive 44 kDa membrane-bound frag-
ment. The second cleavage takes place at the Ala255-
Ile256 peptide bond, in the active site of MT1-MMP,
near the conserved methionine turn, a structural fea-
ture of the catalytic domain of all MMPs. The released
18 kDa soluble fragment has no catalytic activity and
does not bind TIMP-2 (Toth et al., 2002). Hence, the au-
tocatalytic cleavage represents a self-regulatory mecha-
nism that evolved to terminate MT1-MMP-dependent
proteolysis both at the cell surface and in the extracel-
lular space. The remaining 44 kDa degradation product
can even negatively influence enzymatic activity. For
example, it was shown to compete with the full-length
enzyme for collagen binding, reducing collagenolytic
activity, and cellular invasion of a collagen matrix. Ad-
ditionaly, it was speculated that the 44 kDa product
may indirectly reduce pro-MMP-2 activation by reduc-
ing the clustering of MT1-MMP induced by collagen
(Osenkowski et al., 2004). Inhibition of MT1-MMP ac-
tivity slows down autocatalytic enzymatic turnover and
consequently the mature form of the enzyme (57 kDa)
accumulates on the cell surface while the level of the
inactive 44 kDa fragment is reduced. In contrast, au-
tocatalytic processing is promoted in the absence of
inhibitors or under conditions of MT1-MMP overex-
pression. This effect of inhibition on autocatalytic pro-
cessing unveiled a new paradigm in MT1-MMP reg-
ulation because it signaled a potential side effect of
MT1-MMP inhibition: enhancement rather than inhi-
bition of activity (Osenkowski et al., 2004).
To make the picture even more complex, mature
MT1-MMP is also shed from the cell surface via a
non-autocatalytic process that results in the release
of various soluble forms (Toth et al., 2002), and, as
opposed to the autocatalytic processing, it generates
active soluble forms. This shedding occurs in vivo and
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FIGURE 11 Autocatalytic and non-autocatalytic shedding regulates MT1-MMP activity at the cell surface. Active MT1-MMP undergoes
autocatalytic processing on the cell surface, leading to the formation of an inactive 44 kDa fragment and release of the entire catalytic
domain. First, MT1-MMP cleaves itself at the Gly284-Gly285 peptide bond in the hinge region, generating the inactive 44 kDa membrane-
bound fragment. The second cleavage takes place at the Ala255-Ile256 peptide bond, in the active site of MT1-MMP. The resulting 18
kDa soluble fragment has no catalytic activity. MT1-MMP is also shed from the cell surface via a non-autocatalytic process that results
in the release of active soluble forms. This shedding is mediated by an ADAM and produces a minor form of ∼25–32 kDa (not shown)
and a major soluble form ∼50–52 kDa, wich represents the entire ectodomain, including the catalytic domain. Finally, MT1-MMP may as
well be degraded by MT3-MMP. However, no soluble products or cleavage sites of MT3-MMP have been characterized so far. Based on
(Osenkowski et al., 2004), (Toth et al., 2006) and (Shofuda et al., 2001).
produces a minor form of ∼25–32 kDa and a major
soluble form ∼50–52 kDa, wich represents the entire
ectodomain, including the catalytic domain (Figure
11) (Toth et al., 2005). The inhibition pattern of this
shedding process suggests that it is mediated by an
ADAM (Toth et al., 2006).
A third proteolytic mechanism regulates MT1-MMP
acitivity at the cell surface. While studying activities
of MT1- and MT3-MMP in activated smooth mus-
cle cells, it was shown that when MT3-MMP and
MT1-MMP were coexpressed, MT1-MMP degradation
was enhanced. This result supports the possibility
that MT3-MMP can degrade MT1-MMP (Figure 11),
providing another negative regulatory mechanism for
MT1-MMP activity in cells such as smooth muscle cells
and gliomas, or in tissues such as injured blood vessels
and brain, where both MT-MMPs are coexpressed
(Shofuda et al., 2001).
Emerging evidence points to internalization as another
means of controlling MT1-MMP activity at the cell sur-
face. Classical endocytosis depends on clathrin-coated
pits and involves an intracellular pathway in which lyso-
somes fuse with internalized vesicles, degrading their
contents (Shin and Abraham, 2001). MT1-MMP is
cleared from the cell surface by dynamin-dependent
endocytosis in clathrin-coated pits through its cytoplas-
mic domain (Jiang et al., 2001). This type of endocy-
tosis was shown essential for MT1-MMP to stimulate
cell migration and invasion into Matrigel (Uekita et al.,
2001). In addition, MT1-MMP was detected in caveolae
(Annabi et al., 2001; Puyraimond et al., 2001). Remacle
and coworkers (2003) showed that MT1-MMP is also
internalized by a clathrin-independent and caveolae-
dependent pathway in HT1080 cells. Caveolar traffic
is required for proper MT1-MMP localization, activ-
ity and function in migrating endothelial cells (Galvez
et al., 2004). Interestingly, internalized MT1-MMP can
be recycled to the cell surface, which could represent a
rapid mechanism for relocalizing active MT1-MMP at
the leading edge during cell migration (Remacle et al.,
2003).
Regarding the major role of MTl-MMP in tumor
invasion and metastasis (Sato et al., 2005; Itoh and
Seiki, 2006), inhibition of its activity is an obvious
therapeutic approach to block spreading of the cancer.
However, further insight in the proteolytic mecha-
nisms at the cell surface that modulate MT1-MMP
activity is a prerequisite in the development of new
inhibitors, as unexpected effects such as the paradoxical
enhancement of MT1-MMP activity by inhibition of
autocatalytic processing, may fatally alter the outcome
of inhibitor therapy.
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1.4.11 Protease-Activated Receptor-1
(PAR1)
Thus far, the protease-activated receptor (PAR) fam-
ily comprises four members defined as PAR1 to PAR4
(Coughlin, 2000). They form a unique class of GPCRs
that are characterized by a distinctive mechanism of ac-
tivation. Proteolytic cleavage at specific sites in the ex-
tracellular NH2-terminus exposes a new NH2-terminus,
which serves as a tethered ligand and binds to the sec-
ond extracellular loop of the same receptor, activating
it intramolecularly (Figure 12). The activated PARs ini-
tiate signal transduction across the membrane to acti-
vate intracellular G proteins that regulate pathways for
cell shape changes, secretion, cell proliferation, migra-
tion, and adhesion in numerous cell types. Many serine
proteases, including thrombin, factor Xa, granzyme A,
cathepsin G, elastase, trypsin and plasmin cleave the
PAR1 scissile bond at Arg41-Ser42. PAR1 (thrombin re-
ceptor, coagulation factor II receptor) is expressed by a
wide range of tumor cells and has been shown to be up-
regulated in breast carcinomas and pulmonary tumors.
In addition, the level of expression of PAR1 on tumor
cells directly correlates with metastatic potential in both
primary breast carcinoma and in established cancer cell
lines (Ossovskaya and Bunnett, 2004). Neither throm-
FIGURE 12 Proteolytic cleavage by MMP-1 in the NH2-terminus of PAR1 results in intramolecular receptor activation. Proteolytic cleav-
age by MMP-1 at Arg41-Ser42 in the NH2-terminus of PAR1 exposes a new NH2-terminus, which serves as a tethered ligand (L) and
binds to the second extracellular loop of the receptor, activating it intramolecularly. Activated PAR1 initiates signal transduction across
the membrane to activate intracellular G proteins that regulate pathways for cell morphology, secretion, cell proliferation, migration and
adhesion in numerous cell types. EC, extracellular; IC, intracellular. Adapted from Pei (2005).
bin nor other serine proteases appear to be involved in
PAR1-dependent breast cancer cell motility. However,
MMP inhibitors (1,10-phenanthroline and MMP-200,
a hydroxamate inhibitor) block both migration and in-
vasion of breast cancer cells in vitro. Only MMP-1, not
MMP-2, -3, -7, or -9, cleaves and activates PAR1 upon
addition to PAR1-transfected breast cancer cells. MMP-
1 inhibitors reduce both cell migration in vitro and tu-
mor growth in nude mice (Boire et al., 2005; Pei, 2005).
In addition, antagonism of either MMP-1 or PAR1 sig-
nificantly attenuates tumor-induced endothelial cell ac-
tivation (ECA), the transformation of the intravascular
milieu to a prothrombotic, proinflammatory, and cell-
adhesive state, as a result of tumor-endothelial cross-
talk (Goerge et al., 2006). Thus, the MMP-1/PAR1 axis
functions in both ways: host-derived MMP-1 activating
tumor-expressed PAR1, as well as tumor-derived MMP-
1 acting on endothelial PAR1 (see Figure 2). Since both
MMPs and PARs have also been shown to play impor-
tant roles in cardiovascular and inflammatory diseases
(Ossovskaya and Bunnett, 2004), targetting the MMP-
1/PAR1 pathway with therapeutics that block MMP-1
may become an attractive approach in the treatment
of a variety of invasive, proliferative, and inflammatory
conditions.
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1.4.12 Receptor Activator of Nuclear Factor
κB Ligand (RANKL)
Prostate cancer deaths are primarily due to metas-
tases that are resistant to conventional therapies. The
most common site for metastasis of prostate cancer
is the bone, with patients often experiencing severe
bone pain, pathological fractures, leukoerythroblas-
tic anaemia, bone deformity, hypercalcaemia, nerve-
compression syndromes, and immobility (Mundy,
2002). Osteolytic lesions are produced by the interac-
tion between tumor and bone stroma, commonly re-
ferred to as the ‘vicious cycle,’ whereby tumor cells in
the bone can secrete factors such as parathyroid hor-
mone related peptide (PTHrP) that stimulate osteoblast
expression of the receptor activator of nuclear factor
κB ligand (RANKL). By binding to its receptor RANK,
RANKL has been shown to be essential in mediating os-
teoclast activation (Figure 13). The osteoclasts degrade
the bone matrix using a powerful array of proteases
such as the MMPs and the cathepsins (Mundy, 2002).
RANKL, also known as tumor necrosis factor ligand su-
perfamily member 11, CD254, TNF-related activation-
induced cytokine (TRANCE), osteoprotegerin ligand
(OPGL) and osteoclast differentiation factor (ODF), is
a member of the TNF family. RANKL is required in
osteoclast differentiation and activation; T and B cell
maturation; dendritic cell survival; and might also play
a role in the cardiovascular system. The interaction with
its receptor RANK and its decoy receptor osteoprote-
gerin (OPG) forms a molecular triad which can mod-
ulate the bone system, the immune system, and the
cardiovascular system (Theoleyre et al., 2004).
To improve overall patient survival and to identify
new therapeutic targets, the molecular mechanisms un-
derlying prostate tumor-induced changes in the bone
microenvironment need to be elucidated. Therefore,
Lynch and coworkers (2005) developed a murine model
of rat prostate cancer in the bone environment that
mimics the osteoblastic and osteolytic changes associ-
ated with human metastatic prostate cancer. MMP-7
was identified as a proteolytic enzyme whose expres-
sion correlates with tumor-induced osteolysis. Interest-
ingly, MMP-7 was expressed by the osteoclasts at the
tumor-bone interface, and its secretion resulted in the
solubilization of RANKL being presented by the os-
teoblasts, stromal cells or tumor cells in the bone mi-
croenvironment (Figure 13). Cleavage of RANKL by
MMP-7 occurs at the residues Met145-Met146 in the
stalk region of the protein, releasing an active soluble
form of RANKL from the cell surface. MMP-3, but not
MMP-2, MMP-9, or MMP-13, was also found to cleave
RANKL, although the amount of sRANKL produced
was significantly less. sRANKL released by MMP-7 was
as active and efficient in osteoclast activation as full-
length RANKL. The shedding of RANKL is not with-
out significance, because it eliminates the need for close
contact between RANKL-expressing cells such as os-
teoblasts and tumor cells, and RANK-expressing osteo-
clast precursor cells (Blavier and Declerck, 2005). MMP-
7-mediated release of RANKL was also shown in vivo,
as sRANKL was clearly detected in the tumor-bone in-
terface lysates from wild-type mice, while little or no
sRANKL was detected in MMP-7 deficient animals. In
addition, tumor-induced osteolysis was significantly re-
duced in MMP-7 deficient mice (Lynch et al., 2005).
Hence, these results make MMP-7 an attractive ther-
apeutic target for the control of cancer-induced bone
metastasis.
Interestingly, RANKL was also reported to be solubi-
lized by MT1-, MT2-, MT3-, and MT5-MMP, which
will be discussed in a later section (see Section 3.4.2.2).
1.5 Inflammatory Processes and
Immune Escape in Cancer
1.5.1 Intercellular Adhesion Molecule-1
(ICAM-1)
Intercellular adhesion molecule-1 (ICAM-1, major
group rhinovirus receptor, CD54) is a transmembrane
glycoprotein expressed on multiple cell types includ-
ing leukocytes, epithelial cells, endothelial cells and fi-
broblasts. It is involved in multiple transient cellular
interactions that regulate infiltration, activation and ef-
fector functions of leukocytes. Interaction of ICAM-
1 with its physiological ligand lymphocyte function-
associated antigen-1 (LFA-1, CD11a/CD18 or αLβ2, the
prototypic β2-integrin) (see Section 1.4.3) is crucial for
leukocyte arrest on endothelial cells, stabilization of in-
teractions between antigen-presenting cells and T lym-
phocytes by the so-called immune synapse, and for ad-
hesion of cytotoxic T cells and NK cells to their target
cells. Besides LFA-1, ICAM-1 binds other ligands such
as Mac-1 (Complement receptor 3, CD11b/CD18 or
αMβ2 integrin), rhinoviruses and malaria-infected red
blood cells (Fiore et al., 2002; Hopkins et al., 2004).
ICAM-1 expression on resting vascular endothelial cells
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FIGURE 13 The shedding of RANKL by MMP-7 promotes cancer-induced osteolysis. Osteolytic lesions in bone metastasis are pro-
duced by the interaction between tumor and bone stroma, whereby tumor cells in the bone can secrete factors that stimulate osteoblast
expression of RANKL. By binding to its receptor RANK, RANKL has been shown to be essential in mediating osteoclast activation. The
osteoclasts degrade the bone matrix using a powerful array of proteases such as the MMPs and the cathepsins. MMP-7 has been shown
to mediate solubilization of RANKL on osteoblasts, stromal cells or tumor cells in the bone microenvironment. Cleavage of RANKL by
MMP-7 occurs at the residues Met145-Met146 in the stalk region of the protein. sRANKL released by MMP-7 was as active and efficient
at osteoclast activation as full-length RANKL. The shedding of RANKL is noteworthy because it eliminates the need for cell-cell contact
between RANKL-expressing cells such as osteoblasts, stromal cells and tumor cells, and RANK-expressing osteoclast precursor cells.
Based on Mundy (2002) and Blavier and Declerck (2005).
and lymphocytes is low, whereas its expression on
monocytes is moderate. Leukemia and carcinoma cells
express ICAM-1 as well, and this would make them
an easier target for CTLs (Cho et al., 2000). However,
ICAM-1 can be released from the surface of tumor cells.
This cleavage inhibits cell-mediated cytotoxicity, form-
ing a defence mechanism of primary tumor cells against
CTLs and NK cells. The protease in charge of this release
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is MMP-9 (Fiore et al., 2002). Sequencing of sICAM-1
peptides points to a cleavage site in the hinge region be-
tween Arg441 and the transmembrane domain (see Fig-
ure 2), with the Glu442-Val443 peptide bond being the
most probable cleavage site (Sultan et al., 2004) in accor-
dance with the substrate specificity of MMP-9 (Kridel
et al., 2001). However, the exact site of proteolysis re-
mains to be experimentally determined. In conclusion,
MMP-9 might be involved in tumor cell evasion of im-
mune surveillance.
1.5.2 Interleukin-2 Receptor-α Chain
(IL-2Rα)
Not infrequently, cancer cell spreading occurs despite
the apparent presence of TILs. These autologous CTLs
seem unable to display their anti-tumor capacities in
the tumor microenvironment. One of the various im-
mune escape mechanisms of cancer cells (see Figure
2) is down-regulation of the interleukin-2 Receptor-α
chain (IL2-Rα, p55, TAC antigen, CD25). As IL2-Rα
is an essential receptor for the proliferation of T-cells,
decreased expression of this receptor in vivo may re-
sult in poor clonogenicity of TILs and cause immune
suppression. An in vitro cervical cancer model shows
that cervical cancer cells can induce the release of sol-
uble IL2-Rα from encountered T-cells, a process inhib-
ited by TIMPs. Immunohistochemical stainings show
abundant expression of MMP-1, MMP-2 and MMP-9
in cervical cancer tissues, and MMP-9, and to a lesser
extent MMP-2, are capable of IL-2Rα truncation in vitro
(Sheu et al., 2001). Consequently, as MMP-9 may con-
tribute to tumor cell evasion of immune surveillance by
ectodomain cleavage of ICAM-1 as well as IL-2Rα, its
inhibition may be an attractive perspective in counter-
ing this type of immune escape of cancer cells.
2. MODIFICATION OF MEMBRANE
PROTEINS IN DISEASES AFFECTING
VASCULAR AND EPITHELIAL
INTEGRITY
2.1 Shedding of MMP Substrates in
Cardiovascular Diseases
2.1.1 HB-EGF
sHB-EGF is a potent chemoattractant and mitogen for
vascular smooth muscle cells. Atherogenesis in the ar-
terial wall is characterized by the formation of fibrous
lesions and the proliferation of neointimal smooth mus-
cle cells. Smooth muscle cells and macrophages in
atherosclerotic plaques have indeed been reported to
produce large amounts of HB-EGF. Moreover, sHB-
EGF-induced proliferation of smooth muscle cells is a
key step in the progressive neointimal thickening seen in
the development of transplant arteriosclerosis, a major
obstacle to long-term graft survival after clinical organ
transplantation (Higashiyama, 2004). Release of sHB-
EGF is mediated bij ADAM-12 in the heart and by
MMP-7 in large mesenteric arteries as a result of ligand
binding to GPCRs (see Figure 4), like some adrenore-
ceptors and angiotensin receptors (Hao et al., 2004). The
role of MMP-7 in large mesenteric arteries is taken over
by MMP-2 and MMP-9 in the case of increased lu-
minal pressure in small mesenteric resistance arteries
(Lucchesi et al., 2004). As the EGFR transactivation is
triggered by agonists typically overexpressed in hyper-
tension, its blockade may have therapeutical potential
for simultanously inhibiting pathological vasoconstric-
tion and growth in hypertensive disorders like vascular
inflammation, atherosclerosis, left ventricular hypertro-
phy, and cardiac hypertrophy (Shah and Catt, 2003;
Hao et al., 2004; Shah and Catt, 2004b).
2.1.2 EMMPRIN
MMPs seem to play an important role in atheroscle-
rotic plaque growth, neointima formation, and plaque
disruption by inducing smooth muscle migration and
proliferation (e.g.,after release of sHB-EGF, as discussed
before), and by enhancing ECM degradation (Rouis,
2005). Deposition of low-density lipoproteins (LDLs)
in the vessel wall and their oxidative modification
seem to initiate, or at least accelerate, the atheroscle-
rotic process by several mechanisms, including promo-
tion of foam cell formation, chemotactic effects on
monocytes, and mitogenic effects on smooth muscle
cells. In addition, oxidized LDLs increase the expres-
sion of MMPs in endothelial cells, monocyte-derived
macrophages, and smooth muscle cells (Haug et al.,
2004). EMMPRIN (see Section 1.4.8) regulates MMP
release and activity in fibroblasts, endothelial cells, and
tumor cells (Gabison et al., 2005; Yan et al., 2005). In ad-
dition, EMMPRIN has been shown to be expressed in
macrophage-rich atheromas from human coronary ar-
teries (Major et al., 2002) and in cultured human coro-
nary artery smooth muscle cells (HCA-SMCs) (Haug
et al., 2004). Oxidized LDLs significantly enhanced the
release of soluble EMMPRIN (∼50 kDa), as well as
the release of MMP-1 and MMP-2 into HCA-SMC
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supernatants. Oxidized LDL-induced release of solu-
ble EMMPRIN was parallelled by a decrease in cell-
associated EMMPRIN. These effects were antagonized
by antioxidants as well as by EDTA and the MMP
inhibitor GM6001. In addition, MMP-1 and MMP-2
cleaved off the cytoplasmic and transmembrane do-
mains of EMMPRIN in vitro. Purified soluble EMM-
PRIN significantly enhanced MMP-1 and MMP-2 re-
lease by HCA-SMC. Thus, oxidized LDLs might induce
an amplification cascade of increased MMP activity,
enhanced MMP-dependent shedding of soluble EMM-
PRIN, and EMMPRIN-induced upregulation of MMP
production. This cascade might accelerate ECM degra-
dation in atherosclerotic plaques and thereby promote
plaque growth and plaque destabilization (Haug et al.,
2004). Thus, inhibiting MMP-mediated production of
soluble EMMPRIN-molecules, which may diffuse and
act on multiple cells, may be an interesting therapeutic
tactic to interupt or prevent the atherosclerotic cascade.
2.2 Degradation of Intercellular
Junction Proteins in Inflammation,
Stroke, Acute Renal Failure and
Ophtalmic Pathologies
Adhesion between vertebrate cells is generally mediated
by three types of adhesion junctions: 1) tight junctions,
FIGURE 14 Degradation of tight junction proteins by MMPs disrupts endothelial integrity. Occludin and claudins are the major com-
ponents of tight junctions in endothelial cell sheets. Both, occludin and claudins have four transmembrane domains and their NH2- and
COOH-terminal ends are located in the cytoplasm. This conformation generates two extracellular loops that are supposed to provide the
intercellular interaction sites. Degradation of intercellular junction proteins is mediated by various MMPs and increases microvascular
permeability. The widening of interendothelial tight junctions allows for increased solute exchange and immune cell diapedesis, which is
a hallmark of inflammation and brain damage after BBB opening.
2) adherens junctions, and 3) desmosomes. Together
they constitute the intercellular junctional complex,
which has an important role in defining the physio-
logical function of a cell; that is, they define whether
and how a cell will be integrated in functional struc-
tures, such as organ epithelia or stroma (Cavallaro and
Christofori, 2004).
Occludin and claudins were identified as the major inte-
gral membrane proteins forming the tight junctions in
epithelial and endothelial cell sheets. Tight junctions
are sites of cell-cell contacts composed of a number
of transmembrane and cytoplasmic proteins, assembled
into a complex tethered to the cytoskeleton. Paracellu-
lar permeability, or the flow of ions and molecules be-
tween cells, is regulated by these tight junctions. Both,
occludin and claudins have four transmembrane do-
mains and their NH2- and COOH-terminal ends are
located in the cytoplasm. This conformation generates
two extracellular loops that are supposed to provide the
intercellular interaction sites (Figure 14). The COOH-
terminal domains of occludins and claudins serve as
binding sites for a complex set of signaling proteins in-
cluding zonula occludens (ZO)-1, -2 and -3, kinases and
phosphatases. Compared to occludin (65 kDa), how-
ever, claudins are smaller (20 to 25 kDa). Different cel-
lular sheets have their own unique set of claudin species,
and this compositional heterogeneity explains the
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diversified barrier properties of tight junctions.
Claudin-5 (also named transmembrane protein deleted
in velo-cardio-facial syndrome [VCFS]) was shown to
be a key molecule in the blood-brain barrier (BBB)
in mice (Feldman et al., 2005; Koval, 2006; Bazzoni,
2006; Furuse and Tsukita, 2006). Adherens junctions
and desmosomes are cell-cell junctions that are formed
by cadherins and additional associated proteins into
which actin filaments are inserted.
Degradation of intercellular junction proteins by
MMPs disrupts endothelial and/or epithelial integrity
and has major consequences in inflammation, stroke,
acute renal failure and ophthalmic pathologies, which
will be illustrated in the following paragraphs.
2.2.1 Occludin and Claudin-5 Degradation
in Inflammation
Increased microvascular permeability is a central hall-
mark of inflammation and allows for increased solute
exchange and extravasation of leukocytes into the in-
flamed tissue. These inflammatory changes in microvas-
cular permeability are correlated with the reorganiza-
tion and widening of interendothelial tight junctions.
MMPs have been reported to be responsible for the
tight junction disruption by degradation of occludin
and some claudins (Figure 14) (Alexander and Elrod,
2002). In human umbilical vein endothelial cells and
in porcine brain capillary endothelial cells, the tyro-
sine phophatase inhibitor phenylarsine oxide (PAO) in-
duced increased MMP activity, which was parallelled by
severe disruption of cell-cell contacts and degradation
of occludin. PAO-induced occludin proteolysis could
be prevented by different MMP inhibitors (GM6001
and 1,10-phenantroline) (Wachtel et al., 1999; Lohmann
et al., 2004). In addition, MMP-7 has been reported to
proteolyse VE-cadherin (see Section 1.3.3). Degradation
of intercellular junction proteins by MMPs thus con-
tributes to increased endothelial permeability, a prereq-
uisite for solute exchange and leukocyte extravasation
during inflammation.
2.2.2 Occludin and Claudin-5 Degradation
in the Blood-Brain Barrier
Tight junction proteins in endothelial cells such as oc-
cludin and claudins are major structural components of
the BBB formed by components of the neurovascular
unit (Bazzoni, 2006). Cerebral ischemia is a complex
insult that involves a loss of blood flow accompanied
by depletion of oxygen and essential nutrients. In vitro
models of the BBB have indicated that hypoxia and
hypoxia/reoxygenation lead to increased permeability
and/or disruption of BBB tight junctions (Hawkins and
Davis, 2005). Focal ischemia with reperfusion in spon-
taneously hypertensive rats lead to opening of the BBB
and degradation of occludin and claudin-5 (see Figure
14). Treatment with an MMP inhibitor (BB-1101) pre-
vented the opening and reversed the degradation of the
tight junction proteins (Yang et al., 2007). In addition,
using green fluorescent protein (GFP)-tagged occludin
and live cell imaging, it was shown that monocytes
scroll over the brain endothelial surface toward cell-cell
contacts, inducing gap formation, which is associated
with local disappearance of GFP-occludin, and subse-
quently traverse the endothelium paracellularly. The
broad spectrum MMP inhibitor BB-3103 significantly
inhibited endothelial gap formation, occludin loss, and
the ability of monocytes to pass the endothelium (Rei-
jerkerk et al., 2006). In addition, after lipopolysaccha-
ride (LPS)-induced opening of the BBB, less BBB dis-
ruption was observed in MMP-3 deficient mice than
in wild-type controls, as well as diminished degrada-
tion of claudin-5 and occludin (Gurney et al., 2006).
Hence, use of MMP inhibitors in stroke might reduce
or prevent BBB damage by minimizing degradation of
tight junction proteins and subsequent immune cell
diapedesis.
2.2.3 Degradation of E-Cadherin,
N-Cadherin and Occludin in Acute Renal
Failure
Acute renal failure (ARF) is characterised by a rapid
fall in glomerular filtration rate, clinically manifested
as an abrupt and sustained raise in urea and creatinine
in plasma. Life threatening consequences include vol-
ume overload, hyperkalemia, and metabolic acidosis.
ARF is increasingly common and carries a high mor-
bidity and mortality (Hilton, 2006). Although ischemia
is a leading cause of ARF, the molecular mechanisms
leading to renal injury and failure are not completely
understood. In ischemia-induced ARF, a loss of epithe-
lial integrity and shedding of epithelial cells occurs in
the tubuli. After injury, both viable and non-viable cells
are shed, leaving the basement membrane as the only
barrier between filtrate and interstitium, which allows
for backleak of the filtrate and tubular obstruction by
intraluminal aggregation of cells, proteins, and glyco-
proteins, such as fibronectin (Bonventre and Weinberg,
2003).
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FIGURE 15 Degradation of intercellular junctions by MMPs in acute renal failure. Cadherins in the adherens junctions and occludins
in the tight junctions are key molecules in the regulation of paracellular permeability by the intercellular junction. In ischemia-induced
ARF, MT1-MMP-mediated degradation of E-cadherin and N-cadherin results in disruption of epithelial integrity and shedding of epithelial
cells in the tubuli, leaving the basement membrane as the only barrier between filtrate and interstitium, which allows for backleak of the
filtrate and tubular obstruction by intraluminal aggregation of cells and proteins. In addition, degradation of occludin by MMP-9 leads to
the disruption of intercellular endothelial junctions and concomitant cell detachment and vascular injury.
Application of an in vitro model of ischemia-reperfusion
resulted in selective fragmentation/loss of E-cadherin
and loss of N-cadherin (neural-cadherin, cadherin-2,
CD325) levels from normal rat kidney cells that could
be blocked by the MMP inhibitors GM6001 and TAPI-
0 (Figure 15). TIMP-3 completely blocked both cleav-
age and/or loss of E-cadherin and N-cadherin, whereas
TIMP-2 protected full-length E-cadherin protein ex-
pression and TIMP-1 had no effect (Covington et al.,
2005). This implies that different MMPs may play a role
in E-cadherin and N-cadherin regulation. Chemical in-
hibitors against a number of soluble MMPs (1, 2, 3, 8,
and 9) failed to completely attenuate ischemia-induced
E- and N-cadherin loss. Under ischemic conditions,
there was increase in active MT1-MMP, and the role of
MT1-MMP in ischemia-induced cadherin loss was con-
firmed by blocking MT1-MMP activity with a neutral-
izing antibody or by blocking MT1-MMP expression
with siRNA constructs, which protected full-length E-
and N-cadherin during ischemia and preserved cell-cell
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contacts (Covington et al., 2006). Consequently, thera-
peutic inhibition of MT1-MMP may preserve epithelial
integrity and inhibit epithelial cell shedding in ARF. In
normal physiology, MMP-7-mediated shedding of E-
cadherin is required for the repair of injured lung ep-
ithelium (McGuire et al., 2003). Similarly, N-cadherin
cleavage also occurs under physiological conditions. In-
deed, MT5-MMP was shown to produce a ∼35 kDa N-
cadherin degradation product in neurons, possibly con-
tributing to mechanisms of synaptic regulation (Monea
et al., 2006). Therefore, targetting MT1-MMP in ARF
must occur by using extremely specific inhibitors, as
not to disturb any vital physiological process.
As discussed above, occludin is one of the major inte-
gral membrane proteins forming the tight junctions in
endothelial cell sheets. During acute in vivo reversible
ischemia induced in rat kidneys by vascular clamping,
pro-MMP-2, pro-MMP-9, and active MMP-9 were up-
regulated in the endothelial cell fractions. This increase
in MMP-9 during ischemia is accompanied by a lower
level of occludin in endothelial fractions. This finding
suggests that the induction of MMP-9 during kidney
ischemia leads to an increased degradation of occludin
(Caron et al., 2005). Thus, ischemia in kidneys could
lead to the disruption of intercellular endothelial junc-
tions by MMP-9 and concomitant cell detachment and
vascular injury (Figure 15). In addition, active MMP-
9 in ischemic kidney may also contribute to vascular
basement membrane degradation and increased perme-
ability. Accordingly, blocking MMP-9 and MT1-MMP
may be a way to reduce mortality in ARF.
2.2.4 Occludin Proteolysis in Ophtalmic
Pathologies
Breakdown of the blood-retinal barrier (BRB) is an early
feature of proliferative diabetic retinopathy (PDR) and
results in vascular leakage and the developent of retinal
edema (Frank, 2004). As in the BBB (see Section 2.2.2),
tight junction proteins such as occludin and claudins
are an integral structural component of the BRB. Both
TGF-β and MMP-9 increased the permeability of reti-
nal endothelial cells and reduced the levels of occludin
(see Figure 14) (Behzadian et al., 2001). Treatment of
retinal microvessel endothelial cells and retinal pigment
epithelial cells with MMP-2 and MMP-9 also revealed
specific degradation of occludin, but not of claudin-5
(Giebel et al., 2005). These results suggest that elevated
expression of MMPs in the retina may facilitate an in-
crease in vascular permeability by a mechanism involv-
ing proteolytic degradation of occludin, followed by
disruption of the entire tight junction complex. Thus,
a greater understanding of the role of MMPs in alter-
ing tight junction proteins in PDR may provide future
targets for therapeutic intervention.
Corneal epithelial disease, termed keratoconjunctivitis
sicca (KS), is a severe and sight-threatening complica-
tion of dry eye syndrome. A key clinical feature of KS is
disruption of epithelial barrier function. This results in
eye irritation, corneal surface irregularity, blurred and
fluctuating vision, and increased risk for corneal ulcer-
ation (Pflugfelder, 1998; Pflugfelder et al., 2005). Con-
centration and activity of MMP-9 in the tear fluid was
found to be significantly increased in these eyes, as well
as in an experimental murine model of dry eye. Corneal
epithelial permeability increased in dry eye wild-type
mice, but not in MMP-9 deficient mice. Compared to
MMP-9 knockout mice, wild-type mice showed greater
desquamification of differentiated apical corneal ep-
ithelial cells and this was accompanied by an increase
in lower sized (50 kDa) occludin in the corneal epithe-
lia of wild-type mice. The same effects were observed
in cultured human corneal epithelial cells treated with
active MMP-9 (Pflugfelder et al., 2005). These observa-
tions show that increased MMP-9 activity on the ocular
surface in response to dryness disrupts corneal epithelial
barrier function (Figure 16). The mechanism appears to
be similar to BBB and BRB disruption (see above), that
is, through disruption of tight junctions by proteolysis
of occludin. Accordingly, reducing barrier degradation
in human KS by targeting MMP-9 may lessen the sever-
ity of clinical disease.
3. SHEDDING OF MMP SUBSTRATES
IN THE MODULATION OF
INFLAMMATION AND INNATE
IMMUNITY
Innate immunity comprises several rapid defence mech-
anisms against invading microorganisms and other
types of damage to the host. During inflammatory reac-
tions, MMP-mediated cleavage of cell surface molecules
leads to activation of pro-inflammatory cytokines. This
is a fundamental step in the regulation of leukocyte re-
cruitment and homeostasis. In addition, the previously
mentioned modifications of mHB-EGF, E-cadherin,
integrin subunit precursors, MUC1, ICAM-1 and
IL-2Rα, also have major effects on immune responses
and wound healing. Finally, proteolysis of cell surface
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FIGURE 16 MMP-9-mediated degradation of occludin increases corneal epithelial permeability in keratoconjunctivitis sicca. Occludins
in the tight junctions between epithelial cells mediate intercellular adhesion and hence, are essential in epithelial barrier function. Increased
MMP-9 activity on the ocular surface in response to dryness leads to degradation of occludin and disruption of the corneal epithelial
barrier. Subsequent desquamification of apical corneal epithelial cells leads to keratoconjunctivitis sicca.
proteins by MMPs plays a non-negligible role in various
autoimmune diseases.
3.1 Activation of Membrane-Bound
Pro-Inflammatory Cytokines
3.1.1 Tumor Necrosis Factor-α (TNF-α)
Tumor necrosis factor-α (TNF-α, tumor necrosis factor
ligand superfamily member 2, cachectin) is a pleiotropic
cytokine with potent immunomodulatory and pro-
inflammatory properties. Excessive or prolonged pro-
duction of TNF-α is a feature of septic shock and sev-
eral important autoimmune diseases like rheumatoid
arthritis, Crohn’s disease and multiple sclerosis (Kol-
lias et al., 1999). TNF-α is initially expressed on T cells
and macrophages as an active 26 kDa membrane-bound
protein (pro-TNF-α), which is cleaved by TACE to form
the 17 kDa soluble cytokine (Black et al., 1997; Moss
et al., 1997; Mohan et al., 2002). TNF-α proteolysis is
inhibited in vitro and in vivo by broad-spectrum metal-
loproteinase inhibitors (McGeehan et al., 1994; Mohler
et al., 1994). MMP-1, MMP-2, MMP-3, MMP-7, and
MMP-9 also cleave recombinant pro-TNF-α fusion pro-
teins in vitro, as do MMP-12, MT1-MMP, MT2-MMP
and MT4-MMP (Gearing et al., 1994; Gearing et al.,
1995; Chandler et al., 1996; d’Ortho et al., 1997; English
et al., 2000). Of all these MMPs, only MMP-7 processes
pro-TNF-α at the natural cleavage site, between Ala76
and Val77 (Table 3). However, this reaction shows a
30-fold lower specificity constant relative to the TACE-
mediated proteolysis (Mohan et al., 2002). MMP-7 and
MMP-12 are both capable of TNF-α shedding from iso-
lated macrophages. MMP-7-mediated release of TNF-α
from peritoneal macrophages is essential for the induc-
tion of MMP-3 in coculture with vertebral disc cells.
This MMP-3 in turn generates a macrophage chemoat-
tractant, resulting in the macrophage infiltration that is
essential for the spontaneous resorption of herniated
discs (Haro et al., 2000a; Haro et al., 2000b). TNF-α
solubilization by MMP-12 is a crucial step in acute
cigarette smoke-induced inflammation, which causes
emphysema and chronic obstructive pulmonary disease
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(Churg et al., 2003). To summarize, it may be stated that,
whereas TACE is the main enzyme responsible for the
inducible release of TNF-α in response to bacteria and
pathogen-associated molecular patterns (the ligands of
Toll-like receptors), MMP-7 and MMP-12 may cause
constitutive TNF-α release from macrophages during
common processes as tissue resorption and resolution
in response to injury (Parks et al., 2004).
3.1.2 Interleukin-1β (IL-1β)
Interleukin-1β (IL-1β, catabolin, endogenous pyrogen,
granulocytic pyrogen, leukocytic pyrogen, lymphocyte
activating factor, hemopoietin-1, osteoclast activating
factor, mononuclear cell factor [MCF]) is a strong pro-
inflammatory cytokine that induces fever, inflamma-
tion, induction of acute phase reactants, tissue destruc-
tion, and, in some cases, shock and death (Dinarello,
2000). IL-1β lacks a typical transmembrane domain
and most of its precursor is stored in the cytoplasm.
In addition, a small fraction of the precursor can be
found in the extracellular space. We discuss its cleav-
age in the context of the functional analogy with the
above mentioned TNF-α proteolysis. IL-1β is primar-
ily produced by activated macrophages, monocytes and
polymorphonuclear phagocytes (Delaleu and Bickel,
2004). It lacks a secretory signal peptide and, as a re-
sult, it is not secreted through the classical exocytic
route, but presumably through exocytosis of secretory
lysosomes, a mechanism that still requires further clar-
ification (Andrei et al., 2004; Wewers, 2004). Whereas
the COOH-terminal 17 kDa segment has full biologi-
cal activity (Van Damme et al., 1985), the 33 kDa pro-
form of IL-1β is inactive and its maturation requires
proteolytic processing into the mature protein by the
IL-1β-converting enzyme (ICE or caspase-1), an intra-
cellular cysteine protease (Kostura et al., 1989). The pos-
sibility of extracellular precursor proteolysis and in vivo
studies with ICE deficient mice suggest the existence
of ICE-independent mechanisms of IL-1β activation
(Delaleu and Bickel, 2004). Indeed, various proteases
cleave recombinant IL-1β in vitro, including bacterial
enzymes, trypsin, chymotrypsin, leukocyte elastase and
granzyme A. However, with the exception of granzyme
A, all of these cleavages result in fragments >17 kDa.
On the contrary, proteolysis by MMP-2, MMP-3, and
especially by MMP-9, yields biologically active forms
(Scho¨nbeck et al., 1998). In addition, prolonged incuba-
tion of mature IL-1β with MMP-3, and to a lesser extent
with MMP-1, MMP-2, and MMP-9, results in degrada-
tion of the mature cytokine (Ito et al., 1996). IL-1β is
one of the classical inducers of these MMPs in inflam-
mation. In addition, IL-1β is an autoregulating protein
with the ability to induce its own gene expression. Thus,
at sites of acute or chronic inflammation the presence
of MMP-9 might result in biologically active IL-1β,
whereas MMP-3 can degrade the active IL-1β form, me-
diating downregulation of its activities. As IL-1β plays
a crucial role in multiple inflammatory and autoim-
mune diseases, including rheumatoid arthritis, inflam-
matory bowel disease, and multiple sclerosis (Delaleu
and Bickel, 2004), and seems to be involved in tumor
invasion and angiogenesis as well (Voronov et al., 2003),
it is a principal target for drug development (Braddock
and Quinn, 2004). In this regard, understanding IL-1β
activity modulation by MMPs is crucial.
3.2 Regulation of Leukocyte
Recruitment, Migration and
Homeostasis in Inflammation
3.2.1 Syndecan-1
The influx of inflammatory cells to skin or mucosal
sites of injury is largely directed by signals from the ep-
ithelium, but how these cells generate and modulate
chemotactic gradients has not yet been completely elu-
cidated. In murine lungs, a potential mechanism for
the formation of neutrophil-attracting chemotactic gra-
dients is based on the interaction of three components
of the epithelial tissue: a secreted protease (MMP-7),
a cell-bound proteoglycan (syndecan-1) and a CXC
chemokine (KC) (Li et al., 2002). When damaged, lung
epithelial cells secrete the chemokine KC (and proba-
bly other chemokines as well), which binds to preexist-
ing syndecan-1 molecules. MMP-7 is also induced by
tissue injury, secreted by wound-edge epithelia and an-
chored to the heparan sulfate chains of cell surface pro-
teoglycans (Yu and Woessner, 2000). MMP-7 cleaves the
syndecan-1 core protein to release the ectodomain-KC
complex. The shed complex is then transported, either
actively or passively, to the apical surface where it forms
a chemotactic gradient which guides neutrophils to the
alveolar space (Li et al., 2002). Syndecan-1 ectodomain
shedding by MT1-MMP results in enhanced tumor cell
migration (see Section 1.4.6), while cleavage by MMP-7
is required for directing neutrophil migration to injured
lung tissue. Further clarification of such chemotactic
processes is important to allow control of the inflam-
matory process, in order to improve the removal of
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micro-organisms and the repair of tissues, while limit-
ing damage (Li et al., 2002; Shapiro, 2003).
3.2.2 Leukocyte-Selectin (L-Selectin)
Leukocyte-selectin (L-selectin, lymph node homing re-
ceptor, leukocyte adhesion molecule-1 [LAM-1], leuko-
cyte surface antigen Leu-8, TQ1, leukocyte-endothelial
cell adhesion molecule-1 [LECAM-1], gp90-MEL,
MEL-14 antigen, CD62L) is a member of the se-
lectin family of adhesion molecules. L-, P-, and E-
selectins each possess a C-type lectin domain, special-
ized to recognize specific oligosaccharides on mucins
and other glycoproteins. Selectins mediate the process
of reversible “rolling” in the binding of leukocytes in
the bloodstream onto (activated) endothelial cells and
specialized endothelial cells lining the high endothelial
venules (HEVs) in lymph nodes (Gallatin et al., 1983;
Ley and Kansas, 2004).
L-selectin shows the unique property of being cleaved
in the membrane-proximal extracellular domain with
concomitant release of a soluble fragment that contains
the functional lectin and EGF domains. This provides
a rapid mechanism for the regulation of L-selectin lev-
els on leukocytes, and hence, controls their ability to
migrate into tissues. An extended variety of stimuli,
such as chemotactic factors, phorbol ester activation
and reagents that cross-link L-selectin, induce L-selectin
proteolysis (Preece et al., 1996). The hydroxamic acid-
based MMP inhibitor, Ro 31-9790, completely prevents
shedding of L-selectin from leukocytes in mice, rats,
and humans. In vitro reduction of L-selectin-positive
leukocytes is mediated by MMP-1, and to a lesser extent
by MMP-3, while MMP-2 and MMP-9 have no such
effect. However, lymphocytes do not express MMP-1
and MMP-3, and L-selectin levels are not affected by
TIMP-1. Moreover, the L-selectin sheddase only acts
in cis (on the same cell) and not in trans configura-
tion (Preece et al., 1996). This shedding is only inhibited
by TIMP-3, and not by TIMP-2 (Borland et al., 1999).
TACE was identified as the L-selectin sheddase follow-
ing PMA stimulation (Peschon et al., 1998). However,
multiple agents induce L-selectin shedding and have
structural requirements that differ from PMA-induced
shedding (Smalley and Ley, 2005). In addition, with the
use of TACE deficient mice, a significant sheddding of
L-selectin was still detected, and a small fraction of this
shedding was not inhibited by a metalloprotease in-
hibitor, suggesting that there may be more than one
additional sheddase (Walcheck et al., 2003). Thus, sepa-
rate proteolytic mechanisms of L-selectin shedding may
play a role under a variety of distinctive conditions, for
instance to regulate distinct antiadhesive mechanisms.
As L-selectin mediates crucial leukocyte adhesion and
migration processes in inflammation, the elucidation
of the functional implications of L-selectin shedding
was of paramount importance. Using inhibitors of L-
selectin shedding it was demonstrated that L-selectin re-
lease participates in regulating neutrophil rolling. More-
over, shedding of L-selectin limits leukocyte activation
and thus may limit inflammation. Interestingly, plasma
of healthy humans and mice contains approximately
1.6 µg/mL of soluble L-selectin. As sL-selectin concen-
trations of 0.9 µg/mL already reduce lymphocyte migra-
tion to peripheral lymphe nodes by over 30%, shedded
L-selectin was suggested to regulate normal lympho-
cyte trafficking and possibly the inflammatory response
(Smalley and Ley, 2005). Studies with transgenic mice
expressing shedding-resistant L-selectin showed that L-
selectin shedding has a role in minimizing reentry of
T-cells into peripheral lymph nodes following activa-
tion and limits neutrophil adhesion at sites of inflam-
mation. Mice lacking the ability to shed L-selectin on
neutrophils also showed reduced neutrophil migration
to inflammatory chemokines, suggesting that L-selectin
shedding is required for efficient transendothelial mi-
gration (Smalley and Ley, 2005). Specification of the
other sheddases in charge might contribute to further
understanding and control of leukocyte mobility in in-
flammatory processes.
3.2.3 Kit-Ligand (KitL)
Kit ligand (c-KitL, stem cell factor [SCF], mast cell
growth factor [MGF]) is a 31 kDa membrane-bound
growth-stimulating cytokine, which is proteolyzed into
an active soluble form (sKitL, 164 amino acids) (Heis-
sig et al., 2002). KitL exists in homodimers, and bind-
ing to its cell surface receptor c-Kit (SCF receptor or
CD117) thus causes dimerization of this TKR. Dimer-
ization of c-Kit in turn results in autophosphorylation
and activation of the receptor and of downstream sig-
nal transduction proteins, involved in cell proliferation,
survival and chemotaxis. KitL is found on stromal cells
of the bone marrow, on vascular smooth muscle cells
and on endothelial cells, whereas c-Kit is expressed on
a variety of cell types, including mast cells, hematopoi-
etic progenitor cells, melanocytes, germ cells and
gastrointestinal pacemaker cells (Akin and Metcalfe,
2004).
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sKitL plays a key role in the maintenance and recon-
sitution of the stem and progenitor cell pool. Under
steady-state conditions, quiescent c-Kit+ hematopoi-
etic stem cells (HSCs) and circulating endothelial
progenitors (CEPs) reside in a niche in close contact
with stromal cells from the bone marrow, including
osteoblasts. Membrane-bound cytokines such as KitL
transmit survival signals and support the adhesion of
stem cells to the stroma. Bone marrow ablation (e.g.,by
cytotoxic agents) induces upregulation of MMP-9,
which cleaves KitL. Released sKitL confers signals that
enhance mobility of c-Kit+ HSCs and CEPs. As a
result, they can translocate into a vascular-enriched
proliferative zone, which stimulates differentiation
and mobilization into the peripheral blood stream
(Heissig et al., 2002). The net number of circulating
leukocytes is dependent on the balance between
production in the bone marrow, and margination and
migration of leukocytes into peripheral tissues and
spleen (Opdenakker et al., 1998). Consequently, sKitL
release by MMP-9 is crucial for the maintenance of
leukocyte homeostasis in the blood, and might be a
key step in the recruitment of bone marrow stem cells
during cell therapy for cancer and other diseases.
In addition, MMP-9-mediated shedding of KitL also
affects smooth muscle function and development of
intimal hyperplasia, as this process, characterized by
transformation of medial smooth muscle cells from a
quiescent contractile to a synthetic proliferative pheno-
type, seems to be influenced by autocrine sKitL/c-Kit
signal transduction (Hollenbeck et al., 2004). The im-
portance of KitL ectodomain proteolysis by MMP-9 is
further confirmed by the extended variety of physiolog-
ical processes affected by KitL/c-Kit signaling, such as
maintenance of adult lymphopoiesis in bone marrow
and thymus (Waskow et al., 2002), survival, differenti-
ation, chemotaxis, and functional activation of mast
cells, melanocyte development and regulation of ooge-
nesis, folliculogenesis, and spermatogenesis (Akin and
Metcalfe, 2004).
3.3 Recognition and Clearance of
Pathogens in Innate Host Defense
3.3.1 CD14
Surfactant protein-D (SP-D) and CD14 are impor-
tant innate immune defense molecules that mediate
clearance of pathogens and apoptotic cells from the
lung. CD14 (monocyte differentiation antigen CD14,
myeloid cell-specific, leucine-rich glycoprotein) is a 55
kDa pattern recognition receptor that is present on the
surface of monocytes, macrophages and neutrophils.
As a GPI-linked receptor, it lacks a cytoplasmic sig-
naling domain and, therefore, it requires interaction
with other receptors to elicit its biological responses.
CD14 binds LPS and interacts with toll-like receptor
4 (TLR4) and myeloid differentiation protein 2 (MD-
2) enhancing MAPK signaling and production of cy-
tokines and chemokines (Antal-Szalmas, 2000). Addi-
tional biological functions mediated by CD14 include
the transport of lipids, phagocytosis of bacteria, and
clearance of apoptotic cells. CD14 also exists as a solu-
ble molecule (sCD14) found in normal human serum
and in culture supernatans of monocytes and cell lines.
Two molecular forms of sCD14 with different origins
have been characterized. First, some CD14 molecules
escape GPI anchor attachment. They are stored intra-
cellularly and released spontaneously as 55 to 56 kDa
full-length molecules upon a short temperature shift
at 37◦C. Second, various stimuli such as PMA, inter-
feron (IFN)-γ or LPS, induce shedding of the GPI-
anchored CD14, resulting in sCD14 with a molecular
mass of 48 to 49 kDa (Antal-Szalmas, 2000). SP-D plays
a central role in the pulmonary host defence and is a
member of the collectin (collagen-lectin) family, which
form multimeric structures consisting of a collagenous
NH2-terminal domain and a globular COOH-terminal
carbohydrate recognition domain that binds oligosac-
charides at the surfaces of many microorganisms and
mediates phagocytosis and killing by phagocytic cells.
SP-D knockout mice (SP-D−/−) develop progressive
emphysema that is characterized by chronic inflam-
mation, accumulation of surfactant phospholipids,
and infiltration with lipid-laden alveolar macrophages
(Hartl and Griese, 2006). CD14 is reduced on alve-
olar macrophages from SP-D−/− mice and is associ-
ated with reduced uptake of LPS and decreased pro-
duction of TNF-α after LPS stimulation. In addition,
sCD14 is increased in the bronchoalveolar lavage (BAL)
fluid from SP-D−/− mice, while MMP-9 and MMP-
12 activities are enhanced in the lungs. Since treat-
ment of macrophages with MMP-1 reduced the level
of cell surface CD14 (Bryniarski et al., 2003), MMP-9
and/or MMP-12 were also candidates for the prote-
olysis of cell surface CD14 to release sCD14 in SP-
D−/− mice. sCD14 was indeed significantly reduced
in BAL fluid from MMP-9−/−/SP-D−/− and MMP-
12−/−/SP-D−/− mice compared with SP-D−/− mice.
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In addition, MMP-12 treatment of RAW 264.7 cells in-
creased sCD14 in the cell culture medium, supporting
the concept that MMP-12 cleaves CD14 from the alve-
olar macrophage cell surface (Senft et al., 2005). Since
it was not investigated whether MMP-9 cleaves CD14
in vitro, and MMP-12 is decreased in MMP-12−/−/SP-
D−/− mice, the exact contribution of MMP-9 remains
unclear.
In conclusion, SP-D loss results in reduced innate
host defence activities, such as decreased LPS uptake
and TNF-α production, through shedding of CD14
by MMP-12. In addition, upon recognition of Gram-
negative bacterial LPS, sCD14 has a dual regulatory
role that is concentration- and environment-dependent.
Low concentrations of sCD14 seem to promote bene-
ficial pro-inflammatory responses to LPS at local sites
of infection, whereas high circulating sCD14 concen-
trations may help control potentially harmful systemic
responses to LPS (Kitchens and Thompson, 2005). In
summary, MMP-12 may be an interesting target in
the regulation of microbial clearance and inflammatory
processes that are important for host defense and pul-
monary homeostasis. However, more investigation will
be required to better understand the dual activities of
sCD14 in the host during infection.
3.4 Membrane-bound MMP
Substrates in Autoimmune Diseases
3.4.1 Bullous Pemphigoid
3.4.1.1 Bullous Pemphigoid Antigen-2
(BP180)
Bullous pemphigoid (BP) is an autoimmune blistering
disease of the skin affecting primarily the elderly. Blis-
ter formation by detachment of the epidermis from the
underlying dermis occurs within the lamina lucida of
the basement membrane and is initiated by deposition
of IgG autoantibodies and complement components
along the basement membrane zone. These autoan-
tibodies are directed against two major hemidesmo-
somal components, the 230 kDa intracellular pro-
tein BP230 (Bullous pemphigoid antigen-1 [BPAG1],
Hemidesmosomal plaque protein, Dystonia musculo-
rum protein, Dystonin) and the 180 kDa transmem-
brane protein BP180 (Bullous pemphigoid antigen-2
[BPAG2]/HD4/Type XVII collagen). Autoantibody de-
position causes complement activation and mast cell
degranulation, essential for the recruitment and infil-
tration of inflammatory cells with subsequent degrada-
tion of hemidesmosomal and ECM components (Liu,
2003). Proteinases and reactive free radicals from in-
filtrating inflammatory cells contribute to tissue dam-
age in BP lesions. Blister fluid and fluid at lesional
and perilesional regions indeed contain proteolytic en-
zymes such as neutrophil elastase (NE), plasmin and
plasminogen activators, cathepsin G, collagenases and
gelatinases, MMP-2 and MMP-9 (Liu et al., 1998; Liu
et al., 2000 a; Liu et al., 2000b). In vitro experiments show
that NE as well as MMP-9 cleave the extracellular, col-
lagenous domain of a recombinant BP180-Glutathion
S-transferase (GST) fusion protein. NE deficient and
MMP-9 deficient mice are resistant to blister formation
after intracutaneous injection of BP180-specific anti-
bodies, although these mice show deposition of au-
toantibodies at the dermis-epidermis junction. More-
over, blister formation is completely abolished by the
α1-proteinase inhibitor (α1-PI), the major NE inhibitor
(Liu et al., 2000b) and in vivo BP180 is proteolyzed
by NE, but not by MMP-9 (Liu et al., 2000a). Con-
sequently, NE is the main tissue-damaging enzyme in
murine experimental BP, whereas neutrophil MMP-9
most likely contributes indirectly by inactivating α1-PI,
in this way potentiating NE action. In addition, MMP-
9 might collaborate with NE in the fragmentation of
other proteins, in this way generating and/or maintain-
ing the chemoattractant gradients needed for neutrophil
infiltration, an essential step in the blistering process
of experimental BP (Liu et al., 1997; Liu et al., 2000b).
MMP-9 activation was shown to be plasmin-dependent
and independent of MMP-3 (Liu et al., 2005). NE is the
BP180-cleaving enzyme in human BP as well (Verraes
et al., 2001). In addition, TIMP-1 is present in five-fold
molar excess to MMP-9, indicating that cleavage of α1-
PI by MMP-9 is less probable in human BP. However,
in an in vitro model of BP, inhibition of MMP-9 with a
specific monoclonal antibody does abolish blister for-
mation (Shimanovich et al., 2004). As a consequence,
the contribution of MMP-9 to disease progression is
not as clear in humans as it is in mice. This discrep-
ancy might be explained by the differences that exist
between murine and human BP. For instance, the ma-
jority of biopsies from BP patients show large num-
bers of eosinophils in their lesional skin, whereas in
mice neutrophils are the predominant inflammatory
cells. However, some patients may have neutrophil-
rich or cell-poor lesions. These varying and different
pathological features in human BP indicate that BP
is a heterogenous disease. Subepidermal blistering can
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be caused by several mechanisms and cell types, the
above mentioned immunopathological cascade being
one of them (Liu, 2003). Since BP180 is also an au-
toantibody target in several other subepidermal blis-
tering diseases including cicatricial pemphigoid, herpes
gestationis, linear IgA bullous dermatosis, and lichen
planus pemphigoides (Liu, 2003), further identification
of the tissue damaging-proteases in these skin autoim-
mune disorders might allow to develop therapies based
on the use of synthetic protease inhibitors or inhibitory
monoclonal antibodies.
3.4.2 Rheumatoid Arthritis
3.4.2.1 FasL
Rheumatoid arthritis is a chronic inflammatory autoim-
mune disease, which results in inflammation of the syn-
ovial lining and destruction of the adjacent bone and
cartilage. Synovial macrophages, fibroblasts and lym-
phocytes are critical for the pathogenesis of this dis-
ease, in which apoptosis may play divergent roles (Liu
and Pope, 2003). Insufficient intra-articular apoptosis
induces proliferation of the synovial membrane (Sakai
et al., 1998; Okamoto et al., 1998). In joints of patients
with active rheumatoid arthritis, few apoptotic cells are
detected, which might contribute to persistence of the
disease (Pope, 2002). MMP-3 concentrations in the syn-
ovial fluid of rheumatoid arthritis patients are closely
correlated with increased sFasL levels and with disease
activity. Consequently, MMP-3 might contribute to the
pathogenic mechanism by cleaving FasL, in this way
reducing apoptosis (sFasL is a less potent apoptosis-
inducer than its membrane-bound precursor, see Sec-
tion 1.2.1). However, sFasL shedding was not com-
pletely blocked by an MMP inhibitor alone, indicating
that further investigation is needed for detection of the
other proteases involved (Matsuno et al., 2001). More-
over, rheumatoid arthritis is characterized by a very het-
erogenous disease course with strong synovial prolifera-
tion in early disease, whereas in the later stages synovial
proliferation is reduced and often replaced by connec-
tive tissue (Smith and Walker, 2004). As a consequence,
stimulation of apoptosis, for instance by MMP inhibi-
tion, might have some therapeutic benefit, but requires
further insight into the exact role of apoptosis in the
subsequent stages of rheumatoid arthritis.
3.4.2.2 RANKL
Another important TNF family member in rheuma-
toid arthritis is RANKL. In the absence of RANKL or
RANK, osteoclast differentiation from monocyte pre-
cursors does not occur (see Figure 13). RANKL is ex-
pressed on T-cells and fibroblasts within the synovial
inflammatory tissue of patients with rheumatoid arthri-
tis and its expression is regulated by pro-inflammatory
cytokines. In animal models of arthritis, blockade of
RANKL-RANK interactions, or a genetic absence of
RANKL or RANK, protects against joint damage de-
spite the presence of joint inflammation (Schett et al.,
2005).
As discussed before, RANKL is a transmembrane gly-
coprotein that can be converted to a soluble form
by ectodomain shedding (see Section 1.4.12). Besides
MMP-7, TACE cleaves RANKL in vitro (Lum et al.,
1999), but further in vitro experiments show no dif-
ference in sRANKL shedding from fibroblasts with or
without TACE (Schlondorff et al., 2001). However, two
other RANKL shedding activities can be discerned in
these fibroblast cultures. One is induced by the tyrosine
phosphatase inhibitor pervanadate and its TIMP inhi-
bition profile is similar to that of several MT-MMPs.
The other is constitutive and is insensitive to any
TIMP. MT1-MMP overexpression indeed causes in-
creased RANKL release, the ectodomain being cleaved
between Met145 and Met146 (Schlondorff et al., 2001).
In accordance with these observations, Western Blot
of sRANKL shows two bands with molecular weights
of 25 kDa and 24 kDa, that are produced by cleav-
age at Arg138-Phe139 and Met145-Met146, respectively
(Hikita et al., 2006). Experiments with inhibitors suggest
that the upper band is produced by an ADAM and the
lower band by an MMP. A large number of MMPs
were shown to cleave RANKL in a RANKL shed-
ding activity screening system, with a fusion protein.
However, only MT1-MMP, MT2-MMP, MT3-MMP,
and MT5-MMP cleaved full-length RANKL and gen-
erated sRANKL with the expected molecular weight.
Real-time PCR showed that MT1-MMP mRNA level
was much higher than that of MT2-, MT3-, and MT5-
MMP in a bone marrow stromal cell line and in pri-
mary osteoblasts, suggesting that MT1-MMP is mainly
involved in the production of the 24 kDa band. Re-
duced MT1-MMP expression in primary osteoblasts by
siRNA or its deficiency in MT1-MMP knockout mouse
osteoblasts reduced RANKL shedding and increased
membrane-bound RANKL, which led to increased os-
teoclastogenic activity in the cells. Conversely, overex-
pression of MT1-MMP in osteoblasts suppressed osteo-
clastogenesis. In addition, although sRANKL produced
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by MT1-MMP induced osteoclastogenesis from bone
marrow macrophages, the culture medium of activated
primary osteoblasts did not induce osteoclastogenesis,
even when MT1-MMP was overexpressed. These results
suggest that membrane-bound RANKL induces osteo-
clastogenesis more efficiently than sRANKL, and the
ectodomain shedding of RANKL by MT1-MMP neg-
atively regulates osteoclastogenesis, which is in accor-
dance with a previous report (Nakashima et al., 2000).
Consistent with these in vitro observations, soft X-ray
images of MT1-MMP deficient mice displayed osteo-
porosis and a much higher osteoclast number, while
the serum level of sRANKL in the MT1-MMP knock-
out mice was undetectable (Hikita et al., 2006). In con-
clusion, MT1-MMP was identified as the major en-
dogenous RANKL sheddase in primary osteoblasts and
RANKL shedding seemed to downregulate local osteo-
clastogenesis.
As MMP-7-released sRANKL is as efficient in osteo-
clast activation as its full-length precursor (see Section
1.4.12 and Figure 13), it seems paradoxical that cleav-
age by MT1-MMP at the same site in the ectodomain
releases a less active form. However, Hikita and col-
leagues indeed mentioned that the concentration of the
sRANKL produced by MT1-MMP in the culture me-
dia was more than tenfold lower than the concentration
needed to induce osteoclastogenesis with recombinant
sRANKL in vitro. It is possible that when the expres-
sion of RANKL is highly upregulated, MMP-released
sRANKL does have substantial effects on general bone
metabolism. Hence, further insight into RANKL shed-
ding by MMPs and its concomitant biological conse-
quences in vivo may be crucial in the clarification of
some osteoarticular pathologies, including rheumatoid
arthritis.
3.4.2.3 ADAMTS-4
Aggrecan hydrates the collagen network and thus pro-
vides cartilage with its properties of compressibility and
elasticity. Degradation of aggrecan can be mediated
by two proteases of the ADAMTS family: ADAMTS-
4 and ADAMTS-5 (Malfait et al., 2002). ADAMTS-4
(aggrecanase-1, ADMP-1) is synthesized as a protein
containing a signal peptide, prodomain, catalytic do-
main with a Zn2+-binding motif, disintegrin-like do-
main, thrombospondin Type I motif, a spacer region
and a cysteine-rich domain (Tortorella et al., 1999).
The intracellular proprotein convertases (PCs), furin,
PACE4 and PC5/6 efficiently remove the prodomain
through cleavage at Arg212-Phe213, generating an
active enzyme. Interestingly, the secreted proteases
trypsin, MMP-9, and in a much lesser extent MMP-
13, are also effective in removing the prodomain of
ADAMTS-4, but the cleavage by MMP-9 occurs at
a site other than the PC/trypsin cleavage site. The
MMP-9-activated species cleaves the aggrecan peptide
substrate, but not native aggrecan, suggesting that the
alternative cleavage site changes substrate specificity
of the enzyme (Tortorella et al., 2005). In addition to
NH2-terminal activation, it has been suggested that
truncation of the COOH-terminus of ADAMTS-4 by
a TIMP-1-sensitive GPI-anchored MMP, MT4-MMP,
is required for full catalytic activity against aggrecan
(Gao et al., 2002). ADAMTS-4 (p100) and MT4-MMP
are first processed intracellularly by furin-mediated re-
moval of the prodomains, followed by their associa-
tion in the secretory pathway. The GPI-anchored MT4-
MMP/ADAMTS-4 (p68) complex moves to the cell sur-
face, where MT4-MMP removes the spacer domain of
ADAMTS-4 (p68), generating the p53 form, which can
be found in association with both chondroitin and hep-
aran sulfate on syndecan-1. ADAMTS-4 (p40) is gen-
erated by removal of the spacer region as well as the
cysteine-rich domain, and appears in the medium. Anal-
ysis with specific antibodies shows that MT4-MMP
cleaves at the Lys694-Phe695 and Thr581-Phe582, to
generate the p53 and the p40 form, respectively (Gao
et al., 2004). Modification of synthesis, furin-mediated
activation and/or GPI-anchoring of MT4-MMP may
thus be ways to control ADAMTS-4 activation specif-
ically, in this way preventing the destructive aggre-
canolysis seen in human joint diseases such as arthri-
tis. Therapeutic agents interfering with the association
of ADAMTS-4, MT4-MMP and syndecan-1 on the
cell surface might also be promising in this cartilage-
protecting approach. In addition, if MMP-9 activates
ADAMTS-4 extracellularly, it will be important to es-
tablish which ECM proteins are cleaved by MMP-9-
activated ADAMTS-4, and whether it has an impact on
cartilage turnover in joint diseases.
3.4.3 Multiple Sclerosis
3.4.3.1 Myelin Basic Protein (MBP)
Multiple sclerosis is a chronic neurological disorder
of the central nervous system (CNS), characterised by
the breakdown of the BBB, perivascular infiltration
of inflammatory cells and demyelination. Extracellular
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proteases, such as some MMPs, plasmin and plasmino-
gen activators form an amplification cascade in this au-
toimmune disease by: 1) increasing the permeability
of the BBB; 2) demyelination through degradation of
myelin basic protein (MBP, myelin A1 protein, myelin
membrane encephalitogenic protein), a major compo-
nent of the myelin sheath and one of the most abun-
dant proteins of the CNS; 3) release of antigenic pep-
tides which contribute to autoimmunity; and 4) fa-
cilitating infiltration and migration of immune cells
through the ECM and the basal membrane (Opde-
nakker and Van Damme, 1994; Chandler et al., 1995;
Cuzner and Opdenakker, 1999; Opdenakker and Van
Damme, 2002; Opdenakker et al., 2003). Various MMPs
cause MBP degradation in vitro, the most active en-
zymes on this substrate being MMP-2 and MMP-12,
followed by MMP-3; and by MMP-1, MMP-7, and
MMP-9 with comparable but lesser activity (Proost
et al., 1993; Chandler et al., 1995; Chandler et al., 1996).
MMP-9 activity is detected in the cerebrospinal fluid
of patients with multiple sclerosis and other neurolog-
ical inflammatory disorders (Gijbels et al., 1992). Fur-
thermore, young MMP-9 deficient mice are resistant
to experimental autoimmune encephalomyelitis (EAE),
a murine model for multiple sclerosis (Dubois et al.,
1999). MMP-9 generates encephalitogenic peptides by
cleavage of human MBP at four different sites in vitro:
between Phe90-Lys91, Ser110-Leu111, Phe114-Ser115,
and Asp133-Tyr134 (Proost et al., 1993). Furthermore,
in vivo MBP degradation is also exerted by MMP-9, as
MBP proteolysis after transient focal ischemia is signif-
icantly reduced in MMP-9 knockout mice compared
with wild-types (Asahi et al., 2001).
3.4.3.2 NG2 Proteoglycan
Conversely, besides these disease-promoting roles in
multiple sclerosis, MMP-9 also has a beneficial role af-
ter demyelinating CNS injury. MMP-9 knockout mice
are impaired in myelin reformation after lysolecithin-
induced demyelination. This might be explained by the
role of MMP-9 in the clearance of injury-induced de-
posits of NG2 proteoglycan (chondroitin sulfate pro-
teoglycan NG2, melanoma-associated chondroitin sul-
fate proteoglycan), an inhibitory transmembrane pro-
teoglycan that retards the maturation and differenti-
ation of oligodendrocytes needed for remyelination.
Consequently, MMP-9 is needed for an efficient re-
myelination and in this way also has a reparative func-
tion in multiple sclerosis (Larsen et al., 2003).
3.4.3.3 β-Dystroglycan
Dystroglycan (dystrophin-associated glycoprotein 1) ex-
ists as an extracellular highly glycosylated α-subunit and
a non-covalently associated transmembrane β-subunit,
which are products derived from one gene and result
from posttranslation processing of the glycoprotein.
The α-subunit binds to several extracellular ligands, in-
cluding laminin, agrin, perlecan and neurexin, while
β-dystroglycan connects intracellularly to dystrophin,
which binds to the actin cytoskeleton. Dystroglycan is
expressed in many cell types and the broad range of
ECM ligand partners indicates that it has an impor-
tant role in the assembly and maintenance of basement
membranes (Barresi and Campbell, 2006).
The 43 kDa β-subunit was shown to be processed to a 30
kDa fragment by MMPs, the inhibitor profile pointing
to MMP-2, MMP-9, and MT1-MMP as possible candi-
dates (Yamada et al., 2001). Kaczmarek and coworkers
observed β-dystroglycan breakdown in the brain in re-
sponse to kainate in a temporal pattern parallel to in-
creased MMP-2 and MMP-9 activities (Kaczmarek et al.,
2002). This temporal parallelism of MMP-2 increase
and β-dystroglycan proteolysis was also observed in the
superior cervical ganglion after postganglionic nerve le-
sion (Leone et al., 2005; Paggi et al., 2006). However,
Agrawal and coworkers (2006) were the first to show
that MMP-2 and MMP-9 cleave β-dystroglycan in vitro
as well as in vivo, as they identified β-dystroglycan as
a key substrate of MMP-2 and MMP-9 in EAE. This
study demonstrates that leukocyte cuffing, as it occurs
in human multiple sclerosis, is the consequence of the
containment of leukocytes between the endothelial and
the adjacent parenchymal basement membranes around
the blood vessels in the CNS. Obviously, as long as the
leukocytes are contained by the parenchymal basement
membrane, synthesized by the astrocyte endfeet of the
glia limitans, no disease symptoms occur. Gelatinases,
both MMP-2 and MMP-9, cleave in situ β-dystroglycan
in the parenchymal basement membrane and this pro-
cess coincides with barrier breakdown, infiltration of
the CNS parenchyma by leukocytes and development
of disease symptoms. As a result, double MMP-9 and
MMP-2 knockout mice are completely resistant against
disease development. This cleavage is a critical event,
since this MMP substrate is localized on the inter-
face between the extracellular milieu and the astro-
cytes: its cleavage results in complete desintegration of
the glia limitans structure and function (Agrawal et al.,
2006).
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Proteolysis of β-dystroglycan by MMPs may also con-
tribute to cancer growth and spread (Jing et al., 2004),
as well as to skeletal muscle degeneration in the muscu-
lar diseases sarcoglycanopathy and Duchenne muscular
dystrophy (Matsumura et al., 2005).
Administration of synthetic MMP inhibitors to rodents
with EAE significantly ameliorates clinical symptoms
and pathological signs (Cuzner and Opdenakker, 1999).
Therefore, a major challenge in multiple sclerosis ther-
apy development is the design of selective and spe-
cific MMP inhibitors, taking into account the multiple
disease-affecting functions of some MMPs, like for in-
stance the role of MMP-9 in demyelination as well as
in remyelination (Opdenakker et al., 2003).
3.4.4 Systemic Sclerosis
3.4.4.1 uPAR
Systemic sclerosis (Ssc), also called scleroderma, is a
clinically heterogenous, systemic disorder which affects
the connective tissue of the skin, internal organs and the
walls of blood vessels. It is characterized by alterations
of the microvasculature, disturbances of the immune
system and massive deposition of collagen and other
matrix substances in the connective tissues (Haustein,
2002; Chen et al., 2003). Defective angiogenesis, result-
ing in tissue ischemia, is particularly prominent in the
diffuse form of Ssc. As the u-PA/uPAR system is crit-
ical in angiogenesis (see Section 1.3.1), microvascular
endothelial cells (MVECs) were isolated from the der-
mis of healthy individuals and from the dermis of pa-
tiens with diffuse Ssc to examine u-PA and uPAR levels.
Compared with MVECs from healthy skin, MVECs
from Ssc patiens showed higher expression of uPAR.
However, in Ssc MVECs, uPAR undergoes truncation
between its D1 and D2 domains (see Figure 7), which
impairs u-PA binding to uPAR. These properties of Ssc
MVECs were associated with poor spontaneous and
u-PA-dependent invasion, proliferation, and capillary
morphogenesis. The uPAR cleavage occurring in Ssc
MVECs was associated with overexpression of MMP-
12 and both a general hydroxamate inhibitor of MMP
activity and anti-MMP-12 antibodies restored this Ssc
MVEC-induced impaired functioning (D’Alessio et al.,
2004). In addition, fibroblasts from Ssc patients over-
express MMP-12, which cleaves uPAR of MVECs, thus
contributing to the failure of Ssc-endothelial cells to in-
duce an efficient angiogenic programme (Serrati et al.,
2006). The overexpression of MMP-12 by both Ssc en-
dothelial cells and Ssc fibroblasts indicates that MMP-
12 overproduction may have a critical pathogenic role
in Ssc-associated vascular alterations. Hence, selective
inhibitors of MMP-12 are likely to be efficient at in-
ducing reversal of Ssc-associated lack of angiogenesis,
whereas MMP-12 itself seems disease limiting in cancer
by blocking angiogenesis (see Section 1.3.1).
4. PROTEOLYSIS OF CELL SURFACE
PROTEINS IN NEURODEGENERATIVE
DISORDERS: ALZHEIMER’S DISEASE
Alzheimer’s disease is a neurodegenerative disease of
the CNS associated with progressive loss of recent
memory, resulting in dementia. A clinical diagnosis
of Alzheimer’s disease is confirmed by observing neu-
ritic (amyloid) plaques and neurofibrillary tangles in
the hippocampus, amygdala, and association neocortex
(Selkoe, 2004). The plaques are formed extracellularly
and are composed of the 42- and 40-residue β-amyloid
proteins (Aβs). In healthy individuals, 90% of the Aβs
produced by brain cells throughout life are Aβ40 pep-
tides versus only 10% of Aβ42. In the cortex of mentally
normal elderly patients the Aβ deposits found are al-
most exclusively ‘diffuse’ plaques that seem to represent
the relatively benign precursor lesions. These diffuse
plaques are composed of Aβ42, which is far more prone
to aggregation than the slightly shorter and less hydro-
fobic Aβ40. The Aβ hypothesis predicts that gradual
elevation of Aβ42 levels in brain interstitial fluid, and
perhaps also inside neurons, can lead to the oligomer-
ization of the peptide and eventually to its fibrillization,
that is, amyloid formation. Such insoluble amyloid fib-
rils are characteristic for ‘neuritic’ plaques which are
associated with local microglial activation, astrocytosis,
and cytokine and acute phase protein release. These lo-
cal inflammatory processes and other neurotoxic effects
of oligomerized Aβs finally lead to extensive neuronal
and synaptic dysfunction and neurotransmitter deficits,
which all contribute to memory impairment (Selkoe,
2004; Walsh and Selkoe, 2004).
4.1 Amyloid Precursor Protein (APP)
and β-Amyloid Proteins (Aβs)
Aβ is derived from a membrane-bound Aβ precur-
sor protein (APP, cerebral vascular amyloid peptide
(CVAP), protease nexin-II (PN-II), Alzheimer disease
amyloid protein, PreA4) after sequential cleavages by
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a β-secretase and a γ -secretase (Selkoe, 2004). In nor-
mal processing of APP, the most common cut is carried
out by the α-secretase and occurs between Lys 687 and
Leu 688, that is 12 residues NH2-terminal to the trans-
membrane region, between Lys16 and Leu17 of the Aβ
region (Figure 17). This cleavage creates a large, soluble
ectodomain fragment (sAPPα) that is released from the
cell surface and leaves a COOH-terminal fragment of
83 amino acids embedded in the membrane. APP is also
cleaved between Met671 and Asp672 by a β-secretase,
releasing a slightly shorter fragment of APP (sAPPβ)
and leaving a membrane-embedded COOH-terminus
of 99 amino acids. This 99 amino acid fragment can
then be cleaved by a γ -secretase to create Aβ. In sum-
FIGURE 17 Differential cell surface proteolysis of APP and Aβ leads to accumulation or clearance of pathogenic Aβ peptides in
Alzheimer’s disease. Aβ (β-amyloid protein) is derived from the membrane-bound Aβ precursor protein (mAPP) after sequential cleavages
by a β-secretase and a γ-secretase. However the most common processing of APP is carried out by the α-secretase and occurs between
Lys 687 and Leu 688, that is between Lys16 and Leu17 of the Aβ region. This cleavage creates a large, soluble ectodomain fragment
(sAPPα). A different processing of APP, between Asn579-Met580, is catalyzed by MT1-MMP and MT3-MMP, and releases a COOH-terminally
truncated APP fragment (sAPPtrc) that lacks the MMP-2 inhibitor domain (INH). MT3-MMP cleaves the APP ectodomain at additional
sites: at Ala463-Met464, His622-Ser623, and His685-Gln686, which is near the α-secretase cleavage site. Similar to α-secretase cleavage,
proteolysis of the His685-Gln686 peptide bond destroys the Aβ-sequence, which diminishes pathologic Aβ formation and accumulation.
Once released, Aβ may be cleared by MMP-2 and MMP-9, which cleave it at multiple sites. In addition, MMP-9 has been shown to degrade
Aβ fibrils, by proteolytic cleavage at Phe20-Ala21 and Ala30-Ile31. Adapted from (Higashi and Miyazaki, 2003b).
mary, proteolysis by an α-secretase releases sAPP from
the cell surface, while sequential cleavages by a β- and
a γ -secretase lead to Aβ formation (Selkoe, 2004).
The α-secretase is a membrane-associated metallopro-
teinase, the activity of which is readily inhibited by
hydroxamate-based synthetic inhibitors (Higashi and
Miyazaki, 2003b). Furthermore, release of sAPP is ex-
tremely diminished in fibroblasts from TACE deficient
mice vs. control mice, making TACE a prime candi-
date for the α-secretase activity (Buxbaum et al., 1998).
MMP-2 is capable of processing APP in vitro, but it
is not clear whether the cleavage occurs between Lys
687 and Leu 688, like an α-secretase (Miyazaki et al.,
1993; Miyazaki et al., 1994) or between Glu668-Val669,
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like a β-secretase (LePage et al., 1995). Furthermore, in
vivo studies with MMP-2 knockout mice suggest that
MMP-2 does not play an essential role in the generation
of APP fragments at physiological conditions (Itoh et al.,
1997). MMP-3 was also reported to cleave a synthetic
APP peptide spanning the β-secretase cleavage site at
the residues Glu668-Val669 and Glu674-Phe675 in vitro,
but this was not further investigated (Rapala-Kozik et al.,
1998). APP binds to the ECM and contains an MMP-
2-inhibitory domain, which is located in the COOH-
terminal glycosylated region of the sAPPs (Miyazaki
et al., 1993) within the ISYGNDALMP sequence cor-
responding to the residues 586 to 595 of APP (Hi-
gashi and Miyazaki, 2003a). Another cell-bound MMP
might thus be responsible for APP proteolysis. Cell-
mediated activation of MMP-2 is indeed accompanied
by a different processing of APP, between Asn579 and
Met580, which is catalyzed by MT1-MMP and releases
a COOH-terminally truncated APP fragment (sAPPtrc)
that lacks the MMP-2 inhibitor domain (Figure 17) (Hi-
gashi and Miyazaki, 2003b).
An analogy exists in cancer biology, in which APP pro-
teolysis at the ruffling edge of migrating cancer cells (see
Figure 2) may be another mechanism by which MT1-
MMP promotes migration and invasion (see Section
1.4). It may indeed be suggested that the interplay of
MT1-MMP, sAPPtrc, and MMP-2 takes part in the reg-
ulation of MMP-2-catalyzed ECM degradation. On the
cell surface, where the MT1-MMP concentration is low,
APP is liberated mainly as sAPP that inhibits MMP-2 ac-
tivity. sAPP (as well as APP) binds to the ECM, which
might concentrate and enhance the inhibitory effects
of sAPP, in this way protecting the ECM near the cell
surface from MMP-2 degradation. In contrast, a high
(local) concentration of MT1-MMP converts APP to
sAPPtrc, which displaces ECM-associated APP or sAPP,
thereby removing the MMP-2 inhibitory activity from
the ECM. In addition, MT1-MMP activates MMP-2,
which can then freely exert its proteolytic activity on the
ECM (Higashi and Miyazaki, 2003b). Since autodegra-
dation is a highly critical step in the regulation of MT1-
MMP activity (see Section 1.4.10), excess expression
of substrates such as APP or syndecan-1 may interfere
with the autodegradation and consequently augment
the MT1-MMP activation of MMP-2, further promot-
ing MMP-2 proteolytic action.
However, MT1-MMP is not the only MT-MMP ex-
pressed in the brain as MT3-MMP expression levels
are highest in the brain and localized in microglial
cells in all brain tissues (Takino et al., 1995; Yoshiyama
et al., 1998), whereas MT5-MMP is also present in
all brain tissues, but most strongly expressed in cere-
bellum (Sekine-Aizawa et al., 2001). After cotransfec-
tion, MT3-MMP and MT5-MMP, but not MT2-, MT4-
and MT6-MMP, indeed caused cleavage and shedding
of the APP ectodomain with a fragmentation pattern
almost identical to that of MT1-MMP. MT3-MMP
induced shedding of APP most efficiently, followed
by MT1-MMP and MT5-MMP (Ahmad et al., 2006).
MT3-MMP cleaves the APP ectodomain at multiple
sites that are Ala463-Met464, Asn579-Met580, His622-
Ser623 and His685-Gln686, which is within the Aβ se-
quence (Figure 17), indicating that MT3-MMP could be
an α-secretase. Since the APP fragmentation seen after
cleavage by MT1-MMP, MT3-MMP and MT5-MMP
was almost identical, MT1-MMP and MT5-MMP may
cleave APP at the same sites as MT3-MMP (Ahmad
et al., 2006). As cleavage of APP by an α-secretase de-
stroys the Aβ-sequence, shedding of APP by MT1-,
MT3- and MT5-MMP might mitigate pathologic Aβ
formation and accumulation.
Although familial Alzheimer’s disease appears to be
caused by Aβ overproduction, sporadic Alzheimer’s
disease (the most prevalent form) may be caused by
impaired Aβ clearance. Aβ40 is a potent inducer of
MMP-2, MMP-3 and MMP-9 expression in vitro (Deb
and Gottschall, 1996). Furthermore, MMP-2 is capa-
ble of degrading Aβ40 and Aβ42 in vitro at the Lys16-
Leu17, Leu34-Met35 and Met35-Val36 peptide bonds,
although this does not lead to a complete clearing of
Aβ (Roher et al., 1994). Treatment of cells overexpress-
ing APP with the metal ligand clioquinol and Cu2+ or
Zn2+ resulted in an ∼85 to 90% reduction of Aβ40 and
Aβ42. This loss of Aβ was not caused by altered APP
processing, but was mediated through upregulation of
MMP-2 and MMP-3. Inhibitors of MMP-2 and MMP-3
indeed abrogated the loss of Aβ40 caused by clioquinon
and Cu2+ (White et al., 2006). However, further inves-
tigation will be necessary to determine wether MMP-2-
and MMP-3-mediated cleavage is a rate-limiting step
in the rapid clearance of secreted Aβ in vitro as well
as in vivo. Interestingly, the human hippocampus of
Alzheimer’s disease patients shows increased levels of
pro-MMP-9 near the amyloid plaques (Backstrom et al.,
1996) and the same increase was reported in amyloid-
positive beagle brains (Lim et al., 1997). In addition,
levels of circulating MMP-9 are significantly elevated
in the plasma of Alzheimer’s disease patients compared
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to controls (Lorenzl et al., 2003). MMP-9 processes sol-
uble Aβ40 and Aβ42 in vitro at multiple sites that are
Lys16-Leu17; Phe20-Ala21; Asp23-Val24; Ala30-Ile31;
Gly33-Leu34; Leu34-Met35 and Gly37-Gly38 (Figure
17) (Backstrom et al., 1996; Yan et al., 2006) However,
in contrast to other proteases that also degrade sAβ such
as endothelin-converting enzyme, insulin-degrading en-
zyme, and neprylisin, MMP-9 was the only one to de-
grade Aβ fibrils in vitro. In addition, amorphous struc-
tures suggestive of decomposed fibrils were observed af-
ter incubation with MMP-9. Fibril disruption by MMP-
9 produced Aβ fragment with molecular weights cor-
responding to Aβ20 and Aβ30, suggesting that pro-
teolytic cleavage at Phe20-Ala21 and Ala30-Ile31 may
be important for fibril degradation. MMP-9 was also
shown to degrade compact amyloid plaques in brain
sections from aged APP/presenilin(PS)1 mice. Fibrillar
Aβ in compact plaques is believed to be extremely re-
sistant to degradation and clearance, but growing evi-
dence suggests that endogenous mechanisms for plaque
clearance exist, as amyloid plaque size in brains of AD
patients does not invariably increase with disease du-
ration and in aged APP/swedisch mutation(sw) mice
(overpoducing APPβ), some isolated plaques even de-
crease in size over time. Furthermore, MMP-9 is ex-
pressed in astrocytes surrounding plaques in the brains
of aged APP/PS1 mice, and its activity is specifically
detected in compact plaques (Yan et al., 2006). Thus,
MMP-9 may contribute to clearance of plaques from
amyloid-laden brains. In vivo, significant increases in
the steady-state levels of sAβ were found in the brains
of MMP-2 and MMP-9 deficient mice compared with
wild-type controls. In addition, pharmacological inhi-
bition of the MMPs with the broad-spectrum inhibitor
GM6001 increased brain interstitial sAβ levels and half-
life in APP/sw mice. Under these disease-free steady-
state conditions, gene deletion of mmp-2 appeared to
have a greater effect on brain Aβ levels compared with
mmp-9 gene deletion (Yin et al., 2006). However, it is
possible that under pathological conditions, MMP-9
may play a greater role in Aβ clearance, as its expres-
sion was shown to be increased in astrocytes surround-
ing amyloid plaques, as mentioned above. In summary,
a better understanding of the role of MMPs in the
clearance of extracellular sAβ and in the degradation
of Aβ fibrils in amyloid plaques, may point to alterna-
tive therapeutical approaches that reduce plaque for-
mation and slow down the disease cascade in early
stages.
4.2 FasL
The growing evidence that Aβ accumulation is a deter-
mining factor in Alzheimer’s disease makes it impor-
tant to elucidate the mechanism by which Aβ induces
neuronal cell death. It was shown that Aβ induces neu-
ronal cell apoptosis and that inhibition of FasL and
Fas function led to a decrease in Aβ-induced neuronal
apoptosis (Morishima et al., 2001). As discussed before,
MMP-7 releases sFasL, which is a less potent apoptosis-
inducer than its membrane-bound precursor (see Sec-
tion 1.2.1). Whereas treatment of neuronal cell cultures
with sAβ alone increased the appearance of morpho-
logically apoptotic cells and nuclei, addition of MMP-7
increased sFasL shedding in the culture media and com-
peletely protected neuron cultures from Aβ toxicity
(Ethell et al., 2002). Hence, FasL shedding by MMP-7 is
another important MMP-mediated proteolytic process
at the cell surface. Factors that affect this shedding pro-
cess may play a role in the progression of Alzheimer’s
disease and may provide an avenue for therapeutic in-
tervention.
5. MEMBRANE-ASSOCIATED
PROTEOLYSIS IN REPRODUCTIVE
ENDOCRINOLOGY
5.1 LRP
Similar to the intense tissue remodelling associated with
cancer progression, the human endometrium under-
goes cyclic growth and tissue remodelling throughout
the reproductive life of women, with the succession of
proliferative, secretory, and menstrual phases. In this
rapidly changing environment, successful embryo im-
plantation requires a tight control of the integrity of
the endometrial tissue at the early and mid-secretory
phase. This implies a strict control of u-PA and MMPs,
which are repressed by progesterone. As discussed be-
fore (see Section 1.4.9), LRP-mediated internalization
of proteases is an important regulation mechanism for
proteolytic activity at the cell surface. Interestingly, the
expression of LRP mRNA also varies during the men-
strual cycle, with a significant increase from the prolif-
erative to the secretory phase, when progesterone con-
centration is the highest, possibly promoting further re-
pression of MMP acitivity (Emonard et al., 2005). Fur-
thermore, LRP is an important molecule during em-
bryonic development (Herz et al., 1992). LRP is highly
expressed in the placenta and increased levels of soluble
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LRP (sLRP) were detected in cord blood from healthy
pregnancy. While sLRP release from BeWo choriocarci-
noma cells is prevented by the hydroxamic acid com-
pound, INH-38SS-PI (Quinn et al., 1999), the cleavage
is not mediated by MT-MMPs as it involves endopro-
teolysis of the membrane-spanning β-chain (LRP-85),
whereas MT-MMPs cleave in the COOH-terminal part
of the α-chain (LRP-515) (see Section 1.4.9 and Figure
10) (Rozanov et al., 2004a). In addition, the metallo-
proteinase responsible for the cleavage is not induced
by PMA. The BeWo cell line, which is derived from a
human gestational choriocarcinoma, displays morpho-
logical and functional characteristics of both invasive
cytotrophoblast and syncytiotrophoblast. The release of
biologically active sLRP by trophoblast cells may have
implications regarding the biology of the placenta. The
pattern of LRP expression in the placenta is consistent
with roles for the receptor in trophoblast invasion, a
tightly regulated process that involves the coordinated
activation of proteases and the transport of cholesterol.
In term placenta, LRP is expressed in the syncytium,
which comprises the maternal-fetal interface. Increased
levels of sLRP in cord blood may reflect cellular dys-
function and increased metalloproteinase activity at this
important interface (Quinn et al., 1999). Hence, further
investigation into the release of sLRP and its interaction
with cellular LRP might be of interest to predict or mon-
itor complications during embryonic development.
5.2 HB-EGF
Transmembrane and soluble HB-EGF have a crucial
role in some events of female reproduction biology.
Firstly, in blastocyst implantation, mHB-EGF, but not
sHB-EGF, has been shown to promote adhesion be-
tween the blastocyst and the uterine wall, whereas sHB-
EGF has been reported to induce an increase in blas-
tocyst number and an increase in the rate of blastocyst
zona pellucida hatching (Raab and Klagsbrun, 1997;
Iwamoto and Mekada, 2000). Furthermore, cleavage of
mHB-EGF by MMP-7 and the subsequent activation of
ErbB4/HER4 by sHB-EGF appear to play a role in the
regulation of postpartum uterine and lactating mam-
mary gland involution and maintenance of lactation.
CD44 plays a key role in this TMPS (by assembling
MMP-7, mHB-EGF and ErbB4 in a cell surface com-
plex (see Section 1.4.7 and Figure 9) (Yu et al., 2002).
Moreover, release of sHB-EGF by MMP-2 and MMP-
9 is a crucial step in neuroendocrine regulation by the
gonadotropin-releasing hormone (GnRH) which regu-
lates the synthesis and secretion of the gonadotropins
luteinizing hormone (LH) and follicle stimulating hor-
mone (FSH) in the pituitary gland. Inhibition of MMP-
2 and MMP-9 by selective inhibitors (Ro28–2653) or
by specific ribozymes indeed blocks transactivation of
the EGFR, induced by the binding of GnRH to its re-
ceptor (a GPCR) (Roelle et al., 2003; Shah et al., 2004).
MT1-MMP comes out as an additional player in this
TMPS through the activation of MMP-2 (Shah and
Catt, 2004c). Similar to GnRH, the steroid hormone
estradiol (E2) also binds GPCRs, an alternative type of
estrogen receptors, and rapidly stimulates signal trans-
duction through transactivation of the EGFR. In this
TMPS sHB-EGF release is also mediated by MMP-2
and MMP-9 (Razandi et al., 2003). Thus, ectodomain
cleavage of HB-EGF by MMPs is a crucial event in the
regulation of some neuroendocrine and reproductive
functions.
5.3 Occludin
In the low-resistance human vaginal-cervical epithelia,
occludin is present in two main forms: the full-length
65 kDa wild-type isoform, and a truncated 50 kDa form.
A shift from 65 kDa to 50 kDa can be induced by
treatment with estrogen and is associated with a re-
versible decrease in the resistance of the tight junctions.
MMPs were already described as being responsible for
TABLE 3 pro-TNF-α cleavage sites
Protease Cleavage site(s) Test system References
TACE Ala76-Val77 In vitro and
in vivo
3
MMP-1 Ala74-Gln75 and
Ala76-Val77
In vitro 1,2,3
MMP-2 Not defined In vitro 1,2
MMP-3 Not defined In vitro 1,2,3
MMP-7 Ala76-Val77 In vitro and
ex vivo
1,2,3,6
MMP-9 Ala74-Gln75 In vitro 1,2,3
MMP-12 Ala74-Gln75 and
Ala76-Val77
In vitro and
in vivo
7,8
MT1-MMP Ala76-Val77 and
before Leu113
In vitro 4
MT2-MMP Ala76-Val77 and
before Leu113
In vitro 4
MT4-MMP Ala74-Gln75 In vitro 5
1, (Gearing et al., 1994); 2, (Gearing et al., 1995); 3, (Mohan et al.,
2002); 4, (d’Ortho et al., 1997);
5, (English et al., 2000); 6, (Haro et al., 2000b); 7, (Chandler et al.,
1996); 8, (Churg et al., 2003).
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TABLE 4 Potential membrane-bound MMP and MP substrates
Substrate1 CD Inhibitor Specificity2 Reference
ACE CD143 EDTA, O-phen MP (Parvathy et al., 1997)
Batimastat (BB-94) Broad spectrum MMP and TACE
TAPI-2 Zn2+-dependent MP
TAPI(-1) Collagenase, gelatinase, ADAM-10,
TACE
(Schwager et al., 1998;
Schwager et al., 1999)
ANF-R / EDTA MP (Abe and Misono, 1992)
AR / Batimastat (BB-94) Broad spectrum MMP and TACE (Vecchi et al., 1998;
Brown et al., 1998)
C1qRp CD93 O-phen MP (Bohlson et al., 2005)
Not inhibited by:
TAPI-1, TAPI-2 and
the broad spectrum
MMP inhibitors
Ro-31–9790,
Ro-32–7315
CD27 CD27 GI5402 MMP-1,-3,-9,-13 and TACE (Dekkers et al., 2000)
CD30 CD30 EDTA, O-phen MP (Parvathy et al., 1997)
(Hansen et al., 1995;
Hooper et al., 1997)
BB2116 MMP-3, -7, -2, -9
CD40L CD154 EDTA MP (Furman et al., 2004;
Otterdal et al., 2004)
Ilomastat (GM6001) Broad spectrum MMP and TACE
KB8301 Zn2+-dependent MP (Kato et al., 1999;
Jin et al., 2001)
Batimastat (BB-94) Broad spectrum and TACE
c-Met / TIMP-3 Broad spectrum MMP
ADAM-10, -12, -17, -19
ADAMTS-4 and -5 (Nath et al., 2001)
Batimastat (BB-94) Broad spectrum MMP and TACE
Not inhibited by
TIMP-1 and TIMP-2
CXCL16 / Ilomastat (GM6001) Broad spectrum MMP and TACE (Hara et al., 2006)
MMP inhibitor III∗ Broad spectrum MMP
Desmocollin-3 / FN-439 (MMP
inhibitor I∗)
MMP-1, MMP-8 > MMP-9 > MMP-3 (Weiske et al., 2001)
Not inhibited by
TAPI(-1)
Desmoglein-1 / TAPI-0 Collagenase, gelatinase, TACE (Dusek et al., 2006)
FN-439 (MMP
inhibitor I∗)
MMP-1, MMP-8 > MMP-9 > MMP-3
Ilomastat (GM6001) Broad spectrum MMP and TACE
Desmoglein-3 / FN-439 (MMP
inhibitor I∗)
MMP-1, MMP-8 > MMP-9 > MMP-3 (Weiske et al., 2001)
Not inhibited by
TAPI(-1)
EGF / EDTA, EGTA MP (Dempsey et al., 1997)
Batimastat (BB-94) Broad spectrum MMP and TACE
FcyRIII CD16 GI5402 MMP-1,-3,-9,-13 and TACE (Dekkers et al., 2000)
O-phen MP (Bazil and Strominger,
1994) (Galon et al.,
1998)
RU36156 MMP-8, MMP-9 and TACE (Galon et al., 1998;
Mota et al., 2004)
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TABLE 4 Potential membrane-bound MMP and MP substrates (Continued)
Substrate1 CD Inhibitor Specificity2 Reference
FcεRII CD23 O-phen MP (Bailey et al., 1998)
Batimastat (BB-94) Broad spectrum MMP and TACE
Folate-R / EDTA, O-phen MP (Elwood et al., 1991)
GHR / BB-3103 Broad spectrum MMP and TACE (Amit et al., 2001)
Ro31-9790 Broad spectrum MMP and TACE
GM-CSF-Rα CD116 Batimastat (BB-94) Broad spectrum MMP and TACE (Prevost et al., 2002)
GP VI / TAPI(-1) Collagenase, gelatinase, ADAM-10,
TACE
(Stephens et al., 2005)
Ilomastat (GM6001) Broad spectrum MMP and TACE
HER2 CD340 TIMP-1 Soluble MMPs (Codony-Servat et al.,
1999; Molina et al.,
2001)
TAPI(-1) Collagenase, gelatinase, ADAM-10,
TACE
Batimastat (BB-94) Broad spectrum MMP and TACE
HER4 / Batimastat (BB-94) Broad spectrum MMP and TACE (Vecchi et al., 1998)
IL-1RII CD121b Batimastat (BB-94) Broad spectrum MMP and TACE (Penton-Rol et al.,
1999)
IL-4R CD124 O-phen MP (Jung et al., 1999)
IL-6Rα CD126 TAPI(-1) Collagenase, gelatinase, ADAM-10,
TACE
(Mullberg et al., 1995)
RU36156 MMP-8, MMP-9 and TACE (Gallea-Robache et al.,
1997)
TAPI-2 Zn2+-dependent MP (Arribas et al., 1996)
O-phen MP
LDL-R / EDTA, EGTA MP (Begg et al., 2004)
TAPI(-1) Collagenase, gelatinase, ADAM-10,
TACE
Leukosialin CD43 O-phen MP (Bazil and Strominger,
1994)
LIGHT CD258 EDTA MP (Otterdal et al., 2006)
Ilomastat (GM6001) Broad spectrum MMP and TACE
M-CSF / RU36156 MMP-8, MMP-9 and TACE (Gallea-Robache et al.,
1997)
Megalin / MMP inhibitor III∗ Broad spectrum MMP (Zou et al., 2004)
TAPI(-1) Collagenase, gelatinase, ADAM-10,
TACE
TAPI-2 Zn2+-dependent MP
MICA / Batimastat-derivative Zn2+-dependent MP (Salih et al., 2002)
MICB / Batimastat-derivative Zn2+-dependent MP (Salih et al., 2006)
MMR-1 CD206 BB2116 MMP-3, -7, -2, -9 (Martinez-Pomares
et al., 1998)
N-CAM L1 CD171 BB-3103 Broad spectrum MMP and TACE (Mechtersheimer et al.,
2001)
Ro-31-9790 Broad spectrum MMP and TACE
TAPI(-1) Collagenase, gelatinase, ADAM-10,
TACE
(Beer et al., 1999;
Gutwein et al., 2005)
Nectin-1α CD111 O-phen MP (Tanaka et al., 2002)
Batimastat (BB-94) Broad spectrum MMP and TACE
KB-R7785 MMP-1,-2,-3,-9,-14
TACE, ADAM12
Netrin-1 / Ilomastat (GM6001) Broad spectrum MMP and TACE (Galko and
Tessier-Lavigne, 2000)
TAPI-2 Zn2+-dependent MP
(Continued on next page)
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TABLE 4 Potential membrane-bound MMP and MP substrates (Continued)
Substrate1 CD Inhibitor Specificity2 Reference
NGF-R / EDTA, O-phen MP (Diaz-Rodriguez et al.,
1999)
TAPI-2 Zn2+-dependent MP
NKR BY55 CD160 O-phen MP (Giustiniani et al., 2007)
PECAM-1 CD31 Ilomastat (GM6001) Broad spectrum MMP
and TACE
(Ilan et al., 2001)
MMP-2/MMP-9
Inhibitor I∗
MMP-2, MMP-9
NNGH (MMP-3
Inhibitor II∗)
MMP-3
MMP-8 Inhibitor∗ MMP-8
PSGL-1 CD162 EDTA MP (Davenpeck et al., 2000)
Not inhibited by:
O-phen, Batimastat
and Marimastat
Sialophorin CD43 O-phen MP (Bazil and Strominger,
1994)
SorLA / BB-3103 Broad spectrum MMP
and TACE
(Hampe et al., 2000)
SRCR M130 CD163 TAPI-0 MMP-1, MMP-9, TACE (Hintz et al., 2002)
Syndecan-3 / BB-3103 Broad spectrum MMP
and TACE
(Asundi et al., 2003)
Batimastat (BB-94) Broad spectrum MMP
and TACE
pro-TGF-α / RU36156 MMP-8, MMP-9 and
TACE
(Gallea-Robache et al.,
1997)
TAPI-2 Zn2+-dependent MP (Arribas et al., 1996)
TAPI(-1) Collagenase,
gelatinase, ADAM-10,
TACE
(Shao et al., 2004)
O-phen MP (Arribas et al., 1996)
Batimastat (BB-94) Broad spectrum MMP
and TACE
(Merlos-Suarez et al.,
2001)
Ilomastat (GM6001) Broad spectrum MMP
and TACE
(Yoshisue and
Hasegawa, 2004;
Shao et al., 2004)
Marimastat
(BB-2516)
Broad spectrum MMP
and TACE
Tie-1 / EGTA Ca2+-dependent MP (Yabkowitz et al., 1999)
BB-24 Zn2+-dependent MP
Not inhibited by:
TIMP-2
TNF-R55/60 CD120a TAPI(-1) Collagenase,
gelatinase, ADAM-10,
TACE
(Mullberg et al., 1995)
RU36156 MMP-8, MMP-9 and
TACE
(Gallea-Robache et al.,
1997)
BB-2275 Zn2+-dependent MP (Williams et al., 1996)
TNF-R75/80 CD120b TAPI(-1) Collagenase,
gelatinase, ADAM-10,
TACE
(Crowe et al., 1995)
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TABLE 4 Potential membrane-bound MMP and MP substrates (Continued)
Substrate1 CD Inhibitor Specificity2 Reference
RU36156 MMP-8, MMP-9 and
TACE
(Gallea-Robache et al.,
1997)
TSHR / BB2116 MMP-3, -7, -2, -9 (Couet et al., 1996;
Misrahi and Milgrom,
1997;
de Bernard et al., 1999)
Not inhibited by
TIMP-1, TIMP-2
(de Bernard et al., 1999)
ULBP2 / Batimastat (BB-94) Broad spectrum MMP
and TACE
(Waldhauer and
Steinle, 2006)
MMP inhibitor III∗ Broad spectrum (Waldhauer and
Steinle, 2006)
VCAM-1 CD106 Marimastat
(BB-2516)
Broad spectrum MMP
and TACE
(Hummel et al., 2001)
VPR V2 / O-phen MP (Kojro and Fahrenholz,
1995)
1Substrate acronyms: ACE, angiotensin-converting enzyme; ANF-R, atrial natriuretic factor receptor; C1qRp, complement component 1 q subcompo-
nent receptor 1; AR, amphiregulin; c-Met, met proto-oncogene TKR; CXCL16, transmembrane chemokine CXCL16; FcyRIII, low affinity Ig γ Fc receptor III;
FcεRII, low affinity Ig ε Fc receptor II; GHR, growth hormone receptor; GM-CSF-Rα, granulocyte-macrophage colony-stimulating factor receptor α chain;
GP VI, glycoprotein VI; HER4, Tyrosine kinase-type cell surface receptor HER4; IL -R, interleukin receptor; LDL-R, low-density lipoprotein receptor; LIGHT, ho-
mologous to lymphotoxins, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator, a receptor
expressed by T lymphocytes; M-CSF, macrophage-colony stimulating factor; MICA/B, MHC class I chain-related gene A/B; MMR-1, Macrophage mannose
receptor-1; N-CAM L1, neural cell adhesion molecule L1; NGF-R, nerve growth factor receptor; NKR BY55, NK cell receptor BY55; NNGH, N-Isobutyl-N-(4-
methoxyphenylsulfonyl)-glycylhydroxamic acid; O-phen, 1,10-phenantroline; PECAM-1, platelet endothelial cell adhesion molecule-1; PSGL-1, P-selectin
glycoprotein ligand-1; -R, receptor; SorLA, sorting protein-related receptor containing LDL-R class A repeats; SRCR M130, scavenger receptor cysteine-rich
type 1 protein M130; TAPI, TNF-α Protease Inhibitor; Tie-1, tyrosine kinase receptor tie-1; TSHR, thyrotropin receptor; ULBP2, UL16-binding protein 2;
VCAM-1, Vascular cell adhesion molecule-1; VPR V2, V2 vasopressin receptor. Additional acronyms can be found in the list of abbreviations.
2Inhibitor specificities: for detailed information, the reader is referred to the reviews (Kontogiorgis et al., 2005), (Sang et al., 2006) and (Whittaker
et al., 1999).
∗Additional information on the inhibitor structure and characteristics can be found at http://www.merckbiosciences.co.uk/home.asp.
occludin degradation and increased permeabilization
of endothelial cell and epithelial sheets (see Section
2.2 and Figures 14 to 16). Treatment of human nor-
mal vaginal-cervical cells with natural doses of 17β-
estradiol upregulated activation of MMP-7 intracellu-
larly, in the Golgi network, and augmented secretion
of activated MMP-7. This MMP-7 was shown to be
necessary and sufficient to produce estrogen-mediated
decrease of tight junctional resistance and extracellu-
lar modulation of occludin. Hence, MMP-7-mediated
proteolysis of occludin might be an essential step in
the estrogen modulation of paracellular permeability in
vivo (Gorodeski, 2007).
6. POTENTIAL CELL
SURFACE-ASSOCIATED MMP
SUBSTRATES
Processing of various membrane-bound molecules
is inhibited by metalloproteinase-specific inhibitors,
although the involved metalloproteinase has not been
identified yet. These substrates have been grouped in
Table 4 with the protease inhibitor profiles and the
inhibitor specificities. As discussed before, the inhibi-
tion pattern of a proteolytic process yields informa-
tion on the involved enzyme(s) or protease class(es).
Ectodomain shedding of a whole array of membrane-
bound molecules is inhibited by the non-specific cation
chelators EDTA, EGTA, and 1,10-phenantroline (e.g.,
ANF-R, IL-4R, leukosialin). It is relevant to notice that
the affinity of EDTA is higher for light metal cations,
whereas 1,10-phentroline favours the binding of heavy
metal cations. In addition, EGTA preferentially chelates
Ca2+ ions, thus inhibiting Ca2+-dependent proteases.
Broad-spectrum MMP inhibitors, such as most hydrox-
amates, also inhibit TACE and other ADAMs. Hence, a
shedding process inhibited by batimastat, marimastat,
GM6001, etc. is not necessarily mediated by an MMP
and requires further investigation of the protease(s) in
charge (e.g.,desmoglein-1, HER4, megalin, VCAM-1).
Along this line, inhibition by TIMPs does not guaran-
tee that the cleaved molecule is an MMP substrate, as
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TABLE 5 Cell surface MMP substrates without transmembrane domain
Substrate Type of cell membrane association Cleaving MMP Reference
ADAMTS-4 Association with chondroitin and
heparan sulfate chains on
syndecan-1
MMP-9, MMP-13 (Tortorella et al., 2005)
MT4-MMP (Gao et al., 2002;
Gao et al., 2004)
C3b Amide and ester bonds with cell
surface molecules
MT1-MMP (Rozanov et al., 2004b)
C4b Amide and ester bonds with cell
surface molecules
MT1-MMP (Rozanov et al., 2004b)
Galectin-3 Binding to IgE and multiple cell
surface molecules
MMP-2, MMP-9 (Ochieng et al., 1994; Ochieng
et al., 1998)
Galectin-9 Binding to cell surface molecules ND MMP (Chabot et al., 2002)
KiSS protein Complex with pro-MMP-2,-9 MMP-2,-9
MT1-, MT3-, MT5-MMP (Takino et al., 2003)
pro-TGF-β ECM association MMP-2,-3,-9
MT1-MMP (Yu and Stamenkovic, 2000)
tTG Binding to integrins MT1-MMP, MMP-2
MT2-, MT3-MMP (Belkin et al., 2001;
Belkin et al., 2004)
ApoE Complex with pro-MMP-2 MT1-MMP, MMP-7 (Aoki et al., 2005)
gC1qR Binding to the hemopexin domain
of MT1-MMP
MT1-MMP (Rozanov et al., 2002)
apoE, apolipoprotein E; C3b, complement component 3b; C4b, complement component 4b; gC1qR, receptor of complement component 1q.
TIMP-3 inhibits various ADAMs and some proteases of
the ADAMTS family (see Table 1). However, some con-
clusions can be drawn from a TIMP inhibition pattern.
As TIMP-2 and TIMP-4 only inhibit MMPs, inhibition
or absence of inhibition by these TIMPs, respectively,
identifies or rejects MMPs as the operating sheddases
(e.g.,c-Met, tie-1, TSHR). A metalloprotease inhibited
by TIMP-1 is likely to be an (MT-)MMP, as ADAM-
10 is the only non-MMP to be inhibited (e.g.,HER2).
Thus, as long as few specific MMP inhibitors exist, par-
ticular care must be taken when drawing conclusions
about the identity of the sheddase. Additional cell sur-
face molecules that are modulated by ectodomain shed-
ding have been described (Hooper et al., 1997; Blobel,
2000; Dello and Rovida, 2002; Arribas and Borroto,
2002; Garton et al., 2006).
Finally, some MMP substrates without transmembrane
domain are located at the cell surface by receptor bind-
ing, by a membrane vesicle, a membrane-bound pro-
teoglycan or another transmembrane protease. For that
reason, these have not all been discussed in detail in
the above survey. Some examples of such cell surface-
associated proteins are galectin-3 and -9 (Ochieng et al.,
1994; Ochieng et al., 1998; Chabot et al., 2002); tTG
(Belkin et al., 2001; Belkin et al., 2004); the KiSS pro-
tein/metastin (Takino et al., 2003); pro-TGF-β (Yu and
Stamenkovic, 2000); ADAMTS-4 (Gao et al., 2004); the
complement components C3b and C4b (Rozanov et al.,
2004b); apolipoprotein E (Aoki et al., 2005) and gC1qR,
the receptor of complement component 1q (Rozanov
et al., 2002) (Table 5).
CONCLUSION
Due to the rapid development of innovative biochemi-
cal techniques and the expanding use of transgenic and
knockout animals, it became obvious that the action ra-
dius of MMPs is not restricted to massive ECM destruc-
tion in physiological tissue remodelling and pathologi-
cal tissue degradation. Identification of specific matrix—
as well as non-matrix—components as MMP substrates
showed that MMPs also play significant roles in highly
complex processes such as the regulation of cellular be-
havior, cell-cell communication and tumor progression
(McCawley and Matrisian, 2001). An extended variety
of bioactive molecules is modified by MMPs in partic-
ular physiopathological processes (Sternlicht and Werb,
2001).
The above survey points out that MMPs do not only
cleave multiple soluble substrates, but also process a
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whole array of membrane-bound proteins. These pro-
teolytic events on the cell surface may have extremely
diverse biological implications (see Table 2), ranging
from maturation (e.g.,pro-α integrin subunits), activa-
tion (e.g.,PAR1) and potentiation (HER2) of a cell sur-
face component, to its inactivation (e.g.,syndecan-1)
or even its degradation (e.g.,NG2 proteoglycan and β-
dystroglycan). Besides the regulation of cell-bound ac-
tivity, ectodomain proteolysis of substrates may also be
required for the diffusion of the reaction product(s) into
the extracellular environment to facilitate receptor ac-
tivation on adjacent or even more distal cells (e.g.,pro-
TNF-α and RANKL). In addition, a liberated receptor
fragment might as well possess inhibitory power by act-
ing as a soluble decoy receptor that binds soluble lig-
ands, preventing their interaction with the cell-bound,
signal-transducing receptor (e.g.,FGFR-1).
Through these distinct effects on the biological activity
of the substrates, proteolysis of cell surface proteins by
MMPs has a major impact on a multitude of physio-
logical functions, as well as on onset and evolution of
many diseases. In addition, MMP activity itself can be
directly regulated by proteolysis of cell surface proteins.
For instance, MMPs cleave their membrane-bound in-
ducer, EMMPRIN, allowing the active fragment to in-
duce MMP activity in adjacent cells or in more distal
tissues. Conversely, they also modulate their own inter-
nalization and degradation by degrading their scavenger
receptor, LRP, assuring sustained MMP activity. Finally,
MMPs can terminate their own activity by autocatalytic
proteolysis.
Inhibition of MMPs seems to be the ideal solution in
many pathologies. However, the enthusiasm generated
by a large number of in vitro and in vivo studies has
been dramatically mitigated in recent years by the fail-
ure of MMP inhibitors to block tumor progression in
clinical trials (Coussens et al., 2002). This fiasco could
be explained partly by the fact that inhibitors were ad-
ministered only to late-stage cancer patients, whereas
proteases are often involved in early stages of tumor pro-
gression. In addition, the lack of selectivity and speci-
ficity of inhibitors is a problem, as tumor invasion and
metastasis require the concerted action of particular
MMPs. However, as stated by Del Rosso and coworkers
(2005), our understanding of protease-environment in-
teractions is far from exhaustive. The initial, naı¨ve view
of proteases acting in the soluble phase has evolved into
a kaleidoscope of images in which proteolytic reactions
in tissue remodelling mostly occur at, and are modu-
lated by, the cell surface. As a consequence, insight in
the modification of cell surface proteins by MMPs and
the associated implications, is essential to elucidate the
cross-talk between proteases at the cell surface and with
the extracellular environment. In conclusion, starting
with the exploration of the cell surface could become a
prerequisite in the succesful development of new MMP
inhibitors and innovative therapeutic approaches for
cancer and inflammatory diseases.
ABBREVIATIONS
Aβ , β-amyloid protein; ACE, angiotensin-converting
enzyme; ADAM, a disentegrin and metalloproteinase;
ADAMTS, a disentegrin and metalloproteinase with
thrombospondin-like motif; ANF-R, atrial natriuretic
factor receptor; AP, alkaline phosphatise; ApoE,
apolipoprotein E; APP, amyloid precursor protein;
AR, amphiregulin; ARF, acute renal failure; BBB,
blood-brain barrier; BP, bullous pemphigoid; BP-
180, BP antigen-2; BRB, blood-retinal barrier; C1qRp,
complement component 1 q subcomponent recep-
tor 1; C3b/4b, complement component 3b/4b; CD,
cluster of differentiation of human (glyco)proteins;
CD44ICD, intracellular domain of CD44; c-Met, met
proto-oncogene TKR; CNS, central nervous system;
CTL, cytotoxic T cell; EAE, experimental autoimmune
encephalomyelitis; E-cadherin, epithelial cadherin;
ECM, extracellular matrix; EDTA, ethylenediaminete-
traacetic acid; EGF(R), epidermal growth factor (re-
ceptor); EGTA, ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid; EMMPRIN, extracellular
matrix metalloproteinase inducer; FasL, Fas ligand;
FcyRIII, low affinity Ig γ Fc receptor III; FcεRII, low
affinity Ig ε Fc receptor II; FGF, fibroblast growth
factor; FGFR-1, FGF receptor-1; gC1qR, receptor
of complement component 1q; GHR, growth hor-
mone receptor; GM-CSF-Rα, granulocyte-macrophage
colony-stimulating factor receptor α chain; GnRH,
gonadotropin-releasing hormone; GP VI, glycopro-
tein VI; GPCR, G protein-coupled receptor; GPI, gly-
cosyl phosphatidylinositol; HB-EGF, heparin-binding
epidermal growth factor-like growth factor; HER2/4,
tyrosine kinase-type cell surface receptor HER2/4;
ICAM-1, intercellular adhesion molecule-1; ICE, IL-
1β-converting enzyme; Ig, immunoglobulin; IL- (R),
interleukin- (receptor); IL-1β , interleukin-1β; KitL, Kit
ligand; KS, keratoconjunctivitis sicca; LDL(-R), low
density lipoprotein (receptor); LIGHT, homologous to
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lymphotoxins, exhibits inducible expression, and com-
petes with herpes simplex virus glycoprotein D for
herpes virus entry mediator, a receptor expressed by
T lymphocytes; LPS, lipopolysaccharide; LR, 34/67
kDa laminin receptor; LRP, low-density lipoprotein
receptor-related protein; L-selectin, leukocyte-selectin;
m-, membrane-bound; MBP, myelin basic protein;
M-CSF, macrophage-colony stimulating factor; MEVC,
microvascular endothelial cell; MICA/B, MHC class
I chain-related gene A/B; MMP, matrix metallo-
proteinase; MMR-1, macrophage mannose receptor-
1; MP, metalloproteinase; MT-MMP, membrane-type
MMP; MUC1, mucin-1; N-cadherin, neuronal cad-
herin; N-CAM L1, neural cell adhesion molecule L1;
NE, neutrophil elastase; NGF-R, nerve growth factor
receptor; NK cell, natural killer cell; NKR BY55, NK
cell receptor BY55; PAR1, protease-activated receptor-
1; PC, proprotein convertase; PDGF, platelet-derived
growth factor; PDR, proliferative diabetic retinopathy;
PECAM-1, platelet endothelial cell adhesion molecule-
1; PLAD, preligand assembly domain; PMA, phorbol
12-myristate 13-acetate; PSGL-1, P-selectin glycopro-
tein ligand-1; PVR, proliferative vitreoretinopathy; -R,
receptor; RANK(L), receptor activator of nuclear fac-
tor κB (ligand); s-, soluble; SDF-1, stromal cell-derived
factor-1; SorLA, sorting protein-related receptor con-
taining LDL-R class A repeats; SP-D, surfactant protein-
D; SRCR M130, scavenger receptor cysteine-rich type
1 protein M130; Ssc, systemic sclerosis; TACE, TNF-
α-converting enzyme; TAPI, TNF-α protease inhibitor;
TGF-α/β , transforming growth factor-α/β; Tie-1 , tyro-
sine kinase receptor tie-1; TIL, tumor infiltrating lym-
phocyte; TIMP, tissue inhibitor of metalloproteinases;
TKR, tyrosine kinase receptor; TMD, transmembrane
domain; TMPS, triple membrane-passing signal mecha-
nism; TNF-α, tumor necrosis factor-α; t-PA, tissue-type
plasminogen activator; TSHR, thyrotropin receptor;
tTG, tissue transglutaminase; ULBP2, UL16-binding
protein 2; u-PA, urokinase-type plasminogen activa-
tor; uPAR, urokinase-type plasminogen activator recep-
tor; VCAM-1, vascular cell adhesion molecule-1; VE-
cadherin, vascular endothelial-cadherin; VEGF, vascu-
lar endothelial growth factor; VPR V2, V2 vasopressin
receptor; X, Xenopus.
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Matrix metalloproteinases (MMPs) are classically associated with the turnover of secreted
structural and functional proteins. Although MMPs have been shown to process also a
kaleidoscope of membrane-associated substrates, little is known about the processing of
intracellular proteins by MMPs. Physiological and pathological cell apoptosis, necrosis and
tumor lysis by chemotherapy, radiotherapy or immunological cytotoxicity, are examples of
conditions inwhich an overload of intracellular proteins becomes accessible to the action of MMPs.
We used a model system of dying human myelomonocytic cells to study the processing of
intracellular protein substrates by gelatinase B/MMP-9 in vitro. Adenylyl cyclase-associated
protein-1 or CAP1was identified as a novel andmost efficient substrate of gelatinase B/MMP-9. The
presence of CAP1 in the extracellular milieu in vivowas documented by analysis of urine of patients
with systemic autoimmune diseases. Whereas no active MMP-9 could be detected in urines of
healthy controls, all urine samples of patients with clinical parameters of renal failure contained
activated MMP-9 and/or MMP-2. In addition, in some of these patients indications of CAP1
cleavage are observed, implying CAP1 degradation in vivo. The high turnover rate of CAP1 byMMP-
9, comparable to that of gelatin as the natural extracellular substrate of this enzyme, may be critical
to prevent pathological conditions associated with considerable cytolysis.
© 2008 Elsevier Inc. All rights reserved.
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Introduction
Matrix metalloproteinases or MMPs are notably known for their
cleavage of extracellular matrix components. In addition, they play
critical regulatory functions by the proteolytic release of signaling
molecules and by the modification of the biological functions of
e.g. hormones, cytokines and chemokines [1]. With the develop-
ment of knock-out and knock-in mice, recombinant MMPs, and
selective inhibitors, it becomes possible to determine biologically
relevant substrates of particular MMPs [2]. In this way, a whole
range of membrane-associated substrates, including adhesion
molecules, mediators of apoptosis, receptors, chemokines, cyto-
kines, growth factors, proteases, intercellular junction proteins,
and structural molecules has been identified [3]. An unanswered
question is whether intracellular proteins are biological MMP
substrates, i.e. whether conditions exist in which such proteolysis
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is useful or necessary to maintain the integrity of the host. When
tissues or cells are damaged by trauma or other stress factors, such
as mechanical (crush lesions), thermal (burns and frost), infections
(viruses), inflammatory (reactive oxygen intermediates), (bio-)
chemical (toxins), oxygen or nutrient deprivation, or even genetic
factors (e.g. cytotoxicity in storage diseases), necrosis or apoptosis
mechanisms initiate a cascade of events leading to degradation of
cellular macromolecules and macromolecular complexes, and to
recycling mechanisms. In all these conditions extracellular pro-
teases in the stroma or other body compartments may access
intracellular substrates. Similarly, during normal physiological
processes such as development, thymic selection and when
endogenous cancer cells are eliminated by cytotoxic natural killer
cells or T lymphocytes, the complete set of (glyco)proteins,
including intracellular ones, must be degraded. Intracellular
MMP substrates have been found in some studies, but the
physiological or pathological roles of these cleavages have not
always been clarified. Examples are the proteolysis of the
intraneuronal protein SNAP-25 by MMP-7 [4] and the cleavage of
poly-(ADP-ribose)-polymerase (PARP) by MMP-2 [5]. An interest-
ing group of intracellular MMP substrates are the crystallins, some
of which are associated with multiple sclerosis [6] or with lens
cataract development [7]. In the example of αB-crystallin in
association with multiple sclerosis, the concept that this molecule
acts as a functional protective factor has recently been reinforced
by genetic knock-out studies in mice [8]. The example of lens
crystallins illustrates that intracellular structural proteins may be
MMP substrates. For these reasons, the further search for
intracellular substrates (structural and functional ones) is amongst
the next challenges for MMP research. Here, we provide cell
biological, biochemical and in vivo evidences for this concept and
identify a cytoskeletal protein as one of the most efficient MMP-9
substrates.
Materials and methods
Cell culture
The human myelomonocytic cell line THP-1 was cultured in RPMI
1640 medium (Bio Whittaker Europe, Verviers, Belgium), supple-
mented with 10% fetal calf serum (Invitrogen, Carlsbad, California,
USA) and 1.5% sodium bicarbonate. Prior to the experiments, cells
were washed three times and resuspended in serum-free RPMI
1640 with 1.5% sodium bicarbonate at a concentration of 1×106
cells/ml or 10×106 cells/ml in multi-well dishes (Nunc, Roskilde,
Denmark).
Induction of cytolysis in THP-1 cells and detection by flow
cytometry
THP-1 cells were resuspended at a concentration of 1×106 cells/ml
in serum-free medium and incubated for 40 h at 37 °C in the
absence or presence of a general proteinase inhibitor cocktail (PIn,
Complete Mini EDTA-free, Roche, Basel, Switzerland) (1 tablet/
10 ml), 10 mM 1,10-o-phenanthroline (O-Phen, Sigma, St. Louis,
MO, USA) and 17 μM Z-Val-Ala-Asp.fluoromethylketone (Z-VAD.
fmk, Sigma). Alternatively, cells were resuspended at 10×106 cells/
ml and incubated in serum-free conditions for 4.5 h at 37 °C. After
incubation, cells and culture media were separated by centrifuga-
tion and culture media were stored at −20 °C. 106 cells per
condition were washed with phosphate buffered saline (PBS) and
stained with 100 μl of Annexin-V-fluorescein (FITC) and Propidium
iodide labeling solution (Annexin-V-FLUOS Staining kit, Roche)
according to the manufacturer's recommendations. Flow-cyto-
metric analysis was performed on a FACSCalibur™ flow cytometer
and data were processed with the Cell Quest® software (Becton
Dickinson, San Jose, CA, USA).
Preparation of THP-1 cell extracts and cytosolic fractions
Cell pellets obtained after 4.5 h incubation in serum-free
conditions were washed twice and resuspended at the original
concentration (10×106 cells/ml) in reducing SDS-PAGE loading
buffer (0.125 M Tris/HCl, pH 6.8, 4% SDS, 20% glycerol, 10% β-
mercaptoethanol, 0.05% bromophenol blue). After sonication and
centrifugation of the cell extracts, the resulting supernatant was
analyzed by SDS-PAGE. For the cytosol extraction, 600×106 cells
were washed three times with assay buffer and resuspended in
6 ml assay buffer (100 mM Tris/HCl, pH 7.4, 100 mM NaCl, 10 mM
CaCl2) supplemented with 0.01% Tween-20 and a general
proteinase inhibitor cocktail (PIn, Complete Mini EDTA-free,
Roche) (1 tablet/10 ml). The cells were lysed by 4 freeze-thaw
cycles and DNA was sheared by sonication. Cytosol and
membrane fractions were separated by ultracentrifugation at
110,000 g with a swing-out rotor SW50.1 in a Beckman L7-55
Ultracentrifuge (Beckman Coulter, Fullerton, CA, USA) during
75 min at 4 °C. The resulting supernatant or cytosolic fraction
was kept at −20 °C for further analysis.
Purification and activation of recombinant human MMPs
Recombinant human MMP-9 and MMP-9 domain deletion
mutants were expressed in Sf9 insect cells and purified by
gelatin-Sepharose affinity chromatography as described previously
[9,10]. The purified MMP-9 variants (10 μM) were activated with
0.1 μM of the catalytic domain of human MMP-3 (cd-MMP-3,
Calbiochem, Darmstadt, Germany) for 1.5 h at 37 °C in assay buffer
supplemented with 0.001% Tween-20 (Sigma). MMP-1, MMP-8
and MMP-13 were activated with APMA (p-aminophenylmercuric
acetate) according to the instructions of the manufacturer (R&D
Systems, Abingdom, UK). The commercial preparation of MMP-2
(R&D systems) was found to be active without activation and
therefore used as such.
Incubation of THP-1 cells or cytosol with activated MMP-9
THP-1 cytolysis was induced as described above. Before the start of
induction, 1 μM activated MMP-9 was added to the cells (10×106
cells/ml). As a control, cells were incubated without MMP-9 or in
the presence of equivalent amounts of the activator, cd-MMP-3
(10 nM). An additional control consisted of MMP-9 incubated at
equivalent concentration (1 μM) in serum-free medium. After 4.5 h
of incubation, culture media were harvested by centrifugation and
stored at −20 °C. To assess cleavage efficiency and inhibition
profiles of the major substrate(s), culture medium of THP-1 cells,
harvested after 4.5 h of cytolysis induction was used as source of
substrate(s). This culture medium was incubated for 4.5 h in the
presence of the indicated concentrations ofMMP-9 and cd-MMP-3,
as well as with addition of 20 mM EDTA, 33 μg/ml TIMP-1 (R&D
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Systems), 10 mM 4-(2-aminoethyl)benzenesulfonyl fluoride
hydrochloride (Pefabloc®, Roche), 50 mM benzamidine (Sigma)
and 2 μg/ml E64 (Sigma). THP-1 cytosol was incubated for the
indicated time intervals in the absence or presence of activated
MMP-9 (0.8–500 nM), cd-MMP-3 (3.3 nM and 100 nM), MMP-1, -2,
-8, -13 (5 nM and 100 nM), 100 mM EDTA and 400 μM Ac-DEVD-
CHO (N-Acetyl-Asp-Glu-Val-Asp-aldehyde, Sigma).
Digestion of recombinant CAP1 by activated MMP-9 variants
Recombinant glutathione-S-transferase (GST)-tagged CAP1
(Abnova, Niehu, Taipei, Taiwan) was dialyzed against assay buffer
to remove residual glutathione. The protein concentration was
determined with the Bradford protein assay (Bio-Rad, Hercules,
CA, USA) as described [11] with bovine serum albumin (Sigma) as a
standard. 315 ng CAP1was incubated during 75 min in the absence
or presence of the activated MMP-9 variants at the indicated
concentrations (0.37–29 nM): full-length MMP-9, MMP-9 with
deletion of the O-glycosylated domain (MMP-9ΔOG), of the
hemopexin domain (MMP-9ΔHem), and with deletion of both
the hemopexin and O-glycosylated domains (MMP-9ΔOGHem)
[10]. As a control, all MMP-9 variants were also incubated
separately in assay buffer.
SDS-PAGE and Western blot analysis
Cell extracts, (digested) culture media of THP-1 cells and
recombinant CAP1 digestions were analyzed by reducing Tris-
glycine SDS-PAGE (9% and 15% acrylamide) and visualized by silver
staining analysis (Silverquest™ Silver Staining kit, Invitrogen). For
Western blot analysis, THP-1 cytosol digestions, prepared as
described above, were separated by reducing Tris-tricine SDS-
PAGE (14% Prosieve® 50 Gel Solution, Lonza, Basel, Switzerland).
After electrophoresis, the proteins were transferred from the gels
to PVDF (Millipore Corporation, Billerica, MA, USA) or nitrocellu-
lose membranes (0.2 μm, Sigma) by electroblotting. Blotting was
performed semi-dry for all blots, except for the blots of the urine
samples (vide infra), which were wet-blotted. The membranes
were blocked with 5% non-fat dry milk (Bio-Rad) in Tris-buffered
saline (20 mM Tris/HCl, pH 7.6, 137 mM NaCl) containing 0.1%
Tween-20 and then probed with a mouse polyclonal antibody
raised against full-length recombinant GST-tagged CAP1 (Abnova).
After washing, the membrane was incubated with a peroxidase-
conjugated secondary goat anti-mouse antibody (Jackson Immu-
noResearch,West Grove, PA, USA) and after the final wash, proteins
were detected according to the manufacturer's recommendations
of the ECL plus™ chemiluminescence kit (GE Healthcare, Uppsala,
Sweden). Alternatively, the IgG fraction of the polyclonal CAP1
antiserumwas biotinylated after purification on a GammaBind Plus
Sepharose column (GE Healthcare) and peroxidase-conjugated
streptavidin (Jackson ImmunoResearch) was used as secondary
reagent. For fluorescent detection, the purified polyclonal CAP1
antibody was labeled with Cy5-NHS (GE Healthcare) resulting in a
final dye/product (D/P) ratio of 6.4/1. The monoclonal CAP1
antibody (Abnova) was labeled with Cy3-NHS (GE Healthcare),
giving a final D/P ratio of 4.8/1. Non-immune IgGwas purified from
murine serum (C57Bl/6) on a GammaBind Plus Sepharose column
and subsequently labeled with Cy3-NHS, resulting in a final D/P
ratio of 6.2/1. Urine blots were probed with the Cy5-conjugated
polyclonal CAP1 antibody (4 μg/ml) and the Cy3-labeled non-
immune IgG (4 μg/ml), followed by probing with Cy3-labeled
monoclonal CAP1 antibody (2 μg/ml) and fluorescence was
detected on the Ettan DIGE Imager (GE Healthcare).
NH2-terminal Edman sequencing and protein identification
by LC-MS/MS
Proteins were separated by SDS-PAGE and electroblotted onto
PVDF membranes. After washing with H2O and staining with
Coomassie Brilliant Blue R-250 (Sigma), the protein band(s) of
interest were excised from the blot and applied to a capillary
protein sequencer (Procise 491 cLC, Applied Biosystems, Foster
City, CA, USA) for NH2-terminal Edman degradation. For LC-MS/
MS, proteins were stained with Coomassie Brilliant Blue R-250
after SDS-PAGE analysis and the protein band(s) of interest were
excised from the gel and identified by electrospray ionization (ESI)-
tandem mass spectrometry (MS/MS) after in-gel tryptic digest
(Eurogentec S.A., Seraing, Belgium).
Patients and urine samples
All patients contributing to the present study gave informed
consent and the study protocol was in accordance with interna-
tional standards and approved by the Local Ethical Committee for
clinical studies. Clinical and laboratory data were decoded and
provided by the treating physician-specialist. Urine samples from
the patients and four healthy volunteers were collected on ice and
immediately (b15 min) frozen at −78.5 °C on dry ice before
analysis. For zymographic analysis, 0.5 ml urine was first
prepurified on gelatin-Sepharose as described [12]. Gelatin
zymography was performed as previously detailed [9] and the
relative migrations of pro-gelatinase B in covalent complex with
neutrophil gelatinase B-associated lipocalin (NGAL), of the pro-
MMP-9 and pro-MMP-2, as well as of the activated forms thereof,
were determined with the use of laboratory standards. Western
blot analysis of CAP1 in 50 μl urine per samplewas carried out with
Cy dye-labeled primary antibodies and fluorescent detection, as
described above.
Results
Gelatinase B/MMP-9 clears intracellular proteins from dying
THP-1 cells
In order to study the accessibility of intracellular proteins towards
extracellular proteases, an experimental model of cell death by
nutrient deprivation was used in a cell line of the myeloid lineage.
Humanmyelomonocytic THP-1 cells were incubated in serum-free
conditions for 40 h. To prevent released proteins from degradation,
a general protease inhibitor cocktail (PIn) was added, as well as
1,10-o-phenanthroline (O-Phen). The pan-caspase inhibitor Z-VAD.
fluoromethylketone (Z-VAD.fmk) was used to counter apoptosis
induction. The percentages of apoptotic and necrotic cells were
assessed by flow cytometry (Fig. 1) as described in the section
‘Materials and methods’. In comparison with untreated cells, the
addition of PIn and O-Phen induced additional cytolysis, which
was diminished by Z-Vad.fmk. As expected from the flow
cytometry data, considerable cytolysis was obvious after 40 h,
resulting in abundant protein content in the culture media. To
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avoid the aspecific cytolysis caused by PIn and O-Phen, shorter
incubation times (b5 h) were combined with the use of high cell
densities (10×106 cells/ml) as this combines the benefit of high
levels of released THP-1 proteins in the culture media with a
shorter incubation of these proteins in the presence of aggressive
cellular proteases. When these culture media were compared with
THP-1 cell extracts by SDS-PAGE analysis, most proteins in the
culture media corresponded to extracted cellular proteins (Fig. 2A).
In order to define MMP-9 substrates, THP-1 cells were
incubated in the absence or presence of recombinant human
MMP-9, activated with the catalytic domain of stromelysin-1/
MMP-3 (cd-MMP-3). Subsequently, equivalent amounts of culture
media were analyzed by SDS-PAGE. After incubation of dying THP-
1 cells for 4.5 h in the presence of activated MMP-9 (1 μM), one
major and severalminor protein bands disappeared, whereas other
low-abundancy (fragment) bands became visible (Fig. 2B). Control
incubations with equivalent amounts of cd-MMP-3 (10 nM), used
to activate pro-MMP-9, did not show any protein degradation,
ruling out that cd-MMP-3 would be the effector of the protein
degradation. To distinguish cellular protein bands from MMP-9
bands, an equivalent amount of MMP-9 (1 μM) was incubated in
serum-free medium and analyzed in parallel. The detection of
several differential bands confirms that various THP-1 proteins are
efficiently fragmented or cleared by MMP-9.
An abundant 57 kDa protein is efficiently cleaved by MMP-9
Most prominently, an abundant 57 kDa protein band completely
disappeared after 4.5 h incubation in the presence of MMP-9
(closed arrowhead, Fig. 2B). In order to examine the cleavage
efficiency of this 57 kDa protein, culture media of THP-1 cells were
incubated in the presence of various concentrations of activated
MMP-9. The 57 kDa protein was proteolysed in an MMP-9
concentration-dependent way (Fig. 3). Complete turnover of the
57 kDa substrate was achieved with only 9 nM MMP-9 and partial
cleavage still occurred at 0.36 nM MMP-9. This corresponded to a
cleavage efficiency comparable with that of gelatin, the most
efficient MMP-9 substrate [10].
Inhibition profiling confirms cleavage of the 57 kDa protein
by MMP-9
In order to verify that proteolysis of the 57 kDa protein indeed
results from MMP-9 action, inhibition tests with various protease
inhibitors were performed. Protein profiling of THP-1 culture
media, containing the 57 kDa protein, with 20 nM MMP-9 in the
presence or absence of inhibitors, showed that cleavage of the
57 kDa protein was MMP-specific. In the presence of EDTA (a
general metalloproteinase inhibitor) and TIMP-1 (which inhibits
mainly MMPs and MMP-9 with a particularly high affinity) the
Fig. 2 – MMP-9 clears intracellular proteins released by dying
THP-1 cells. (A) THP-1 cells were incubated in serum-free
conditions during 4.5 h. After separation by centrifugation, cell
extract (CE) and culturemedium(CM)wereanalyzedby SDS-PAGE.
Many protein bands in the culture mediummatch in migration
profile with cell extract proteins, indicating that cell death leads
to the release of many intracellular THP-1 proteins into the
culture medium. (B) THP-1 cells were incubated during 4.5 h in
the absence or presence of MMP-9 (1 μM). As a control, MMP-9
(1μM)was incubated in serum-freemediumwithout THP-1 cells.
In the culture media of THP-1 cells incubated in the presence of
activatedMMP-9, someproteinbandsdisappeared (closedarrows
and arrowhead), while various protein fragments became visible
(open arrows). Negative control incubation with cd-MMP-3
(10 nM) (used to activate pro-MMP-9) did not result in obvious
protein degradation. The acrylamide (AA) gel percentages used to
separate the proteins are shown at the right bottom of each gel
panel. A representative protein profile of 4 independent
experiments is shown.
Fig. 1 – Incubation of THP-1 cells in serum-free medium
induces cytolysis. THP-1 cells were incubated in serum-free
medium for 40 h to induce cell death by nutrient deprivation.
To prevent released proteins from being degraded, a general
protease inhibitor cocktail (PIn) was added, as well as
1,10-o-phenanthroline (O-Phen). The pan-caspase inhibitor
Z-Val-Ala-Asp.fluoromethylketone (Z-VAD.fmk) was used to
counter apoptosis induction. Annexin-V-positive cells
represent the early apoptotic cells (lower right quadrants),
whereas the double-positive cells correspond to late apoptotic
or necrotic cells (upper right quadrants). The residual viable
cells are double-negative (lower left quadrants). The numbers
within each quadrant indicate the cell percentages within the
total cell populations.
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substrate remained intact when MMP-9 was added (Supplemen-
tary Fig. 1). However, addition of the serine protease inhibitors
Pefabloc® and benzamidine, or the thiol protease inhibitor E64,
did not prevent degradation, confirming thatMMP-9 is responsible
for this cleavage. The fact that released cellular proteases also
present in the culture medium do not degrade the 57 kDa protein
(Supplementary Fig. 1, t4.5h vs. t0) is an additional indication of the
high specificity of this cleavage.
Identification of CAP1 as the 57 kDa MMP-9 substrate by
LC-MS/MS
Culture medium of THP-1 cells was incubated in the absence or
presence of MMP-9, and the 57 kDa protein was subjected to NH2-
terminal Edman sequencing as described in the section ‘Materials
and methods’. However, the 57 kDa protein appeared to be
resistant to Edman degradation. Hence, the 57 kDa protein was
submitted to LC-MS/MS analysis after in-gel tryptic digest and
identified as adenylyl cyclase-associated protein-1 (GenBank
accession no. AAP35816) or CAP1 (Fig. 4), an intracellular protein
with a theoretical mass of 51,641 Da, which is involved in actin
polymerization [13].
Western blot analysis of CAP1 proteolysis
In order to confirm the LC-MS/MS identification of CAP1 as an
MMP-9 substrate, recombinant GST-tagged CAP1 (315 ng) was
incubated with various concentrations of activated MMP-9.
Recombinant CAP1 was cleaved by MMP-9 concentrations as low
as 0.37 nM and complete degradation was observed with 3.2 nM,
which corresponded to enzyme:substrate ratios of 1:1175 and
1:145, respectively (Supplementary Fig. 2). Densitometric analysis
of the intact recombinant CAP1 band after incubation in the
absence or presence of MMP-9 yielded a CC50 (enzyme concentra-
tion resulting in 50% cleavage) of 0.5 nM after only 75 min of
incubation. This pointed again to a highly efficient proteolysis, as
the cleavage of the prototypic MMP-9 substrate, gelatin, is
Fig. 4 – Identification of CAP1 as a prominent MMP-9 substrate. Culture medium of THP-1 cells was incubated in the absence
or presence of MMP-9 and separated by SDS-PAGE, followed by staining with Coomassie Blue. The 57 kDa protein band was excised
and subjected to LC-MS/MS analysis after in-gel tryptic digest. It was identified as adenylyl cyclase-associated protein-1 or CAP1.
LC-MS/MS peptides matching with the CAP1 sequence are shown on a black background. The central poly-proline stretch (residues
230–241) is in italics and boxed in a gray background.
Fig. 3 – An abundant 57 kDa protein is cleaved with high
efficiency. Culture medium of THP-1 cells containing the 57 kDa
protein (arrows) was incubated for 4.5 h in the absence or
presence of various MMP-9 concentrations. MMP-9 (270 nM)
incubated in serum-freemediumwas used as a control. Cleavage
of the 57 kDa protein was observed with MMP-9 concentrations
as low as 0.36 nM. Control incubations with 2.7 nM cd-MMP-3
did not cause degradation of the 57 kDa protein band. Analysis
of culture medium of THP-1 cells before incubationwith MMP-9
is marked as t0. THP-1 culture medium after 4.5 h of incubation
without MMP-9 is indicated by t4.5h. A representative protein
profile of 2 independent experiments is shown.
Fig. 5 – Western blot analysis confirms efficient CAP1 cleavage
by MMP-9. (A) Specificity of the CAP1 antibody was confirmed
with THP-1 cell extract (CE), showing a single protein band at
57 kDa (arrow). (B) Initial CAP1 fragments, present in the cytosol
extract before incubation, are shown in the first lane (t0).
Control incubations included addition of EDTA and the caspase-
3/7 inhibitor Ac-DEVD-CHO. THP-1 cytosol was incubated for
4.5 h without MMP-9 (t4.5h) or in the presence of various MMP-
9 concentrations. All incubations were subjected toWestern blot
analysis with a polyclonal antibody against recombinant CAP1,
showing efficient degradation of the CAP1 band (arrow) by
MMP-9. Multiple fragment bands appear (⁎) and are further
degraded at higher MMP-9 concentrations. Addition of
equivalent amounts of cd-MMP-3 (3.3 nM) did not result in CAP1
fragmentation.
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characterized by a CC50 of 1 nM after 60 min [10]. As CAP1 is an
intracellular protein, the extracted cytosolic fraction of THP-1 cells
was used as a natural source of CAP1 to further confirm the
identification and cleavage byWestern blot analysis. THP-1 cytosol
incubated during 4.5 h in the absence or presence of MMP-9 was
subjected to Western blot analysis with a polyclonal antibody
against recombinant CAP1. Specificity of the CAP1 antibody was
confirmed with THP-1 cell extract, showing only one protein band
at 57 kDa (Fig. 5A). The procedure of cytosol extraction was the
cause of the initial fragmentation seen before incubation (Fig. 5B).
Control incubations in the absence of MMP-9 included addition of
EDTA, the caspase-3/7 inhibitor Ac-DEVD-CHO, and equivalent
amounts of cd-MMP-3. The protective effect observed with EDTA
shows that CAP1 might also be degraded by an endogenous
metalloprotease. This enzyme may be endogenous MMP-9, as well
as another endogenous MMP or another metalloproteinase, as the
inhibitory power of EDTA extends to all the proteases that depend
on light metal cations for activity. The dose-dependent fragmenta-
tion pattern generated by MMP-9 confirms the specificity and
efficiency of CAP1 degradation by MMP-9.
The kinetics of CAP1 cleavage were investigated by incubating
THP-1 cytosol with 4 nM activated MMP-9 and visualization of
cleavage at different time points byWestern blot analysis (Fig. 6A).
Semi-quantitative kinetic data were obtained from densitometric
scanning of the intact CAP1 band (arrow, Fig. 6B). After 1.5 h, 60% of
CAP1was cleared, leaving less than 20% of the intact substrate after
4.5 h of MMP-9 action. In summary, a fast and highly efficient
clearance of CAP1 by MMP-9 was corroborated by Western blot
analysis.
CAP1 cleavage is confirmed with MMP-9 deletion mutants
Binding of MMP substrates to enzyme exosites, which are discrete
substrate-binding sites on domains outside the catalytic domain,
enhances considerably the substrate affinity and is crucial for
efficient proteolysis of particular substrates [14]. For example, the
hemopexin domain is indispensable for classical collagenases
(MMP-1, -8 and -13) to cleave native, triple helical collagens, since
deletion of the hemopexin domain results in loss of their
collagenolytic capacity [15]. As the CAP1 cleavage efficiency was
in the same order of magnitude as gelatin degradation, binding of
CAP1 to an MMP-9 exosite might be involved. In order to
investigate potential roles of the O-glycosylated domain and the
hemopexin domain of MMP-9 in the cleavage of CAP1, recombi-
nant CAP1 was incubated with full-length recombinant MMP-9, as
well as with three recombinant MMP-9 domain deletion mutants.
More specifically, we used MMP-9 variants with deletion of the
hemopexin domain (MMP-9ΔHem), the O-glycosylated domain
(MMP-9ΔOG) and with deletion of both the hemopexin and O-
glycosylated domains (MMP-9ΔOGHem). As can be observed from
Supplementary Fig. 2, CAP1 was efficiently cleaved by the wildtype
and by the three domain deletion mutants. No difference in
cleavage efficiency was observed between the MMP-9 variants,
demonstrating that neither the hemopexin domain, nor the O-
glycosylated domain played a key role in CAP1 cleavage.
CAP1 degradation is an MMP-9-specific process
Frequently, MMP substrates can be cleaved by different MMPs
according to the pathophysiological context [1,3]. In order to
investigate whether CAP1 degradation might also be performed by
other MMPs, THP-1 cytosol was incubated for 4.5 h with 5 and
100 nM of the gelatinases MMP-9 and MMP-2, of the collagenases
MMP-1, -8 and -13, as well as with 100 nM of the catalytical
domain of stromelysin-1 (cd-MMP-3). Western blot analysis with
the biotinylated polyclonal CAP1 antibody showed that at high
MMP concentrations (100 nM) total clearance of the intact CAP1
band, indicated by the arrow, was achieved by MMP-9, -2, -8 and -
13, whereas MMP-1 was hardly capable of fragmentation and cd-
MMP-3 did not cleave CAP1 at all (Fig. 7A). Thus, extracellular CAP1
cleavage was achieved by different MMPs. However, CAP1
degradation by MMP-9 was more pronounced as it generated the
smallest fragments. In addition, at lower protease concentrations
(5 nM), MMP-9 was the only MMP that was still capable of CAP1
Fig. 6 – Semi-quantitative kinetics of CAP1 cleavage by MMP-9. (A) THP-1 cytosol was incubated in the presence of 4 nM activated
MMP-9. Samples were taken at the indicated time points and analyzed by Western blotting with a polyclonal CAP1 antibody for
detection. Densitometric analysis of the intact CAP1 band (arrow) yielded semi-quantitative kinetic data, which were plotted in a
graph vs. duration of incubation. Analysis of THP-1 cytosol before incubation is marked as t0. (B) 60% of CAP1 was degraded after
1.5 h of incubation and an additional 20% was cleared during the next 3 h. Fragments, present at the start or generated by MMP-9
after 1.5 h, were further degraded after 12 to 24 h of incubation.
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clearance (Fig. 7B), showing that – of the MMPs tested – MMP-9
was most efficient at CAP1 degradation. In order to investigate
synergistic actions between MMP-9 and MMP-2 or MMP-8, THP-1
cytosol was co-incubated for 4.5 h with 5 and 100 nM of MMP-9
and MMP-2 or -8. However, at both concentrations the fragmenta-
tion patterns were identical to those generated by MMP-9 alone,
suggesting that in the presence of MMP-9, less efficient MMPs did
not contribute to better CAP1 cleavage. In conclusion, CAP1 was
efficiently cleaved by 5 nM MMP-9, a concentration that is
physiologically attainable in many body compartments.
Analysis of coincident CAP1 and MMP-9 in vivo
To substantiate the in vivo relevance of the previous biological and
biochemical findings, we undertook additional studies of clinical
samples from leukemia patients under chemotherapeutic treat-
ment, and from patients with systemic autoimmune diseases. We
first screened a limited number of plasma and serum samples from
such patients by the described Western blot technique. However,
direct detection of CAP1 in plasma and serum samples was not
possible because of the overlapping molecular weights of CAP1
(57 kDa) and the highly abundant serum proteins albumin
(migrating between 50 and 75 kDa on SDS-PAGE) and the
immunoglobulin heavy chain (50–55 kDa on SDS-PAGE), which
mask the CAP1 band. In view of our anticipation that intact CAP1
(57 kDa) and consequently also CAP1 fragments might pass
through the kidney filter, we examined available urine samples
from patients with systemic autoimmune diseases. In addition,
CAP1 was previously identified as an autoantigen in a systemic
lupus erythematosus (SLE) patient with active disease and
nephritis [16] and in rheumatoid arthritis (RA) patients [17].
Other types of autoimmune diseases, including Sjögren's syndrome
(SS) and arteritis temporalis (AT) are as well characterized by tissue
damage and vascular involvement that may lead to circulating
CAP1. Relevant clinical information of 11 patients with SLE, SS or AT
was collected (Table 1). An increased C-reactive protein (CRP) level
reflects an acute inflammation, whereas increased serum creati-
nine levels and proteinuria are indicative for renal failure.
The primary mouse polyclonal CAP1 antibody was labeled with
the fluorescent dye Cy5 for direct fluorescence detection of
immunoreactivity (Fig. 8, panel A). Intact CAP1 was detected in
the urines of patients and controls, except for patients P10 and P11.
Interestingly, CAP1 was clearly increased in the urine of some
patients (e.g. P1, P3, P5 and P6) in comparison with control urine
samples (C1–C4). In a few patients, immunoreactive bands at a
lower molecular weight were detected (⁎ and open arrowheads)
that were potential CAP1 fragments. To investigate the specificity
Table 1 – Diagnosis and clinical parameters of patients with systemic autoimmune diseases
Diagnosis Sex (M/F) Age (years) CRP (mg/l) Serum creatinine
(mg/dl)
Increased
proteinuria
P1 SLE (drug-induced) F 15 2.4 0.71 No
P2 SLE M 71 2.1 1.54 a ND
P3 SLE F 37 7.8 0.97 ND
P4 SLE F 79 b1 0.79 No
P5 SLE F 77 b1 1.36 a Yes
P6 SLE F 21 b1 0.91 Yes
P7 SLE F 27 1.2 1.07a Yes
P8 AT F 73 1 0.95 Yes
P9 SS F 54 1 0.92 ND
P10 SS F 40 26 a 1.7 a ND
P11 SS and cryoglobulinemia F 71 3 1.06 a Yes
SLE, systemic lupus erythematosus; AT, arteritis temporalis; SS, Sjögren's syndrome; M, male; F, female; CRP, C reactive protein.
a Values in bold and italics are above the healthy threshold for the measured parameter.
Fig. 7 – CAP1 degradation is an MMP-9-specific process.
THP-1 cytosol was incubated for 4.5 h without MMP (t4.5h)
or in the presence of 100 nM (A) and 5 nM (B) of activated
MMP-9, -2, -1, -8, -13 and the catalytic domain of MMP-3
(cd-MMP-3). Synergistic actions between MMP-9 and MMP-2 or
MMP-8 were investigated by co-incubation of both MMPs with
THP-1 cytosol for 4.5 h. All incubations were analyzed by
SDS-PAGE and Western blot analysis with a biotinylated
polyclonal CAP1 antibody. A. At high protease concentrations
total degradation of the intact CAP1 band (arrow) is achievedby
MMP-9, -2, -8 and -13, whereas little or no cleavage is observed
with MMP-1 and cd-MMP-3, respectively. B. In the presence of
physiologic MMP concentrations, only MMP-9 is still capable of
CAP1 degradation, showing that MMP-9 is most efficient at
CAP1 clearance. Analysis of THP-1 cytosol before incubation is
marked as t0.
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of the immunoreactive bands, non-immune IgG was purified from
murine serum and labeled with Cy3 under the same conditions
used to purify and label the polyclonal CAP1 antibody. Since
fluorescent detection on Western blots is suitable for multiple
labeling, the same urine blots were then probed with the Cy3-
labeled non-immune murine IgG, which showed the specificity of
the intact CAP1 band, as it was not detected with non-immune IgG
(Fig. 8, panel B). However, non-immune IgG reactedwith one of the
potential CAP1 fragments (⁎), showing that this was a non-specific
immunoreactivity. In contrast, the other immunoreactive bands at
lower molecular weight (open arrowheads) were not observed
with non-immune IgG. As an additional confirmation of CAP1
detection in vivo, the same urine blots were subsequently probed
with a Cy3-conjugated monoclonal CAP1 antibody (Fig. 8, panel C).
Fig. 8 – Coincident CAP1 and MMP-9 in urine samples of patients with systemic autoimmune diseases. Urine samples (50 μl) from
11 patients (P1–P11) with systemic lupus erythematosus (SLE), arteritis temporalis (AT) or Sjögren's syndrome (SS) and 4 healthy
controls (Con) were subjected toWestern blot analysis. THP-1 cytosol incubated for 4.5 h with EDTA (first lane, THP-1, −) was used as
a source of intact CAP1 (closed arrows) and was spiked into 8-fold amounts of THP-1 cytosol incubated during 4.5 h with 4 nM
MMP-9 as a positive control for MMP-9-generated CAP1 fragments (second lane, THP-1, +). (A) Blotted urine samples were analyzed
with a Cy5-labeled polyclonal CAP1 antibody (final concentration 4 μg/ml). Intact CAP1 (closed arrows) was detected in the urines of
healthy controls and in patient urines, except for P10 and P11. In some patients, immunoreactive bands were detected at lower
molecular weight (⁎ and open arrowheads). (B) To confirm the specificity of the immunoreactive bands, the same urine blots were
also probed with non-immune IgG, labeled with Cy3 (final concentration 4 μg/ml). Hence, one potential fragment band was shown
to be non-specific (⁎). (C) As a final validation of CAP1 detection in vivo, the blots were then probedwith Cy3-conjugatedmonoclonal
CAP1 antibody (final concentration 2 μg/ml), showing similar detection of intact CAP1 (closed arrows) and CAP1 fragments (open
arrowheads) as with the polyclonal antibody in panel A. (D) Urine samples from patients and controls (500 μl) were prepurified on
gelatin-Sepharose beads and analyzed by gelatin zymography. The highest MMP-9/gelatinase B and MMP-2/gelatinase A levels were
found in urines samples from P10 and P11 with SS and indications of renal injury. Whereas no activated MMP-9 was detected in
control urines, all urines of patients with pathological clinical parameters suggesting renal failure contained activated MMP-9.
Pro-MMP-9-NGAL is neutrophil MMP-9 complexed with gelatinase B-associated lipocalin (NGAL).
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Intact CAP1 and CAP1 fragments (open arrowheads) reappeared
and were indeed recognized by both the polyclonal and mono-
clonal antibodies.
For the detection of the CAP1-degrading enzymeMMP-9, 500 μl
of the urine samples was prepurified on gelatin-Sepharose, as
previously described [12]. When urinary gelatinase A/MMP-2 and
gelatinase B/MMP-9 levels were analyzed by zymography (Fig. 8,
panel D), the highest levels were found in urines from patients P10
and P11 with SS and indications of renal damage. To facilitate the
interpretation of the P10 and P11 zymograms, the equivalent of
only 20 μl of urine after prepurificationwas analyzed and shown in
parallel in Supplementary Fig. 3. Interestingly, all patients with
clinical parameters suggesting renal damage had activated MMP-9
and/or MMP-2 in their urines. In the urines of patients P10 and P11
with the highest level of pro- and activated MMP-9 and MMP-2,
the intact CAP1 band was decreased in comparison with the CAP1
levels in the urines of healthy control donors. In addition, in
patients with a clear but less pronounced increase of pro- and
activated MMP-9 (P4, P5, P7 and P8), CAP1 levels were slightly
higher than in the controls, whereas in samples without MMP-9 or
with low levels of activated MMP-9, an increased amount of CAP1
was detected (P1, P3 and P6). These inverse relations between the
levels of intact CAP1 and activated MMP-9, as well as the detection
of possible CAP1 fragments, suggest that MMP-9 is involved in
CAP1 degradation in vivo.
In conclusion, we demonstrated the presence of intact extra-
cellular CAP1 in the urine of patients with systemic autoimmune
diseases and healthy controls. Whereas healthy control urines did
not contain active MMP-9, all urine samples of patients with
clinical parameters pointing to renal failure showed activation of
MMP-9 and/or MMP-2. In addition, in some patient urines with an
overload of pro- and activated MMP-9 and/or MMP-2, the intact
CAP1 band disappeared, whereas urines from patients without
urinary MMP-9 or with low levels of active MMP-9 contained an
increased level of intact CAP1.
Discussion
MMPs in general, and MMP-9 in particular, cleave extracellular
structural (e.g. gelatins) and functional substrates (e.g. chemo-
kines). Proteolysis by gelatinase B/MMP-9 is of physiological
importance in reproduction and development, leukocyte mobiliza-
tion and tissue repair. MMP-9 is known for its contribution to the
pathogenesis of inflammation, vascular diseases, cancer and
autoimmune diseases [18]. Indeed, MMP-9 was proposed to act as
a switch and catalyst in both innate and specific immunity as it
activates pro-inflammatory cytokines such as IL-1β, modifies
chemokine activities and assists in leukocyte mobilization and
migration across basement membranes. MMPs cleave autoanti-
genic molecules into immunodominant epitopes for T cells [19].
However, the knowledge of intracellular MMP substrates is rather
limited.
In this study, a myeloid cell model system was used to define
critical and efficient MMP-9 substrates associated with cytolysis.
CAP1 was thus identified by mass spectrometry analysis and the
cleavage efficiency was corroborated by Western blot analysis.
Recombinant CAP1 was degraded at enzyme:substrate ratios
exceeding 1:1000 and at an estimated CC50 of 0.5 nM after
75 min of incubation. Hence, CAP1 degradation is more efficient
than cleavage of gelatin (CC50 of 1 nM after 60 min incubation) and
βB1 crystallin (CC50 of 3 nM after 180 min incubation) [7,10], the
two most efficient known MMP-9 substrates. As exosite interac-
tions may be crucial for a high cleavage efficiency [14], it was
hypothesized that CAP1 would bind to an MMP-9 exosite.
However, with the use of MMP-9 domain deletion mutants, the
hemopexin domain and the O-glycosylated domain were excluded
as modules bearing exosites for CAP1 binding. The fibronectin
domain of gelatinases is required for the binding of gelatin, laminin
and collagens type I and IV. In addition, binding to exosites in the
fibronectin domain strongly enhances gelatin affinity [20]. Inter-
estingly, CAP1 contains a centrally located stretch of poly-proline
residues (cfr. Fig. 4) [21] and may possibly mimic exosite binding of
proline-rich gelatin to the fibronectin domain, in this way
acquiring the ideal position for efficient cleavage. However, by
immunoprecipitation experiments, interactions between CAP1
and the MMP-9 fibronectin domain, or any other MMP-9 exosite,
were ruled out (data not shown), which leads us to the conclusion
that the interaction with the catalytic site of MMP-9 is ideal and
leads to the high cleavage rate of CAP1. In addition, when
comparing CAP1 degradation by various MMPs, we found that
MMP-9 was the most efficient CAP1-degrading MMP and the only
protease of the tested MMPs to clear CAP1 at low protease
concentrations. This showed that CAP1 degradation by MMP-9 is
not only a highly efficient but also an MMP-specific process.
Cyclase-associated proteins or CAPs constitute a family of
highly conserved monomeric actin-binding proteins (molecular
weight: 50–60 kDa) present in a wide range of organisms
including yeasts, flies, plants and mammals. CAP (Srv2/ASP56)
was originally isolated as a component of the Saccharomyces
cerevisiae adenylyl cyclase complex, which is implicated in Ras
signaling. The C-terminal-binding site for monomeric or globular
(G)-actin is well conserved in CAP1 molecules in various species
[13]. In addition, all CAP homologs contain a centrally located
proline-rich region, which is recognized by the SH3-domains of
several proteins, suggesting that CAP could mediate interactions
between SH3-domain proteins and monomeric actin [21]. In
mammals two different CAP genes have been found, CAP1 and
CAP2, which share 64% amino acid identity [22,23]. Analysis of
CAP1-deficient cells showed that it promotes rapid actin dynamics
and is important for cell morphology, migration and endocytosis,
as well as for the localization and function of actin-depolymerizing
cofilin [24,25].
Several reasons incited us to use THP-1 cells as an experi-
mental cell model. One rationale to use and to induce apoptosis/
necrosis in this human myelomonocytic leukemia cell line THP-1
was drawn from the knowledge that chemotherapy for leukemia
induces cytolysis. Moreover, in tumor lysis syndrome, aggressive
chemotherapy causes rapid tumor cell destruction and a massive
release of intracellular contents into the systemic circulation.
This results in metabolic disturbances, leading to multi-organ-
failure and even death [26]. The highly efficient clearance of
CAP1 by MMP-9 may be important during such (extensive)
cytolysis. Indeed, dying cells release intracellular proteins into
the extracellular milieu, creating a strong pro-inflammatory
stimulus which engenders or enhances inflammation. The
intracellular material can be removed by phagocytes or first be
degraded by proteases, such as MMP-9, which is stored in the
granules of neutrophils and released within minutes to 1 h after
neutrophil stimulation [9]. In addition, CAP1 was identified as an
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endothelial cell-associated autoantigen in a systemic lupus
erythematosus patient with active disease and nephritis [16]
and in rheumatoid arthritis patients [17]. As CAP1 is an abundant
and ubiquitous protein, the efficient clearance of this antigen
may be of physiological importance to avoid autoimmune or
other reactions.
Another potential effect of fast CAP1 degradation may be the
removal of the actin monomer-sequestering activity of CAP1.
Indeed, when cells die, monomeric and filamentous actins are
released into the extracellular space and reach the systemic
circulation. In the plasma, where the ionic strength, pH and
temperature promote polymerization, actin monomers can form
long filaments together with coagulation factor Va, which triggers
disseminated intravascular coagulation if not rapidly resolved
[27–30].
Interestingly, other actin-binding proteins have also been
described as MMP substrates. α-Actinin, which is known to
connect actin filaments of adjacent sarcomeres, is cleaved by
MMP-2 in vitro and it is hypothesized that this proteolysis would
mediate cytoskeletal disorganization and peroxynitrite-induced
injury in the heart [31]. Gelsolin is cut into several fragments by
various MMPs, including MMP-9, resulting in considerable loss of
its actin-depolymerizing activity [32,33], whichmay as well lead to
intravascular coagulation by increasing the concentration of actin
filaments in the circulation.
In conclusion, CAP1 is released upon cytolysis into the
extracellular milieu in vitro and thus becomes a highly efficient
MMP-9 substrate. In addition, we showed that the CAP1 antigen
can be detected by Western blot analysis in only 50 μl of urine
without prepurification steps. Hence, CAP1 is present in the
extracellular milieu in vivo. In some urine samples of patients with
systemic autoimmune diseases, an inverse relation was observed
between the levels of intact CAP1 and activated MMP-9/-2,
suggesting CAP1 degradation by MMP-9/-2 in these patients.
Degradation of intracellular proteins may result in the generation
of new autoantigens [34,35]. In addition, CAP1 degradation by
MMP-9/-2 might affect acute pathological conditions caused by
extracellular actin toxicity. Therefore, further elucidation of the
effects of the release and cleavage of CAP1 and other intracellular
substrates after cytolysismay yield intriguing new insights in these
pathologies.
Acknowledgments
The authors thankHelene Piccard, Chris Dillen, Dr. Francis Descamps
and Nele Berghmans for their experimental help and constructive
criticisms, and Helga Keunen and Marina Lejeune for their
assistance with clinical data collection. This study was supported
by the Centre of Excellence (EF/05/015), the Fund for Scientific
Research of Flanders (FWO — Vlaanderen), the ‘Geconcerteerde
OnderzoeksActies’ (GOA-15) and the Charcot Foundation. PVDS is a
postdoctoral fellow of the FWO — Vlaanderen.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.yexcr.2008.07.008.
R E F E R E N C E S
[1] M.D. Sternlicht, Z. Werb, Howmatrix metalloproteinases regulate
cell behavior, Annu. Rev. Cell Dev. Biol. 17 (2001) 463–516.
[2] C. Lopez-Otin, C.M. Overall, Protease degradomics: a new
challenge for proteomics, Nat. Rev., Mol. Cell Biol. 3 (2002)
509–519.
[3] B. Cauwe, P.E. Van den Steen, G. Opdenakker, The biochemical,
biological, and pathological kaleidoscope of cell surface substrates
processed by matrix metalloproteinases, Crit. Rev. Biochem. Mol.
Biol. 42 (2007) 113–185.
[4] A. Szklarczyk, G. Oyler, R. McKay, C. Gerfen, K. Conant, Cleavage
of neuronal synaptosomal-associated protein of 25 kDa by
exogenous matrix metalloproteinase-7, J. Neurochem. 102 (2007)
1256–1263.
[5] J.A. Kwan, C.J. Schulze, W. Wang, H. Leon, M. Sariahmetoglu, M.
Sung, J. Sawicka, D.E. Sims, G. Sawicki, R. Schulz, Matrix
metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac
myocytes and is capable of cleaving poly (ADP-ribose) polymerase
(PARP) in vitro, FASEB J. 18 (2004) 690–692.
[6] S. Starckx, P.E. Van den Steen, R. Verbeek, J.M. van Noort, G.
Opdenakker, A novel rationale for inhibition of gelatinase B in
multiple sclerosis: MMP-9 destroys alpha B-crystallin and
generates a promiscuous T cell epitope, J. Neuroimmunol. 141
(2003) 47–57.
[7] F.J. Descamps, E. Martens, P. Proost, S. Starckx, P.E. Van den
Steen, J. Van Damme, G. Opdenakker, Gelatinase B/matrix
metalloproteinase-9 provokes cataract by cleaving lens betaB1
crystallin, FASEB J. 19 (2005) 29–35.
[8] S.S. Ousman, B.H. Tomooka, J.M. van Noort, E.F. Wawrousek, K.C.
O'Connor, D.A. Hafler, R.A. Sobel, W.H. Robinson, L. Steinman,
Protective and therapeutic role for alphaB-crystallin in
autoimmune demyelination, Nature 448 (2007) 474–479.
[9] S. Masure, P. Proost, J. Van Damme, G. Opdenakker, Purification and
identification of 91-kDa neutrophil gelatinase. Release by the
activatingpeptide interleukin-8, Eur. J. Biochem.198 (1991) 391–398.
[10] P.E. Van den Steen, I. Van Aelst, V. Hvidberg, H. Piccard, P. Fiten, C.
Jacobsen, S.K. Moestrup, S. Fry, L. Royle, M.R. Wormald, R. Wallis,
P.M. Rudd, R.A. Dwek, G. Opdenakker, The hemopexin and
O-glycosylated domains tune gelatinase B/MMP-9 bioavailability
via inhibition and binding to cargo receptors, J. Biol. Chem. 281
(2006) 18626–18637.
[11] M.M. Bradford, A rapid and sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of
protein-dye binding, Anal. Biochem. 72 (1976) 248–254.
[12] F.J. Descamps, E. Martens, G. Opdenakker, Analysis of gelatinases
in complex biological fluids and tissue extracts, Lab. Invest. 82
(2002) 1607–1608.
[13] A.V. Hubberstey, E.P. Mottillo, Cyclase-associated proteins:
CAPacity for linking signal transduction and actin polymerization,
FASEB J. 16 (2002) 487–499.
[14] C.M. Overall, G.A. McQuibban, I. Clark-Lewis, Discovery of
chemokine substrates for matrix metalloproteinases by exosite
scanning: a new tool for degradomics, Biol. Chem. 383 (2002)
1059–1066.
[15] H. Piccard, P.E. Van den Steen, G. Opdenakker, Hemopexin
domains as multifunctional liganding modules in matrix
metalloproteinases and other proteins, J. Leukoc. Biol. 81 (2007)
870–892.
[16] G. Frampton, S. Moriya, J.D. Pearson, D.A. Isenberg, F.J. Ward, T.A.
Smith, A. Panayiotou, N.A. Staines, J.J. Murphy, Identification of
candidate endothelial cell autoantigens in systemic lupus
erythematosus using a molecular cloning strategy: a role for
ribosomal P protein P0 as an endothelial cell autoantigen,
Rheumatology 39 (2000) 1114–1120.
[17] A. Kinloch, V. Tatzer, R. Wait, D. Peston, K. Lundberg, P. Donatien,
D. Moyes, P.C. Taylor, P.J. Venables, Identification of citrullinated
2748 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 4 ( 2 0 0 8 ) 2 7 3 9 – 2 7 4 9
Author's personal copy
alpha-enolase as a candidate autoantigen in rheumatoid arthritis,
Arthritis Res. Ther. 7 (2005) R1421–R1429.
[18] P.E. Van den Steen, B. Dubois, I. Nelissen, P.M. Rudd, R.A. Dwek, G.
Opdenakker, Biochemistry and molecular biology of gelatinase
B or matrix metalloproteinase-9 (MMP-9), Crit. Rev. Biochem. Mol.
Biol. 37 (2002) 375–536.
[19] G. Opdenakker, P.E. Van den Steen, J. Van Damme, Gelatinase B: a
tuner and amplifier of immune functions, Trends Immunol. 22
(2001) 571–579.
[20] J.A. Allan, A.J. Docherty, P.J. Barker, N.S. Huskisson, J.J. Reynolds, G.
Murphy, Binding of gelatinases A and B to type-I collagen and
other matrix components, Biochem. J. 309 (1995) 299–306.
[21] N.L. Freeman, T. Lila, K.A. Mintzer, Z. Chen, A.J. Pahk, R. Ren, D.G.
Drubin, J. Field, A conserved proline-rich region of the
Saccharomyces cerevisiae cyclase-associated protein binds SH3
domains and modulates cytoskeletal localization, Mol. Cell. Biol.
16 (1996) 548–556.
[22] G. Yu, J. Swiston, D. Young, Comparison of human CAP and CAP2,
homologs of the yeast adenylyl cyclase-associated proteins
J. Cell. Sci. 107 (1994) 1671–1678.
[23] V. Peche, S. Shekar, M. Leichter, H. Korte, R. Schroder, M.
Schleicher, T.A. Holak, C.S. Clemen, Y. Ramanath, G. Pfitzer, I.
Karakesisoglou, A.A. Noegel, CAP2, cyclase-associated protein 2, is
a dual compartment protein, Cell. Mol. Life Sci. 64 (2007)
2702–2715.
[24] E. Bertling, P. Hotulainen, P.K. Mattila, T. Matilainen, M. Salminen,
P. Lappalainen, Cyclase-associated protein 1 (CAP1) promotes
cofilin-induced actin dynamics in mammalian nonmuscle cells,
Mol. Biol. Cell 15 (2004) 2324–2334.
[25] K. Moriyama, I. Yahara, Human CAP1 is a key factor in the
recycling of cofilin and actin for rapid actin turnover, J. Cell Sci. 115
(2002) 1591–1601.
[26] R.V. Tiu, S.E. Mountantonakis, A.J. Dunbar, M.J. Schreiber Jr., Tumor
lysis syndrome, Semin. Thromb. Hemost. 33 (2007) 397–407.
[27] J.G. Haddad, K.D. Harper, M. Guoth, G.G. Pietra, J.W. Sanger,
Angiopathic consequences of saturating the plasma scavenger
system for actin, Proc. Natl. Acad. Sci. U. S. A 87 (1990) 1381–1385.
[28] B. Dahl, The extracellular actin scavenger system in trauma and
major surgery. Clinical and experimental studies, Acta Orthop.
Suppl 76 (2005) 2–24.
[29] W.M. Lee, R.M. Galbraith, The extracellular actin-scavenger
system and actin toxicity, N. Engl. J. Med. 326 (1992) 1335–1341.
[30] U. Meier, O. Gressner, F. Lammert, A.M. Gressner, Gc-globulin:
roles in response to injury, Clin. Chem. 52 (2006) 1247–1253.
[31] M.M. Sung, C.G. Schulz, W. Wang, G. Sawicki, N.L. Bautista-Lopez,
R. Schulz, Matrix metalloproteinase-2 degrades the cytoskeletal
protein alpha-actinin in peroxynitrite mediated myocardial
injury, J. Mol. Cell. Cardiol. 43 (2007) 429–436.
[32] I.K. Hwang, S.M. Park, S.Y. Kim, S.T. Lee, A proteomic approach to
identify substrates of matrix metalloproteinase-14 in human
plasma, Biochim. Biophys. Acta 1702 (2004) 79–87.
[33] S.M. Park, I.K. Hwang, S.Y. Kim, S.J. Lee, K.S. Park, S.T. Lee,
Characterization of plasma gelsolin as a substrate for matrix
metalloproteinases, Proteomics 6 (2006) 1192–1199.
[34] A. Rosen, L. Casciola-Rosen, Autoantigens as substrates for
apoptotic proteases: implications for the pathogenesis of systemic
autoimmune disease, Cell Death Differ. 6 (1999) 6–12.
[35] P. Eggleton, R. Haigh, P.G. Winyard, Consequence of
neo-antigenicity of the ‘altered self’, Rheumatology (Oxford)
47 (2008) 567–571.
2749E X P E R I M E N T A L C E L L R E S E A R C H 3 1 4 ( 2 0 0 8 ) 2 7 3 9 – 2 7 4 9
100 | P a g e  
 
SUPPLEMENTARY MATERIAL 
 
Supplementary Figure 1. Inhibition profile confirms cleavage of the 57 kDa protein by MMP-9.  Culture medium 
of THP-1 cells containing the 57 kDa protein (arrow) was incubated for 4,5h in the absence or presence of 20 nM 
MMP-9, as well as various protease inhibitors.  Addition of the general metalloproteinase inhibitor EDTA, or the MMP 
inhibitor TIMP-1 prevented degradation of the 57 kDa protein.  In contrast, the serine protease inhibitors Pefabloc® 
(PEFA) and benzamidine (BENZ), as well as the cysteine protease inhibitor E64 did not inhibit the cleavage.  Analysis 
of culture medium of THP-1 cells before incubation with MMP-9 is marked as t0.  THP-1 culture medium after 4,5h of 
incubation without MMP-9 is indicated by t4.5h. 
 
 
 
Supplementary Figure 2.  Characterization of CAP1 cleavage with MMP-9 deletion mutants.  Recombinant GST-
tagged CAP1 (315 ng, 78 kDa) (arrows) was incubated during 75 min. in the absence or presence of various 
concentrations of activated MMP-9 variants: full-length MMP-9, MMP-9 with deletion of the O-glycosylated domain 
(MMP-9∆OG), of the hemopexin domain (MMP-9∆Hem), and with deletion of both the hemopexin and O-glycosylated 
domains (MMP-9∆OGHem).  CAP1-GST was cleaved efficiently by MMP-9 and this cleavage is characterized by a 
CC50 of 0.5 nM.  All MMP-9 variants cleaved CAP1 at equivalent concentrations.  As a control for non-specific 
fragment bands, all MMP-9 variants were also incubated without the substrate.  Recombinant CAP1 before and after 75 
min. of incubation without MMP-9 variants is indicated by t0 and t75, respectively.  The molecular mass standard is 
marked by St. 
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Supplementary Figure 3. Clarification of the gelatin zymograms of the urines of patients P10 and P11.  Urine 
samples from patients P10 and P11 (500 µL) were prepurified on gelatin-Sepharose beads.  To avoid overloading (cf. 
Figure 8, Panel D), 25 times less or the equivalent of 20 µl urine (instead of 500 µl) was analyzed by gelatin 
zymography and shown in parallel with the prepurifications of 500 µl.  Pro-MMP-9-NGAL is neutrophil MMP-9 
complexed with gelatinase B-associated lipocalin (NGAL). 
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The action radius of matrix metalloproteinases or MMPs is not restricted to massive extracellular
matrix (ECM) degradation, it extends to the proteolysis of numerous secreted and membrane-
bound proteins. Although many instances exist in which cells disintegrate, often in conjunction
with induction of MMPs, the intracellular MMP substrate repertoire or degradome remains
relatively unexplored. We started an unbiased exploration of the proteolytic modiﬁcation of
intracellular proteins by MMPs, using gelatinase B/MMP-9 as a model enzyme. To this end,
multidimensional degradomics technology was developed by the integration of broadly available
biotechniques. In this way, 100–200 MMP-9 candidate substrates were isolated, of which 69 were
identiﬁed. Integration of these results with the known biological functions of the substrates
revealed many novel MMP-9 substrates from the intracellular matrix (ICM), such as actin,
tubulin, gelsolin, moesin, ezrin, Arp2/3 complex subunits, ﬁlamin B and stathmin. About 2/3 of
the identiﬁed candidates were autoantigens described in multiple autoimmune conditions and in
cancer (e.g. annexin I, nucleolin, citrate synthase, HMGB1, a-enolase, histidyl-tRNA synthetase,
HSP27, HSC70, HSP90, snRNP D3). These ﬁndings led to the insight that MMPs and other
proteases may have novel (immuno)regulatory properties by the clearance of toxic and
immunogenic burdens of abundant ICM proteins released after extensive necrosis. In line with the
extracellular processing of organ-speciﬁc autoantigens, proteolysis might also assist in the
generation of immunodominant ‘neo-epitopes’ from systemic autoantigens. The study of
proteolysis of ICM molecules, autoantigens, alarmins and other crucial intracellular molecules
may result in the discovery of novel roles for proteolytic modiﬁcation.
Introduction
Matrix metalloproteinases or MMPs constitute a family
of Zn2+-dependent proteases with a widespread substrate
collection, ranging from extracellular matrix (ECM) proteins
to signaling molecules, cytokines, chemokines, hormones as
well as a kaleidoscope of membrane-associated substrates.1,2
Although MMPs ﬁrst came into the spotlights as ECM
wreckers, recent evidence shows that they also degrade some
intracellular matrix (ICM) proteins.3–6 These ﬁndings suggest
that intracellular substrates may be proteolyzed into ‘‘remnant
epitopes’’, generating immunodominant epitopes for auto-
reactive T-cells, in this way initiating or exacerbating systemic
autoimmunity.7 Alternatively, degradation of abundant ICM
proteins may be critical to avoid (actin) toxicity and immuno-
genicity after extensive cell death. Indeed, after cell necrosis,
actin monomers may enter the systemic circulation and form
long ﬁlaments together with coagulation factor Va, triggering
disseminated intravascular coagulation if not rapidly cleared.
Department of Microbiology and Immunology, Laboratory of
Immunobiology, Rega Institute for Medical Research, University of
Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
E-mail: ghislain.opdenakker@rega.kuleuven.be; Fax: 0032 16 337340;
Tel: 0032 16 337341
w Electronic supplementary information (ESI) available: Representa-
tive SDS-PAGE gels. See DOI: 10.1039/b904701h
Insight, innovation, integration
Proteolytic modiﬁcation of intracellular substrates by
extracellular proteases is an innovative concept in protease
research. The aim of this study was to contribute to this new
domain by characterizing the proteolysis of intracellular
proteins by matrix metalloproteinases (MMPs) using un-
biased, high-throughput approaches. By the integration of
basic biochemical techniques, a multidimensional degrado-
mics technology platform was applied to THP-1 cytosol with
gelatinase B/MMP-9 as a model enzyme. About 70 intra-
cellular proteins were identiﬁed as MMP-9 candidate
substrates. Integration of these identiﬁcations with current
biological knowledge about the substrates led to the insight
that MMPs and other extracellular proteases may have novel
(immuno)regulatory properties by the removal and modiﬁca-
tion of toxic and possibly immunogenic intracellular contents
released into the extracellular space after extensive necrosis.
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Functional organ decompensation may culminate into severe
pathological conditions such as hepatic necrosis, adult
respiratory distress syndrome (ARDS) and septic shock.8–12
Finally, in acute necrotic conditions such as tumor lysis
syndrome, the high tumor load and/or aggressive chemo-
therapy cause rapid tumor cell necrosis and a massive release
of intracellular proteins into the systemic circulation.13 As the
resulting metabolic imbalances may lead to (fatal) multi-organ
failure, rapid removal of the overload of toxic and immuno-
genic intracellular contents might be crucial for survival.
In this context, the aims of the present study were to identify
novel intracellular MMP targets and to answer the question
whether a previously undescribed task of MMPs may reside in
the proteolytic modiﬁcation of ICM proteins and (systemic)
autoantigens. Extracellular proteolysis of extracellular matrix
proteins, e.g. collagens,14 or other secreted molecules, e.g.
myelin basic protein15 and insulin,16 by the inﬂammatory
protease gelatinase B/MMP-9 has previously been shown to
contribute to organ-speciﬁc autoimmune diseases, respectively,
rheumatoid arthritis, multiple sclerosis and diabetes. In
many systemic autoimmune diseases, e.g. systemic lupus
erythematosus (SLE), the autoantigens are ubiquitous intra-
cellular proteins. Hence, we used MMP-9 as a model
proteolytic enzyme to investigate whether the link between
extracellular proteolysis and organ-speciﬁc autoimmune
diseases may be extended to systemic autoimmunity.
In order to investigate the cleavage of intracellular proteins by
MMPs, we tried to expand the limited list of intracellular MMP
substrates by high-throughput degradomic identiﬁcation of
MMP-9 targets in the cytosolic fraction of THP-1 cells.
Degradomics aims at characterizing the natural substrate reper-
toire or ‘degradome’ of a protease in a cell, tissue or organism.17
In the present study, two multidimensional degradomic
approaches were used as unbiased tools to explore the intra-
cellular MMP-9 degradome. In the ﬁrst dimension of the
two-dimensional degradomics approach or ‘2D-degradomics’,
ion exchange chromatography (IEC) separated the THP-1
proteins by their net charge and/or isoelectric point (pI),
whereas in the second dimension, potential substrates were
separated by molecular weight upon SDS-PAGE analysis. In a
second approach termed ‘fragment degradomics’, the THP-1
protein pool was ﬁrst cleaved and low-molecular weight
‘fragment fractions’ were subsequently enriched by centrifugal
ﬁltration and concentration to visualize generated fragments or
low-molecular weight substrates upon SDS-PAGE analysis. This
straightforward, inexpensive and broadly applicable technology
allowed us to isolate numerous candidate substrate (fragment)
bands, B70 of which were identiﬁed as potential MMP-9
substrates. As proofs-of-principle, various substrates were
corroborated as previously identiﬁed gelatinase B (candidate)
substrates by literature searches. Novel candidate substrates were
conﬁrmed by Western blot analysis of digested cytosol or by
in vitro cleavage assays of the recombinant or puriﬁed substrate.
Remarkably, integration of the results generated by the
multidimensional degradomics technology with the current
state of biological knowledge in the literature revealed many
novel MMP-9 substrates from the ICM. In addition, 2/3 of the
identiﬁed candidates were autoantigens described in one or
multiple autoimmune conditions and in cancer. These ﬁndings
lead to the insight that MMPs and other proteases may have
novel (immuno)regulatory properties by the removal of the
toxic and immunogenic burden of abundant ICM proteins
released after extensive necrosis and/or by the generation of
immunodominant ‘neo-epitopes’ from systemic autoantigens.
Results
Development of two-dimensional degradomics
or ‘2D-degradomics’
Recently, we identiﬁed a cytoskeletal protein, adenylyl cyclase-
associated protein-1 or CAP1, as a highly eﬃcient intracellular
MMP-9 substrate by a one-dimensional degradomics approach
on dying THP-1 cells.6 Additional candidate substrates were
discerned, but identiﬁcation was not possible due to their low
abundancy and/or overlap with other protein bands. In order to
reduce the complexity of the initial protein pool and visualize
potential MMP-9 substrates, an extra biochemical dimension
was added to the previous one-dimensional approach. During
2D-degradomics, the proteins are ﬁrst separated according to
their net charge and/or pI by subsequent cation and anion
exchange chromatography (CEC and AEC) (Fig. 1A). Before
chromatography, the pH of the protein mixture is increased to
pH 9.2 to generate a net negative charge in the majority of the
proteins. Alkaline proteins are bound and eluted by the ﬁrst
CEC round. CEC ﬂow through fractions are pooled and further
fractionated by AEC chromatography. All AEC and CEC
elution fractions, as well as the AEC ﬂow through fractions,
are dialyzed to remove the salt overload and concentrated.
Next, each substrate fraction is incubated in the absence or
presence of activated MMP-9. In the second dimension,
digested and undigested fractions are separated by molecular
weight upon SDS-PAGE analysis. Disappearing or decreasing
of protein bands, or appearance of novel fragment bands after
incubation with MMP-9 point to potential substrate proteins.
The IEC fractions with the diﬀerential bands are then electro-
blotted onto PVDF for identiﬁcation of the candidate substrate
and/or cleavage site by Edman degradation. As many intra-
cellular proteins are NH2-terminally blocked, an alternative is
to cut the diﬀerential bands out of the gels for identiﬁcation by
tandem mass spectrometry (MS/MS) after in-gel tryptic digest.
Finally, a literature search is done to search for known MMP-9
substrates. Novel MMP-9 substrates are conﬁrmed by cleavage
of the recombinant or puriﬁed substrate in vitro or by Western
blot analysis of digested and undigested cytosol with a
substrate-speciﬁc antibody.
Application of 2D-degradomics to THP-1 cytosol unveils
multiple MMP-9 candidate substrates
THP-1 cytosol was extracted by ultracentrifugation at pH 9.2
and 2D-degradomics was applied as described above and in
the section of ‘Materials and Methods’. About 80 IEC
fractions were dialyzed, concentrated 2–10 times and
incubated in the absence or presence of 100 nM MMP-9 for
24 h. The digested fractions were then analyzed on multiple
SDS-PAGE gels, a representative gel of which is shown as
an illustration in ESI, Fig. A.w Hence, with an estimated
average ofB25 protein bands per fraction, a total number of
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Fig. 1 Flow charts of 2D-degradomics and fragment degradomics. (A) Before 2D-degradomics, the pH of the cell or tissue extract to be analyzed is ﬁrst
adjusted to pH 9.2, creating a net negative charge in the bulk of the proteins. In the ﬁrst dimension, the protein mixture is applied to a cation exchange
chromatography column (CEC) that binds and fractionates the alkaline proteins (with a positive charge at pH 9.2). The ﬂow through fractions with the
negatively charged proteins are pooled and fractionated by anion exchange chromatography (AEC). All resulting elution and ﬂow through fractions are
dialyzed to remove the salts, concentrated and incubated separately in the absence or presence of MMP-9. In the second dimension, cleaved and
uncleaved fractions are further fractionated by molecular mass upon SDS-PAGE analysis. Protein bands that disappear or decrease after incubation with
MMP-9 or novel fragments that appear indicate potential MMP-9 substrates. These diﬀerential bands are cut out of the gels and identiﬁed by MS/MS
after in-gel tryptic digestion. Alternatively, the analyzed fractions are electroblotted onto PVDF and identiﬁed by Edman degradation. Finally, a
literature search is performed to seek for substrates that have already been described. Other candidate substrates are conﬁrmed biochemically by cleavage
of the recombinant or puriﬁed substrate in vitro or by Western blot analysis of cleaved and uncleaved cytosol with substrate-speciﬁc primary antibodies.
(B) Before fragment degradomics, the pH of the cell or tissue extract/fraction to be analyzed is brought to pH 9.2, and subjected to cation exchange
chromatography (CEC), as described for 2D-degradomics. The pooled CEC ﬂow through fractions are neutralized and incubated in the absence or
presence of 100 nMMMP-9 for 24 h. Next, the ‘fragment fractions’ (3–50 kDa) are enriched on micro-spin columns by centrifugal ﬁltration through a
50 kDa cut-oﬀ membrane, and subsequent centrifugal dialysis and concentration of the ﬁltrate on a 3 kDa limiting membrane. Finally, the concentrated
‘fragment fractions’ are analyzed on SDS-PAGE to detect MMP-9-generated diﬀerential bands. Protein bands that disappear or decrease after
incubation withMMP-9 or novel fragments that appear are potential MMP-9 substrates. These diﬀerential bands are cut out of the gels and identiﬁed by
MS/MS after in-gel tryptic digests. Alternatively, the analyzed fractions are electroblotted onto PVDF and identiﬁed by Edman degradation. Finally, a
literature search is performed to seek for known substrates. Other candidate substrates are conﬁrmed biochemically by cleavage of recombinant or
puriﬁed substrates in vitro or by Western blot analysis of cleaved and uncleaved cytosol with substrate-speciﬁc primary antibodies.
406 | Integr. Biol., 2009, 1, 404–426 This journal is c The Royal Society of Chemistry 2009
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B2000 proteins were separated and visualized by 2D-degradomics.
In this way, 100–200 potential MMP-9 substrates were
detected. Subsequently, B60 substrates were identiﬁed by
MS/MS after in-gel tryptic digests, whereas one substrate
fragment was also identiﬁed by Edman degradation (Table 1).
Additional potential MMP-9 substrates identiﬁed by
‘fragment degradomics’
In an alternative degradomic approach refered to as ‘fragment
degradomics’ (Fig. 1B), the total protein mixtures (pooled CEC
ﬂow through fractions) were incubated in the absence or
presence of 100 nM MMP-9 for 24 h. Next, the ‘fragment
fractions’ (3–50 kDa) were enriched on micro-spin columns by
subsequent centrifugation through a 50 kDa cut-oﬀ membrane,
followed by centrifugal dialysis and concentration of the ﬁltrate
on a 3 kDa membrane. Finally, the concentrated retentate was
analyzed on SDS-PAGE to detectMMP-9-generated diﬀerential
bands as exempliﬁed in ESI, Fig. B.w The fragments of
potential MMP-9 substrates were cut out of the gel and
identiﬁed by MS/MS. Substrates (e.g. stathmin and adenylyl
cyclase-associated protein-1) that were previously identiﬁed by
2D-degradomics were also detected by fragment degradomics
(Table 2). In addition, seven novel candidate substrates were
identiﬁed by this fragment-enriching approach.
Conﬁrmation of the cleavage of intracellular candidate
substrates by MMP-9
As a ‘proof-of-principle’ of both multidimensional degrado-
mic approaches, our data were confronted with an in-depth
literature search for known MMP-9 substrates. Indeed, the
intracellular MMP-9 substrate CAP1 that was discovered by
our one-dimensional degradomic approach6 was identiﬁed by
both multidimensional methods. Of the 69 candidate
substrates discovered by 2D-degradomics and fragment
degradomics, 14 proteins (20%) were previously identiﬁed as
MMP-9 (candidate) substrates (Table 1 and 3) by highly
diverging approaches, ranging from 2-dimensional gel electro-
phoresis to a label-free ultra performance liquid chromato-
graphy (UPLC)-based approach.3,4,20,21 Hence, this 20%
overlap with other methods is a ﬁrst corroboration of our
approaches. In addition, about half of the substrates listed in
Table 1 are known MMP (candidate) substrates (Table 3).
Conﬁrmed MMP substrates (discovered by proteomic or other
approaches and validated biochemically or by in vivo cleavage)
are considered to be high-conﬁdence MMP-9 candidate sub-
strates. Potential substrates that were identiﬁed both as a
substrate (band disappearing or decreasing after incubation
with MMP-9) and as a fragment (a novel protein band
appearing in the presence of MMP-9), or that were identiﬁed
in many fractions, also represent strong candidate substrates.
However, we acknowledge that these high-conﬁdence candi-
date substrates need to be conﬁrmed in vivo or by biochemical
assays with puriﬁed MMP-9 before being considered as novel
MMP-9 substrates. Selection of candidate substrates for bio-
chemical validation was based on the propensity of the protein
to be an interesting physiological target. The availability of
recombinant or puriﬁed proteins and primary antibodies
of good quality was another crucial factor. In addition,
both strong and low conﬁdence candidate substrates (single
identiﬁcation) were chosen for validation.
THP-1 cytosol was incubated in the absence or presence of
various concentrations of activated MMP-9, supplemented or
Table 2 MMP-9 (candidate) substrates identiﬁed in THP-1 cytosol
by ‘fragment degradomics’
Candidate substrates previously identiﬁed by 2D-degradomics
Adenlyl cyclase-associated protein-1
Stathmin
Novel candidate substrates identiﬁed by fragment degradomics
Carbonic anhydrase II
Cyclophilin A
Glutathion S-transferase P
ISG15 ubiquitin-like modiﬁer
Peroxiredoxin 6
Tubulin-speciﬁc chaperone A
UMP-CMP kinase
Table 3 Known MMP-9 or MMP (candidate) substrates identiﬁed
by 2D-degradomics and fragment degradomics
(Candidate) substrate MMP(s) responsiblea Ref(s).
b-Actin MMP-9 21
g-Actin MMP-9 21
Actin regulatory protein
CAP-G
MMP-9, MMP-2, -14 18, 19, 21
Actin-related protein 2 MMP-14 18
Adenylyl cyclase-associated
protein-1
MMP-9, MMP-2, -8,
-13, -14
6, 18
Aldolase A MMP-9, MMP-14 18, 21
Annexin I MMP-2 19
Cyclophilin A MMP-9, MMP-14 18, 21
Elongation factor 1-a1 MMP-9, MMP-14 18, 21
Elongation factor 2 MMP-14 18
Endoplasmic reticulum protein
Erp29
MMP-14 18
a-Enolase MMP-2 19
Eukaryotic translation
Initiation factor 5A
MMP-14 18
Ezrin MMP-14 18
Gelsolin MMP-9, MMP-1, -2,
-3, -14
3, 4
High-mobility group
protein B1
MMP-14 18
High-mobility group
protein B2
MMP-2, -14 18, 19
Heat shock cognate protein 70 MMP-9, MMP-2, -14 18, 19, 21
Heat shock protein 90a MMP-2, -14 18, 19, 21
Heat shock protein 90b MMP-9 21
Jo-1 MMP-2, -14 18, 21
Moesin MMP-9, MMP-14 18, 21
Nucleolin MMP-2 19
Nucleoside diphosphate kinase MMP-9 21
Oxygen-regulated protein 150 MMP-14 18
Peroxiredoxin-6 MMP-9, MMP-2 20
Phosphoglycerate kinase 1 MMP-9, MMP-14 18, 21
Small nuclear
ribonucleoprotein Sm D3
MMP-14 18
Threonyl-tRNA synthetase MMP-9, MMP-14 18, 21
a-Tubulin MMP-9, MMP-14 18, 21
b-Tubulin MMP-9, MMP-14 18, 21
a MMP substrates that were only identiﬁed by a proteomic approach
and not yet conﬁrmed by biochemical assays or in vivo cleavage are
considered MMP candidate substrates. MMP(s) cleaving bio-
chemically conﬁrmed substrates are shown in bold, whereas MMP(s)
cleaving candidate substrates are shown in italics.
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not with the metalloprotease inhibitors 1,10-o-phenanthroline
or EDTA. Western blot analysis of these digestions with
substrate-speciﬁc primary antibodies led to the conﬁrmation
of annexin I, nucleolin, stathmin, HMGB1 and b- and g-actin as
novel intracellular MMP-9 substrates (Fig. 2). Interestingly,
no HMGB1 cleavage was observed after Western blot analysis
of unfractionated cytosol (data not shown). However, in vitro
cleavage of HMGB1 by MMP-9 was conﬁrmed by Western
blot analysis of the concentrated IEC fraction in which it was
identiﬁed during 2D-degradomics (Fig. 2). This underscores
that multidimensional degradomics allows for the identiﬁca-
tion of lower abundancy and lower-aﬃnity, but still
physiologically interesting substrates, that may be missed with
other methods that are restricted in their loading capacity.
For the cleavage assays the recombinant or puriﬁed candi-
date proteins were incubated with various MMP-9 concentra-
tions, supplemented or not with the metalloprotease inhibitor
EDTA and analysed by SDS-PAGE. In this way, we validated
a- and b-tubulin, a-, b- and g-actin, citrate synthase, the
autoantigen Jo-1 and most subunits of the actin-related
protein-2/3 (Arp2/3) complex as intracellular MMP-9 targets
(Fig. 3 and 4). Both rabbit skeletal muscle (a-actin, Fig. 3) and
human non-muscle platelet actin (b- and g-actin, Fig. 4) were
cleaved by MMP-9. Human skeletal muscle actin (a-actin) and
human non-muscle actin (b- and g-actin) were cleaved
with comparable eﬃciencies (data not shown), which is not
surprising since the amino acid-homology between the three
main actin isotypes is more than 90%. All subunits of the
Arp2/3 complex were cleaved after long incubation intervals
and with high enzyme/substrate ratios, except for actin-related
protein 3 (ARP3) (Fig. 3 and 4). The subunits ArpC1A and
ArpC5L, were cleaved most eﬃciently. Of the candidate
substrates selected for validation by in vitro cleavage assays,
only carbonic anhydrase II was not conﬁrmed (data not
shown), suggesting the action of a proteolytic cascade
including MMP-9 in the IEC fraction.
When clear and abundant fragment bands were detected,
the digested and undigested substrates were analyzed by
SDS-PAGE and transferred to PVDF by electroblotting.
Cleavage sites were determined by Edman sequencing of the
fragment NH2-termini (Fig. 4). In addition, cleavage sites may
also be determined directly in electroblotted IEC fractions, as
was done for stathmin (cf. Fig. 4E). Several protein bands
were resistant to Edman sequencing (indicated by asterisks in
Fig. 4), but others were identiﬁed by direct protein sequencing.
When non-human puriﬁed proteins were used for in vitro
cleavages and cleavage site determinations, all detected
cleavage sites were in stretches of 100% amino acid identity
between the human and other species. Likewise, the major
actin cleavage site (Glu46-Met47) was determined in human
platelet actin (a mixture of b- and g-actin) in a region of 100%
identity between the three main actin isotypes (a, b and g).
Most MMP substrates are cleaved by more than one MMP
due to the broad homology and redundancy in the MMP
family.2,18 Table 3 shows that proteolysis of intracellular
substrates is not restricted to MMP-9. Hence, Western blot
analysis and in vitro cleavage assays of several substrates were
repeated with equal amounts of activated MMP-9, gelatinase
A/MMP-2, the collagenases MMP-1, MMP-8 and MMP-13
and the catalytical domain of stromelysin-1/cd-MMP-3
(Fig. 5). The tested substrates were all cleaved by various
MMPs, with a variable substrate-dependent eﬃciency pattern
among the MMPs used. Carbonic anhydrase II, which was not
clearly proteolyzed by MMP-9 in vitro, was cleaved by
MMP-13, conﬁrming it as an MMP target. Interestingly,
MMP-13 was able to cleave all the tested intracellular
proteins, most of these with high eﬃciency (Fig. 5).
Degradation of the intracellular matrix (ICM) by MMPs
As recent studies showed that MMPs also degrade various
proteins of the intracellular matrix (ICM), 3–6 we examined
whether the candidate substrates identiﬁed by multi-
dimensional degradomics (Table 1) include ICM proteins.
A literature search was performed to investigate which mole-
cules are associated with the cytoskeleton, more speciﬁcally
Fig. 2 Conﬁrmation of novel intracellular MMP-9 substrates by
Western blot analysis. THP-1 cytosol was incubated in the
absence (tF, ) or presence (+) of activated MMP-9 (200–1.6 nM,
decreasing from lane 3 to 6; 500–0.8 nM, decreasing from lane 3 to 7
for actin). Control incubations included incubation with 40 nM
activated MMP-9 supplemented with 10 mM of the metalloprotease
inhibitors 1,10-o-phenantroline or EDTA (MP-I), and addition of
equivalent amounts of the catalytical domain of MMP-3 (cd-MMP-3,
2 nM), used to activate MMP-9. Western blot analysis with substrate-
speciﬁc primary antibodies conﬁrmed cleavage of the substrates
annexin I, nucleolin, stathmin, HMGB1 and b- and g-actin by
MMP-9. To detect actin cleavage, antibodies against the NH2-terminus
(NH2-AB) or against the COOH-terminus (COOH-AB) were used
separately to discern NH2- and COOH-terminal truncations. Analysis
of the substrate before incubation is marked as t0. Incubation intervals
were 4.5 h for annexin I, nucleolin and stathmin analysis, 18 h for
HMGB1 and 24 h for actin cleavage.
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with the actin meshwork and/or with microtubuli (Table 4).
About 40% of the identiﬁed candidate substrates are compo-
nents of the ICM or associated with ICM proteins. 30% of the
substrates are connected with the actin cytoskeleton, whereas
17% show association with microtubuli.
Multiple intracellular MMP-9 candidate substrates are
described autoantigens
To integrate the results in a broad immunological context, a
literature search was conducted to determine if the list of
MMP-9 candidate substrates (Table 1) contained known
autoantigenic molecules. Candidate substrates that have been
described as autoantigenic molecules and the pathology in
which they were discovered are listed in Table 5. Interestingly,
autoantibodies against 61% of the discovered intracellular
MMP-9 candidate substrates have been described in patho-
logic conditions. About 50% of the candidate substrates
are autoantigens in one or more autoimmune conditions,
whereas 30% of the intracellular MMP-9 substrates are
known cancer-associated antigens. Many candidate substrates
correspond to autoantigens in multiple conditions. 32% of the
potential substrates are autoantigens in the prototypic
systemic autoimmune condition systemic lupus erythematosus
(SLE). Known prevalences (%) of these autoantigens in SLE
were added to Table 5. Furthermore, 16% of the identiﬁed
substrates are autoantigens in systemic sclerosis, 17% in
Sjo¨gren’s syndrome, 27% in rheumatoid arthritis, 20% in
inﬂammatory bowel disease and 20% in various (autoimmune)
liver diseases. In conclusion, proteolysis of intracellular
autoantigens by MMP-9 or other inﬂammation-associated
proteases may aﬀect multiple (systemic) pathologies.
Discussion
Matrix metalloproteinases (MMPs) are notoriously known for
their ECM remodeling functions as well as for their regulatory
‘processing’ of cytokines, protein hormones, chemokines and
cell membrane-bound molecules.1,2 However, the intracellular
Fig. 3 Conﬁrmation of novel intracellular MMP-9 substrates by in vitro cleavage of recombinant or puriﬁed proteins. Proteins were incubated in the
absence (tF, ) or presence (+) of various concentrations of activated MMP-9 (decreasing from lane 3 to 6 or 7). Control incubations included
incubation with activated MMP-9 supplemented with the metalloprotease inhibitor EDTA and addition of equivalent amounts of the catalytical
domain of MMP-3 (cd-MMP-3), used to activate MMP-9. In addition, the highest concentration of MMP-9 was also incubated separately in assay
buﬀer as a control for non-substrate fragment bands. Molar enzyme : substrate (E : S) ratios ranged between (1 : 1250 to 1 : 10) for tubulin, Jo-1
and citrate synthase, and between (1 : 6250 to 1 : 10) for skeletal muscle actin. For the Arp2/3 complex mass E : S ratios were (1 : 625 to 1 : 5). The
duration of incubation was 4.5 h for tubulin cleavage, 18 h for proteolysis of Jo-1, the Arp2/3 complex and citrate synthase, and 24 h for actin.
SDS-PAGE analysis shows concentration-dependent degradation of the substrates by MMP-9 and generation of multiple fragments (*).
Visualization of the substrate before incubation is indicated by t0. Apparent molecular masses are shown in Da at the right side of the gels.
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Fig. 4 Identiﬁcation of the MMP-9 cleavage sites by Edman sequencing. Recombinant/puriﬁed proteins were incubated in the absence (tF, ) or
presence (+) of various concentrations of activated MMP-9. The highest MMP-9 concentration was also incubated separately in assay buﬀer as a
control for non-substrate fragment bands. The incubated samples were transferred to PVDF by electroblotting and novel NH2-termini of fragment
bands were sequenced by Edman degradation. Identiﬁed NH2-terminal sequences are indicated on a black background together with the MMP-9
cleavage sites (grey arrows). When sequences were detected in multiple fragment bands (white arrowheads on the blots), the numbers of these
fragments were added between brackets above the black background of the sequenced stretch. Protein bands that were resistant to Edman
sequencing are marked with an asterisk (*). The intact substrate is indicated by a black arrow. Visualization of the substrate before incubation is
indicated by t0. Apparent molecular masses are shown in Da at the right side of the gels. Molar enzyme : substrate ratios and incubation intervals
were (1 : 50 to 1 : 5) and 4.5 h for tubulin (A); (1 : 10 to 1 : 2) and 18 h for Jo-1 (B); mass E : S (1 : 5 to 1 : 1) and 18 h for the Arp2/3 complex (C),
and (1 : 20 to 1 : 2) and 24 h for non-muscle platelet actin (D). Stathmin (E) was the only substrate to be identiﬁed by Edman degradation after
blotting of the ion exchange (IEC) fraction. Although the intact protein was resistant to Edman degradation, the NH2-terminal fragment that
misses the ﬁrst 28 amino acids could be sequenced.
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degradome of MMPs still remains relatively unexplored.219 In
our previous work we showed that gelatinase B/MMP-9
cleaves multiple intracellular protein substrates released dur-
ing cellular necrosis of human myelomonocytic THP-1 cells.6
In order to further characterize the intracellular degradome of
MMP-9, multidimensional degradomic approaches were
developed and applied to the cytosolic fraction of THP-1 cells.
By the application of both high-throughput methods termed
‘2D-degradomics’ and ‘fragment degradomics’, we were able
to isolate 100–200 candidate substrates of which a selection
was isolated and subjected to MS/MS. Of this selection, about
70 intracellular MMP-9 candidate substrates were identiﬁed.
The intracellular MMP-9 substrate CAP1, discovered by our
one-dimensional degradomics approach,6 was corroborated
with both new approaches. In addition, about 25% of the
deﬁned substrates were identiﬁed previously as MMP-9
candidate substrates by diverse proteomic approaches,
ranging from two-dimensional gel electrophoresis to a label-
free ultra performance liquid chromatography (UPLC)-based
approach.3,4,20,21 Biochemically or in vivo conﬁrmed MMP
substrates are considered to be high-conﬁdence MMP-9
candidate substrates. Potential substrates that were identiﬁed
both as a substrate and as a fragment or corroborated
by identiﬁcation in many diﬀerent IEC fractions, also
represent high-conﬁdence candidate substrates. A selec-
tion of both strong and low conﬁdence candidates (single
identiﬁcation) was subjected to in vitro cleavage of the recom-
binant or puriﬁed substrate, or to substrate-speciﬁc Western
blot analysis of MMP-9-digested and intact cytosol (or IEC
fractions) for conﬁrmation. In this way, the tested high-
conﬁdence (a-, b- and g-actin, HMGB1, stathmin) and low-
conﬁdence (a- and b-tubulin, annexin I, nucleolin, Arp2/3
complex subunits, Jo-1, citrate synthase, carbonic anhydrase
II) candidates were conﬁrmed as novel intracellular MMP-9
substrates. The only exception was carbonic anhydrase II,
whose original cleavage might have been indirect e.g. by an
MMP-9-activated protease. However, carbonic anhydrase II
was clearly degraded by MMP-13 (Fig. 5). MMP-13 was most
eﬃcient at the cleavage of several tested intracellular sub-
strates. Interestingly, a recent study found activated MMP-13
in the nucleus of neural cells after cerebral ischemia,220
identifying MMP-13 as a probable candidate for intracellular
proteolytic actions. These biochemical conﬁrmations point to
the robustness of our multidimensional degradomics
approaches, and also highlight the need for conﬁrmation of
proteomic results by complementary methods. Besides the
high validity of the identiﬁcations, these unprejudiced,
systematic approaches have a number of advantages in
comparison with other current methods. First, the substantial
loading capacity of ion exchange columns makes it possible to
start with a high protein amount. This, together with the
concentration of the ion exchange fractions in 2D-degradomics,
Fig. 5 Proteolysis of novel intracellular MMP-9 substrates by various MMPs. THP-1 cytosol and the puriﬁed or recombinant substrates were
incubated without (tF) or in the presence of active MMP-9, -2, -1, -8, -13 and the catalytical domain of MMP-3 (cd-MMP-3). THP-1 cytosol was
incubated for 4.5 h and MMP concentrations were 100 nM for actin and stathmin, and 5 nM for nucleolin. Molar enzyme : substrate (E : S) ratios
were (1 : 20) for tubulin, and Jo-1, and (1 : 30) for carbonic anhydrase II. Mass E : S for the Arp2/3 complex was (1 : 2.7). The substrates were
incubated for 18 h, except for tubulin (4.5 h). SDS-PAGE and/or Western blot analysis of these digestions show a comparison of the proteolysis of
the intracellular substrates by the MMPs tested. Analysis of the substrate before incubation is marked as t0.
416 | Integr. Biol., 2009, 1, 404–426 This journal is c The Royal Society of Chemistry 2009
allowed us to identify low abundancy class substrates that
might have been missed starting from a small unfractionated
protein sample. HMGB1, HMGB2, hepatoma-derived growth
factor, nitrilase homolog 2, positive cofactor 4 and c-myc-
responsive protein Rcl are examples of low abundancy class
molecules identiﬁed in our screening. Second, by incubating
fractionated cytosol with MMP-9, less bias occurs for highly
abundant, high-aﬃnity substrates that ‘consume’ the protease
in a complex mixture and mask lower-aﬃnity, but still
potential physiological substrates. Indeed, HMGB1 was not
cleaved in unfractionated cytosol in the presence of highly
abundant substrates such as actin, tubulin and CAP1.
However, cleavage by MMP-9 was clearly detected in the
corresponding ion exchange fraction and may be of physio-
logical interest during necrosis (vide infra). In addition,
2D-degradomics, with fractionation before MMP-9 cleavage,
yields 10–20 times more identiﬁcations in comparison with
cleavage of the total protein pool in fragment degradomics.
Third, as these straightforward degradomic approaches do not
require complex and expensive equipment, the application of
this technology is accessible to every laboratory with interest in
protease degradomics. Fourth, although these methods only
yield in vitro substrates, the extensive and unbiased list of
candidates generated by this technology may reveal unexpected
target proteins that can be further validated in the corresponding
in vivo disease models. Finally, multidimensional degradomics
can be extended to other cell types, culture media, tissues or
body ﬂuids, to various time points or concentrations, and
to the use of additional MMPs, proteases and protease
inhibitors, turning it into a novel powerful tool for the
mapping of the intracellular MMP degradome, as well as for
high-throughput identiﬁcation of new protease substrates.
Remarkably, about 40% of the identiﬁed candidate sub-
strates are components of the intracellular matrix (ICM) or
associated with ICM proteins. Identiﬁcation of less abundant
substrates, for example by the use of the more sensitive silver
stain technique, or by the application of other more sensitive
technology may lower this 40% of ICM molecules in the
substrate list. However, the fact that so many ICM molecules
are degraded byMMP-9 and other MMPs is noteworthy. 30%
of the potential substrates are connected with the actin
cytoskeleton, whereas 17% of the candidates show association
with microtubuli. Both actin and tubulin proteins were shown
to be degraded into multiple fragments. This suggests that
MMP-9 may facilitate extracellular clearance of these highly
abundant proteins. The major cleavage of actin by MMP-9 at
the NH2-terminus between Gly46 and Met47 may suppress
actin polymerization as the actin NH2-terminus (Asp2-Val43)
contains one of the sites for protein-protein interaction that
are involved in the actin ﬁlament formation.221,222 Indeed,
actin truncated by neutrophil elastase between Val43-Met44
was no longer able to polymerize.223 Besides a binding site for
actin-binding proteins that regulate actin function and
polymerisation,224,225 the actin NH2-terminus contains the
DNaseI-binding loop of actin (residues 38-52).222 Proteolytic
modiﬁcations of loop 38-52 by subtulisin, chymotrypsin and
other proteases have been shown to perturb or abolish salt-
induced polymerization and the DNaseI-inhibitory capacity of
actin.226–230 In addition, the NH2-terminal polypeptide
cleaved oﬀ by neutrophil elastase (residues 2–43) suppresses
neutrophil motility and chemotaxis, as well as elastase
production by stimulated neutrophils.223 Integration of this
knowledge leads to the conclusion that the major MMP-9
cleavage of actin at Gly46-Met47 has profound eﬀects on
physiological and pathological actin functions.
The other main cytoskeleton component is the microtubule-
building block, tubulin, which is composed of a heterodimer of
a- and b-tubulin, both of which were shown to be extensively
cleaved by MMP-9. The acidic COOH-terminal tails of a- and
b-subunits have considerable functional signiﬁcance as they
form the docking site for many microtubule-regulating
proteins and are the subject of most post-translational
modiﬁcations that regulate actin function.231 Removal of the
COOH-terminal ends of both subunits by subtulisin lowers the
critical concentration for polymerization about 50-fold.232
Likewise, proteolysis of a-tubulin by granzyme B
(at Asp438-Ser439) and by granzyme M (at Leu269-Ala270)
both signiﬁcantly enhance polymerization rates in vitro and
induce microtubule network disorganization in tumor cells
in vivo, which likely contributes to cell death.233–235 b-Tubulin
is not cleaved by granzyme A and B, but by granzyme K
(at Arg62-Ala63 and Arg282-Ala283).236 In addition,
COOH-terminal truncations of b-tubulin lacking Ala428 yield
tubulins which are not compatible with microtubule
formation.237 As MMP-9 removes the acidic tails in both
a- and b-subunits, including Ala428 in b-tubulin, it is very
likely that proteolytic modiﬁcation of tubulin by MMP-9
perturbs or abolishes tubulin functions.
Besides the major cytoskeleton constituents, actin and
tubulin, many high-conﬁdence or conﬁrmed MMP-9 targets
are cytoskeleton-associated proteins which regulate actin and
microtubule polymerization and function. Degradation of
these essential actin/tubulin-binding proteins may avert
branching and polymerization in the extracellular space, thus
preventing concomitant extracellular cytoskeleton toxicity.
The actin-related protein-2/3 (Arp2/3) complex has a crucial
role in the formation of branched-actin-ﬁlament networks
during diverse processes ranging from cell motility to
phagocytosis.23 CAP1 promotes rapid actin turnover and is
important for cell morphology, migration and endocytosis.26,27
Ezrin and moesin are members of the Ezrin/radixin/moesin
(ERM) family of proteins, which have been reported to
function as cross-linkers between the plasma membrane and
the cortical cytoskeleton.30 Filamin-B is one of the ﬁlamins,
which can crosslink actin ﬁlaments to form orthogonal
networks and connect membrane proteins to the actin
cytoskeleton.32 Gelsolin is an actin-ﬁlament severing and
capping protein involved in cell motility, phagocytosis and
apoptosis.33 In addition to this cytoplasmic regulator of actin
organization, the gelsolin gene expresses a splice variant
coding for a distinct isoform, plasma gelsolin, which is
secreted into extracellular ﬂuids. The secreted form of gelsolin
has been implicated in a number of processes such as the
extracellular actin-scavenging system and the presentation of
lysophosphatidic acid and other inﬂammatory mediators to
their receptors.238 The extracellular actin-scavenging system in
the vascular compartment involves 2 proteins: gelsolin that
releases monomers from the toxic ﬁlaments, and Gc-globulin,
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which complexes the freed monomers. Both actin-gelsolin and
actin-Gc-globulin complexes are subsequently cleared by the
hepatic phagocytosis system much more eﬃciently than free
proteins (half-lives of 30 min vs. 1–2 days, respectively).
Nevertheless, excessive release of cellular actins or decreased
activity of the actin-scavenger system causes severe patho-
logical conditions such as hepatic necrosis, adult respiratory
distress syndrome (ARDS), septic shock, and complications of
pregnancy, as discussed previously.8–12 Plasma gelsolin has
been shown to be cut into several fragments by various
MMPs, including MMP-9, which resulted in considerable loss
of its depolymerizing activity.3,4 This suggests that MMPs may
weaken the extracellular actin-scavenging system by cleaving
gelsolin, culminating in or enhancing pathological conditions
induced by extracellular actin. Conversely, as MMP-9 and
other MMPs degrade actin, they may contribute to actin
clearance and scavenging. Hence, it is a great challenge to
elucidate whether the sum of the proteolytic activities present
at the site of injury enhance or, on the contrary, decrease
clearance of extracellular actin.
Among the microtubule-binding proteins, stathmin was
shown to be a key regulator of microtubule dynamics.
Stathmin causes depolymerization of microtubule ﬁlaments
into small tubulin oligomers and inhibits polymerization of
tubulin monomers. This activity is inhibited by reversible
phosphorylation of four serine residues (Ser16, Ser25, Ser38,
Ser63).41,239 Proteolysis of stathmin by MMP-9 between Ser28
and Lys29 removes two of these regulatory phosphorylation
sites as well as a tubulin binding site. In addition, the
NH2-terminal capping domain, which inhibits longitudinal
protoﬁlament contacts,239 is disrupted by MMP-9. As a
consequence, disturbing stathmin actions may be an
additional eﬀect of MMP-9 on tubulin function. In
conclusion, unveiling the biological signiﬁcance of ICM
protein proteolysis by MMPs and its consequences on inﬂam-
mation and extracellular actin toxicity and immunogenicity
after tissue injury, may attribute novel (immuno)regulatory
properties to MMP-9 and other ICM-degrading proteases.
The role of gelatinase B/MMP-9 in the pathogenesis of
organ-speciﬁc autoimmune diseases has been well established,
e.g. generating remnant epitopes of myelin basic protein,15
interferon-b240 or aB-crystallin241 in multiple sclerosis, of
insulin in diabetes16 and of collagen type II in rheumatoid
arthritis.14 Most of these substrates are naturally occurring in
the extracellular milieu. One of the goals of the present study
was to examine systemic autoimmune antigens, which most
often are ubiquitous intracellular proteins. We found that
autoantibodies against about 2/3 of the discovered intra-
cellular MMP-9 candidate substrates have been described in
multiple pathologies: 50% of the candidate substrates were
found to be autoantigenic targets in (an) autoimmune
condition(s), whereas 30% of the intracellular MMP-9
substrates were described as cancer-associated antigens.
Systemic autoimmune diseases are a genetically complex
heterogenous group of diseases in which the immune system
targets a diverse, but highly speciﬁc group of ubiquitous
intracellular autoantigens. It has not been fully clariﬁed how
these normally sequestered molecules are rendered capable of
sustaining a prolonged autoimmune response. However,
increasing evidence points to a tolerance-breaking role for cell
death abnormalities, such as increased rates of apoptosis
and/or defective clearance of apoptotic cells.242,243 Indeed, in
systemic autoimmune diseases associated with impaired
clearance of apoptotic cells, the unphagocytosed apoptotic
cell load may undergo secondary necrosis, exposing intra-
cellular proteins to cell death-associated post-translational
modiﬁcations. These modiﬁcations may enhance autoantigen
immunogenicity by presenting novel or cryptic self epitopes
to the immune system for which tolerance has not been
established. Repeated stimulation by these neo-epitopes could
induce and sustain an autoantibody response.244–247 Auto-
antigen proteolysis is one of the major post-translational modiﬁ-
cations generating neo-epitopes.7,244,248 Interestingly, Casiano
and co-workers showed that distinct autoantigen cleavage
products are generated during necrosis vs. apoptosis, probably
by diﬀerent proteases, as the cleavages were caspase-independent
vs. caspase-dependent, respectively.249 In addition, the
progression from apoptosis to secondary necrosis was also
shown to be associated with additional proteolysis of speciﬁc
autoantigens in a caspase-independent manner.250 As MMP-9
was shown to proteolyse intracellular proteins released
from necrotic cells,6 it would be tempting to speculate that
MMPs may contribute to these necrosis-associated caspase-
independent cleavages, triggering or stimulating systemic
autoimmunity. For example, cleavage of the autoantigen
Jo-1 or histidyl-tRNA synthetase by MMP-9 between the
residues Ala43 and Gln44 releases the Jo-1 NH2-terminus
which contains the major immunodominant epitope(s).251–253
In addition, both intact and granzyme B-cleaved Jo-1
(residues 1–48) can recruit CD4+ and CD8+ T cells, immature
Table 4 ICM-associated MMP-9 (candidate) substrates
Cytoskeleton association
Substrate Actin Microtubuli Ref(s).
a-Actin Yes No 22
b-Actin
g-Actin
Actin-related protein 2/3 complex Yes No 23
Apoptosis-linked-gene-2-
interacting-protein X
Yes No 24
Annexin I Yes No 25
Adenylyl cyclase-associated
protein-1
Yes No 26, 27
Actin regulatory protein CAP-G Yes No 28
Cyclophilin A No Yes 29
Ezrin Yes No 30
Fascin Yes No 31
Filamin B Yes No 32
Gelsolin Yes No 33
Heat shock protein 27 Yes Yes 34, 35
Heat shock cognate protein 70 Yes Yes 34
Heat shock protein 90a/b Yes Yes 34, 36
IQ motif containing GTPase
activating protein 1
Yes Yes 37
Microtubule-associated protein RP No Yes 38
Moesin Yes No 30
Nucleolin Yes No 39
Nucleoside diphosphate kinase No Yes 40
Stathmin No Yes 41
Tubulin-speciﬁc chaperone A No Yes 42
a-Tubulin No Yes 43
b-Tubulin
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Table 5 Autoantigenic MMP-9 (candidate) substrates
Substrate Disease (autoantigen %)a Ref(s).
a-Actin SLE (9–26%), systemic sclerosis, autoimmune and chronic hepatitis, various liver
disorders, coeliac disease (90%), Sjo¨gren’s syndrome, rheumatoid arthritis,
idiopathic nephrotic syndrome, autoimmune inner ear disease, autoimmune
neutropenia, Crohn’s disease, ulcerative colitis, cardiovascular diseases, acute
leukemia, EAU, visceral leishmaniasis
44–66
b-Actin
g-Actin
Aldolase A Rheumatoid arthritis, diabetic retinopathy, Alzheimer’s disease, chronic myloid
leukemia, acute and chronic hepatitis
67–71
Annexin I SLE (23–32%), rheumatoid arthritis, dermatomyositis, psoriasis, inﬂammatory
bowel disease, immunoinfertility, lung cancer, asthma
55, 72–80
Adenylyl cyclase-associated
protein-1
SLE, rheumatoid arthritis 55, 81, 82
Carbonic anhydrase II SLE (24–32%), systemic sclerosis, Sjo¨gren’s syndrome, polymyositis, type 1
diabetes, primary biliary cirrhosis, ulcerative colitis, Graves’ disease, autoimmune
pancreatitis, (autoimmune) liver disease, endometriosis
55, 83–91
Citrate synthase SLE, rheumatoid arthritis, systemic sclerosis, undiﬀerentiated connective tissue
disease, polymyositis/dermatomyositis, Raynaud syndrome, Sjo¨gren’s syndrome,
primary biliary cirrhosis, allograft vasculopathy
92–94
Cyclophilin A SLE, Lyme disease 95, 96
Elongation factor 1-a1 SLE, rheumatoid arthritis, myositis, Q fever, atopic dermatitis 55, 81, 82, 97–99
Elongation factor 2 SLE 100
a-Enolase SLE (24–27%), systemic sclerosis, mixed cryoglobulinemia, Hashimoto’s
encephalopathy, rheumatoid arthritis, Behc¸et’s disease, Kawasaki disease,
relapsing polychondritis, acute and chronic myloid leukemia, opsoclonus myclonus
syndrome, autoimmune and cancer-associated retinopathy, multiple sclerosis, lung
cancer, premature ovarian failure, ‘‘wet’’ age-related macular degeneration, severe
asthma, pituitary diseases, post-streptococcal autoimmune CNS disease,
autoimmune liver disease, membranous nephropathy, inﬂammatory bowel disease,
endometriosis, vasculitis, coeliac disease
55, 65, 66, 71, 82,
101–122
Eukaryotic translation
initiation factor 5A
Ovarian cancer 123
Ezrin Rheumatoid arthritis 124
Ferritin light chain Rheumatoid arthritis 125
Filamin B Experimental lupus nephritis, myasthenia gravis, chronic lymphocytic leukemia 126–128
b-glucuronidase Wegener’s granulomatosis, polyarteritis, Churg Strauss syndrome,
glomerulonephritis, inﬂammatory bowel disease
129–131
Glutathione S-transferase P Autoimmune hepatitis, glaucoma 132, 133
Hepatoma-derived growth
factor
Ulcerative colitis 134
Histidyl-tRNA synthetase Anti-synthetase syndrome (60–80%), myositis, SLE, rheumatoid arthritis,
Sjo¨gren’s syndrome, cutaneous lupus, Sharp’s syndrome, Crohn’s disease,
cutaneous vasculitis, cirrhosis
97, 135, 136
High-mobility group
protein B1
SLE (HMGB1 37%; HMGB2 18%), rheumatoid arthritis, drug-induced lupus,
Sjo¨gren’s syndrome, systemic sclerosis, autoimmune hepatitis, primary biliary
cirrhosis, chronic hepatitis B and C, ulcerative colitis
55, 137–143
High-mobility group
protein B2
Heat shock protein 27 Guillain–Barre´ syndrome, Graves’ disease, immunoinfertility, glaucoma,
gynecologic cancer
35, 72, 144–147
Heat shock cognate
protein 70
SLE (35%), rheumatoid arthritis (5%), psoriatic arthritis (5%), juvenile
dermatomyositis, chronic hepatitis, Guillain–Barre´ syndrome, immune
thrombocytopenic purpura, type I diabetes, mixed connective tissue disease,
localized scleroderma, systemic sclerosis, autoimmune liver diseases, multiple
sclerosis, chronic myeloid leukemia, glaucoma, autoimmune hearing loss,
atherosclerosis, asthma, graft-versus-host-disease, heat-induced diseases, malaria,
Menie`re’s disease, cancer-associated retinopathy, Behc¸et’s disease, sarcoidosis, pars
planitis, Vogt–Koyanagi–Harada disease, autoimmune thyroiditis, Crohn’s disease
(8–14%), ulcerative colitis (23%), Sjo¨gren’s syndrome (0–8%), dilated
cardiomyopathy, Parkinson’s disease, schizophrenia, hepatocellular carcinoma,
ESCC, experimental autoimmune orchitis
48, 71, 109, 146,
148–173
Heat shock protein 90a/b SLE (25–50%), multiple sclerosis, Guillain–Barre´ syndrome, Crohn’s disease (4%),
ulcerative colitis (0–8%), Sjo¨gren’s syndrome (0–4%), acute mania, ovarian cancer,
breast cancer, autism, schizophrenia, graft-versus-host-disease, heat-induced
diseases, malaria, osteosarcoma
55, 146, 149, 157–159,
171, 174–182
IQ motif containing
GTPase activating
protein 1
Ovarian cancer, bullous skin disease 174, 183
Moesin Acquired aplastic anemia, rheumatoid arthritis 124, 184
Nucleolin SLE (17–64%), rheumatoid arthritis, Sjo¨gren’s syndrome, systemic sclerosis,
polymyositis, polymyalgia rheumatica, acute hepatitis A, infectious mononucleosis,
scleroderma-like graft-versus-host-disease
55, 185–187
Nucleosome assembly
protein 1-like 1
Colon adenocarcinoma 188
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dendritic cells and activated monocytes, whereas an NH2-
terminal deletion mutant has no such ‘recruiting’ activity.254
Remarkably, a unique form of Jo-1 exists in the lung that is
highly susceptible to cleavage by granzyme B and may be
associated with the onset of anti-Jo-1 myositis-interstitial lung
disease overlap syndrome. Since MMP-9 also releases the Jo-1
NH2-terminus (residues 1–43) this cleavage may contribute to
the onset and propagation of anti-Jo-1 autoimmunity in
myositis.
Auto-antibodies to both annexin I and nucleolin are found
with high incidence in systemic lupus erythematosus
(references in Table 5) and are degraded very eﬃciently by
MMP-9. Annexin I is a Ca2+/lipid-binding protein with
anti-inﬂammatory properties in its NH2-terminus. Annexin I
reduces neutrophil adhesion and emigration to inﬂamed
vessels and stimulates neutrophil apoptosis, possibly
preventing further tissue damage after inﬂammation.255,256
These anti-inﬂammatory actions of annexin I may be
terminated by proteolytic degradation. Indeed, a 33 kDa
truncation product was found in bronchoalveolar lavage ﬂuid
from patients with cystic ﬁbrosis. Annexin I appeared to be
truncated by neutrophil elastase at the NH2-terminal portion,
resulting in greatly diminished functional activity.257 Annexin
I was cleaved in a similar way by neutrophil proteinase 3. This
may be one of the proteinase 3 actions underlying its
pro-inﬂammatory phenotype, that is, removal of the
neutrophil-inhibitory properties of annexin I.258 Interestingly,
annexin I co-localizes with MMP-9 in the gelatinase granules
of neutrophils.259 In addition, MMP-9 also generates a 33 kDa
fragment from annexin I (Table 1).
High mobility group box 1 protein (HMGB1) is a
non-histone nuclear protein with a dual function. Inside the
cell, it binds DNA and regulates a variety of processes such as
transcription. During primary and secondary necrosis—but
not apoptosis—HMGB1 is passively released from the cell and
can function as an alarmin or ‘damage-associated molecular
pattern’ (DAMP)260 to alert the immune system after tissue
damage.261 As an alarmin, HMGB1 may play an important
pro-inﬂammatory role in the pathogenesis of multiple
rheumatic diseases.262 Development of autoantibodies to
HMGB1 is a common feature of many autoimmune disorders
(cf. Table 5). Increased levels of HMGB1 are found in the sera
of mice and patients with SLE.263 In addition, HMGB1-
nucleosome complexes detected in plasma from SLE patients
induce maturation of antigen-presenting cells, which may be
crucial for breaking the immunological tolerance against
nucleosomes/dsDNA.264 Thrombomodulin, an endothelial
thrombin-binding protein, binds HMGB1 and enhances
thrombin-mediated HMGB1 cleavage decreasing the
proinﬂammatory activity of HMGB1.265 In the light of these
major pro-inﬂammatory and ‘adjuvant’ roles of HMGB1, it
would be exciting to examine whether HMGB1 cleavage by
MMP-9 decreases or enhances its pathogenic eﬀects in
systemic autoimmune diseases. In conclusion, investigating
the eﬀect of proteolysis of intracellular autoantigens by
MMP(-9) on their immunogenic potential may yield novel
insights in the roles of MMPs in systemic autoimmunity.
Proteolysis is a key regulatory process that promotes the
(in)activation, translocation, and/or degradation of proteins.
As a consequence, the development of novel degradomics
tools is a booming ﬁeld.21,266–269 By the application of
multidimensional degradomics we started an unbiased
exploration of the proteolytic modiﬁcation of intracellular
proteins. Identiﬁcation of the intracellular MMP-9 substrate
repertoire and characterization of the cleavage sites are
essential for understanding the biological functions of intra-
cellular protein processing by MMP-9 and other proteases.
Extracellular proteolysis may be crucial to remove abundant
ICM proteins, in this way avoiding actin toxicity and immuno-
genicity after extensive necrosis, and dampening inﬂammation
after tissue injury. In accordance with the immunogenetic
make-up of an individual, proteolytic modiﬁcation of systemic
Table 5 (continued )
Substrate Disease (autoantigen %)a Ref(s).
Nucleoside diphosphate
kinase
Hepatocellular carcinoma 189
Oxygen-regulated protein
150
Type I diabetes 190
Peroxiredoxin 2 Breast carcinoma, immunoinfertility 72, 191
Peroxiredoxin 6 ESCC, periodontitis 192, 193
Phosphoglycerate kinase 1 SLE, experimental autoimmune orchitis 170, 194
Rho GDP dissociation
inhibitor (GDI) b
Acute leukemia 65
Small nuclear
ribonucleoprotein Sm D3
SLE (10–55%), Sjo¨gren’s syndrome, Chagas’ disease, tuberculosis, lymphoma 55, 195–200
SUMO-1 activating
enzyme subunit 2
Dermatomyositis 201
Threonyl-tRNA synthetase Anti-synthetase syndrome (5–15%), systemic sclerosis, polyarthritis, sclerodactyly 97, 202
a-Tubulin SLE, rheumatoid arthritis, multiple sclerosis, demyelinating polyneuropathies,
autoimmune thyroid diseases, Guillain–Barre´ syndrome, LHON, type I diabetes,
relapsing polychondritis, chronic myloid leukemia, Sydenham’s chorea, allergic
rhinitis, autoimmune hearing loss, nasopharyngeal carcinoma, hepatocellular
carcinoma, neuroblastoma, parasitic infections, acute leukemia, breast carcinoma,
EAU
49, 54, 55, 60, 64, 65,
71, 112, 189, 191,
203–218
b-Tubulin
a CNS, central nervous system; EAU, experimental autoimmune uveoretinitis; ESCC, esophageal squamous cell carcinoma; LHON, Leber’s
hereditary optic neuropathy; SLE, systemic lupus erythematosus. Known prevalences (%) of the autoantigen in a particular disease are shown in
parentheses.
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autoantigens may contribute to the generation of immuno-
dominant ‘neo-epitopes’, initiating or sustaining systemic
autoimmunity. The further study of the physiological and
pathological consequences of proteolysis of ICM molecules,
autoantigens, alarmins and other key molecules may result in
the discovery of novel roles for proteolytic modiﬁcation and
yield surprising immunologic and therapeutic insights. In this
way, our in vitro ﬁndings might be corroborated or challenged
by future data from in vivo experiments.
Materials and methods
Substrates and antibodies
Recombinant human Jo-1 was purchased from Diarect
(Freiburg, Germany). Porcine citrate synthase, bovine carbonic
anhydrase II and rabbit skeletal muscle actin were from Sigma
(St. Louis, MO, USA). Human skeletal actin, human
non-muscle platelet actin, bovine brain tubulin and the bovine
brain Arp2/3 complex were purchased from Cytoskeleton
(Denver, CO, USA). Rabbit polyclonal anti-annexin I
antibody (H-65) was purchased from Santa Cruz Biotechno-
logy (Santa Cruz, CA, USA). Rabbit polyclonal anti-nucleolin,
anti-HMGB1 and anti-actin antibodies were from Sigma.
Rabbit polyclonal anti-stathmin antibody was from
Calbiochem (Darmstadt, Germany).
Preparation of THP-1 cytosol
The human myelomonocytic cell line THP-1270 was cultured in
RPMI 1640 medium (Bio Whittaker Europe, Verviers,
Belgium), supplemented with 10% fetal calf serum
(Invitrogen, Carlsbad, California, USA) and 1.5% sodium
bicarbonate. At the end of the log phase, cells were collected
by centrifugation, washed 3-4 times with phosphate-buﬀered
saline (PBS) or physiological assay buﬀer (20 mM Tris/HCl,
pH 7.4, 150 mM NaCl, 10 mM CaCl2) and cell pellets were
stored at 20 1C. For ion exchange chromatography, the cell
extracts were resuspended in 20 mM ethanolamine pH 9.5
supplemented with a general proteinase inhibitor cocktail
(PI, Complete Mini EDTA-free, Roche, Basel, Switzerland)
(1 tablet/10 mL). Alternatively, for cleavage assays the cell
extracts were diluted in assay buﬀer (100 mM Tris/HCl, pH
7.4, 100 mM NaCl, 10 mM CaCl2) supplemented with 0.01%
Tween-20 (Applichem Inc., Cheshire, CT, USA) and PI. The
cells were lysed by 3–4 freeze–thaw cycles and DNA was
sheared by sonication. The membrane fraction was removed
by ultracentrifugation at 110 000 g with a swing-out rotor
SW50.1 in a Beckman L7-55 Ultracentrifuge (Beckman Coulter,
Fullerton, CA, USA) during 75 min at 4 1C. The resulting
supernatant cytosol was kept at 20 1C for further analysis.
Ion exchange chromatography (IEC)
THP-1 cytosol in ethanolamine buﬀer (pH 9.2) was ﬁltrated
(0.22 mm) and applied to a 1 mL cation exchange column
(S1-Uno, Bio-Rad, Hercules, CA, USA). Proteins were eluted
with a 40 mL linear gradient from 0 M to 0.5 M NaCl,
followed by a 10 mL linear gradient from 0.5 to 1 M NaCl.
Elution fractions were neutralized with 1M Hepes, pH 7.45
and kept at 20 1C for further analysis, whereas ﬂow through
fractions were pooled and loaded onto a 1 mL anion exchange
column (Q1-Uno, Bio-Rad). Elution was carried out with a
40 mL linear gradient from 0 to 0.5 M NaCl, followed by a
10 mL linear gradient from 0.5 to 1 M NaCl. Eluted factions
were neutralized with 1M Hepes, pH 7.45.
Puriﬁcation and activation of recombinant human MMPs
Recombinant human MMP-9 was expressed in Sf9 insect cells
and puriﬁed by gelatin-Sepharose aﬃnity chromatography as
described previously.271,272 Puriﬁed pro-MMP-9 (10 mM) was
activated with 0.1 mM of the catalytic domain of human
MMP-3 (cd-MMP-3, Calbiochem) for 1.5 h at 37 1C in assay
buﬀer supplemented with 0.001% Tween-20 (Sigma). MMP-1,
MMP-8 and MMP-13 were activated with APMA (p-amino-
phenylmercuric acetate) according to the instructions of the
manufacturer (R&D Systems, Abingdom, UK). The commercial
preparation of MMP-2 (R&D Systems) was found to be active
without activation and therefore used as such.
Concentration and incubation of the IEC fractions
Cation and anion exchange (CEC and AEC) elution fractions
were dialyzed against salt-free assay buﬀer (100 mM Tris/HCl,
pH 7.4, 10 mM CaCl2) supplemented with 0.01% Tween-20
and concentrated 2–10 times on micro-spin columns with a
10 kDa cut-oﬀ membrane (Microcon YM-10, Millipore
Corporation, Billerica, MA, USA). Before and after concen-
tration, protein concentrations of the fractions were
determined with the Bradford protein assay (Bio-Rad) as
described.273 Concentrated fractions were incubated in the
absence or presence of 100 nM activated MMP-9 for 24 h at
37 1C. For fragment degradomics, pooled CEC ﬂow through
was neutralized and incubated in the absence or presence of
100 nM activated MMP-9 for 24 h at 37 1C. Fragments
generated by incubation were enriched by ﬁltration through
a 50 kDa limitating membrane (Microcon YM-50, Millipore
Corporation). Flow through fractions of the 50 kDa micro-
spin columns were dialyzed against salt-free assay buﬀer and
further concentrated on a 3 kDa membrane (Microcon YM-3,
Millipore Corporation).
In vitro cleavage assays
THP-1 cytosol and recombinant or puriﬁed proteins were
incubated for the indicated time intervals in the absence or
presence of activated MMP-9, cd-MMP-3, 40 nM activated
MMP-9 supplemented with 10 mM of the metalloprotease
inhibitors 1,10-o-phenanthroline or EDTA and with active
MMP-1, -2, -8, -13 (5 nM or 100 nM). As a control for non-
substrate fragments, the highest concentration of activated
MMP-9 was incubated separately in assay buﬀer without
addition of substrate. The corresponding molar enzyme : substrate
ratios can be found in the ﬁgure legends. Incubations were
stopped with 2 Laemmli sample buﬀer (0.125 M Tris/HCl,
pH 6.8, 4% SDS, 20% glycerol, 10% b-mercaptoethanol,
0.05% bromophenol blue).
SDS-PAGE and Western blot analysis
Incubated fractions and digested recombinant or puriﬁed
proteins were analyzed using SDS-PAGE with Tris-tricine as
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running buﬀer (10%, 14% or 18% Prosieves 50 Gel Solution,
Lonza, Basel, Switzerland) and visualized with Coomassie
Brilliant Blue R-250 (Sigma) or by silver staining analysis
(Silverquestt Silver Staining kit, Invitrogen) for actin. After
electrophoresis, the proteins were transferred from the gels to
PVDF (0.45 mm, Applied Biosystems, Foster City, CA, USA)
or nitrocellulose membranes (0.2 mm, Whatman, Maidstone,
UK) by semi-dry or wet electroblotting. The membranes were
blocked with 5% non-fat dry milk (Bio-Rad) or 2% ECL
advance blocking reagent (GE Healthcare) in Tris-buﬀered
saline (20 mM Tris/HCl, pH 7.6, 137 mM NaCl) containing
0.1% Tween-20 and then probed with a substrate-speciﬁc
primary antibody. After washing, the membrane was incubated
with the appropriate peroxidase-conjugated secondary
antibody (Jackson ImmunoResearch, West Grove, PA,
USA). Finally, proteins were detected according to the
manufacturers recommendations of the ECL plust chemi-
luminescence kit (GE Healthcare).
Protein identiﬁcation by tandem mass spectrometry (MS/MS)
For MS/MS, proteins were stained with Coomassie Brilliant
Blue R-250 after SDS-PAGE analysis and the protein
band(s) of interest were excised from the gel and identiﬁed
by matrix-assisted laser desorption ionization time-of-ﬂight/
time-of-ﬂight (MALDI-TOF/TOF) mass spectrometry
(Alphalyse, Odense, Denmark).
NH2-terminal Edman sequencing
Proteins were separated by SDS-PAGE analysis and electro-
blotted onto PVDF membranes as described above. After
washing with H2O and staining with Coomassie Brilliant Blue
R-250 (Sigma), the protein band(s) of interest were excised
from the blot and applied to a capillary protein sequencer
(Procise 491 cLC, Applied Biosystems) for NH2-terminal
Edman degradation.
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Representative gels generated by 2D-degradomics and fragment degradomics.  A. After 
incubation in the absence (-) or presence (+) of MMP-9 (100 nM) for 24h, the ion exchange 
(IEC) fractions were separated by molecular mass upon SDS-PAGE analysis.  Protein bands that 
were present in the uncleaved fractions (-) but disappeared or decreased in the cleaved fractions 
(+) were considered to be candidate MMP-9 substrates and indicated by black arrowheads.  
Protein bands that appeared or increased in intensity in the digested fractions (+) were potential 
substrate fragments (depicted by grey arrowheads).  Apparent molecular masses are shown on 
the right in Da.  B. The pooled CEC flow through fractions (FT) were neutralized and incubated 
with (+) or without (-) activated MMP-9 (100 nM) for 24 h.  Fragment fractions (FR) were 
enriched by fragment degradomics and analyzed by SDS-PAGE.  Protein bands that were present 
in the uncleaved fragment fraction (FR, -) but disappeared or decreased in the cleaved fragment 
fraction (FR, +) were considered to be candidate MMP-9 substrates (black arrowheads).  Protein 
bands that appeared or increased in intensity in the digested fragment fraction (FR, +) were 
potential substrate fragments (grey arrowheads).  As a control for non-specific MMP-9 
fragments, activated MMP-9 (100 nM) was also subjected to fragment degradomics and 
analyzed on the same gel (lane 4).  Apparent molecular masses are shown on the left in Da. 
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ABSTRACT 
Gelatinase B/matrix metalloproteinase-9 (MMP-9) is a key enzyme involved in inflammatory, 
hematological, vascular and neoplastic diseases. Although the absence of MMP-9 has been shown to 
enhance allograft rejection and T cell alloreactivity, the role of MMP-9 in lymphocyte homeostasis is not 
well studied.  B6lpr/lpr mice with defective Fas-mediated apoptosis were used to investigate the functions of 
MMP-9 in lymphocyte proliferation and in the development of systemic autoimmunity.  Combined Fas and 
gelatinase B deficiency resulted in extreme lymphoproliferative disease with enhanced lymphadenopathy and 
splenomegaly, and significantly reduced survival compared with single Fas deficiency. At the cellular level, 
this was corroborated by increased lymph node accumulation of activated and ‘double negative’ T cells, B 
cells and myeloid cells.  In addition, higher autoantibody titers and more pronounced autoimmune tissue 
injury were found in the absence of MMP-9, culminating in chronically enhanced lupus-like autoimmunity.  
As ‘uncleaved’ autoantigens seemed to be better stimuli for autoantibody production, MMP-9 may suppress 
systemic antibody-mediated autoimmunity by clearance of autoepitopes in immunogenic substrates. Thus, 
new protective functions for MMP-9 were revealed in the suppression of lymphoproliferation and dampening 
of systemic autoimmunity, cautioning against the long-term use of MMP inhibitors in autoimmune 
lymphoproliferative syndrome (ALPS) and systemic lupus erythematosus (SLE).  
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INTRODUCTION 
Gelatinase B or matrix metalloproteinase-9 
(MMP-9) is a secreted protease involved in the 
remodeling of the extracellular matrix and the 
migration of normal and tumor cells.1 MMP-9 has 
physiological roles in reproduction and 
development, and in the repair of tissues, but is 
mostly known for its pathological effects in cancer, 
in vascular diseases and in autoimmune diseases.2 In 
contrast with the constitutive presence of gelatinase 
A (MMP-2), MMP-9 is an inducible protease. In an 
infectious or inflammatory context, gelatinase B 
secretion is stimulated by Toll-like receptor (TLR) 
agonists, cytokines and chemokines and affects 
immune functions by processing cytokines and 
chemokines and mobilizing leukocytes.3 
Organ-specific autoimmune diseases, in which 
MMP-9 exerts an exacerbating role, are multiple 
sclerosis4 - and its animal model of experimental 
autoimmune encephalomyelitis (EAE)5-, bullous 
pemphigoid6 and rheumatoid arthritis.7 Acute 
exacerbations of these diseases are associated with 
increased production of MMP-9, whereas knocking 
out the MMP-9 gene in experimental models 
diminishes the clinical symptoms of acute 
relapses.6,8,9  In terms of antigen processing and 
lymphocyte activation, organ-specific autoimmune 
diseases typically are T cell-mediated disorders and 
the autoantigens are often extracellular proteins.  
Little is known, however, about the functional role 
of MMP-9 in systemic autoimmunity and on long-
term effects in chronic autoimmune models. Often, 
these are B cell- and antibody-mediated diseases and 
the antigens are intracellular proteins or 
macromolecules, including double-stranded (ds) and 
single-stranded (ss) DNA, small nuclear ribonucleic 
proteins (snRNPs) and heat shock proteins 
(HSPs).10,11  In previous studies, we explored the 
intracellular degradome of MMP-9 and found many 
intracellular matrix (ICM) proteins and systemic 
autoantigens as novel intracellular gelatinase B 
substrates.12,13 These findings led to the insight that 
MMPs and other proteases may have novel 
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(immuno)regulatory properties by the clearance of 
toxic and immunogenic burdens of (abundant) ICM 
proteins and intracellular autoantigens released after 
extensive necrosis (e.g. caused by trauma, burns, 
frost bite, irradiation). In addition, the prototypic 
systemic autoimmune disease systemic lupus 
erythematosus (SLE) is associated with accelerated 
leukocyte apoptosis14,15 and impaired clearance of 
apoptotic cells.16  Hence, the unphagocytosed 
apoptotic cell load progresses to secondary necrosis, 
releasing intracellular proteins and systemic 
autoantigens into the extracellular milieu. 
Besides its roles in leukocyte mobilization and in 
proteolytic processing of cytokines, chemokines and 
autoantigens, MMP-9 also functions in adaptive 
immune reactions. Deficiency of MMP-9 leads to 
enhanced T cell alloreactivity in heterotypic tracheal 
and cardiac allografts. This T cell alloreactivity in 
MMP-9-deficient mice is mediated by enhanced 
dendritic cell stimulatory as well as enhanced T cell 
responsive capacities.17,18 Although expression of 
MMP-9 by T and B cells is known2, the direct 
effects of MMP-9 or its deficiency on activation and 
proliferation of T and B lymphocytes have not been 
well studied.  
Following the general view that MMP-9 plays 
functional roles in inducible phenotypes and that 
MMP-9 influences homeostasis of normal T cells, 
we investigated the effect of MMP-9 in vivo in mice 
with the lpr (lymphoproliferative) loss-of-function 
mutation in the apoptosis mediator Fas as treshhold-
altering event.  Fas mutant mice on the MRL 
background (MRLlpr/lpr) develop a severe lupus-like 
syndrome with vasculitis, arthritis, early-onset 
splenomegaly, progressive lymphadenopathy and 
immune complex-mediated glomerulonephritis.19  
However, on the C57Bl/6 background (B6lpr/lpr), 
disease development is subdued and delayed, with 
moderate lymphoproliferation, later onset of 
autoantibody production and little 
immunopathology.20,21  In the present study, we 
discovered that the genetic knockout of MMP-9 in 
B6lpr/lpr mice (B6lpr/lprMMP-9-/-) resulted in highly 
augmented and earlier onset lymphoproliferation, 
increased autoantibody production against multiple 
autoantigens and more pronounced autoimmune 
tissue injury.  These data suggest that MMP-9 is a 
protective factor in the development of autoimmune 
lymphoproliferation. 
 
 
 
 
MATERIALS AND METHODS 
Mice 
MMP-9 deficient mice (B6.MMP-9-/-) were 
generated as described previously8 and backcrossed 
to the C57Bl/6 strain for ten generations. B6lpr/lpr 
mice were purchased from Jackson Laboratory (Bar 
Harbor, Maine, ME, USA). Crossing of B6.MMP-9-
/- and B6lpr/lpr mice yielded F1 heterozygotes that 
were mated to obtain B6lpr/lprMMP-9-/- and 
B6lpr/lprMMP-9+/+ in the F2 generation.  In each 
individual mouse, the genotype was confirmed by 
PCR.  Mice were bred in the specific pathogen-free 
(SPF) breeding facility of the Rega Institute for 
Medical Research (University of Leuven, Leuven, 
Belgium) and moved to non-SPF conditions after 
weaning.  All experimental procedures were 
approved by the institutional Ethics Committee 
under license LA1210243 for animal welfare 
(Project 06009). 
Genotyping 
Genomic DNA was obtained from tail or peripheral 
blood cells using the EZNA tissue DNA purification 
kit (Omega Bio-Tek, Inc., Norcross, GA, USA).  
Detection of MMP-9 deficiency was performed as 
described previously8 with slightly modified 
primers: forward: 5’-TCCATCCACAGGCATAC-
TTGTACC-3’; reverse 1 for the knock-out allele: 5’-
TGTCAGTTTCATAGCCTGAAGAACG-3’; and 
reverse 2 for the wild-type allele:  5’-ATCTG-
CTGTCCCTTCTACTCTGTC-3’.  Denaturation 
was attained with 5 min at 95°C, followed by 50 
amplification cycles (1 min at 95°C, 30 s at 64°C, 1 
min at 72°C), and a final extension step of 10 min at 
72°C.  PCR for the lpr mutation was carried out as 
suggested by Jackson Laboratory. The following 
nucleotides were used to distinguish the lpr allele 
from the wild-type Fas allele:forward 5’-GTAAA-
TAATTGTGCTTCGTCAG-3’; reverse 1 for the lpr 
allele: 5’-TAGAAAGGTGCACGGGTGTG-3’; and 
reverse 2 for the wild-type allele: 5’-CAAATCTAG-
GCATTAACA-GTG-3’. PCR conditions were 3 
min at 94°C, then 35 cycles (30s at 94°C, 1 min at 
59°C, 1 min at 72°C), with a final extension of 7 
min at 72°C. The amplified products of the MMP-9 
and lpr PCR were separated on a 2% and 3% 
agarose gel, respectively, and visualized by ethidium 
bromide staining. 
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Phenotyping 
Peripheral blood samples were incubated with 
high concentrations (1 µM) of formyl-Methionyl-
Leucyl-Phenylalanine (fMLP) (Sigma, St. Louis, 
MO, USA) for 1h at 37°C to trigger extensive 
neutrophil degranulation.  Plasma samples were 
obtained by centri-fugation and first prepurified 
on gelatin-Sepharose beads as described.22  
Gelatin zymography was then performed as 
previously detailed.23  The relative migrations of 
pro-MMP-9/gelatinase B and pro-MMP-2/gelati-
nase A, and of activated forms, were determined 
with the use of laboratory standards of deletion 
mutants of MMP-9.24 
Macroscopic pathology staging 
To summarize pathological observations, a semi-
quantitative macroscopic pathology score was 
established as follows.  A score of 0; 0.25; 0.5 or 1 
was given in accordance with the degree of swelling 
of axillary and inguinal lymph nodes (0 to 1); 
cervical lymph nodes (0 to 1) and mesenteric lymph 
nodes (0 to 1). A visibly affected liver was scored as 
1 (vs. 0 for non-affected livers).  Enlargement of the 
thymus was scored with 0.5 or 1.Hence, the total 
summed macroscopic pathology scores ranged 
between 0 and 5. 
Flow cytometry analysis and antibodies 
Single-cell suspensions were prepared from spleen 
and (axillary and inguinal) lymph nodes using nylon 
cell strainers (Becton Dickinson, San Jose, CA, 
USA).  Erythrocytes were depleted by hypotonic 
lysis with NH4Cl solution (0.083% NH4Cl in 0.01M 
Tris/HCl, pH 7.4).  Peripheral leukocytes were 
obtained after two erythrocyte depletions.  Cells 
were washed twice with phosphate buffered saline 
(PBS) + 2% fetal calf serum (Invitrogen, Carlsbad, 
CA, USA) and counted.  106 cells were first 
incubated with Fc-receptor blocking antibodies 
(anti-mouse CD16/CD32; Miltenyi Biotec, Bergisch 
Gladbach, Germany) followed by washing and 
staining with combinations of the following anti-
mouse antibodies (eBioscience, San Diego, CA, 
USA): FITC-labeled anti-CD3, anti-GR1, anti-
CD11c; PE-labeled anti-B220, anti-F4/80, anti-
CD40; APC-labeled anti-CD4 and anti-CD11b, and 
PerCP-Cy5.5-labeled anti-CD8.  Data collection was 
carried out on a FACSCaliburTM flow cytometer and 
data were processed with the Cell Quest® software 
(Becton Dickinson). 
 
 
 
 
Proliferation assays 
Single-cell suspensions (0.5x106 cells/mL), prepared 
as mentioned before, were incubated in the absence 
or presence of hamster anti-mouse CD3 (3 µg/mL, 
purified from 145-2C11 hybridoma cell 
supernatant25) or anti-IgM (5 µg/mL, Jackson 
ImmunoResearch, West Grove, PA, USA).  After 
48h of incubation, cells were pulsed for 18h with 
3H-thymidine (1 µCi/well, GE Healthcare, Uppsala, 
Sweden).  Finally, cells were harvested and 3H-
thymidine incorporation was measured in a liquid 
scintillation analyzer (Tri-Carb 2100 TR, Packard, 
Canberra, Australia).   
In vitro autoantigen cleavage by MMP­9 
Recombinant human MMP-9 was expressed in 
Sf9 insect cells and purified by gelatin-Sepharose 
affinity chromatography as described 
previously.24  Purified MMP-9 (10 µM) was 
activated with 0.1 µM of the catalytic domain of 
human MMP-3 (cd-MMP-3, Calbiochem, 
Darmstadt, Germany) for 1.5h at 37°C.  The 
autoantigens (100 µg/mL, Diarect, Freiburg, 
Germany) U1 small nuclear ribonucleoprotein 
(U1snRNP) 70 kDa, U1snRNP A, Smith antigen 
(UsnRNP B/B’), ribosomal protein P0 and Ro-52 
were incubated for 5h (or 20h) at 37°C in the 
absence or presence of activated MMP-9 (1.6 to 
200 nM), with equivalent amounts of the 
catalytical domain of MMP-3 (2 nM) used to 
activate the MMP-9 and with 200 nM activated 
MMP-9 supplemented with 20 mM of the 
metalloprotease inhibitor ethylene 
diaminetetraacetic acid (EDTA).  As a control for 
non-substrate fragments, the highest 
concentration of activated MMP-9 was incubated 
separately without addition of substrate.  
Incubated autoantigen samples were analyzed by 
SDS-PAGE on 12.5 % acrylamide gels 
(Prosieve® 50 Gel Solution, Lonza, Basel, 
Switzerland) and visualized with Coomassie 
Brilliant Blue R-250 (Sigma). 
Measurement of autoantibodies 
Autoantibody titers in individual plasma samples 
were determined by enzyme-linked immunosorbent 
assay (ELISA) as adapted from Cohen and 
Maldonado.26  Briefly, ELISA plates were coated 
overnight (4°C) with one of the following 
autoantigens: plasmid DNA (2 µg/mL, Diarect); 
rabbit IgG (purified on a protein A Sepharose 
column, GE Healthcare); human Smith antigen (U 
snRNP B/B’, 0.4 µg/mL, Diarect); calf thymus 
histones (5 µg/mL, Sigma); rabbit skeletal muscle 
actin (3 µg/mL, Cytoskeleton, Denver, CO, USA); 
bovine brain tubulin (3 µg/mL, Cytoskeleton) and 
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chicken erythrocyte chromatin (5 µg/mL) extracted 
from chicken red blood cells (TCS Biosciences, 
Buckingham, UK) as described previously.26  For 
the U1snRNP ELISA, plates were coated with the 
three polypeptides that are unique to the U1snRNP 
complex: U1snRNP 70 kDa, U1snRNP A and 
U1snRNP C (0.5 µg/mL, Diarect).  Plates were 
blocked with 0.5% bovine serum albumin (BSA, 
Cohn fraction V, Sigma) + 0.2% Tween-20 
(AppliChem, Darmstadt, Germany) in PBS for at 
least 2h at room temperature and washed.  Serial 
plasma dilutions (in PBS with 0.5% BSA and 0.2% 
Tween-20) from individual mice were added, 
incubated overnight at 4°C and washed with PBS 
containing 0.2% Tween-20.  Horseradish peroxidase 
(HRP)-conjugated goat anti-mouse IgG (Jackson 
ImmunoResearch, West Grove, PA, USA) was used 
as a secondary detection antibody.  After 1h of 
incubation at 37°C, plates were washed and HRP 
activity was visualized by adding the substrate 
tetramethylbenzidine.  After reaction termination 
with 2M H2SO4, optical densities were determined at 
450 nm in a microplate spectrophotometer (Power 
Wave XS, Biotek, Winooski, VT, USA).  Various 
plasma samples were pooled to form a laboratory 
standard that was given the value of 100 units.  
Standard curves were constructed by plotting the 
laboratory standard dilutions vs. the optical densities 
(ODs), yielding an equation that was used to 
calculate the autoantibody units in the individual 
samples.   
Competitive ELISA 
ELISA was performed as described above but with 
the following modifications. Plates were coated with 
intact ribosomal protein P0 or U1snRNP A (0.5 
µg/mL). After blocking, dilution series of free 
autoantigen (previously cleaved by MMP-9 or 
intact) were added, starting from a 50x excess, 
followed by addition of the plasma samples. When 
free antigen (intact or cleaved) competed with 
coated intact antigen for autoantibody binding, the 
formed immune complexes were not bound to the 
plates, resulting in a drop in OD.  No addition of free 
antigen was considered as 0% competition and 
100% OD. 
Histologic examination of tissues  
At 9 months, lymph nodes (axillary, inguinal, 
cervical, mesenteric, renal, pyloric, lumbal), spleen, 
thymus, liver, lung and kidneys were excised, 
weighed and fixed in 10% formalin.  Specimens 
were then inbedded in paraffin, sectioned (4 µm) 
and stained with hematoxylin and eosin (H&E) or 
periodic acid-Schiff (PAS) stain for the kidney 
sections.  All sections were scored by two 
pathologists blinded to the study (X.S. and H.H.). 
Lymph nodes were determined as normal (score 0), 
with slight (score 1) or moderate (score 2) 
perturbation of the structure when a visible 
distinction between cortex and medulla and 
discernible follicles were still present.  A score of 3 
was attributed when cortex, medulla and follicles 
could no longer be discerned.  Spleen scores were 
based on the expansion of the white pulp vs. the red 
pulp, the appearance of nodular structures distorting 
the white pulp, and lymphocyte infiltration in the red 
pulp.  The overall severity of these combined 
observations was graded from 0 to 3.  Liver and lung 
scores were determined by the degree of lymphocyte 
infiltration.  A liver infiltration score of 1 
represented a moderate periportal lymphocytic 
infiltration, whereas a score of 2 was given in case 
of a severe periportal and parenchymal infiltration.  
For lung infiltration, score 1 was attributed to a 
moderate peribronchial infiltration; score 2 to a 
considerable peribronchial and alveolar lymphocyte 
infiltration and an (additive) score of 3 for 
bronchiolitis obliterans organizing pneumonia 
(BOOP).  For immunohistochemistry, slides were 
stained with anti-CD3, anti-B220, anti-CD4, anti-
CD8, anti-IgM, anti-IgD and anti-CD68 (Dako, 
Glostrup, Denmark) as previously described.27 
As initially no kidney samples were fixed for 
electron microscopy, small samples from the frozen 
blocs were thawed and fixed in 2.5% glutaraldehyde, 
0.1 M phosphate buffer, pH 7.2 at 4°C overnight. 
After 1h post-fixation in 2% osmium tetroxide, 0.1 
M phosphate buffer, pH 7.2 at 4° C, the samples 
were dehydrated in graded series of alcohol and 
embedded in epoxy resin.  Ultra-thin sections of 50 
to 60 nm were cut, stained with uranyl acetate and 
lead citrate and examined at 50 kV using a Zeiss EM 
900 electron microscope (Oberkochen, Germany). 
Images were recorded digitally with a Jenoptik 
Progress C14 camera system (Jena, Germany) 
operated using Image-Pro express software (Media 
Cybernetics, USA). 
Assessment of renal function 
Microalbuminuria was determined by sandwich 
ELISA using a standard curve of known 
concentrations of mouse serum albumin (MSA, 
Sigma).  Briefly, ELISA plates were coated 
overnight (4°C) with goat anti-mouse albumin 
(United States Biological, Swampscott, MA, USA), 
blocked with PBS containing 0.5% and 0.2% 
Tween-20 and washed (with PBS + 0.1% Tween-
20).  Dilutions of urine samples and a standard of 
MSA were applied, incubated overnight at 4°C and 
washed.  Detection with goat anti-mouse albumin 
(United States Biological) as a secondary antibody 
and calculations were carried out as detailed in 
‘Measurement of autoantibodies’.  Urinary 
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creatinine levels were measured with the 
Quantichrom™ Creatinine Assay Kit (BioAssay 
Systems, Hayward, CA, USA) according to the 
manufacturers recommendations.  Albumin-to-
creatine ratios (ACR) were obtained by normalizing 
the albumin concentrations to the creatinine levels. 
Patients samples 
All patients contributing to the present study gave 
informed consent and the study protocol was in 
accordance with international standards and 
approved by the Local Ethical Committee for 
clinical studies.  
Statistical analysis 
Data were analyzed with GraphPad Prism 5.02 
(GraphPad, San Diego, CA, USA).  Graphs combine 
a scatter dot plot of individual data points with bars 
or lines representing the medians.  Differences 
between two groups were analyzed by the 
nonparametric Mann-Whitney U-test.  Proportions 
were compared with the Fisher’s exact test.  Survival 
and cumulative incidence were analysed by the Log-
Rank (Mantel Cox) Test.  Associations were 
determined by two-tailed Spearman rank correlation.  
Two-tailed P values less than .05 were considered 
statistically significant. 
 
 
Figure 1. Enhanced lymph node swelling and decreased survival in B6lpr/lpr.MMP-9-/- mice vs. B6lpr/lpr.MMP-9+/+ 
mice.  (A) Representative pictures of pronounced lymphadenopathy at the chest and axills in MMP-9-deficient and MMP-
9-sufficient B6lpr/lpr mice.  The age of each individual mouse is shown at the bottom of the picture.  Cumulative incidence of 
lymph node swelling was compared over an observation period of 10 months (B) between B6lpr/lpr.MMP-9-/- mice and 
B6lpr/lpr.MMP-9+/+ mice and (D) between male and female B6lpr/lpr.MMP-9-/- mice.  Survival was monitored until the age of 
10 months in (C) B6lpr/lpr.MMP-9-/- mice vs. B6lpr/lpr.MMP-9+/+ mice and (E) in male vs. female B6lpr/lpr.MMP-9-/- mice.  The 
numbers of mice (n) in each group are depicted in the graph legend.  ***, P < .0001, cumulative readout by the Log-Rank 
(Mantel Cox) Test. 
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Figure 2. Enhanced lymphadenopathy and macroscopic pathology in B6lpr/lpr.MMP-9-/- mice vs. control mice.  (A) 
Dissection analysis of MMP-9-deficient and MMP-9-sufficient B6lpr/lpr mice with pronounced lymphadenopathy, revealing 
enlargement of cervical, axillary and inguinal lymph nodes. (B) Pathological findings of the dissection analysis were 
summarized in a macroscopic pathology score. (C) Body weight (bw) as well as (D) spleen, thymus and various lymph 
node (LN) weights normalized over the respective body weights (w/bw, weight per body weight) were compared between 
B6lpr/lpr.MMP-9-/- mice  and B6lpr/lpr.MMP-9+/+ mice. AX + Ing LN, axillary and inguinal lymph nodes. Horizontal lines 
indicate the group medians. Each dot represents data from a single animal. *P < .05, **P < .01. 
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RESULTS 
Lack  of  MMP­9  induces  severe 
lymphoproliferation  and  decreased  survival 
in B6lpr/lpr mice 
With the aim of investigating the influence of 
MMP-9 in the development of lymphoproliferation 
and systemic autoimmunity in B6lpr/lpr mice, we 
generated mice lacking both MMP-9 and functional 
apoptosis-inducing receptor Fas (B6lpr/lpr.MMP-9-/-) 
(with both parental strains backcrossed onto a 
C57Bl/6 background for 10 generations).  
Zymographic analysis of plasma samples after 
induction of neutrophil degranulation confirmed the 
phenotype of MMP-9 deficiency (Supplementary 
Figure 1). While the B6lpr/lpr mice developed 
moderate lymph node swelling as expected, many 
B6lpr/lpr.MMP-9-/- mice developed extreme 
lymphadenopathy at the chest and axills (Figure 1A).  
Onset of lymph node swelling was advanced and the 
overall cumulative incidence was markedly 
increased in the absence of MMP-9 (P < .0001) 
(Figure 1B). In addition, survival was significantly 
reduced in a large-size B6lpr/lpr.MMP-9-/- cohort over 
an observation period of 10 months (P < .0001) 
(Figure 1C). No differences in lymph node swelling 
or mortality were observed between male and female 
B6lpr/lpr.MMP-9-/- mice (Figure 1D-E).   
Dissection of 9 months old mice showed that the 
externally observed lymphadenopathy was caused 
by extreme enlargement of cervical, axillary and 
inguinal lymph nodes, while B6lpr/lpr mice showed 
moderate or hardly visible swelling (Figure 2A). 
Besides the superficial lymph nodes, renal, 
mesenteric, lumbar and pyloric lymph nodes were 
also markedly enlarged and often highly 
vascularized or even hemorrhagic in B6lpr/lpr.MMP-9-
/- mice (Supplementary Figure 2A-C). Extreme 
lymphadenopathy was frequently associated with 
splenomegaly, enlargement of the thymus, and a 
visibly affected liver with blunt edges and a granular 
surface (Supplementary Figure 2D, E and F, 
respectively).  To summarize these pathological 
findings in a macroscopic pathology score, we 
developed a semi-quantitative staging system, as 
outlined in ‘Materials and methods’. The results 
showed significantly increased pathological stages 
(P < .05) in the absence of MMP-9 (Figure 2B).  
In order to corroborate the observed amplification 
in lymphoproliferation with quantitative data, organ 
and lymph node weights from both groups of mice 
were compared.  Previously, it has been 
demonstrated that MMP-9-/- mice have a 
spontaneous phenotype of impaired bone formation 
and reduced body weight.28 As in the present study 
the total body weights of B6lpr/lpr.MMP-9-/- mice were 
also decreased vs. B6lpr/lpr.MMP-9+/+ mice (P < .01) 
(Figure 2C), we normalized the organ weights over 
the respective body weights.  Higher lymph node (P 
< .05), spleen (P < .05) and thymus weights (P < 
.01) confirmed the severe lymphoproliferation 
caused by MMP-9 deficiency (Figure 2D). In the 
analysis of lymph nodes at different anatomical sites, 
this trend persisted and was significant for axillary 
and inguinal, for mesenteric, and for renal lymph 
nodes. Of note, lung, liver and kidney weights were 
not significantly different between B6lpr/lpr.MMP-9-/- 
and B6lpr/lpr.MMP-9+/+ mice. 
The  accumulation  of  T  and  B  cells  in 
peripheral  lymphoid  organs  is  more 
pronounced in the absence of MMP­9 
The peripheral repertoire of mice bearing Fas with 
the lpr mutation is predominated by unusual 
CD3+B220+CD4-CD8- double negative (DN) T 
cells.21  A recent study showed that very low 
percentages of these DN T cells exist in the 
periphery of normal wildtype mice (1% to 5%) and 
these cells die at very high rates by Fas-mediated 
apoptosis.  In the absence of functional Fas, they 
progressively accumulate in lymph nodes and spleen 
causing lymphadenopathy and splenomegaly.29  The 
increased lymphadenopathy observed in 
B6lpr/lpr.MMP-9-/- vs. B6lpr/lpr.MMP-9+/+ mice was 
further confirmed by increased cell numbers in 
lymph nodes and spleens (P < .01), consisting 
mainly of DN T cells (Figure 3 and Supplementary 
Figure 3).  In the absence of MMP-9, macroscopic 
lymphadenopathy was more pronounced than 
splenomegaly, which was reflected by massive DN 
T cell accumulation and higher numbers of CD4+ 
and CD8+ T cells and B cells (B220+CD3-) in the 
lymph nodes. In the peripheral blood, cell numbers 
were rather constant.  DN T cells only showed an 
increasing trend in B6lpr/lpr.MMP-9-/- mice (Figure 3).  
Although DN T cells are anergic in vitro21 and do no 
proliferate in vivo in lymph nodes and spleen29, the 
massive expansion of DN T cells suggested that 
MMP-9 deficiency might induce proliferation (as 
observed with alloreactive T cells17,18).  However, 
polyclonal stimulation of T and B cells derived from 
lymph nodes and spleen showed very low in vitro 
proliferation of B6lpr/lpr cells in comparison with T 
and B cells from B6.MMP-9-/- and B6 mice 
(Supplementary Figure 4), especially for the T cells, 
confirming DN T cell anergy.  No significant 
differences in proliferation were observed with or 
without MMP-9 in both B6lpr/lpr and B6 control mice.  
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Figure 3. Peripheral lymphoid organs of B6lpr/lpr.MMP-9-/- mice show increased infiltration by double negative (DN) 
T cells in comparison with control mice.  Axillary and inguinal lymph node cells (top), splenocytes (middle) and 
peripheral blood cells (bottom) were isolated from 6 to 9 months old mice (age-matched groups) and stained as detailed in 
‘Flow cytometry and antibodies’.  Double negative (DN) T cells were obtained by gating on CD3+B220+ cells followed by 
gating on CD4-CD8- cells.  Histograms show from left to right: total cell numbers (Cell no.), total numbers of CD3+B220+ 
cells, DN T cells (CD4-CD8-), CD4+ T cells, CD8+ T cells and B220+CD3- B cells.  Data from B6.MMP-9-/- and B6 mice 
are also included for comparison.  Histograms indicate group medians and aligned scatter plots show the range of the 
individual data points. *P < .05, **P < .01, ***P < .001. 
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Figure 4. Peripheral lymphoid organs of B6lpr/lpr.MMP-9-/- mice vs. control mice show increased infiltration by 
myeloid cell subsets. (A) Axillary and inguinal lymph node cells and (B) splenocytes were isolated from 6 to 9 months old 
mice (age-matched groups) and stained as described in ‘Flow cytometry and antibodies’.  Total numbers of neutrophils 
(CD11bHighLy6G/C+), macrophages (CD11bHighF4/80+), immature dendritic cells (DCs, CD11bHighCD11c+CD40-) and 
activated dendritic cells (CD11bHighCD11c+CD40+) are depicted in the graphs and compared between groups. Histograms 
indicate group medians and each dot represents data from a single animal. *P < .05, **P < .01, ***P < .001. 
MMP­9  deficiency  increases  myeloid  cell 
numbers in lymph nodes and spleen 
Myeloid cells, such as neutrophils, macrophages and 
dendritic cells are the major producers of MMP-9 
during inflammation.3  Hence, we wondered whether 
the absence or presence of MMP-9 would affect 
myeloid cell subsets in the periphery of B6lpr/lpr mice.  
Populations with high and intermediate expression of 
CD11b were significantly increased in the periphery 
of B6lpr/lpr.MMP-9-/- vs. the three groups of genetically 
appropriate control mice (Figure 4).  This expansion 
was again more pronounced in the lymph nodes 
(Figure 4A) of B6lpr/lpr.MMP-9-/- mice compared with 
the spleens of these mice (Figure 4B).  Further 
analysis showed significantly increased neutrophil, 
macrophage, immature and activated dendritic cell 
numbers in the lymph nodes of B6lpr/lpr.MMP-9-/- mice, 
whereas in the spleen only the immature dendritic 
cells were increased in comparison with B6lpr/lpr and 
control mice. 
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Table 1. Correlation between autoantibody titers at 9 months and severity of lymphoproliferation or 
macroscopic pathology. 
Autoantibody specificity No.†
B6lpr/lpr.MMP-9-/- 
anti-dsDNA IgG 13 0,65 * 0,64 * 0,69 **
anti-chromatin IgG 11 0,28 0,35 0,59
Rheumatoid factor IgG 13 0,54 0,32 0,47
anti-Histone IgG 13 0,70 ** 0,63 * 0,63 *
anti-U1snRNP IgG 13 0,61 * 0,59 * 0,73 **
anti-Smith IgG 13 0,68 * 0,60 * 0,60 *
anti-actin IgG 13 0,79 ** 0,69 ** 0,75 **
anti-tubulin IgG 13 0,74 ** 0,65 * 0,84 ***
B6lpr/lpr.MMP-9+/+
anti-dsDNA IgG 10 0,50 0,09 0,73 *
anti-chromatin IgG 11 0,37 0,64 * 0,22
Rheumatoid factor IgG 11 0,22 0,36 -0,11
anti-Histone IgG 11 0,58 0,23 0,18
anti-U1snRNP IgG 10 0,24 -0,10 0,64 *
anti-Smith IgG 10 0,48 0,31 0,52
anti-actin IgG 10 0,32 0,09 0,22
anti-tubulin IgG 10 0,32 -0,12 0,29
LN w/bw Spleen w/bw MPS
 
Depicted are Spearman correlation coefficients with their significance levels, which are indicated by 
*P < .05, **P < .01, ***P < .001.  
†Number of pairs analysed by the Spearman rank correlation test.  
LN, lymph nodes; MPS, macroscopic pathology score; w/bw, weight/body weight. 
 
 
 
MMP­9  suppresses  the  production  of 
autoantibodies in B6lpr/lpr mice 
Since MMP-9 was shown to cleave many systemic 
autoantigens12,13, MMP-9 function may affect 
development of systemic autoimmunity.  Hence, 
autoantibody titers in plasma samples of B6lpr/lpr mice 
and control mice were analysed by specific ELISAs 
and compared.  Titers of rheumatoid factor and 
autoantibodies against dsDNA, chromatin and nuclear 
autoantigens showed a clear age-dependent increase in 
B6lpr/lpr.MMP-9-/- mice and were significantly higher 
than those of B6lpr/lpr.MMP-9+/+  and control mice 
(B6.MMP-9-/- and B6), the latter showing no 
significant autoantibody production, as expected 
(Figure 5).  Interestingly, most autoantibody titers in 9 
months old B6lpr/lpr.MMP-9-/- mice (except for anti-
chromatin IgG and rheumatoid factor IgG) showed 
positive and significant correlations with the degree of 
lymphoproliferation (as defined by lymph node and 
spleen weights) and with the macroscopic pathology 
score (Table 1).  In contrast, in B6lpr/lpr.MMP-9+/+ 
mice, only a few significant correlations were found, 
suggesting that the absence of MMP-9 links 
lymphoproliferation to autoantibody production.  
Correlations between autoantibody titers and the 
weights of other organs were not detected.   
Since our previous study showed cleavage of SLE 
autoantigens by MMP-9, various autoantigens used 
for the ELISAs were incubated in the absence or 
presence of activated MMP-9.  Interestingly, dose-
dependent cleavages of U1snRNP A and Smith 
antigen (UsnRNP B/B’) by MMP-9 were observed 
after 5h of incubation (Figure 6A), whereas U1snRNP 
70 kDa was hardly cleaved, even after a longer 
duration of incubation (20h, data not shown).  In 
addition, other major SLE autoantigens such as 
ribosomal protein P0 and Ro-52 (Sjögren’s syndrome 
antigen A or SSA) were also efficiently cleaved by 
MMP-9 after 5h of incubation (Figure 6B).  As 
‘uncleaved’ autoantigens seemed to result in higher 
autoreactive B cell stimulation in B6lpr/lpr.MMP-9-/- 
mice, autoantibodies against two previously identified 
MMP-9 substrates, actin and tubulin13, were also 
evaluated in all groups of mice.  Autoantibody levels 
against actin and tubulin were significantly higher in 
B6lpr/lpr mice lacking MMP-9 (Figure 6C).     
 
MMP‐9 SUPPRESSES AUTOIMMUNE  LYMPHOPROLIFERATION 
 
141 | P a g e  
 
 
 
Figure 5. Autoantibody titers are significantly higher in B6lpr/lpr.MMP-9-/- mice vs. control mice.  Plasma samples 
from four groups of genetically different mice were taken at 3 and 6 or 9 months. Autoantibody titers were determined 
by ELISA as detailed in ‘Measurement of autoantibodies’ and compared to a laboratory standard of 100 units. 
Horizontal lines indicate group medians and each dot represents the titration of serum level from a single animal.  
Indications of statistical significance are only shown for the comparison between B6lpr/lpr.MMP-9-/- and B6lpr/lpr.MMP-
9+/+ mice, since both these groups always showed significantly higher titers in comparison with B6.MMP-9-/- and B6 
mice, with exception of anti-dsDNA IgG at 6 months and anti-histone IgG at 3 months, which were not significantly 
different between B6lpr/lpr.MMP-9+/+ compared with B6.MMP-9-/- and B6 mice, respectively.  No significant differences 
in autoantibody titers were observed between B6.MMP-9-/- and B6 mice, except for anti-Smith IgG titers, which were 
significantly higher in 3 months old B6.MMP-9-/- vs. B6 mice. *P < .05, **P < .01, ***P < .001. 
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Figure 6. Autoantibody responses against MMP-9 substrates are higher in B6lpr/lpr mice lacking MMP-9. The 
autoantigens (A) U1snRNP A and Smith antigen (UsnRNP B/B’), as well as (B) ribosomal protein P0 and Ro-52 were 
incubated for 5h in the absence (tF, -) or presence (+) of various concentrations of activated MMP-9 (200 nM to 1.6 
nM, decreasing from lane 3 to 6) and analysed by SDS-PAGE. Control incubations included incubation with activated 
MMP-9 (200 nM) supplemented with the metalloprotease inhibitor EDTA (20 mM) and incubation with the catalytical 
domain of MMP-3 (cd-MMP-3, 2 nM), used to activate MMP-9.  In addition, the highest concentration of MMP-9 was 
also incubated separately as a control for non-substrate fragment bands (lane 9). Visualization of the intact substrate 
(arrow) before incubation is shown under t0.  Fragments generated by MMP-9 are indicated with an asterisk (*). 
Apparent molecular masses are shown next to the gels in kDa.  (C) Anti-actin and anti-tubulin IgG titers in plasma 
samples from 3, 6 and 9 months old mice from the four different genotype cohorts were determined by ELISA as 
detailed in ‘Measurement of autoantibodies’ and compared to a laboratory standard of 100 units. Histograms indicate 
group medians and each dot represents data from a single animal.  Indications of statistical significance are only shown 
for the comparison between B6lpr/lpr.MMP-9-/- and B6lpr/lpr.MMP-9+/+ mice, since both these groups always showed 
significantly higher titers in comparison with B6.MMP-9-/- and B6 mice, except for anti-actin IgG at 9 months and anti-
tubulin IgG at 6 and 9 months, which were not significantly different between B6lpr/lpr.MMP-9+/+ compared with 
B6.MMP-9-/- or B6 mice. No significant differences in autoantibody titers were observed between B6.MMP-9-/- and B6 
mice.  *P < .05, **P < .01, ***P < .001. 
 
To analyze whether MMP-9-cleaved autoantigens 
are less well recognized by autoantibodies compared 
with intact antigens, we used competitive ELISA 
(see ‘Materials and methods’) since the direct 
coating of cleaved material is impaired. In 
competitive ELISA an excess of free autoantigen, 
either intact or cleaved, competed with coated intact 
antigen for antibody recognition.  In this way, it 
became clear that after cleavage by MMP-9 
ribosomal protein P0 and U1snRNP A are hardly 
recognized by plasma samples of both B6lpr/lpr.MMP-
9-/- and B6lpr/lpr.MMP-9+/+ mice (Figure 7A), pointing 
to a destruction of B cell epitopes by MMP-9-
mediated proteolysis.  In addition, the same loss of 
immunodominant epitopes was observed with 
autoantibody samples from SLE patients (Figure 
7B).  Hence, these data suggest that intact substrates 
of MMP-9 are better triggers for autoantibody 
production and that MMP-9 exerts a protective 
effect against autoantibody formation by degradation 
of these antigenic stimuli. 
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Figure 7. Loss of B cell epitopes in ribosomal protein P0 and U1snRNP A after proteolysis by MMP-9. Binding of 
autoantibodies from (A) B6lpr/lpr mice and (B) SLE patients to intact (conformational) antigens and MMP-9-generated 
proteolytic fragments was measured by competitive ELISA. Plates were coated with intact ribosomal protein P0 or 
U1snRNP A.  Increasing concentrations of free autoantigen (previously cleaved by MMP-9 or intact) competed with 
coated intact autoantigen for autoantibody binding.   Immune complexes formed with free autoantigen were not retained 
on the plates, resulting in a drop in OD.  No addition of free antigen (0 µg/mL) was considered as 0% competition and 
100% OD.  Final competition was considered as the loss of OD (% OD) after addition of the maximal concentration of 
free autoantigen (25 µg/mL, ratio of free/coated antigen equals 50/1).  **P < .01, ***P < .001. 
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B6lpr/lprMMP­9­/­ mice show more pronounced 
autoimmune tissue injury 
To assess the effects of lymphoproliferation and 
systemic autoimmunity on autoimmune tissue 
injury, histological examination of organs of 9 
months old mice was undertaken.  Both in the lymph 
nodes and in the spleen a complete distortion of the 
lymphoid architecture was visible in various 
B6lpr/lpr.MMP-9-/- mice but not in B6lpr/lpr.MMP-9+/+ 
and other control mice (Figure 8A).  In the lymph 
nodes the distinction between cortex and medulla 
was blurred and follicles could no longer be 
discerned.  In the spleens, the white pulp architecture 
was completely disturbed by the massive 
accumulation of DN T cells forming irregular 
nodules (CD3+B220+CD4-CD8-IgM-IgD-CD68-, as 
determined by immunohistochemistry, data not 
shown) and the red pulp showed massive 
lymphocyte infiltration.  General lymph node and 
spleen pathology scores (determined as described in 
‘Materials and methods’) were increased in the 
absence of MMP-9 (Figure 8C), albeit not 
significantly, except for the renal lymph node score 
(P < .05) (data not shown).   
Histological examination of liver, lungs and 
kidneys revealed increased lymphocyte infiltrations 
in B6lpr/lpr.MMP-9-/- mice in comparison with 
B6lpr/lpr.MMP-9+/+ mice.  A higher proportion of 
B6lpr/lpr.MMP-9-/- mice showed a moderate or severe 
periportal and/or parenchymal liver infiltration (40% 
vs. 9%, respectively), and moderate or high 
peribronchial and/or alveolar lymphocyte infiltration 
(80% vs. 56%, respectively).  In various mice these 
chronic mononuclear cell infiltrations culminated in 
bronchiolitis obliterans organizing pneumonia 
(BOOP).   
The kidneys of the most affected B6lpr/lpr.MMP-9-
/- mice showed signs of mesangial proliferative lupus 
nephritis, whereas no mesangial proliferation was 
observed on kidney sections of B6lpr/lpr.MMP-9+/+ 
mice (Figure 8A).  In some of the most affected 
B6lpr/lpr.MMP-9-/- kidneys, immune complex deposits 
were found by electron microcopy (Figure 8B).  In 
addition, the albumin-to-creatinine ratio (ACR) was 
significantly higher in the absence of MMP-9 (P < 
.05) (Figure 8C), pointing to glomerular barrier 
failure in B6lpr/lpr.MMP-9-/- mice.  A higher incidence 
of thymuses with cortical thymocyte loss was found 
in B6lpr/lpr.MMP-9-/- mice vs. B6lpr/lpr.MMP-9+/+ mice 
(44% vs. 10%, respectively) (data not shown).   
In line with previous data, i.e. absence of 
histological differences between B6.MMP-9-/- and 
B6.MMP-9+/+ mice8, we did not observe any 
differences at 9 months (data not shown).  
Microscopic and macroscopic pathology scores 
showed positive associations in B6lpr/lpr.MMP-9-/- 
mice (Supplementary Table 1).  Likewise, the extent 
of lymphoproliferation was significantly correlated 
with lymph node, spleen and liver pathology scores 
(and positively but non-significantly with lung 
pathology scores).  However, in B6lpr/lpr.MMP-9+/+ 
mice the macroscopic pathology score and degree of 
lymphoproliferation were only positively (non-
significantly) correlated with liver and lung scores.  
These data suggest that lymphadenopathy and 
splenomegaly caused more widespread organ injury 
in the absence than in the presence of MMP-9. As 
expected form the positive correlations between 
lymphoproliferation and autoantibody titers (Table 
1), histopathology scores (except for the lung 
pathology scores) also showed positive correlations 
with autoantibody titers (except for anti-chromatin 
IgG) in B6lpr/lpr.MMP-9-/- mice, but not in 
B6lpr/lpr.MMP-9+/+  mice (Supplementary Table 2), 
suggesting that the absence of MMP-9 results in 
autoantibody-mediated tissue injury. 
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Figure 8. Autoimmune tissue injury is more pronounced in B6lpr/lpr.MMP-9-/- mice vs. control mice.  (A) Tissue 
sections from 9 months old mice were stained with hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS) stain 
(kidney sections) and scored by pathologists as detailed in ‘Histologic examination of tissues’.  Representative 
photomicrographs of axillary and inguinal lymph nodes (×100), spleen (×50), liver (×200)¸ lung (×100) and kidney 
(×400) are shown for each genotype. White arrow, periportal infiltration.  (B) Electron micrographs of glomerular 
capillaries in kidney samples prepared from frozen tissue blocs. Black arrows, immune complex deposits. Scale bars, 1.50 
µm. (C) Histology scores and the albumin-to-creatinine ratio (ACR) for B6lpr/lpr.MMP-9-/- and B6lpr/lpr.MMP-9+/+ mice. 
Horizontal lines indicate group medians.  Each dot represents data from a single animal.  *P < .05. 
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DISCUSSION 
The Fas lpr mutation and the Fas ligand gld 
(generalized lymphoproliferative disease) mutation 
causing lymphoproliferation and lupus-like 
autoimmune symptoms in mice, were a key to the 
understanding of the autoimmune lymphoproliferative 
syndrome or ALPS etiology.30  Patients with ALPS 
present with nonmalignant lymphoproliferation 
(splenomegaly and/or adenopathy) along with increase 
of unusual DN T cells, hypergammaglobulinemia and 
autoimmune disease, caused by heterozygous 
mutations in the Fas gene and concomitant defective 
lymphocyte apoptosis.31  Similarly, it was discovered 
that also abnormal Fas expression was associated with 
expansion of cytokine-producing DN T cells.32  The 
DN T cell population – which only represents 1% to 
2% of peripheral T lymphocytes in healthy persons33 – 
is also expanded in the peripheral blood of SLE 
patients and is characterized by increased levels of 
activation markers, production of IL-4, and induction 
of Ig and pathogenic anti-DNA autoantibodies.34-37 
Recently, IL-17-producing DN T cells were found in 
kidney biopsies of patients with lupus nephritis and 
were shown to induce nephritis in a non-autoimmune 
mouse model.38,39   
Here, we describe the severe expansion of the DN 
T cell subset in the periphery of B6lpr/lpr mice rendered 
genetically deficient in the inflammatory protease 
gelatinase B/MMP-9.  In the lymph nodes, DN T cell 
expansion was accompanied by increased 
accumulation of CD4+ and CD8+ T cells, B cells and 
myeloid cells such as neutrophils, macrophages and 
dendritic cells. The massive lymphoproliferation in 
B6lpr/lpr.MMP-9-/- mice was positively correlated with 
higher autoantibody titers and more pronounced 
autoimmune injury with distortion of spleen and 
lymph nodes architectures, increased lymphocyte 
infiltration in non-lymphoid organs and enhanced 
kidney disease, culminating in increased mortality. 
Various explanations may account for the 
described amplification of lymphoproliferation.  On 
the one hand, the increased DN T cell expansion may 
be caused by an augmented proliferative capacity of 
MMP-9 deficient DN T cells in vivo, analogous to the 
increased alloreactive T cell proliferation observed in 
MMP-9 knockout mice after tracheal or cardiac 
allograft transplantation.17,18  On the other hand, an 
additional apoptosis defect may be triggered by MMP-
9 deficiency in immune cells, causing their increased 
accumulation in the periphery.  In support of this, 
genetic lack of MMP-9 during zymosan peritonitis 
leads to enhanced cyclooxygenase-1 and 
prostaglandin E2 levels, which results in increased 
vascular permeability and decreased capase-3 
expression and activity, the latter leading to impaired 
apoptosis and accumulation of inflammatory 
leukocytes.40-42  
Deficient clearance of dying cells and cellular 
material is proposed to be a central pathogenic 
mechanism in the development and acceleration of 
systemic autoimmune diseases such as SLE.16  
Regarding the suppression of systemic autoimmune 
phenomena by MMP-9, it is tempting to hypothesize 
that MMP-9 deficiency engenders an additional 
clearance deficiency.  Indeed, the massive load of 
accumulated DN T cells and other leukocytes that 
cannot undergo Fas-mediated apoptosis will 
eventually progress to necrosis - as evidenced by the 
hemorrhagic and necrotic appearance of many 
enlarged lymph nodes (Figure 2A) -  and release 
intracellular autoantigens.  MMP-9 was shown to 
degrade many intracellular proteins12,13 and may in 
this way remove their immunogenic potential.  Indeed, 
B cell conformational epitopes are likely to be 
destroyed by proteolysis, which was illustrated here 
by the impaired murine and human autoantibody 
binding to cleaved ribosomal protein P0 and cleaved 
U1snRNP A (Figure 7).  In addition, intact polymeric 
substrate molecules such as actin and tubulin may 
crosslink B cell receptors and activate autoreactive B 
cells.  Similarly, multivalent Toll-like receptor (TLR) 
ligands such as DNA and RNA may serve as co-
activators or carriers for the internalization of bound 
antigens, and autoantigen-containing immune 
complexes may be internalized by autoreactive 
rheumatoid factor-positive B cells.  Subsequently, B 
cell tolerance is broken by combined recognition of 
self-antigens and TLR activation.  The autoantigens 
are processed and presented in MHC II molecules, and 
activate autoreactive T cells that provide help for 
other autoreactive B cells.43  This phenomenon of ‘B 
cell epitope spreading’ may be suppressed by 
proteolysis of the (DNA/RNA-bound) antigen as more 
epitopes can be derived and presented from intact 
molecules as compared to residual carrier-bound 
fragments.  This hypothesis was supported by the 
current observation that ‘uncleaved’ autoantigens 
seemed to be better stimuli for autoreactive B cells 
(Figures 5 to 7).  However, further research is needed 
to define the exact impact of proteolysis on 
antigenicity, as the higher autoantibody titers in 
B6lpr/lpr.MMP-9-/- mice may also result from an overall 
increase in systemic autoimmunity and epitope 
spreading to multiple autoantigens, both substrates 
and non-substrates.  In this study, we have used 
MMP-9 as a model secreted protease, but it cannot be 
excluded that other ‘inflammatory proteases’ such as 
neutrophil elastase, granzyme B and cathepsins, might 
exert similar functions.   
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Upon initiation of the necrotic cascade, cells will 
release so-called damage-associated molecular 
patterns (DAMPs) or alarmins that mediate 
inflammation and immune cell activation.44,45  
Interestingly, many alarmins were found to be 
substrates of MMP-9, including high mobility group 
box 1/2 protein (HMGB1/2), HSP70, HSP90, 
hepatoma-derived growth factor, nucleolin and 
annexin I.13  Proteolytic degradation of these pro-
inflammatory adjuvant molecules may be a way of 
keeping them in check, as was described for HMGB1 
cleavage by thrombin.46  Along this line, activated 
dendritic cells were recently shown to be involved in 
autoimmune kidney injury in MRLlpr/lpr mice through 
secretion of HMGB1.47  Hence, the higher numbers of 
activated dendritic cells combined with the lack of 
HMGB1 proteolysis in B6lpr/lpr.MMP-9-/- mice may 
contribute to the observed enhancement of renal 
failure. As another point, low doses of self-peptides 
generated by proteolysis may promote tolerance by 
the induction of regulatory T cells and anti-
inflammatory cytokines that suppress pathogenic T 
and B cells, as was shown for various peptides in 
murine lupus models.48,49  Less regulatory T cells in 
the absence of MMP-9 may also be at the base of 
higher lymphocyte proliferation. 
Since MMPs were shown to cleave a kaleidoscope 
of cell surface-associated molecules13, proteolysis of 
such membrane molecules by MMP-9 may be an 
additional means of containing lymphocyte 
proliferation and systemic autoimmunity.  For 
example,  upregulation of the MMP-9 substrate 
intercellular adhesion molecule-1 (ICAM-1)50,51 in 
correlation with disease activity was observed in 
patients with SLE and in MRLlpr/lpr mice.52  Lack of 
ICAM-1 turnover by MMP-9 may contribute to the 
excessive leukocyte recruitment observed in 
B6lpr/lpr.MMP-9-/- mice.  Other interesting candidate 
substrates include the complement component 1 q 
subcomponent receptor 1 (C1qRp, CD93), FcγRIII 
(CD16), the IL-4 and IL-6 receptors, TNF receptor-55 
and -75 and vascular cell adhesion molecule-1 
(VCAM-1).53 
In conclusion, this is the first time that genetic 
deficiency of a protease was described to enhance 
lymphoproliferation and systemic autoimmunity.  As 
MMP-9 is an inducible protease, these effects were 
not visible under homeostatic conditions in MMP-9-
deficient mice, but were revealed by the autoimmune 
lymphoproliferative genotype and phenotype of 
B6lpr/lpr mice.  The enhanced pathology in 
B6lpr/lpr.MMP-9-/- mice may be caused by a failure of 
various processes including disturbed lymphocyte 
homeostasis, apoptotic defects, clearance deficiencies 
and persistence of membrane-associated molecules.  
The ensemble of defects caused by MMP-9 deficiency 
in the B6lpr/lpr model is of clinical importance as our 
results suggest that long-term use of (non-selective) 
MMP inhibitors may be disease-promoting in ALPS 
and SLE patients, rather than disease-limiting. 
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SUPPLEMENTARY MATERIAL 
 
 
Supplementary figure 1. Phenotypic confirmation of genetic MMP-9 knockout by zymography analysis of 
plasma samples.  Neutrophils in peripheral blood samples were triggered to degranulate for 1h by fMLP.  
Subsequently, gelatinases were prepurified from the plasma samples on gelatin-Sepharose and further analysed by 
gelatin zymography as described in ‘Phenotyping’.  The various gelatinase forms are indicated by arrows. 
 
 
 
 
 
Supplementary figure 2. Increased macroscopic pathology in B6lpr/lpr.MMP-9-/- mice.  Enlarged (A) renal (R), (B) 
mesenteric (M) and (C) lumbal (L) lymph nodes in 6 to 9 months old MMP-9-deficient B6lpr/lpr mice.  These mice often 
showed (D) splenomegaly, (E) an enlarged thymus and (F) a visibly affected liver with a granular surface and blunt 
edges. 
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Supplementary figure 3. Comparisons of lymphoid cell percentages in four genotype cohorts.  Axillary and inguinal 
lymph node cells (top), splenocytes (middle) and peripheral blood cells (bottom) were isolated from 6 to 9 months old mice 
(age-matched groups) and stained as described in ‘Materials and methods’.  Double negative (DN) T cells were obtained by 
gating on CD3+B220+ cells followed by gating on CD4-CD8- cells.  Histograms show from left to right: percentages of 
CD3+B220+ cells, DN T cells (CD4-CD8-), CD4+ T cells, CD8+ T cells and B220+CD3- B cells.  Histograms indicate group 
medians and aligned scatter plots show the range of the individual data points. *P < .05, **P < .01, ***P < .001. 
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Supplementary figure 4. No differences in T and B cell proliferation between B6lpr/lpr.MMP-9-/- mice and 
B6lpr/lpr.MMP-9+/+ mice. Axillary and inguinal lymph nodes cells and splenocytes were isolated from 9 months old 
mice and stimulated to proliferate with anti-CD3 (as a polyclonal T cell stimulus) and anti-IgM (as an aspecfic B cell 
trigger).  Proliferation was assessed by 3H-thymidine uptake as detailed in ‘Proliferation assays’. Histograms indicate 
group medians and each dot represents data from a single animal.  *P < .05, as compared with the B6lpr/lpr.MMP-9-/- 
group. †P < .05, as compared with the B6lpr/lpr.MMP-9+/+ mice.  
 
 
 
Supplementary Table 1. Correlations between macroscopic and microscopic pathology scores. 
No.†
B6lpr/lpr.MMP-9-/- 
MPS 13 0,59 * 0,61 * 0,59 * 0,41
LN w/bw 13 0,84 *** 0,73 ** 0,83 *** 0,45
Spleen w/bw 13 0,77 ** 0,71 ** 0,76 ** 0,33
B6lpr/lpr.MMP-9+/+
MPS 11 -0,13 -0,05 0,51 0,49
LN w/bw 11 -0,33 -0,19 0,50 0,52
Spleen w/bw 11 -0,59 -0,17 0,50 0,49
LN Spleen Liver Lung 
Histopathology scores of affected organs
 
Depicted are Spearman correlation coefficients with their significance levels, which are indicated by *P < .05, **P < 
.01, ***P < .001.  
†Number of pairs analysed by the Spearman rank correlation test.  
LN, lymph nodes; MPS, macroscopic pathology score; w/bw, weight/body weight. 
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Supplementary Table 2.  Correlations between autoantibody titers at 9 months and histopathology 
scores. 
Autoantibody specificity No.† LN Spleen Liver Lung 
B6lpr/lpr.MMP-9-/- 
anti-dsDNA IgG 13 0,39 0,39 0,49 -0,05
anti-chromatin IgG 11 0,05 -0,01 -0,06 -0,35
Rheumatoid factor IgG 13 0,29 0,23 0,50 0,45
anti-Histone IgG 13 0,54 0,65 * 0,68 ** 0,23
anti-U1snRNP IgG 13 0,28 0,34 0,47 -0,01
anti-Smith IgG 13 0,62 * 0,67 * 0,62 * 0,21
anti-actin IgG 13 0,51 0,41 0,67 * 0,09
anti-tubulin IgG 13 0,41 0,45 0,63 * 0,29
B6lpr/lpr.MMP-9+/+
anti-dsDNA IgG 10 -0,04 -0,07 0,52 0,27
anti-chromatin IgG 11 -0,33 -0,32 0,50 0,46
Rheumatoid factor IgG 11 -0,16 0,18 0,20 0,31
anti-Histone IgG 11 0,19 0,19 0,40 0,12
anti-U1snRNP IgG 10 0,02 -0,20 0,41 0,08
anti-Smith IgG 10 0,15 0,03 0,52 0,31
anti-actin IgG 10 0,17 0,02 0,52 0,49
anti-tubulin IgG 10 0,10 -0,66 * 0,41 0,21
Histopathology scores of affected organs
 
Depicted are Spearman correlation coefficients with their significance levels, which are indicated by *P < .05, **P < 
.01. 
†Number of pairs analysed by the Spearman rank correlation test.  
LN, lymph nodes. 
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DISCUSSION AND PERSPECTIVES 
 
In this section, a number of general findings of the present doctoral research are discussed in a 
wider context and as perspectives for future work.  Part 1 consists of a review on the current status 
of intracellular substrate cleavage by MMPs.  This part integrates our present ideas on intracellular 
MMP-9 substrates with findings obtained for other MMPs, and places the results of Chapters 2 and 
3 in the framework of present knowledge on intracellular MMP substrates in physiology and 
pathology.  Part 2 mainly deals with the conclusions of Chapter 4 in order to link these with the 
observations of Chapters 1, 2 and 3. In addition, it highlights the clinical relevance of further 
research on the roles of MMP-9 in systemic autoimmunity. 
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DISCUSSION PART 1.  INTRACELLULAR SUBSTRATE CLEAVAGE:  
A NOVEL DIMENSION IN THE BIOCHEMISTRY, BIOLOGY AND PATHOLOGY  
OF MATRIX METALLOPROTEINASES 
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ABSTRACT 
Matrix metalloproteinases (MMPs), originally discovered to function in the breakdown of extracellular matrix 
proteins, have gained the status of regulatory proteases in signaling events by liganding and processing hormones, 
cytokines, chemokines, adhesion molecules and other membrane receptors. However, MMPs also cleave 
intracellular substrates and have been demonstrated within cells in nuclear, mitochondrial, various vesicular and 
cytoplasmic compartments, including the cytoskeletal intracellular matrix. Unbiased high-throughput degradomics 
approaches have demonstrated that many intracellular proteins are cleaved by MMPs, including apoptotic 
regulators, signal transducers, molecular chaperones, cytoskeletal proteins, systemic autoantigens, enzymes in 
carbohydrate metabolism and protein biosynthesis, transcriptional and translational regulators, and proteins in 
charge of protein clearance such as lysosomal and ubiquitination enzymes. Besides proteolysis inside cells, 
intracellular proteins may also be modulated by MMPs in the extracellular milieu.  Indeed, many intracellular 
proteins exit cells by non-classical secretion mechanisms or by various conditions of cell death by apoptosis, 
necrosis and NETosis, and become accessible to extracellular proteases. Intracellular substrate proteolysis by 
MMPs is involved in innate immune defense and apoptosis, and affects oncogenesis and pathology of cardiac, 
neurological, protein conformational and autoimmune diseases, including ischemia-reperfusion injury, 
cardiomyopathy, Parkinson’s disease, cataract, multiple sclerosis and systemic lupus erythematosus. Since the 
same MMP may affect physiology and pathology in different and even opposite ways, depending on its 
extracellular or subcellular localization, an additional layer of complexity is added to therapeutic MMP inhibition.  
Hence, further elucidation of intracellular MMP localizations and intracellular substrate proteolysis is a new 
challenge in MMP research. 
KEYWORDS: oxidative stress, apoptosis, cancer, innate immune defense, cardiopathology, neurodegeneration, 
autoimmunity, chaperone 
ABBREVIATIONS: 
2D-PAGE, two-dimensional polyacrylamide gel electrophoresis; AMPA-R, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; ATP, adenosine triphosphate; BBB, blood-brain barrier; CNS, central nervous 
system; DCM, dilated cardiomyopathy; ECM, extracellular matrix; ER, endoplasmatic reticulum; F-actin, 
filamentous actin; G-actin, globular actin; GSH, reduced glutathione; HMGB1/2, High-mobility group box 1/2 
protein; hnRNP, heterogenous nuclear ribonucleoprotein; HSP, heat shock protein; I/R, ischemia-reperfusion; 
IFN-γ, interferon-γ; IL-1, interleukin-1; LPS, lipopolysaccharide; MI, myocardial infarct; MMP, matrix 
metalloproteinase; MS, mass spectrometry; MT-MMP, membrane-type MMP; NMDA-R1, N-methyl-D-
aspartate receptor-1; O-phen, 1,10-phenantroline; PARP, poly (ADP-ribose) polymerase; PC, proprotein 
convertase; PD, Parkinson's disease; PMA, phorbol 12-myristate 13-acetate; PMN, polymorphonuclear 
leukocytes; RNS, reactive nitrogen species; ROS, reactive oxygen species; SDS, sodium dodecyl sulphate; SDS-
PAGE, sodium dodecyl sylphate-polyacrylamide gel electrophoresis; TGN, trans-Golgi network; TIMP, tissue 
inhibitor of metalloproteinases; TJ, tight junction; TNF-α, tumor necrosis factor-. 
 
 
 
 160 | P a g e  
TABLE OF CONTENTS 
 
INTRODUCTION: FROM ‘NOMEN EST OMEN’ TO ‘FORTUNA’................................................................3 
1. MECHANISMS OF EXTRACELLULAR VS. INTRACELLULAR MMP ACTIVATION……………………5 
1.1 Proteolytic cleavage………………………………………………………………………………………..5 
1.2 Oxidative stress and nitrosative stress……………………………………………………………………7 
1.3 Phosphorylation……………………………………………………………………………………………8 
1.4 Alternative splicing………………………………………………………………………………………...8 
2. INTRACELLULAR SUBSTRATE DETECTION BY DEGRADOMICS…………………………………………9 
3. MMP ACTION INSIDE CELLS………………………………………………….....................................................15 
3.1  Intracellular MMP detection: methodological considerations………………………………………..23 
3.2  Subcellular localization mechanisms of MMP…………………………………………………………25 
3.2.1 Cytosolic MMP activity…………………………………………………………………………….25 
3.2.2 MMP activity in the secretory pathway…………………………………………………………….26 
3.2.3 MMP activity associated with the cytoskeleton………………………....………………………….30 
3.2.4 MMPs in the sarcomere…………………………………………………………………………….30 
3.2.5 Mitochondrial MMP activity…………………….………..………………………………………..30 
3.2.6 MMP activity in the nucleus…………………….………………………………………………….30 
3.3 Intracellular proteolysis by MMPs in physiology and pathology……………………………………..31 
3.3.1 Intracellular proteolysis in innate immune defense…………………………………………………31 
3.3.2 Intracellular proteolysis in cancer…………………………………………………………………..36 
3.3.3 Intracellular proteolysis in cardiac disease………………………………………………………….38 
3.3.4 Intracellular proteolysis in acute and chronic neurodegenerative diseases…………………………42 
3.3.5 Intracellular proteolysis and cataract………………………………………………………………..46 
3.3.6 Intracellular proteolysis and apoptosis……………………………………………………………...46 
4 INTRACELLULAR MMP SUBSTRATES DEGRADED OUTSIDE CELLS………………………………….50 
4.1 Extracellular localization mechanisms of intracellular MMP substrates…………………………….51 
4.1.1 Non-classical secretion of intracellular MMP substrates…………………….…………………...51 
4.1.2 Exposure of intracellular substrates to extracellular MMPs by various forms of cell death……..51 
4.2 Extracellular proteolysis of intracellular substrates in physiology and pathology…………………..54 
4.2.1 Extracellular proteolysis of intracellular autoantigens in organ-specific autoimmune diseases: 
multiple sclerosis…..…………………………………………….……………........................................54 
4.2.2 Extracellular proteolysis of intracellular autoantigens in systemic autoimmune diseases: 
SLE…………………………………………………………………………………………….………...55 
4.2.3 Extracellular proteolysis of intracellular autoantigens in acute necrotic conditions…..………...56 
4.2.4 Extracellular proteolysis of intracellular autoantigens in amyloid diseases………….…….....…57 
 
CONCLUSION………………………………………………………………………………………………………………………58 
ACKNOWLEDGMENTS………………………………………………………………………………………………………...59 
DECLARATION OF INTEREST………………………………………………………………………………………………59 
CORRESPONDENCE…………………………………………………………………………………………………………….59 
REFERENCES………………………………………………………………………………………………………………………59 
D I S C U S S I O N   P A R T   1  
161 | P a g e  
INTRODUCTION: FROM ‘NOMEN EST OMEN’ 
TO  ‘FORTUNA’  OR  ‘HOW  AND  OMINOUS 
NAME MAY TURN OUT FORTUNATE’ 
The family of human matrix metalloproteinases 
(MMPs) currently consists of 24 different neutral 
endopeptidases. They play a role in many physiological 
processes such as reproduction, development, immune 
functions and tissue repair, but are also involved in 
pathological conditions such as cancer, inflammation, 
autoimmune diseases, vascular diseases and 
neurodegenerative disorders (Sternlicht and Werb, 
2001; Egeblad and Werb, 2002; Manicone and 
McGuire, 2008; Milner and Cawston, 2005; Hu et al., 
2007; Rosenberg, 2009; Parks et al., 2004).   
Whether it is a good or bad attribute, the name of an 
enzyme needs to make any reader clairvoyant or 
interested in its activities. Originally, the enzymes that 
cleave extracellular matrix molecules (ECM) were 
named according to substrate conversion. For instance, 
collagenase was the name given to a collagen-degrading 
enzyme (Gross and Lapiere, 1962). When we purified a 
gelatin-degrading enzyme to homogeneity (Masure et 
al., 1991), we were instructed by the IUPAC Enzyme 
Commission to name it gelatinase B, because of the 
used substrate and because a different gelatinase, 
henceforth named gelatinase A, was already defined 
(Figure 1). Along similar lines, the stromelysins, 
matrilysins and membrane-type enzymes were 
discovered and named. Stromelysin was, in fact, a better 
name given for a proteoglycan-degrading enzyme than 
proteoglycanase, because the latter name might wrongly 
suggest that the glycan structure (and not the protein) is 
cleaved in the matrix substrate molecule. At a certain 
time point, it was decided to rename these enzymes into 
matrix metalloproteinases. This nomenclature and 
abbreviation as MMP - with a suffix number - was 
based on the historic order of discovery. This renaming 
was not accomplished with perfect logics, since it was 
not decided to strictly adhere to one - e.g. the human – 
species. This led to unfortunate outcomes. For example, 
today MMP-4, MMP-5 and MMP-6 are not on the list 
anymore. The term metalloproteinase has remained a 
correct one, as all members have a catalytic Zn2+ ion in 
the active site. The addition matrix to metalloproteinase 
was correct in the original context of ECM substrates, 
but is recently contested by findings that these enzymes 
contribute also to cytokine, hormone and chemokine 
processing (Sternlicht and Werb, 2001; Parks et al., 
2004) and process many membrane-bound substrates 
(Cauwe et al., 2007). In a recent review, Butler and 
Overall replaced matrix by multifaceted as a sign that 
the biology of these enzymes is gradually broadening 
(Butler and Overall, 2009b). In fact, the ominous nature 
of ECM-eating enzymes has indeed transcended to a 
higher order kind of proteases regulating biological 
control processes. In other words, simple soldiers have 
become generals and MMPs are now considered 
multifunctional entities. Unless the whole nomenclature 
system of these enzymes is reconsidered by means of 
delicate scientific diplomacy, the present adherence in 
more than 20.000 publications to this imperfect man-
made classification has also fortunate side-effects. 
Indeed, as we will review here, MMPs cleave many 
“intracellular matrix” molecules (ICM). In fact, if we 
refer to matrix in its broadest sense, i.e. the organized 
grid or granular substance with multimolecular 
interactions, then the name given to these enzymes 
remains a tribute to many pioneers in the field and 
integrates, in an improved way, recent findings on the 
biology and pathology of MMPs.   
MMPs are multidomain enzymes 
characterised by a conserved three 
His Zn2+-binding motif in the 
catalytic domain and a conserved 
Met turn following the active site 
(Bode et al., 1993; Nagase and 
Woessner, 1999).  The three His 
residues coordinate the Zn2+ ion, 
which interacts with a conserved Cys 
in the propeptide.  This Cys-Zn2+ 
coordination confers latency to the 
MMPs which are synthesized as 
inactive pre-pro-enzymes (Visse and 
Nagase, 2003).  The signal peptide is 
removed during translation, and 
activation of the pro-enzymes or 
zymogens requires disruption of the 
Cys-Zn2+ coordination (cf. Figure 3).  
The active site, now freed of the 
propeptide, binds substrates and the 
Zn2+ ion becomes available for the 
binding of a hydrolytic water 
Figure 1 
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molecule that is essential for catalysis.  Hence, the 
MMP activation mechanism was termed ‘cysteine 
switch mechanism’ (Van Wart and Birkedal-Hansen, 
1990). 
In terms of structure, a typical MMP consist of a 
propeptide, a catalytical domain, a Zn2+-binding 
domain, a linker or hinge region of variable length, 
and a hemopexin domain, which contributes to 
substrate specificity and to interactions with 
endogenous inhibitors and cargo receptors (cf. Figure 
3) (Piccard et al., 2007). Exceptions to this 
multidomain organization rule are MMP-7/matrilysin-
1, MMP-26/matrilysin-2 and MMP-23, which lack the 
hinge region and hemopexin domain. In addition, 
MMP-23/cysteine array (CA)-MMP has a unique Cys-
rich domain and an immunoglobulin-like domain at 
the COOH-terminal side of the metalloproteinase 
domain.  The structures of MMP-2/gelatinase A and 
MMP-9/gelatinase B contain three fibronectin type II 
repeats for the binding of gelatin, and MMP-9 is the 
only MMP to possess a Ser/Thr/Pro-rich O-
glycosylated domain, which forms an anchorage site 
for multiple O-linked sugars (Van den Steen et al., 
2006).  In addition to the secreted MMPs, six human 
membrane-bound MMPs (MT-MMPs) exist.  These 
include four type I transmembrane proteins (MT1-
MMP/MMP-14, MT2-MMP/MMP-15, MT3-
MMP/MMP-16 and MT5-MMP/MMP-24) and two 
glycosyl phosphatidylinositol (GPI)-anchored proteins 
(MT4-MMP/MMP-17 and MT6-MMP/MMP-25) 
(Visse and Nagase, 2003; Nagase et al., 2006).   
As outlined in a number of pertinent review 
articles, MMP levels and activities are strictly 
controlled in a spatial and temporal fashion by 
genetic and epigenetic, by transcriptional, post-
transcriptional and post-translational mechanisms, as 
well as by zymogen activation, receptor-mediated 
endocytosis and inhibition by natural inhibitors 
(Clark et al., 2008; Emonard et al., 2005; Ra and 
Parks, 2007; Nagase et al., 2006; Brew and Nagase, 
2010).  The general protease inhibitor, 2-
macroglobulin, is the principal MMP inhibitor in the 
circulation (Baker et al., 2002), whereas the tissue 
inhibitors of metalloproteinases (TIMPs) are 
considered to be the key inhibitors in tissue (Brew 
and Nagase, 2010).   
A new challenge in MMP research is to (re)assess 
substrate repertoires. Logical but not so much applied 
ways to perform such assessments is by comparing 
and defining specific activities towards substrates, by 
in-depth biological studies to define the topologies of 
MMPs in vivo (Olson et al., 2009; Sela-Passwell et 
al., 2010) and to discover the substrates that are 
cleaved in situ (Agrawal et al., 2006).  The first 
twenty-five years of MMP research were successful 
by tedious purifications and characterizations of 
additional MMPs (Brinckerhoff and Matrisian, 2002; 
Nagase and Woessner, 1999; Nagase et al., 1992).   
 
Figure 2. Comparison of the literature evolution for 
membrane-associated substrates vs. intracellular 
substrates.  The graph of membrane-associated substrates 
is based on a previous review (Cauwe et al., 2007).  For 
literature on intracellular substrates and intracellular MMP 
localization, the Pubmed database was searched for 
combinations of matrix metalloproteinase with 
intracellular, subcellular, intranuclear, nucleus, intracellular 
substrate, intracellular cleavage and intracellular action key 
words.  By comparison of the number of articles during the 
same number of years (>10 years after appearance of the 
first publication), it becomes clear that literature on 
intracellular substrates (middle graph) has not known the 
marked increase of membrane-associated substrate papers 
(top graph).  However, an increase is noticed in the 
combination of data on intracellular MMP substrates and 
intracellular localization of MMPs.  Hence, research on 
intracellular substrates and intracellular MMP actions is 
gaining interest and may catch up with other areas in MMP 
research. 
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The next milestone was the recognition that MMPs 
are not just massive ECM wreckers but also cleave 
many secreted molecules and membrane-associated 
substrates, which allows them to play sophisticated roles 
in the modulation of normal cellular behavior, cell-cell 
communication and tumor progression (McCawley and 
Matrisian, 2001; Sternlicht and Werb, 2001; Cauwe et 
al., 2007).  A dogma in MMP research has always been 
that they are secreted or membrane-associated proteases, 
acting in the extracellular space or at the cell surface. 
Many skeptical readers will acknowledge that true 
secretory enzymes such as MMPs have no business, 
physiologically speaking, cleaving substrates in a 
particular intracellular location.  However, the presence 
of identified and functional subcellular localization 
signals in specific MMPs goes against this skepticism 
(Si-Tayeb et al., 2006; Eguchi et al., 2008). At a 
completely different level, it is easily accepted that 
MMPs may act in the extracellular milieu on many 
intracellular proteins, once they are actively or passively 
released from cells. Accumulating evidence suggests 
that the extracellular and pericellular actions may be 
complemented by intracellular actions, as well as by 
cleavage of intracellular proteins in the extracellular 
space.  By comparison of the evolution of literature on 
membrane-associated substrates vs. intracellular 
substrates (Figure 2, top and middle graphs), it is quite 
obvious that studies on the cleavage of intracellular 
proteins by MMPs are lagging behind.  Although a 
steady amount of articles have been published during 
the last ten years, a spectacular rise, as observed for 
membrane-associated substrates, has not yet been 
observed (Figure 2).  Maybe, the idea of obligatory 
extracellular MMP action still hinders active 
investigation in this field and prevents that novel 
intracellular substrates are reported.  However, when 
complementing publications on intracellular substrates 
with literature on intracellular MMP localization, one 
can see a rising trend, possibly of an opening field 
(Figure 2, bottom graph).  The rationale of the present 
review is aimed at summarizing the current data on 
intracellular MMP localization and activation 
mechanisms.  Furthermore, we will discuss present 
knowledge on the proteolysis of intracellular substrates 
by MMPs, both inside cells or in the extracellular 
milieu, and the concomitant physiopathological 
consequences of these cleavages.  We hope that such an 
integrated view on intracellular substrate proteolysis 
will provide new insights and stimulate further research 
in this novel and exciting field of MMP research. 
1. MECHANISMS OF EXTRACELLULAR VS. 
INTRACELLULAR MMP ACTIVATION 
Disruption of the coordination between the catalytic 
Zn2+ ion and the conserved Cys in the propeptide is 
sufficient for latent MMPs to gain catalytic activity 
(Figure 3).  The thiol-Zn2+ interaction may be broken by 
three mechanisms: 1) direct proteolysis of the 
propeptide by another MMP or protease; 2) 
modification of the free thiol by physiological reagents 
such as oxidants and disulfides, or by nonphysiological 
reagents such as alkylating agents and heavy metal ions; 
3) distortion of the catalytic site by allosteric activation 
or by non-physiological reagents, including 
organomercurials (4-aminophenyl mercuric acetate or 
APMA), chaotropic agents (urea), and detergents (e.g. 
sodium dodecyl sulphate or SDS) (Ra and Parks, 2007; 
Sela-Passwell et al., 2010; Springman et al., 1990; Park 
et al., 2010). The latter two mechanisms may allow 
MMPs to be activated by degradation of their own 
propeptide, which is called autocatalytic activation 
(Figure 3). Here, we discuss the physiological 
mechanisms that may lead to extracellular and 
intracellular MMP activation.  Examples of intracellular 
activation mechanisms are summarized in Table 1. 
1.1 Proteolytic cleavage 
Historically, extracellular activation of pro-MMPs 
has been discovered mainly by in vitro studies with 
individual MMPs.  The first examples were the 
activation of collagenase (MMP-1) by the serine 
protease plasmin (Werb et al., 1977; Eeckhout and 
Vaes, 1977).  These were seminal studies because they 
established a clear link between serine proteases and 
MMPs and reinforced the concept of enzyme 
cascades, as these were known for the complement 
and the coagulation cascades. Many individual studies 
became linked in a chain, called the ECM protease 
cascade (Cuzner and Opdenakker, 1999).  By a critical 
analysis of the interrelations between the plasminogen 
activation system and MMP activations, it became 
clear that different MMPs can also activate each other.  
Hence, it was necessary to denominate all the 
interrelations as a complex network of interactions 
(Van den Steen et al., 2002).  This image of an 
activation network has evolved into a maze of 
dynamic protease interactions with other proteases, 
with inhibitors and with their substrates, which was 
termed the ‘protease web’ (Overall and Kleifeld, 
2006) or the ‘proteolytic internet’ (Kruger, 2009). 
Pei and Weiss were the first to discover a mechanism 
for intracellular MMP activation.  They identified an 
Arg-X-Arg-X-Lys-Arg recognition motif for the 
Golgi-associated pro-hormone convertase furin 
between the pro- and catalytic domain of MMP-
11/stromelysin-3 (Pei and Weiss, 1995).  Furin cleaves 
MMP-11 behind this motif, resulting in an activated 
form of MMP-11 in the trans-Golgi network (TGN), 
which is subsequently secreted (Santavicca et al., 
1996).  Likewise, pro-MT1-MMP is efficiently 
processed by furin and related proprotein convertases 
into an active protease after recognition of two basic 
motifs in the enzyme’s prodomain (Pei and Weiss, 
1996; Yana and Weiss, 2000).  Of interest, such Arg-
X-Lys-Arg motifs are not only found in MMP-11 and 
 164 | P a g e  
MT1-MMP, but also in MMP-23 and in MT1-, MT2-, 
MT3-, MT4- and MT5-MMP.  In addition, either Arg-
X-X-Arg or Lys-X-X-Arg motifs are found in all 
MMPs except in MMP-12/metalloelastase and MMP-
7.  This suggests that a general mechanism exists for 
both intracellular and extracellular MMP activation by 
furin and proprotein convertases (Yana and Weiss, 
2000).  This was indeed confirmed for MT3-MMP, 
which co-localizes with furin in the TGN (Kang et al., 
2002).  MMP-1, however, is not cleaved by furin, and 
MMP-2 is cleaved to an intermediate activation form, 
which is inactive.  In contrast, MMP-3/stromelysin-1 
cleavage by furin yields the anticipated molecular 
weight (MW) of active MMP-3, but its proteolytic 
activity was not verified (Cao et al., 2005).   
Furin-independent intracellular MMP activation 
modes also exist.  For example, a serine protease 
different from furin generates an activated form of 
MMP-3 inside stressed dopaminergic cells (vide infra) 
(Choi et al., 2008).  Interestingly, in MMP-26 the 
latency motif containing the conserved Cys is inactive 
and MMP-26 is activated by autolytic cleavages 
(Marchenko et al., 2002).   In addition, the major 
fraction of synthesized MMP-26 remains intracellularly 
(Strongin, 2006) and may activate pro-MMP-9 in the 
cytoplasm (Uria and Lopez-Otin, 2000; Zhao et al., 
2003).  Hence, the protease interaction network may 
also function inside cells.  Indeed, MT1-MMP may be 
responsible for intracellular MMP-2 activation, since 
both MMPs were found to co-localize in the nuclei of 
aggressive hepatocellular carcinoma cells (Ip et al., 
2007) and in ischemic cell nuclei, which also contained 
co-localized furin (Yang et al., 2010).  A recent study 
showed that intracellular MMP activation may also be 
performed by caspases.  Administration of activated 
caspase-3 to heart homogenates resulted in increased 
MMP activity.  In addition, a cocktail of activated 
caspases generated activated forms of MMP-2, as 
detected by substrate zymography (Yarbrough et al., 
2010).  However, whereas increased MMP activity in 
the heart homogenates was confirmed by cleavage of a 
fluorogenic substrate, this was not verified for the 
activated forms of MMP-2.  This is an essential control, 
since alkylating agents such as dithiothreitol (DTT) 
preserve caspase stability but may activate MMPs by 
catalytic site distortion and autocatalysis.  
 
 
Figure 3. Activation mechanisms of MMPs.  A typical MMP structure consists of a signal peptide (S), a pro-domain (Pro), a 
catalytic domain, a Zn2+-binding domain (Zn2+) and a hemopexin domain. MMPs gain catalytic activity by a mechanism called 
‘cysteine switch activation’, in which the coordination between the catalytic Zn2+ ion and the conserved Cys in the propeptide is 
broken to open up the catalytic site for the binding of a hydrolytic water molecule and a substrate.  The most common 
mechanism for the disruption of the thiol-Zn2+ coordination is the direct proteolysis of the propeptide by another MMP or 
protease.  Other physiological activation pathways include the modification of the free thiol by physiological reagents such as 
oxidants (e.g. ROS) and disulfides (e.g. RNS), leading to oxidation, S-nitrosylation or S-glutathiolation of the Cys in the 
propeptide.  Finally, distortion of the catalytic site by the binding of a receptor or a substrate may lead to allosteric activation.  
Non-physiological activation in vitro can be achieved by the modification of the Cys by alkylating agents and heavy metal ions 
(Me), and by the distortion of the catalytic site by non-physiological reagents, such as organomercurials (APMA), chaotropic 
agents (urea), and detergents (e.g. SDS).  Non-proteolytic activation may lead to subsequent autoproteolytic degradation of the 
propeptide, which is called autocatalytic activation.  Besides post-translational activation mechanisms, alternative splicing may 
yield MMP transcripts lacking the signal peptide and prodomain, which are translated into constitutively active enzymes. 
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1.2 Oxidative stress and nitrosative stress 
In aerobic organisms reactive oxygen species (ROS) 
are constantly generated during normal metabolism and 
in response to both internal and external stimuli.  
Oxidative stress is caused by imbalances in the 
production and removal of ROS and is implicated in 
many pathological settings such as cancer, chronic 
inflammation, premature labor and stillbirth, 
ischemia/reperfusion (I/R) injury, atherosclerosis, 
arthritis and neurodegenerative disorders (Roberts et al., 
2009; Nelson and Melendez, 2004).  ROS include many 
different chemical oxidants such as hydrogen peroxide 
(H2O2), superoxide anion (●O2-), singlet oxygen (1O2), 
and hydroxyl radicals (●OH). Inside the cells, reactive 
oxygen species are constantly generated as side-
products of neutrophil-mediated phagocytosis, by 
cellular respiration, and by various NADPH oxidases.  
Similarly, free radical nitric oxide (NO●) is a ubiquitous 
intracellular messenger able to regulate physiological 
functions (Martinez and Andriantsitohaina, 2009).  
However, when a disequilibrium occurs between the 
levels of ●O2- and NO●, they may react to form 
peroxynitrite (ONOO-), a reactive nitrogen species 
(RNS).  Other RNS include NO●, nitroxyl (HNO), 
nitrosonium cation (NO+), S-nitrosothiols (RSNOs) and 
nitrogen dioxide (NO2).  By analogy with ROS and 
oxidative stress, when the generation of RNS in a 
system exceeds its ability to neutralize and eliminate 
them, nitrosative stress occurs.  In addition, cross-talk 
between ROS and RNS can exacerbate their capacity to 
damage DNA, lipids and proteins (Martinez-Pomares et 
al., 1998; Brandes et al., 2009; Martinez and 
Andriantsitohaina, 2009).   
ROS may play important roles as signaling molecules, 
regulating many genes, including MMP gene expression 
and activity (Nelson and Melendez, 2004).  Indeed, ROS 
interact with the Cys thiol, which disrupts the interaction 
with the catalytic Zn2+ ion and leads to autocatalytic 
activation (cf. Figure 3).  Myeloperoxidase, a heme 
protein secreted by neutrophils, monocytes, and 
macrophages, uses hydrogen peroxide to generate 
hypochlorous acid (HOCl) (Hurst and Barrette, Jr., 1989).  
HOCl activates various pro-MMPs, including MMP-1, 
MMP-7, MMP-8, MMP-9 (Weiss et al., 1985; Peppin 
and Weiss, 1986; Saari et al., 1992; Fu et al., 2001; Meli 
et al., 2003).  Whereas low levels of HOCl rapidly 
activate pro-MMP-7, higher concentrations or prolonged 
exposure inactivate the protease (Fu et al., 2003).  This 
biphasic effect was also observed in the activation of pro-
MMP-2 by H202, which also activates pro-MMP-8, pro-
MMP-9, but not pro-MMP-1 and pro-MMP-7 (Saari et 
al., 1992; Burkhardt et al., 1986; Fu et al., 2001; 
Rajagopalan et al., 1996; Paquette et al., 2003).  Of 
interest, 30% of the MMP-8 released by synovial-fluid 
neutrophils in rheumatoid arthritis was in an activated 
form compared to the pro-MMP-8 form in peripheral 
blood neutrophils of the same patients (Saari et al., 
1992).  This suggests that activation of MMP-8 may 
occur intracellularly before and/or during degranulation. 
RNS induce three main post-translational modifications 
in proteins: 1) S-nitrosylation or the covalent addition of 
an NO● group to a Cys thiol, 2) S-glutathiolation or the 
addition of reduced glutathione (GSH) or other low-MW 
thiols to a Cys thiol, and 3) tyrosine nitration or the 
addition of an NO2 group to Tyr residues (Martinez and 
Andriantsitohaina, 2009).  Hence, similar to ROS-
mediated activation, RNS modification causes activation 
by disrupting the latency-inducing Cys-Zn2+ coordination 
(cf. Figure 3) (Ali and Schulz, 2009).  Various pro-MMPs 
can be activated by S-nitrosylation in vitro, including 
MMP-1, MMP-2, MMP-8, MMP-9 (Rajagopalan et al., 
1996; Maeda et al., 1998; Okamoto et al., 1997; Gu et 
al., 2002; Viappiani et al., 2009). So far, activation by S-
nitrosylation in vivo was only shown for MMP-9 during 
cerebral ischemia (Gu et al., 2002).  In addition, the 
nitrosylated thiol was oxidized further to a sulfinic (-
SO2H) or sulfonic (-SO3H) acid.  This irreversible 
modification may cause prolonged activation of the 
enzyme under pathological conditions and this 
progression represents a graded transition from 
physiological signaling functions to pathological 
nitrosative and oxidative stress, and finally, toxicity 
(Hess et al., 2005).  Activation by S-glutathiolation (with 
ONOO- and GSH) in vitro was demonstrated for pro-
MMP-1, pro-MMP-2, pro-MMP-8 and pro-MMP-9 and it 
was more pronounced than activation with ONOO-  alone  
(Okamoto et al., 2001; Viappiani et al., 2009).  The high 
cellular concentrations of GSH under physiological 
conditions suppress the activation of pro-MMPs, whereas 
prolonged and sustained inflammation will result in high 
levels of pro-MMPs as well as ROS and RNS, which may 
tip the balance to glutathiolation and activation of MMPs 
(Okamoto et al., 2001).  The biphasic effect observed 
with oxidative activation (vide supra) is also detected 
with S-glutathiolation, suggesting that ROS and RNS 
may exert temporal control over MMP activity 
(Viappiani et al., 2009).  Of interest, RNS also inactivate 
TIMP-1, TIMP-2 and TIMP-4 (Frears et al., 1996; Brown 
et al., 2004; Chakraborti et al., 2004; Donnini et al., 
2008), which further enhances MMP action.  
Surprisingly, both the groups of Schulz and Okamoto 
report nitrosative activation without the shift to the 
lower-MW activation form, expected after removal of the 
propeptide.  This suggests that autocatalytic propeptide 
proteolysis does not always occur and that higher MW-
forms may indeed be active. Hence, Schulz and 
coworkers state that the nomenclature of ‘latent pro-
enzymes’ incorrectly assumes that only the lower-MW 
species are active (Ali and Schulz, 2009; Schulz, 2007).  
Here, we will refer to the high MW forms of MMPs as 
the pro-forms and avoid to use the terminology of ‘latent’ 
or ‘inactive’ forms, as these forms may be active in an 
oxidative context or even under physiological levels of 
ROS and RNS.  The low MW forms (LMW) will be 
termed activated forms.   
 166 | P a g e  
Table 1.  (Putative) intracellular activation mechanisms of MMPs 
Activation mode Activator pro-MMP References 
Proteolytic 
activation 
 
furin/proprotein 
convertases 
MMP-11     
MT1-MMP   
MT3-MMP 
(Pei and Weiss, 1996; Pei and Weiss, 1995; 
Yana and Weiss, 2000) 
serine protease MMP-3 (Choi et al., 2008) 
MMP-26 
(autocatalysis) MMP-26 (Marchenko et al., 2002) 
MMP-26 MMP-9 (Uria and Lopez-Otin, 2000; Zhao et al., 2003) 
MT1-MMP MMP-2 (Ip et al., 2007; Yang et al., 2010) 
caspases MMP-2 (Yarbrough et al., 2010) 
Oxidative stress 
oxidation 
(HOCl)  
MMP-1,-7,-
8,-9 
(Weiss et al., 1985; Peppin and Weiss, 1986; 
Saari et al., 1992; Fu et al., 2001; Meli et al., 
2003) 
oxidation 
(H2O2)  
MMP-2,-8,-
9 
(Saari et al., 1992; Burkhardt et al., 1986;  
Fu et al., 2001; Rajagopalan et al., 1996; 
Paquette et al., 2003). 
Nitrosative stress
S-nitrosylation 
(ONOO-, NO2, 
NO) 
MMP-1,-2,-
8,-9 
(Rajagopalan et al., 1996; Maeda et al., 
1998; Okamoto et al., 1997; Gu et al., 2002; 
Viappiani et al., 2009) 
S-
glutathiolation   
(ONOO-, GSH)
MMP-1,-2,-
8,-9 
(Okamoto et al., 2001; Viappiani et al., 
2009) 
Phosphorylation  alkaline phosphatase MMP-2   (Sariahmetoglu et al., 2007) 
Alternative 
splicing  no prodomain MMP-11 (Luo et al., 2002) 
GSH, reduced glutathione; H2O2, hydrogen peroxide; HOCl, hypochloric acid;  
NO, nitric oxide; NO2, nitrogen dioxide; ONOO-, peroxynitrite  
In conclusion, modification of the conserved Cys can 
activate MMPs both outside and inside cells.  The 
conservation of the Cys residue implies that these 
mechanisms may be applicable to most MMPs.  Severe 
oxidative damage will ultimately lead to apoptosis and 
cell death, which has been shown to accompany many 
pathological conditions, such as cancer, cardiovascular 
diseases and neurodegenerative disorders (Martinez and 
Andriantsitohaina, 2009; Brandes et al., 2009).  These 
are all conditions in which intracellular MMP activities 
affect disease, which will be discussed in chapter 3. 
1.3 Phosphorylation 
Phosphorylation is a post-translational modification that 
typically regulates the activity of intracellular proteins 
and is of major importance for intracellular signal 
transduction and regulation of cellular function.  The 
phosphorylation status of a protein is regulated by the 
balanced action of many protein kinases and 
phosphatases.  Phosphorylation by protein kinase C 
diminishes MMP-2 activity in vitro, whereas 
dephosphorylation with alkaline phosphatase 
significantly enhances its activity (Sariahmetoglu et al., 
2007).  MMP-2 contains 29 potential phosphorylation 
sites.  All five sites that were phosphorylated in 
recombinant human MMP-2 purified from mammalian 
cells could be found on accessible residues at the 
surface of the protein.  MMP-2 isolated from HT1080 
cells showed phosphorylation of Thr, Ser and Tyr 
residues.  Since most of the phosphorylation sites are 
within the fibronectin domain, which is essential for 
substrate binding, phosphorylation may also affect 
substrate affinity and specificity.  Furthermore, 
phosphorylation may affect intracellular trafficking, 
protein stability and protein-protein interactions, as is 
the case for intracellular signaling and adaptor 
molecules (Sariahmetoglu et al., 2007). Interestingly, 
MT1-MMP is also phosphorylated in its cytoplasmic 
domain, and impaired phosphorylation of Tyr573 
inhibits tumor cell proliferation in three-dimensional 
matrices in vitro and tumor growth in vivo (Nyalendo et 
al., 2008). Hence, investigation of the effects of 
phosphorylation on MMP activity and determination of 
the phosphorylation status of intracellular MMPs in 
homestatic conditions or under cellular stress, may yield 
information on the regulation of intracellular MMP 
activity. 
1.4 Alternative splicing 
Besides post-translational regulation, MMP activity may 
also be regulated by post-transcriptional regulation.  
Indeed, for MMP-11 an additional gene promoter was 
found that is inducible and controls the expression of a 
novel MMP-11 transcript in cultured cells and in 
placenta (Luo et al., 2002).  This transcript encodes a 40 
kDa isoform that lacks both the signal peptide for 
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secretion and the prodomain (cf. Figure 3).  As a 
consequence, a constitutively active isoform of MMP-
11 is present in the intracellular milieu.  This isoform is 
equally active as the secreted one but produced in 20-
fold lower amounts.  Surprisingly, human MMP-11 
does not degrade the classical components of the ECM, 
unlike other MMPs and unlike mouse MMP-11 (Noel et 
al., 1995).  Remarkably, Luo et al. found a Met codon 
(for the initiation of a second transcript) within the 
DNA sequence of 10 other MMPs, suggesting that 
alternative splicing and promoter usage may be a 
characteristic of many MMPs.  Indeed, splice variants 
lacking an NH2-terminal secretory signal peptide have 
also been found for MMP-2 (e.g. accession number 
AL832088) (Sariahmetoglu et al., 2007).  In addition, a 
soluble vs. transmembrane form of MT3-MMP was 
formed by alternative splicing (Matsumoto et al., 1997) 
and because MMP-23 lacks an NH2-terminal signal 
peptide, it was also suggested to function intracellularly 
(Velasco et al., 1999).  Alternative transcripts have been 
found for various other MMPs and characterization of 
the associated isoforms may shed new light on 
intracellular locations and activities of many MMPs 
(Luo et al., 2002). 
2 INTRACELLULAR  SUBSTRATE 
DETECTION BY DEGRADOMICS 
Whereas proteomics is de study of the entire ensemble 
of proteins produced in a biological system or by an 
organism, degradomics aims at the characterization of 
the complete set of substrates, i.e. the repertoire or 
‘degradome’ of a particular proteinase in a specific cell, 
tissue or organism (Lopez-Otin and Overall, 2002).  
During the last decade, many proteomic approaches 
have been adapted for degradomics and development of 
novel degradomics techniques has boomed.  Since 
excellent and up-to-date reviews exist on this subject 
(Doucet et al., 2008; Butler and Overall, 2009b; Doucet 
et al., 2008; Morrison et al., 2009; Rodriguez et al., 
2009; Demon et al., 2009; Van Damme et al., 2008; 
Agard and Wells, 2009; Diamond, 2007; Doucet and 
Overall, 2008; Overall and Blobel, 2007; Van Damme 
et al., 2008; Impens et al., 2010), we here describe 
briefly the various techniques along with their major 
advantages and drawbacks, and their application in 
MMP research (Table 2).  In addition, we mention the 
major peptide-based techniques that were developed to 
characterize substrate cleavage sites, and provide 
additional references for the interested reader.   
Various degradomics techniques were developed 
specifically for the identification of intracellular 
substrates and were applied for the study of particular 
caspase degradomes (Demon et al., 2009; Van Damme et 
al., 2008; Agard and Wells, 2009).  These applications 
were intuitively developed on the basis that latent 
procaspases are activated and act within cells.  Since the 
cascades of apoptosis, necrosis and netosis may lead to 
intracellular proteases entering the extracellular milieu, it 
is rarely questioned that typical extracellular substrates 
may end up in caspase degradomes.  In contrast, although 
intracellular substrates have been defined as substrates of 
MMPs, both in vitro and in vivo (vide infra), the 
physiological or pathological relevance of such cleavages 
have only started to emerge.  From Table 2, it is quite 
clear that many degradomics methods have not yet been 
used for the complete identification of MMP substrates.  
In addition, degradomics screens that identify in vivo 
substrates by direct comparison of wildtype and MMP 
knockout samples are still under-represented, which is 
probably also due to the lower reproducibility and high 
complexity of biological tissues and organ extracts. 
In MMP research, degradomic approaches were aimed 
at identifying extracellular and membrane-bound 
substrates, and were used mainly to analyze secreted 
proteins in a cellular system or in ‘secretomes’ in the 
absence or presence of a particular MMP or MMP 
inhibitor.  However, these diverging approaches always 
yielded many identifications of intracellular substrates, 
which were often not reported or discarded as 
‘background’ from dying cells (Dean and Overall, 2007; 
Overall et al., 2004; Tam et al., 2004).  Only very 
recently, these intracellular proteins started to be 
appreciated as a specific and novel subset of the MMP 
degradome (Butler and Overall, 2009b; Morrison et al., 
2009; Butler and Overall, 2009a; Cauwe et al., 2008).  
Intracellular substrates may be released from cells during 
necrosis or by non-classical secretion mechanisms, which 
are often poorly characterized.  Hence, many intracellular 
proteins may indeed end up and be cleaved by MMPs in 
the extracellular milieu.  This setting will be discussed in 
detail in chapter 4. 
In contrast with most degradomics methods applied for 
extracellular MMP substrate identification, a two-
dimensional degradomics (2DD) approach was the first 
degradomics screen targeted directly at the identification 
of intracellular substrates.  As illustrated in table 2, 2DD 
combines ion exchange chromatography (IEX) to 
separate proteins according to their isoelectric point (pI) 
before concentration and cleavage with a protease.  
Digested and undigested IEX fractions are then separated 
according to their molecular weight (MW) in adjacent 
SDS-PAGE lanes and differential protein bands are 
isolated for identification by MS/MS or electroblotted 
onto PVDF for identification by Edman degradation, 
which, in the case of a fragment band, results in direct 
identification of the cleavage site (Cauwe et al., 2009).  
Using gelatinase B/MMP-9 as a model enzyme, we 
applied this method to THP-1 cytosol and isolated 100-
200 differential proteins, of which about 70 intracellular 
proteins were identified as MMP-9 candidate substrates.  
Various advantages exist for this multidimensional 
degradomics method.  First and foremost, this technically 
straightforward approach does not require complex and 
expensive equipment, making it broadly accessible and 
easy to start up in every laboratory.   
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Legend Table 2.  IEF, isoelectric focusing; LC-MS/MS, liquid chromatography followed by tandem mass spectrometry; MS, mass 
spectrometry; MSE, high/low collision energy MS; MW, molecular weight; NA, not applicable; ND, not defined; NHS, N-hydroxysuccinimide; 
pI, isoelectric point; PTM, post-translational modification; PVDF, polyvinylidene fluoride; RP-HPLC, reversed phase-high pressure liquid 
chromatography; RT-PCR, real-time PCR; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; TNBS, 2,4,6-
trinitrobenzenesulfonyl chloride; UPLC, ultraperformance liquid chromatography. 
1Substrate type, describes whether the MMP substrates found in the described degradomics screen are in vitro or in vivo substrates. 
2The substrate amino acids surrounding a cleavage site are indicated as Pn…P3-P2-P1 ↓ P1’-P2’-P3’…Pn’, with the cleavage occurring at 
the peptide bond between P1 and P1’ (Berger and Schechter, 1970). 
Although the generation of multiple IEX fractions and 
SDS-PAGE gels may be somewhat labor-intensive, this 
is counterbalanced by the fact that final results can be 
obtained within a few weeks from start-up, as there is no 
need for lengthy and extensive optimization procedures 
as in most complex degradomic approaches.  Second, the 
high loading capacity of the IEX columns and the 
insertion of a concentration step increase the dynamic 
range.  This allows for the identification of both high and 
low abundancy class substrates.  Third, as the protein 
pool is fractionated before proteolysis, less saturation of 
the protease by high abundancy class proteins will occur 
during digestion.  Finally, 2DD can be easily extended to 
any protease, protease inhibitors may be applied to block 
specific enzymes and the technique is applicable with any 
cell type, tissue extract or body fluid.  A selection of 2DD 
candidate substrates was confirmed biochemically by in 
vitro cleavage of the purified or recombinant substrate 
and visualization of cleavage by classical SDS-PAGE 
analysis. Alternatively, THP-1 cytoplasm was digested 
with MMP-9 in vitro and cleavage of specific substrates 
was confirmed by Western blot analysis of cleaved and 
uncleaved cytoplasm with substrate-specific primary 
antibodies.  The collection of identified cleavage sites 
allowed us to analyze the cleavage site preference of 
MMP-9 in intracellular substrates and to compare this 
with observed preferences for extracellular and 
membrane-bound molecules.  This was achieved by the 
generation of a sequence logo, using the bioinformatics 
software WebLogo 3, which adjusts for small samples 
and corrects for natural amino acid abundances (Crooks 
et al., 2004; Schneider and Stephens, 1990) (Figure 4). 
This sequence logo clearly shows similarities between 
extracellular and intracellular MMP substrates.  
When analyzing the biological functions of the 
intracellular MMP-9 (candidate) subtrates, we found that 
about 40% of these proteins were components of the 
cytoskeleton or intracellular matrix (ICM), or associated 
with ICM proteins (Cauwe et al., 2009).  In addition, two 
thirds of the candidates were autoantigens in cancer or in 
(multiple) autoimmune diseases.  In order to gain insight 
into the diversity of intracellular proteins cleaved by all 
MMPs, we scrutinized the results of the MMP 
degradomics studies mentioned in Table 2 and compiled 
a general list of high-confidence degradomic candidate 
substrates (Table 3).  Addition of a substrate to the list 
was based on the identification in various degradomics 
approaches, the (putative) cleavage by more than one 
MMP, the identification of a protein of the same 
subfamiliy or with a similar function as an MMP 
(candidate) substrate or the biochemical confirmation by 
in vitro cleavage or Western blot analysis (vide supra).  
This yielded a table of more than 120 proteins that were 
classified according to functional biological mechanisms.  
From Table 3 it is clear that cytoskeletal or ICM proteins 
constitute a considerable fraction of the intracellular 
degradome.  This suggests that degradation of the ICM is 
a general MMP function.  Other over-represented protein 
classes are carbohydrate metabolic and protein 
biosynthetic enzymes, proteins regulating transcription 
and translation, and molecular chaperones.  The 
(putative) physiopathological contexts engendered by the 
cleavage of these intracellular proteins will be discussed 
throughout the manuscript.  The leading theme is that 
such cleavages do take place and, irrespectively whether 
these are causes or consequences in physiological or 
pathological processes, they need to be considered if we 
critically (re)consider disease processes. 
The fact that very diverging degradomics approaches, 
ranging from gel-based approaches to complex isotope- 
and MS-based methodologies converge to a common list 
of substrates, is not only an internal validation of these 
methods, but also a confirmation that these biochemical 
identifications are not just ‘background noise’ and need 
to be considered as meaningful in pathophysiological 
processes.  The major advantages of degradomics indeed 
lie in the unbiased and high-throughput nature, which 
allows to obtain novel and unexpected views on the 
MMP degradome.  Hence, expanding the application of 
MMP degradomics is of utmost importance and may 
yield many surprising insights and add novel dimensions 
to the kaleidoscope of MMP functions (Cauwe et al., 
2007; Butler and Overall, 2009b). 
3 MMP ACTION INSIDE CELLS 
Intracellular activation of MMPs and presence of 
activated MMPs in various intracellular compartments 
strongly suggests that MMPs may be responsible for 
proteolytic actions on intracellular substrates within the 
cells.  In this chapter, we will first discuss how 
intracellular MMP activity can be detected.  Next, we 
will summarize the present information concerning the 
presence of activated MMPs in various subcellular 
locations and discuss the mechanisms by which MMPs 
(may) enter cells and translocate to specific cellular 
compartments.  Finally, we will discuss the physiological 
and pathological effects of intracellular cleavage by 
MMPs in innate immune defense, cancer, cardiac and 
brain disease, cataract development and in the process of 
apoptosis. 
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Table 3.  Confirmed and high-confidence* intracellular MMP substrates identified by degradomics 
Protein 
name  MMP  Method†  Confirm.‡ 
Subcellular 
localization  (Putative) function  Refs¶ 
CARBOHYDRATE METABOLISM   
Citrate 
synthase  
MMP-2 iTRAQ™ ND mitochondrial 
matrix Tricarboxylic acid cycle enzyme 5,10MMP-9 2DD IVC 
Enolase-α 
MMP-2 iTRAQ™, TAILS 
ND 
cytoplasm, cell 
membrane, 
myofibril, 
sarcomere,  
M-band, nucleus, 
extracellular 
Glycolytic enzyme; role in growth control, hypoxia 
tolerance and allergic responses; receptor and activator of 
plasminogen  
5,10,11
MMP-9 2DD 
Enolase-β MMP-2 TAILS ND 
cytoplasm, 
sarcomere,  
Z-band 
Glycolytic enzyme; function in striated muscle development 
and regeneration; defects are the cause of glycogen storage 
disease type 13 
8,11
MT1-MMP ICAT 
Enolase-γ 
MMP-2 ICAT, TAILS 
IVC 
cytoplasm, cell 
membrane, 
extracellular 
Glycolytic enzyme; has neurotrophic and neuroprotective 
properties 6,8,11MMP-1,-8,-9   
MT1-MMP ICAT 
Fructose-
bisphophate 
aldolase A 
MMP-2 iTRAQ™, ICAT, TAILS 
ND 
cytoplasm, 
cytoskeleton,  
I-band, 
extracellular 
Glycolytic enzyme that catalyzes the reversible conversion 
of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate 
and dihydroxyacetone phosphate; actin filament 
organization; defects are the cause of glycogen storage 
disease type 12 
5,6,
7,8,
10,11MT1-MMP ICAT 
MMP-9 UPLC-MSE, 2DD 
Fructose-
bisphophate 
aldolase C 
MMP-2 ICAT ND cytoplasm, cytoskeleton 
Glycolytic enzyme that catalyzes the reversible conversion 
of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate 
and dihydroxyacetone phosphate 
6
Glyceraldehyde 
3-phosphate 
dehydrogenase 
(GAPDH) 
MMP-2 iTRAQ™, ICAT, TAILS 
ND 
cytoplasm,  
cell membrane, 
extracellular 
Glycolytic enzyme; independent of its glycolytic activity it 
is also involved in membrane trafficking in the early 
secretory pathway. 
5,6,7,
8,11MT1-MMP ICAT 
MMP-9 UPLC-MSE 
Malate 
dehydrogenase 
MMP-2 iTRAQ™, ICAT, TAILS ND cytoplasm, extracellular Tricarboxylic acid cycle enzyme 
5,6,
8,11
MT1-MMP ICAT 
Phosphoglyce-
rate kinase 1 
MMP-2 ICAT, TAILS 
ND cytoplasm, extracellular 
Glycolytic enzyme; putative polymerase α cofactor protein: 
defects are associated with chronic hemolytic anemia 
5,6,
7,8,
10
MT1-MMP ICAT 
MMP-9 UPLC-MSE, 2DD 
Phosphoglyce-
rate mutase 1 MMP-2 ICAT, TAILS ND 
cytoplasm, 
extracellular 
Glycolytic enzyme; interconversion of 3- and 2-
phosphoglycerate with 2,3-bisphosphoglycerate as the 
primer of the reaction 
6,11
Triose 
phosphate 
isomerase 
MMP-2 iTRAQ™, ICAT, TAILS 
ND cytoplasm, extracellular 
Enzyme of the glycolytic and gluconeogenesis pathways; 
defects are the cause of triosephosphate isomerase 
deficiency 
5,6,
7,8,
11MT1-MMP ICAT 
MMP-9 UPLC-MSE 
CYTOSKELETON  
 Actin-β/γ 
MMP-2 TAILS WB 
cytoplasm, 
cytoskeleton, 
nucleus, cell 
projection, 
extracellular 
Vital for cell morphogenesis and motility, endocytosis, 
phagocytosis and cytokinesis  7,10,11
MMP-9 UPLC-MSE, 2DD IVC, WB 
MMP-11 TAILS ND 
MMP-1,-8,-
13 IVC WB 
α-Actinin-1 
MMP-2 ICAT, iTRAQ™ 
(Sung et al., 
2007) 
cytoskeleton, 
myofibril, 
sarcomere, Z-disc, 
nucleolus, 
extracellular 
Connection of actin filaments of adjacents sarcomeres and 
transmission of the force generated by the actin-myosin 
complex 
5,6,
7,8MT1-MMP ICAT 
MMP-9 UPLC-MSE 
 α-Actinin-4 
MMP-2 TAILS 
ND 
cytoplasm, 
cytoskeleton,  
cell projection, 
nucleolus, 
extracellular 
Connection of actin filaments of adjacent sarcomeres and 
transmission of the force generated by the actin-myosin 
complex; defects are the cause of focal segmental 
glomerulosclerosis 
7,8,11MT1-MMP ICAT 
MMP-9 UPLC-MSE 
Actin 
regulatory 
protein CAP-G 
MMP-2 iTRAQ™, ICAT 
ND 
cytoplasm, 
melanosome, 
nucleus, secreted 
Reversible blocking of actin filament barbed ends without 
filament severing; may have important roles in macrophage 
function and regulation of cytoplasmic and/or nuclear 
structures through interactions with actin; potential DNA 
binding 
6,8,
10MT1-MMP ICAT 
MMP-9 2DD 
Actin-related 
protein (Arp) 
2 
MMP-9 2DD IVC cytoplasm, 
cytoskeleton,  
cell projection 
ATP-binding component of the Arp2/3 complex which 
mediates the formation of branched F-actin networks  8,10MT1-MMP ICAT ND 
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Actin-related 
protein (Arp) 
2/3 complex 
subunits 
MMP-9 2DD 
IVC 
cytoplasm, 
cytoskeleton,  
cell projection 
Actin-binding component of the Arp2/3 complex which 
mediates the formation of branched F-actin networks 8,10MMP-1,-2,-
3,-8,-13 IVC 
Adenylyl 
cyclase-
associated 
protein-1 
(CAP1) 
MMP-2,-8,-13 IVC 
(Cauwe et al., 
2008) 
cytoplasm,  
cell membrane 
Enhancement of actin filament turnover; roles in cell 
morphology, migration and endocytosis; promotion of cofilin-
induced apoptosis by shuttling actin to mitochondria 
10
MMP-9 2DD 
Cofilin-1 
MMP-2  ICAT, TAILS 
ND 
cytoplasm, 
cytoskeleton, 
nuclear matrix, 
extracellular 
Actin filament depolymerization and severing protein. 
Promotion of apoptosis by translocating to mitochondria and 
delivering actin 
6,8,
11MT1-MMP ICAT 
Desmin MMP-2 TAILS (Sung et al., 2007) 
cytoplasm, 
cytoskeleton,  
Z-disk 
Intermediate filament protein involved in cellular resistance to 
external stress 11
Ezrin 
MMP-2 iTRAQ™ 
ND 
cytoplasm,  
cell membrane, 
cell projections, 
extracellular 
Cross-linking of cortical actin filaments and plasma 
membranes; roles in ECM interactions, cell-cell 
communication, apoptosis, carcinogenesis and metastasis 
5,8,
10MT1-MMP ICAT 
MMP-9 2DD 
Fascin MMP-9 2DD ND 
cytoplasm, 
cytoskeleton,  
cell membrane 
 Organization of F-actin into bundles with a minimum of 4.1:1 
actin/fascin ratio 10
Filamin A 
MMP-2 iTRAQ™, ICAT, TAILS 
ND 
cytoplasm, 
cytoskeleton, 
nucleus,  
cell membrane, 
extracellular 
Promotion of actin filament branching and connection of the 
actin cytoskeleton to various transmembrane proteins; scaffold 
for a wide range of cytoplasmic signaling proteins; tethers cell 
surface-localized furin, modulates its rate of internalization and 
directs its intracellular trafficking; defects are the cause of 
many developmental diseases 
5,6,
8,11
MT1-MMP ICAT 
Filamin B  
MMP-2 iTRAQ™, ICAT, TAILS 
ND 
cytoplasm, 
cytoskeleton, 
sarcomere,  
Z-disc, cell 
membrane 
Promotion of actin filament branching and connection of the 
actin cytoskeleton to various transmembrane proteins; scaffold 
for a wide range of cytoplasmic signaling proteins; defects are 
the cause of many developmental diseases 
5,6,
8,10,
11MT1-MMP ICAT 
MMP-9 2DD 
Filamin C 
MMP-2 iTRAQ™, ICAT 
ND 
cytoplasm, 
cytoskeleton, 
sarcomere,  
Z-disc, cell 
membrane 
Muscle-specific filamin, putative roles in actin-cross-linking, 
reorganization of the actin cytoskeleton in response to 
signaling events, and structural functions at the Z-disks in 
muscle cells. Critical for normal myogenesis and the structural 
integrity of the muscle fibers; defects are the cause of 
myopathy myofibrillar filamin C-related 
5,6,
8MT1-MMP ICAT 
Gelsolin 
MMP-1,-3 IVC 
(Hwang et al., 
2004; Park et 
al., 2006) 
cytoplasm, 
cytoskeleton, 
secreted 
F-actin capping and severing; nucleation of F-actin assembly; 
scavenging of actin and pro-inflammatory components in the 
plasma; defects are the cause of amyloidosis type 5 or familial 
amyloidosis Finnish type 
1,5,
6,10,
11
MMP-2 iTRAQ™, ICAT, TAILS 
MT1-MMP 2D-PAGE 
MMP-9 2DD 
IQ motif 
containing 
GTPase 
activating 
protein 1 
(IQGAP1) 
MMP-9 2DD ND 
cytoplasm, 
cytoskeleton,  
cell membrane, 
nucleus 
Actin crosslinking/bundling;  E-cadherin-mediated cell-cell 
contacts; microtubule capture/polarity; cell motility and 
invasion; phagocytosis 
10
Microtubule-
associated 
protein RP 
(MAPRE1) 
MMP-2 TAILS 
ND 
cytoplasm, 
microtubule 
network, 
centrosome 
Microtubule formation and stabilization, promoting cell 
migration; binding and inhibition of the F-actin bundling and 
microtubule-associated protein APC  
10,11
MMP-9 2DD 
Moesin 
MMP-2 iTRAQ™, ICAT 
ND 
cytoplasm,  
cell membrane, 
cell projections, 
nucleolus, 
extracellular 
Cross-linking of cortical actin filaments and plasma 
membranes; roles in ECM interactions, cell-cell 
communication, apoptosis, carcinogenesis and metastasis 
5,6,
7,8,
10
MT1-MMP ICAT 
MMP-9 2DD, UPLC-MSE 
Plectin-1 
MMP-2 TAILS 
ND 
cytoplasm, 
cytoskeleton,  
cell membrane 
Interlinks intermediate filaments with microtubules and 
microfilaments and anchors intermediate filaments to 
desmosomes or hemidesmosomes; may bind actin to 
membrane complexes in muscle 
6,8
MT1-MMP ICAT 
Profilin-1 
MMP-2 iTRAQ™, ICAT 
ND 
cytoplasm, 
cytoskeleton, 
extracellular 
G-actin sequestring protein; catalyzes conversion from ADP-
actin to ATP-actin; adds actin monomers to the growing end 
of the actin filament 
5,6,8
MT1-MMP ICAT 
Stathmin 
MMP-9 2DD 
WB cytoplasm, cytoskeleton 
Regulation of microtubule dynamics by microtubule 
depolymerization and inhibition of polymerization 10MMP-1,-2,-
8,-13 IVC 
Trangelin 2 
MMP-2 iTRAQ™, TAILS 
ND 
nuclear 
membrane,  
cell membrane 
Putative actin cross-linking/gelling protein 5,6,7
MMP-9 UPLC-MSE 
 176 | P a g e  
Tubulin-α/β 
MMP-2 ICAT, TAILS IVC 
cytoplasm, 
cytoskeleton,  
cell projection, 
extracellular 
Heterodimers of α- and β-tubulin chains are the major 
constituents of microtubules 
6,8,
10,11
MT1-MMP ICAT ND 
MMP-9 2DD IVC 
MMP-1,-3,-
8,-13 IVC IVC 
Vimentin 
MMP-2 iTRAQ™, ICAT, TAILS ND 
cytoplasm, 
cytoskeleton, 
extracellular 
Predominant subunit of intermediate filaments found in various 
non-epithelial cells, especially mesenchymal cells; organizer of 
critical proteins involved in attachment, migration, and cell 
signaling 
5,6,
8,11MT1-MMP ICAT 
PROTEIN BIOSYNTHESIS  
Elongation  
factor 1-α1 
MMP-2 TAILS 
ND cytoplasm, extracellular 
Promotion of the GTP-dependent binding of aminoacyl-tRNA 
to the A-site of ribosomes during protein biosynthesis 
7,8,
10,11MT1-MMP ICAT 
MMP-9 UPLC-MSE, 2DD 
Elongation  
factor 1-α2 
MMP-2 TAILS 
ND nucleus Promotion of the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis 8,11MT1-MMP ICAT 
Elongation 
 factor 2  
MMP-2  ICAT, TAILS 
ND cytoplasm, extracellular 
Promotion of the GTP-dependent translocation of the nascent 
protein chain from the A-site to the P-site of the ribosome 
6,7,
8,10,
11
MT1-MMP ICAT 
MMP-9 UPLC-MSE, 2DD 
Eukaryotic 
translation 
initiation  
factor 1 
MMP-2 ICAT, TAILS ND cytoplasm 
Necessary for scanning and involved in initiation site selection. 
Promotes the assembly of 48S ribosomal complexes at the 
authentic initiation codon of a conventional capped mRNA. 
6,11
Eukaryotic 
translation 
initiation  
factor 5A  
MMP-2 ICAT 
ND cytoplasm, extracellular 
Promotion of the formation of the first peptide bond during 
protein biosynthesis 
6,
8,10MT1-MMP ICAT 
MMP-9 2DD 
Alanyl-tRNA 
synthetase 
MMP-2 ICAT 
ND cytoplasm Catalyzes the attachment of Ala to its cognate tRNA; edits incorrectly charged tRNA(Ala) via its editing domain 6,8MT1-MMP ICAT 
Aspartyl-tRNA 
synthetase MMP-2 iTRAQ™, TAILS ND cytoplasm Catalyzes the attachment of Asp to its cognate tRNA 5,11
Cysteinyl-tRNA 
synthetase  
MMP-2 iTRAQ™, ICAT 
ND cytoplasm Catalyzes the attachment of Cys to its cognate tRNA 5,6,10MMP-9 2DD 
Histidyl-tRNA 
synthetase  
MMP-9 2DD, UPLC-MSE 
IVC cytoplasm Catalyzes the attachment of His to its cognate tRNA 7,10
MMP-1,-2,-
3,-8,-13 IVC 
Threonyl-tRNA 
synthetase  
MT1-MMP ICAT 
ND cytoplasm Catalyzes the attachment of Thr to its cognate tRNA 8,10
MMP-9 2DD 
Tryptophanyl-
tRNA 
synthetase 
MMP-2 iTRAQ™ ND cytoplasm 
Catalyzes the attachment of Trp to its cognate tRNA; 
regulation of ERK, Akt, and eNOS activation pathways that 
are associated with angiogenesis, cytoskeletal reorganization 
and shear stress-responsive gene expression 
5
Valyl-tRNA 
synthetase MMP-9 UPLC-MS
E ND cytoplasm Catalyzes the attachment of Val to its cognate tRNA 7
REGULATION OF TRANSCRIPTION        
Hepatoma-
derived growth 
factor (HDGF) 
MMP-2 iTRAQ™ 
ND 
cytoplasm, 
nucleus, 
extracellular 
Heparin-binding protein with mitogenic activity for 
fibroblasts; acts as a transcriptional repressor; putative 
alarmin 
6,10
MMP-9 2DD 
High-mobility 
group protein 
B1 (HMGB1) 
MMP-2 iTRAQ™, TAILS 
ND nucleus, 
cytoplasm, 
extracellular 
Intracellular function: stabilization of nucleosome formation 
and facilitation of transcription factor binding by bending 
DNA, role in DNA repair; cytosolic nucleic acid sensor; 
extracellular function: pro-inflammatory cytokine, alarmin 
5,8,
10,11MT1-MMP ICAT 
MMP-9 2DD WB 
High-mobility 
group protein 
B2 (HMGB2) 
MMP-2 iTRAQ™, TAILS 
ND 
nucleus, 
cytoplasm, 
extracellular 
Intracellular function: stabilization of nucleosome formation 
and facilitation of transcription factor binding by bending 
DNA, role in DNA repair; cytosolic nucleic acid sensor 
5,8,
10,11MT1-MMP ICAT 
MMP-9 2DD 
High-mobility 
group protein 
B3 (HMGB3) 
MMP-2 TAILS ND nucleus 
Intracellular function: stabilization of nucleosome formation 
and facilitation of transcription factor binding by bending 
DNA, role in DNA repair; cytosolic nucleic acid sensor; 
regulation of proliferation and differentiation of common 
lymphoid and myeloid progenitors 
11
Histone H1.2 MMP-2 TAILS ND nucleus Histones H1 are necessary for the condensation of nucleosome chains into higher order structures. 11
Histone H1.3 MMP-2 iTRAQ™ ND nucleus Histones H1 are necessary for the condensation of nucleosome chains into higher order structures. 5
Histone H2A MMP-2 TAILS ND nucleus, extracellular 
Core component of nucleosome; central role in transcription 
regulation, DNA repair, DNA replication and chromosomal 
stability 
11
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Histone H2B MMP-2 iTRAQ™ ND nucleus, extracellular 
Core component of nucleosome; central role in transcription 
regulation, DNA repair, DNA replication and chromosomal 
stability 
5
Histone H4 MMP-2 iTRAQ™ ND nucleus, extracellular 
Core component of nucleosome; central role in transcription 
regulation, DNA repair, DNA replication and chromosomal 
stability 
5
Lupus La 
protein 
MMP-2 ICAT 
ND nucleus,  cell surface 
Plays a role in the transcription of RNA polymerase III, 
most probably as a transcription termination factor as it 
binds to the 3' termini of virtually all nascent polymerase III 
transcripts; major autoantigen in SLE 
6,8
MT1-MMP ICAT 
Nucleobindin-1 MMP-2 iTRAQ™, TAILS ND 
Golgi,  
cell membrane, 
extracellular 
Ca2+- and DNA-binding protein; B-cell growth and 
differentiation factor; control of the unfolded protein 
response; regulation of receptor trafficking 
5,11
Nucleolin  
MMP-2 iTRAQ™, ICAT 
WB 
Nucleus, 
cytoplasm,  
cell surface 
Regulation of RNA polymerase I transcription; folding and 
maturation of pre-ribosomal RNA; ribosome assembly; 
nucleo-cytoplasmic transport; histone chaperone activity; 
interaction with viruses at the cell membrane 
5,
6,10
MMP-9 2DD 
MMP-1,-3,-
8,-13 IVC 
Nucleoside 
diphosphate 
kinase B 
MMP-2 ICAT 
ND 
Cytoplasm, 
cytoskeleton, 
nucleus 
Major role in the synthesis of nucleoside triphosphates other 
than ATP; negative regulation of Rho activity; 
transcriptional activator of the Myc gene 
6,10
MMP-9 2DD 
REGULATION OF TRANSLATION  
hnRNP A1 
MMP-2 TAILS 
ND 
cytoplasm, 
nucleus, 
spliceosome 
Involved in the packaging of pre-mRNA into hnRNP 
particles, transport of poly(A) mRNA from the nucleus to 
the cytoplasm and modulatin of splice site selection 
8,11
MT1-MMP ICAT 
hnRNP A/B MMP-2  TAILS ND 
cytoplasm, 
nucleus, 
ribonucleoprotein 
complex 
Binds ssRNA; high affinity for G-rich and U-rich regions of 
heterogenous nuclear RNA. 11
hnRNP A2/B1 MMP-2  TAILS ND 
cytoplasm, 
nucleus, 
spliceosome 
Involved with pre-mRNA processing; forms complexes 
(ribonucleosomes) with at least 20 other different hnRNP 
and heterogeneous nuclear RNA in the nucleous. 
11
hnRNP A3 MMP-2  TAILS ND 
cytoplasm, 
nucleus, 
spliceosome 
Plays a role in cytoplasmic trafficking of RNA; binds to the 
cis-acting response element, A2RE; may be involved in pre-
mRNA splicing 
11
hnRNP D0 MMP-2 ICAT ND 
cytoplasm, 
nucleus, 
ribonucleoprotein 
complex 
Binds with high affinity to RNA molecules that contain AU-
rich elements (AREs) found within the 3'-UTR of many 
proto-oncogenes and cytokine mRNAs;  binds to ds- and 
ssDNA sequences in a specific manner and functions a 
transcription factor; putative roles in telomere elongation 
and translationally coupled mRNA turnover 
6
hnRNP K 
MMP-2 iTRAQ™, TAILS 
ND 
cytoplasm, 
nucleus, 
spliceosome 
Major pre-mRNA-binding protein; binds tenaciously to 
poly(C) sequences; probable role in the nuclear metabolism 
of hnRNAs, particularly for pre-mRNAs that contain 
cytidine-rich sequences; binds poly(C) single-stranded 
DNA. 
5,
6,8
MT1-MMP ICAT 
hnRNP Q 
MMP-2 ICAT, TAILS 
ND 
cytoplasm, 
microsome,  
ER, nucleus 
Involved with pre-mRNA processing; interacts preferentially 
with poly(A) and poly(U) RNA sequences; putative roles in 
translationally coupled mRNA turnover and cytoplasmic 
vesicle-based mRNA transport through interaction with 
synaptotagmins 
5,
6,8
MT1-MMP ICAT 
hnRNP U MMP-2  TAILS ND 
cytoplasm, 
nucleus, 
spliceosome,  
cell surface 
Bind to ds- and ssDNA and RNA; has high affinity for 
scaffold-attached region (SAR) DNA; inhibits elongation of 
transcription by polymerase II 
11
Nucleophosmin 
MMP-2 TAILS 
ND nucleus 
Involved in diverse cellular processes such as ribosome 
biogenesis, centrosome duplication, protein chaperoning, 
histone assembly, cell proliferation, and regulation of tumor 
suppressors; associated with nucleolar ribonucleoprotein 
structures and bind ss nucleic acids 
7,11
MMP-9 UPLC-MSE 
Small nuclear 
ribonucleo-
protein Sm D3 
MT1-MMP ICAT 
ND nucleus,  cytoplasm 
Component of the spliceosome, involved in the nuclear 
processing of pre-mRNA 8,10MMP-9 2DD 
PROTEIN CHAPERONING           
Calreticulin 
MMP-2 iTRAQ™, TAILS 
ND 
Cytoplasm, ER 
lumen, nucleus, 
cell surface, 
secreted, ECM 
Molecular calcium binding chaperone promoting folding, 
oligomeric assembly and quality control in the ER via the 
calreticulin/calnexin cycle; extracellular modulation of cell 
motility and promotion of tumor progression and metastasis 
5,
8,11MT1-MMP ICAT 
βB1-crystallin MMP-9 2D-PAGE IVC cytoplasm Prevention of protein unfolding or aggregation; structural component of the eye lens; defects are the cause of cataract 2
Cyclophilin A   
MMP-2 iTRAQ™, ICAT, TAILS IVC 
cytoplasm, 
nucleus, 
extracellular 
Acceleration of protein folding, catalysis of cis-trans 
isomerization of peptidyl-prolyl bonds in oligopeptides; pro-
inflammatory functions after secretion 
5,6,
7,8,
10,11
MT1-MMP ICAT 
ND MMP-9 UPLC-MSE, 2DD 
MMP-11 TAILS 
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Cyclophilin B   
MMP-2 iTRAQ™ 
ND 
ER lumen, 
melanosome, 
extracellular 
Acceleration of protein folding, catalysis of cis-trans 
isomerization of peptidyl-prolyl bonds in oligopeptides 
5,
7,8MT1-MMP ICAT 
MMP-9 UPLC-MSE 
Cyclophilin D 
MMP-2 TAILS 
ND ER lumen, melanosome 
Acceleration of protein folding, catalysis of cis-trans 
isomerization of peptidyl-prolyl bonds in oligopeptides, 
RNA-binding, putative role in pre-mRNA splicing 
8,11
MT1-MMP ICAT 
Cyclophilin E 
MMP-2 iTRAQ™ 
ND nucleus 
Acceleration of protein folding, catalysis of cis-trans 
isomerization of peptidyl-prolyl bonds in oligopeptides; 
binding of RNA with potential role in pre-mRNA splicing 
5,10
MMP-9 2DD 
Endoplasmin 
MMP-2 TAILS 
ND ER lumen, 
cytoplasm, 
melanosome 
Molecular chaperone that functions in the processing and 
transport of secreted proteins; functions in ER-associated 
degradation  
6,
7,11MMP-9 UPLC-MS
E 
MMP-11 TAILS IVC 
Heat shock 
protein 27  
MMP-9 2DD 
ND 
cytoplasm, 
cytoskeleton, 
nucleus,  
cell surface 
Molecular chaperone involved in stress resistance and actin 
organization (actin capping); regulation of metastasis 10,11MMP-11 TAILS 
Heat shock 
cognate protein 
70 
MMP-2 iTRAQ™, ICAT 
ND 
cytoplasm, 
cytoskeleton, 
nucleus,  
cell surface 
Stabilization of pre-existing proteins against aggregation; 
mediation of the folding of newly translated polypeptides in 
the cytosol and within organelles 
5,6,
7,8,
10
MT1-MMP ICAT 
MMP-9 UPLC-MSE, 2DD 
Heat shock 
protein 70 
MMP-2 ICAT, TAILS 
ND 
cytoplasm, 
nucleus, 
extracellular 
Molecular chaperone involved in stress resistance; 
protection of the centrosome during heat shock 
6,
8,11MT1-MMP ICAT 
Heat shock 
protein 75 MMP-2 TAILS ND mitochondrion 
Molecular chaperone involved in stress resistance; binds to 
the intracellular domain of tumor necrosis factor type 1 
receptor 
11
Heat shock  
protein 90α 
MMP-2 iTRAQ™, TAILS ND cytoplasm, 
cytoskeleton, 
nucleus, ER 
lumen, 
mitochondria,  
cell surface 
Molecular chaperone involved in stress resistance; Role in 
F-actin bundling and cross-linking; promotion of tumor cell 
invasion and metastasis 
5,6,
7,8,
10,11
MT1-MMP ICAT IVC 
MMP-9 UPLC-MSE, 2DD ND 
MMP-11 TAILS ND 
Heat shock  
protein 90β 
MMP-2 TAILS 
ND 
cytoplasm, 
melanosome, 
mitochondrion, 
extracellular 
Molecular chaperone involved in stress resistance 6,7,8,10,11
MT1-MMP ICAT 
MMP-9 UPLC-MSE, 2DD 
MMP-11 TAILS 
Heat shock 
protein 105 MMP-2 ICAT ND 
cytoplasm, 
extracellular 
Prevents the aggregation of denatured proteins in cells under 
severe stress, on which the ATP levels decrease markedly. 
Inhibits heat shock cognate protein 70 ATPase and 
chaperone activities 
6
Oxygen-
regulated 
protein 150 
MT1-MMP ICAT ND ER lumen, 
mitochondria 
Molecular chaperone, cytoprotective role after oxygen 
deprivation 8,10MMP-9 2DD ND 
REDOX REGULATION  
Protein DJ-1 
MMP-2 iTRAQ™, ICAT, TAILS 
IVC 
cytoplasm, 
mitochondria, 
nucleus, 
extracellular 
Redox-reactive signaling intermediate controlling oxidative 
stress in the brain, protects neurons against oxidative stress 
and cell death 
5,6,
8,11MMP-1,-8,-9 IVC 
MT1-MMP ICAT 
Peroxiredoxin 1 MMP-2 iTRAQ™, TAILS ND cytoplasm, extracellular 
Antioxidant by peroxidase activity, control of cytokine-
induced peroxide levels which mediate signal transduction 5,11
Peroxiredoxin 2 MMP-2 iTRAQ™ ND cytoplasm,  cell membrane 
Antioxidant by peroxidase activity, control of cytokine-
induced peroxide levels which mediate signal transduction 
5,
7,10MMP-9 UPLC-MSE, 2DD 
Peroxiredoxin 4 MMP-9 2D LC-MS/MS ND cytoplasm, secreted 
Putative antioxidant by peroxidase acitivity; regulation of 
the activation of NF-κB in the cytosol by a modulation of 
IκB-α phosphorylation 
9
Peroxiredoxin 5 MMP-2 iTRAQ™ ND 
mitochondrion, 
cytoplasm, 
peroxisome 
Antioxidant by peroxidase activity; involved in intracellular 
redox signaling 5
Peroxiredoxin 6  
MMP-2 iTRAQ™, TAILS 
ND 
cytoplasm, 
lysosome, 
mitochondrion 
Involved in redox regulation of the cell by reduction of H2O2 
and short chain organic, fatty acid, and phospholipid 
hydroperoxides; putative roles in the regulation of 
phospholipid turnover and protection against oxidative 
injury 
4,5,
6,10MMP-9 2D-DIGE, 2DD 
SIGNAL TRANSDUCTION  
GDP 
dissociation 
inhibitor  
(GDI) 2 
MMP-9 2DD ND 
cytoplasm,  
cell membrane, 
extracellular 
ND, putative Rab GDP dissociation inhibitor activity 10
Rab GDP 
dissociation 
inhibitor  
(GDI) β 
MMP-2 ICAT, TAILS 
ND 
cytoplasm,  
cell membrane, 
cell surface 
Regulates the GDP/GTP exchange reaction of most Rab 
proteins by inhibiting the dissociation of GDP from them, 
and the subsequent binding of GTP to them 
6,
8,11MT1-MMP ICAT 
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Rho GDP 
dissociation 
inhibitor  
(GDI) α  
MMP-2 TAILS 
ND 
cytoplasm, 
cytoskeleton, 
extracellular 
Regulates the GDP/GTP exchange reaction of the Rho 
proteins by inhibiting the dissociation of GDP, and the 
subsequent binding of GTP 
6,10
MMP-9 2DD 
Rho GDP 
dissociation 
inhibitor  
(GDI) β 
MMP-2 ICAT 
ND 
cytoplasm, 
cytoskeleton,  
cell membrane, 
extracellular 
Regulates the GDP/GTP exchange reaction of the Rho 
proteins by inhibiting the dissociation of GDP, and the 
subsequent binding of GTP 
6,10
MMP-9 2DD 
14-3-3 protein 
β/α MMP-2  TAILS ND 
cytoplasm, 
melanosome 
Adapter protein implicated in the regulation of a large 
spectrum of signaling pathways by binding and modulating 
the activity of a large number of partners, usually by 
recognition of a phospho-Ser or phospho-Thr motif 
11
14-3-3 protein η 
MMP-2 TAILS 
ND 
cytoplasm, 
nucleus, 
extracellular 
Adapter protein implicated in the regulation of a large 
spectrum of signaling pathways by binding and modulating 
the activity of a large number of partners, usually by 
recognition of a phospho-Ser or phospho-Thr motif 
8,11
MT1-MMP ICAT 
14-3-3 protein γ MMP-2 iTRAQ™, TAILS ND cytoplasm, extracellular 
Adapter protein implicated in the regulation of a large 
spectrum of signaling pathways by binding and modulating 
the activity of a large number of partners, usually by 
recognition of a phospho-Ser or phospho-Thr motif 
5,11
14-3-3 protein θ 
MMP-2 iTRAQ™, TAILS 
ND cytoplasm 
Adapter protein implicated in the regulation of a large 
spectrum of signaling pathways by binding and modulating 
the activity of a large number of partners, usually by 
recognition of a phospho-Ser or phospho-Thr motif 
5,
8,11MT1-MMP ICAT 
14-3-3 protein 
ζ/δ 
MMP-2 TAILS 
ND 
cytoplasm, 
mitochondrion, 
nucleus, 
extracellular 
Adapter protein implicated in the regulation of a large 
spectrum of signaling pathways by binding and modulating 
the activity of a large number of partners, usually by 
recognition of a phospho-Ser or phospho-Thr motif 
8,11
MT1-MMP ICAT 
APOPTOSIS  
Apoptosis-
linked-gene-2-
interacting-
protein X (Alix) 
MMP-9 2DD ND 
cytoplasm, 
melanosome, 
centrosome, 
extracellular 
Control of the production of and trafficking through 
endosomes called multivesicular bodies; regulation of 
caspase-dependent and caspase-independent cell death 
10
BH3 interacting 
domain death 
agonist (BID) 
MMP-9 2DD ND 
cytoplasm, 
mitochondrial 
membrane 
Major proteolytic product p15 BID: release of cytochrome c; 
induction of ICE-like proteases and apoptosis; countering 
the protective effect of Bcl-2 
10
Calpain 2 
MMP-2 ICAT ND cytoplasm,  
cell membrane 
Ca2+-regulated non-lysosomal thiol-protease which cleaves 
substrates involved in cytoskeletal remodeling, apoptosis 
and signal transduction. 
6,8
MT1-MMP ICAT ND 
Calpastatin MT1-MMP ICAT ND cytoplasm Specific inhibitor of calpains 8
Cytochrome c MMP-11 TAILS ND 
mitochondrial 
matrix, cytosol, 
nucleus 
Transfer of electrons to the cytochrome oxidase complex, 
the final protein carrier in the mitochondrial electron-
transport chain; released in cytosol during apoptosis 
resulting in activation of caspase-9 
11
LYSOSOMAL DEGRADATION  
β-glucuronidase MMP-9 2D LC-MS/MS, 2DD ND lysosome 
Important role in lysosomal degradation of dermatan and 
keratan sulfates; defects are the cause of 
mucopolysaccharidosis type 7  or Sly syndrome 
9,10
Cathepsin A 
(lysosomal 
carboxypeptidas
e A) 
MMP-2 ICAT ND lysosome, ER, extracellular 
Protective protein appears to be essential for both the 
activity of β-galactosidase and neuraminidase, it associates 
with these enzymes and exerts a protective function 
necessary for their stability and activity. 
6
Cathepsin B 
MMP-2 iTRAQ™, TAILS 
ND 
lysosome, 
mitochondrion, 
melanosome 
Thiol protease which is believed to participate in 
intracellular degradation and turnover of proteins. Has also 
been implicated in tumor invasion and metastasis. 
5,
8,11MT1-MMP ICAT 
Cathepsin D MMP-9 UPLC-MSE ND 
lysosome, 
melanosome, 
extracellular 
Acid protease active in intracellular protein breakdown. 
Involved in the pathogenesis of several diseases such as 
breast cancer and possibly Alzheimer disease; defects are 
the cause of neuronal ceroid lipofuscinosis type 10 
7
Cathepsin E MMP-9 2D LC-MS/MS ND endosome,  ER, Golgi 
May have a role in immune function. Probably involved in 
the processing of antigenic peptides during MHC class II-
mediated antigen presentation. May play a role in 
activation-induced lymphocyte depletion in the thymus, and 
in neuronal degeneration and glial cell activation in the 
brain. 
9
Cathepsin L1 
MMP-2 iTRAQ™, ICAT, TAILS ND lysosome, extracellular 
Important for the overall degradation of proteins in 
lysosomes. 
5,6,
8,11
MT1-MMP ICAT 
Cathepsin Z  
(or X) MMP-9 UPLC-MS
E ND lysosome, ER Implicated in the promotion of cancer progression 7
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ADP, adenosine diphosphate; APC, adenomatous polyposis coli; AMP, adenosine monophosphate; ATP, adenosine triphosphate; CMP, 
cytidine monophosphate; dsDNA, double-stranded DNA; ECM, extracellular matrix; E-cadherin, epithelial cadherin; ER, endoplasmic 
reticulum; F-actin, filamentous actin; G-actin, globular actin; hnRNP, heterogenous nuclear ribonucleoprotein; ICE, interleukin-1β-
converting enzyme; IgE, immunoglobulin E; IκB-α, inhibitor of NFκB-α; IVC, in vitro cleavage; ND, not defined; NFκB, nuclear factor 
κB; ssDNA, single-stranded DNA; UMP, uridine monophosphate;  SLE, systemic lupus erythematosus. 
*Addition of a substrate to the list of high confidence candidate substrates was based on the identification in various degradomics approaches, 
the (putative) cleavage by more than one MMP, the identification of a protein of the same subfamiliy or with a similar function as an MMP 
(candidate) substrate or the biochemical confirmation by in vitro cleavage (IVC) or Western blot analysis (WB). 
†Degradomics method used for the identification of the (candidate) substrate.  The meaning of the acronyms as well as explanations on the 
methods can be found in Table 1. 
‡Confirmation; candidate substrates may be confirmed biochemically by cleavage of the recombinant/purified substrate in vitro (IVC), or by 
Western blot analysis (WB) of digested cytoplasm with substrate-specific primary antibodies. NIVC, not cleaved in vitro. 
¶References are coded as follows: 1,(Hwang et al., 2004); 2, (Descamps et al., 2005); 3,(Sawicki et al., 2005); 4, (Greenlee et al., 2006) ; 
5,(Dean and Overall, 2007); 6, (Dean et al., 2007); 7,(Xu et al., 2008); 8,(Butler et al., 2008); 9,(Vaisar et al., 2009); 10,(Cauwe et al., 2009); 
11,(Kleifeld et al., 2010). 
Iduronate-2-
sulfatase (IDS) 
MMP-2,-8,-9   
MT1-MMP ICAT IVC lysosome 
Required for the lysosomal degradation of heparan sulfate 
and dermatan sulfate; defects are the cause of 
mucopolysaccharidosis type 2 or Hunter disease 
8
Niemann-Pick, 
type C2 (NPC2) MT1-MMP ICAT IVC 
lysosome,  
secreted 
Key role in cellular cholesterol homeostasis by participating 
in intracellular cholesterol trafficking and the production 
production of low-density lipoprotein cholesterol-derived 
oxysterols; defects cause the lysosomal storage disease 
Niemann-Pick disease type C2 
8
UBIQUITINATION  
Ubiquitin-
activating 
enzyme E1 
MMP-2 TAILS ND cytoplasm, nucleus 
Activates ubiquitin by first adenylating its C-terminal 
glycine residue with ATP, and thereafter linking this residue 
to the side chain of a cysteine residue in E1, yielding an 
ubiquitin-E1 thioester and free AMP. 
11
Ubiquitin-
conjugating 
enzyme E2 
variant 1 
MMP-9 2DD ND cytoplasm, nucleus 
Catalysis of non-canonical poly-ubiquitin chain synthesis; 
role in the activation of NF-κB; transcriptional activation of 
target genes; role in the control of cell cycle and 
differentiation; role in error-free DNA repair pathway; 
contribution to cell survival after DNA damage 
1
Ubiquitin-
conjugating 
enzyme E2 L3 
MMP-2 ICAT ND cytoplasm, nucleus 
Catalyzes the covalent attachment of ubiquitin to other 
proteins, mediating the selective degradation of short-lived 
and abnormal proteins 
6
Ubiquitin-
conjugating 
enzyme E2N-
like  
MMP-9 2DD ND nucleus ND, belongs to the ubiquitin-conjugating enzyme family 10
MISCELLANEOUS  
Annexin I 
MMP-2 iTRAQ™ ND cytoplasm,  
cell projection  
cell membrane, 
nucleus, 
extracellular 
Calcium/phospholipid-binding protein which promotes 
membrane fusion and is involved in exocytosis; regulation 
of phospholipase A2 activity;inhibition of neutrophil 
extravasation and induction of neutrophil apoptosis 
5,10
MMP-9 2DD WB 
Carbonic 
anhydrase II 
MMP-9 2DD NIVC cytoplasm, 
nucleus, 
extracellular 
Reversible hydration of carbon dioxide; essential for bone 
resorption and osteoclast differentiation; defects are the 
cause of renal tubular acidosis or Guibaud-Vainsel 
syndrome 
10
MMP-13 IVC IVC 
Ferritin light 
chain 
MMP-2 iTRAQ™ 
ND cytoplasm, extracellular 
Storage of iron in a soluble, non-toxic, readily available 
form; defects are the cause of hereditary hyperferritinemia-
cataract syndrome and neuroferritinopathy 
5,10
MMP-9 2DD 
Galectin-1 
MMP-2 iTRAQ™, TAILS ND 
cytoplasm,  
ECM 
May regulate apoptosis, cell proliferation and cell 
differentiation. Binds a wide array of complex 
carbohydrates. Affects T cell homeostatis by inhibiting 
CD45  protein phosphatase activity; putative alarmin  
5,7,
8,11
MT1-MMP ICAT IVC 
MMP-9 UPLC-MSE ND 
MMP-11 TAILS IVC 
Galectin-3 MMP-2,-9 iTRAQ™ 
(Ochieng et al., 
1994; Ochieng 
et al., 1998) 
nucleus, 
cytoplasm, 
mitochondrion, 
cell membrane, 
secreted,  
cell surface 
Galactose-specificlectin which binds IgE.; may mediate 
integrin-dependent stimulation of endothelial cells 
migration. 
5
Myosin light 
chain MMP-2 2D-PAGE IVC 
cytoplasm, 
cytoskeleton, 
sarcomere, 
extracellular 
Mechanical protein that generates force during muscle 
contraction 3
Progranulin MT1-MMP ICAT IVC cytoplasm, extracellular 
Pluripotent growth factor with roles in development, wound 
repair, inflammation and tumorigenesis; defects cause 
ubiquitin-positive frontotemporal dementia 
8
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3.1 Intracellular MMP detection: 
methodological considerations 
Classical SDS-PAGE-based gelatin zymographic 
analysis, henceforth called ‘substrate zymography’, to 
detect activated forms of MMP-9 and MMP-2 does not 
reveal the actual in situ activity of the proteases.  During 
SDS-PAGE analysis, MMPs undergo an artificial 
nonproteolytic activation by the detergent SDS, which 
denatures the proteases and deviates the propeptide out of 
the catalytic side (vide supra).  After the SDS-PAGE, 
SDS is washed away using Triton X-100 and the 
proteases refold, but the propeptide remains detached 
from the catalytic site, resulting in gelatin degradation by 
artefactually active pro-MMP-9 and pro-MMP-2. In 
contrast, nitrosative-stress induced activation of MMPs 
results in a size modification that is too small to be 
detected by SDS-PAGE (cf. 1.2).  In the latter case, the 
pro-MMP may be a biologically active enzyme.  In 
addition, SDS separates the MMPs from their natural 
inhibitors, i.e. the TIMPs.  As a consequence, in the 
presence of TIMP-1/MMP-9 or TIMP-2/MMP-2 ratios in 
excess of 1, substrate zymographic analysis erroneously 
suggests MMP activities although in the biological 
samples or eventually in the in situ situation, they may be 
kept inactive by TIMP binding.  In addition, one needs to 
keep in mind that not all fragments of pro-MMPs are 
active, because intermediate activation forms exist and 
that ex vivo active forms may be under endogenous 
inhibition in vivo. 
Detection of MMPs by substrate zymography of cell 
lysates excludes determination of subcellular localization 
and may result in artefactual activation of the enzymes by 
detergents in the cell lysis buffer.  Detergent-soluble 
fractions of cellular lysates also contain membrane-
associated proteins and as a consequence do not reflect 
intracellular localization per se.  Hence, native i.e. non-
denaturing subcellular fractionation into membrane, 
cytosolic, mitochondrial, nuclear and other organelle 
fractions, prior to the addition of detergents, is a 
prerequisite to demonstrate intracellular presence of 
activated MMPs by substrate zymography.  Ideally, 
fractionation efficiency needs to be checked by assessing 
the distinctive presence of fraction-specific proteins, e.g. 
histone H3, actin and ICAM-1 as markers for nuclear, 
cytoskeletal and membrane fractions, respectively. Co-
immunoprecipitation of the MMP and its substrate from 
the specific cell fraction gives an additional confirmation 
of subcellular colocalization of target and protease.  To 
gain information on actual subcellular activity, the gel-
based zymographic assay was adapted to assess net 
proteolytic activity in situ (Galis et al., 1995).  A 
substrate, e.g. gelatin or a peptide, is fluorescently 
labeled and applied to tissue sections.  In situ 
zymography preserves the fine morphological details of 
the tissue or cell monolayer.  However, whereas MMP-2 
and MMP-9 are the most active gelatin degraders 
(Mackay et al., 1990), gelatin is not an exclusive 
substrate of the gelatinases, but is also digested by other 
MMPs such as MMP-1, MMP-3, MMP-7, MMP-
13/collagenase-3 and MT-MMPs (Sang and Douglas, 
1996; Pavlaki and Zucker, 2003). Possible candidates 
able to digest both gelatin and type IV collagen are 
MMP-3 and MMP-7 (Sang and Douglas, 1996), MMP-26 
(Park et al., 2000) and serine proteases such as cathepsins 
(Bailey, 2000).  A critical reader will take into 
consideration that the key messages here are the relative 
amounts of the various substrate-cleaving enzymes and 
their specific activities in substrate conversions.  For 
example, a protease with a 100-fold lower activity on 
gelatin compared with for example, MMP-9, will need a 
100-fold higher concentration to be detected by in situ 
zymography with the same intensity as MMP-9.  
Likewise, activity assays based on fluorigenic peptides 
are rarely specific and must be combined with the use of 
specific neutralizing antibodies or cells of wildtype and 
MMP knockout mice. 
Many proteases act in cascades (also called ‘the 
protease web’ or the ‘proteolytic internet’, cf. section 
1.1).  Hence, proteases (and inhibitors) may be the 
substrates of other MMPs.  As a consequence, it will 
often be difficult to define a direct cleavage, because the 
substrate conversion may be indirect, i.e. caused by an 
upstream protease.  Such situations may be resolved in 
vitro (e.g. with the use of ultrapure substrates and 
proteases).  However, to discriminate between direct and 
indirect substrates in vivo, highly specific inhibitors need 
to be developed first. 
At present, the only safe approach to establish a 
causal relationship between a protease and cleavage of a 
specific substrate in vivo is by comparing wildtype and 
mice rendered genetically deficient in the particular 
protease. Of course, this approach has drawbacks and 
limitations i.e. the knockout mice might not be viable or 
subfertile, pushing an already tedious procedure to its 
technical limits.  The comparisons need to be done in 
backcrossed animals and, to avoid genetic confounding, 
these backcrosses need to be performed ideally for more 
than 13 generations.  In addition, one needs to keep in 
mind that differences, genetic and compensatory ones, 
will always exist between men and mice (Hu et al., 
2007). The question remains whether any of the 
established MMP knockout mice provide credence for 
intracellular MMP activities. The answer to this question 
is not simple. First, spontaneous phenotypes in MMP 
knockouts are limited and, to our knowledge, no 
intracellular substrates have been detected so far in 
healthy animals, except for pro-cryptdins (Wilson et al., 
1999). Second, in induced phenotypes of infection and 
inflammation, various intracellular substrates have been 
defined in vivo, e.g. βB1-crystallin (Descamps et al., 
2005), connexin-43 (Lindsey et al., 2006), zona 
occludens-1 (Asahi et al., 2001) and X-ray cross-
complementary factor 1 (Yang et al., 2010). It may be, 
however, that in some of these substrates, the cleavage 
occurs extracellularly. 
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Figure 4. Comparison of the MMP-9-mediated cleavage sites in collagen and gelatin, in extracellular substrates and in 
intracellular substrates.  Cleavage site specificities are visualized by sequence logos, created with the bio-informatics software 
WebLogo 3 and with the application of small sample adjustments and corrections for natural amino acid abundances (Crooks et 
al., 2004; Schneider and Stephens, 1990). The overall height of the stack is a measure of sequence consensus, while the heights 
of the amino acid symbols within each stack indicate the relative frequency of each amino acid in that position. MMP-9 cleaves 
the peptide bonds between positions P1 and P1’ (arrow). A. Cleavage preferences in gelatin type II, procollagen type II and 
collagen type V (Van den Steen et al., 2002). B. Cleavage specificities in extracellular substrates (secreted and membrane-
associated) (Cauwe et al., 2007; Van den Steen et al., 2002; Lin et al., 2008; Chow et al., 2008; Xu et al., 2008; Vaisar et al., 
2009). C. Intracellular substrate specificities (Cauwe et al., 2009; Descamps et al., 2005; Starckx et al., 2003; Levin et al., 
2009).  Although differences exist between the three sequence logos, a general preference subsists in all substrates for 
hydrophobic amino acids at P1’, small amino acids at P1 (Gly, Ala) and a Pro residue at P3, as previously described (Van den 
Steen et al., 2002). 
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An alternative approach is the use of specific 
protease inhibitors.  However, small-molecule inhibitors 
inhibiting only a single MMP have not been discovered 
so far and the only way of specific inhibition is the use of 
highly specific neutralizing antibodies (Hu et al., 2007).  
A third associative method may also be used with patient 
samples.  Indeed, significant inverse correlations between 
intact substrate and MMP levels in large groups of 
biological (patient) samples are strongly suggestive of in 
vivo cleavage.  However, it is important to keep in mind 
that such correlations may be indicative of other 
associations than pure causal relationships. 
As will be outlined, many substrates are cleaved by 
MMPs.  It remains a methodological challenge to verify 
and validate whether such substrates are biologically 
relevant.  With the use of unbiased methods to define 
new substrates, it is possible that biologically irrelevant 
substrates are detected.  However, it is equally possible 
that by such approaches unanticipated relevant new 
functions of MMPs and substrates are discovered in 
physiology and pathology. 
Substrate cleavage sites in vitro may be safely 
determined in two ways.  After cleavage of the substrate 
in solution, the intact molecule and the fragments are 
separated by high performance liquid chromatography 
(HPLC).  Mass spectrometry (MS) analysis of the elution 
fractions determines the mass and thus the sequence of 
the peptide fragments, as compared with database 
searches of theoretical peptide masses (Lopez-Otin and 
Overall, 2002).  Alternatively, the fragments may be 
separated by SDS-PAGE analysis and electroblotted onto 
PVDF for identification of the fragments NH2-termini by 
Edman degradation (Edman, 1970). Excision of fragment 
bands out of SDS-PAGE gels and subsequent MS 
analysis after in-gel trypsin digests will not yield 
cleavage sites and may only be indicative of cleavage 
regions.  Indeed, unless the method is extremely well 
calibrated and sensitive, not all peptides may be captured 
and this will result in false positives.  It is always advised 
to use complementary techniques to corroborate 
identified in vitro cleavage sites.  In addition, with 
presently available tools for high-throughput substrate 
and cleavage site identification (cf. Table 1), it will be 
even more challenging to demonstrate that such 
cleavages are biologically meaningful.  Since MMPs do 
not cleave at stringent substrate recognition sites, but 
only possess general preferences, in silico predicted 
cleavage sites are theoretical and need to be confirmed by 
one of the above methods or by generation and analysis 
of substrates with mutated cleavage sites. 
3.2   Subcellular localization mechanisms 
of MMPs 
As discussed in chapter 1, MMPs may be activated in the 
extracellular milieu or inside cells.  In this chapter we 
will summarize the present data on localization of MMPs 
in various subcellular compartments and the concomitant 
pathophysiological consequences.  In addition, we will 
discuss the information about the mechanisms used by 
specific MMPs to enter cells and to translocate to 
different intracellular locales.  These data are 
summarized in Table 4, showing for each MMP the 
various known subcellular localizations and translocation 
mechanisms in specific cell types, the (putative) 
intracellular activation modes, the intracellular substrates 
and the pathophysiological effects of intracellular 
translocation. 
3.2.1 Cytosolic MMP activity 
The cytoplasm refers to the portion of the cell that is 
enclosed by the plasma membrane and is a collective 
term for the cytosol plus the organelles suspended in the 
cytosol.  When intracellular localization of MMPs was 
determined solely on the basis of immunostainings, and 
not with additional confirmation by subcellular 
fractionation (cf. section 3.1), discrimination between 
cytosolic and/or organelle staining is difficult.  Hence, in 
these cases we use the more general term, cytoplasm.  In 
addition, in the cytoplasm we only consider activated 
MMPs, since presence of pro-MMPs in the cytoplasm is 
mostly associated with protein synthesis in the 
endoplasmatic reticulum (ER) and the Golgi apparatus, 
and reflects MMPs that are prepared for secretion (vide 
infra).   
Many proteins have inefficient signal sequences, 
which may result in a variable fraction (5-20%) that is 
not translocated across the ER membrane but instead 
remains in the cytosol (Hegde and Bernstein, 2006).  An 
example of this mechanism is the ER chaperone protein 
calreticulin, which has additional functions in the cytosol 
and nucleus (Shaffer et al., 2005).  Likewise, the signal 
sequence at the NH2-terminus of MMP-3 contains a Pro 
residue at the fifth position, which was proposed to work 
as a helix breaker, and results in an inefficient signal 
peptide and sorting of MMP-3 to both the cytoplasm and 
the ER-Golgi pathway for further secretion (Eguchi et al., 
2008).  Since a Pro at the start of the signal sequence is 
found in many MMPs, for example MMP-1,-8,-9,-13 and 
MT1-MMP, it would be interesting to investigate 
whether signal sequence inefficiency may be a general 
mechanism for dual sorting of MMPs to the cytosol and 
to the extracellular space. 
Conversely, some MMPs have been found to enter 
cells by endocytosis.  Endocytotic uptake occurs by 
various mechanisms, which can be roughly divided into 
those that are clathrin-dependent and those that are 
clathrin-independent. In clathrin-dependent endocytosis, 
the cytoplasmic domains of membrane-associated 
receptors or ‘cargo proteins’ are specifically recognized 
by adaptor proteins and packaged into clathrin-coated 
vesicles that are brought into the cell (Traub, 2009; Grant 
and Donaldson, 2009).  Clathrin-independent endocytosis 
is less well studied and encompasses many different 
endocytic mechanisms, such as caveolae- and flotilin-
dependent endocytosis, uptake in GPI-enriched early 
endosomal compartments (GEEC) and actin-driven 
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pathways such as macropinocytosis and phagocytosis 
(Grant and Donaldson, 2009; Doherty and McMahon, 
2009).   
MMP-7 may be internalized by clathrin-dependent 
endocytosis, since two inhibitors of clathrin-dependent 
endocytosis (phenylarsine oxide and chlorpromazine) 
inhibit the ability of exogenously added MMP-7 to cleave 
the intraneuronal protein synaptosomal-associated protein 
of 25 kDa (SNAP-25) (Szklarczyk et al., 2007b).  In 
support of this, immunostaining for MMP-7 showed 
translocation of exogenously added MMP-7 to the 
cytoplasmic compartment.  Exogenous MMP-3 was 
shown to enter the cytoplasm of chondrosarcoma cells 
and to further translocate to the nucleus (Eguchi et al., 
2008).  Laser confocal microscopy analysis showed 
colocalization of MMP-3 with low-density lipoprotein-
related protein 1 (LRP1), suggesting that MMP-3 may 
enter cells by clathrin-dependent endocytosis (Traub, 
2009).  Other MMPs are also internalized by LRP-
mediated endocytosis, including MMP-2 (Emonard et al., 
2004; Yang et al., 2001), MMP-9 (Hahn-Dantona et al., 
2001; Van den Steen et al., 2006) and MMP-13 (Barmina 
et al., 1999; Raggatt et al., 2006).   
Regardless of the mode of entry, endocytosed cargo 
proteins and their loads are usually delivered to the early 
endosome.  The lumen of the early endosome is mildly 
acidic, which facilitates ligand release from the cargo 
receptors.  The cargo proteins can be routed to the late 
endosomes and lysosomes for degradation, to the trans-
Golgi network (TGN), or to recycling endosomal carriers 
that recycle the cargo proteins back to the plasma 
membrane (Grant and Donaldson, 2009).  However, the 
internalized ligand proteins remain in the endosomal 
lumen and will be transported to lysosomes for 
degradation.  Indeed, LRP-mediated endocytosis was 
described as a clearance mechanism to eliminate 
excessive MMP activity (Emonard et al., 2005) and it is 
not clear how MMPs may escape endosomal entrapment 
and enter the cytosol.  Some bacterial toxins and viruses 
are able to leave the endosomes by pH-dependent 
conformational changes (Cho et al., 2003) or by pH-
independent mechanisms (Matsuzawa et al., 2004).  
Inhibition of endosomal acidification does not prevent 
SNAP-25 cleavage by exogenous MMP-7.  Hence, 
MMP-7 uses an undetermined pH-independent 
mechanism to escape endosomal entrapment.    
MT1-MMP is internalized by both clathrin-dependent 
(Jiang et al., 2001a; Uekita et al., 2001) and clathrin-
independent caveolae-dependent mechanisms (Remacle 
et al., 2003; Galvez et al., 2004) and is recycled to the 
cell surface, which may be a mechanism to relocalize 
active MT1-MMP at the leading edge during cell 
migration (cf. 3.3.2).  Caveolae are small membrane 
invaginations formed by the polymerization of caveolins 
and contain a subset of lipid-raft components, such as 
sphingolipids and cholesterol.  Caveolae bud off the 
plasma membrane to form endocytic caveolar carriers 
that fuse with the caveosome or with the early endosome, 
or can fuse back to the plasma membrane (Parton and 
Simons, 2007).  MMP-2 was found to colocalize with 
MT1-MMP, TIMP-2 and caveolin on the surface of 
endothelial cells (Puyraimond et al., 2001) and 
cardiomyocytes (Chow et al., 2007a).  Again, the 
question is raised about the mechanisms that MT1-MMP 
and MMP-2 may use to access their cytoplasmic targets 
(vide supra).  Indeed, after endocytosis, the cytoplasmic 
tail of MT1-MMP faces the cytoplasm, whereas the 
catalytical domain resides in the endosomal lumen.  
Hence, it would be interesting to investigate whether 
MT1-MMP could flip-flop, i.e. flip its orientation from 
inwards (as it is after endocytosis) to outwards (with its 
catalytic site in the cytosol and its tail in the endosome).  
Mechanisms for lipid flip-flop in cellular membranes 
have been described and are important in various 
biological processes such as membrane biogenesis, 
vesicle formation and the biosynthesis of glycolipid 
precursors of cell surface glycoconjugates (Pomorski and 
Menon, 2006).  The same mechanism may apply for 
MMP-2 as it associates with the endocytic membrane 
through the binding of the caveolin scaffolding domain of 
caveolin-1 and caveolin-3 (Chow et al., 2007a) or by 
association with TIMP-2 and MT1-MMP (Puyraimond et 
al., 2001). 
3.2.2 MMP activity in the secretory pathway 
Classically, vesicles carrying secretory proteins are 
transported from the endoplasmatic reticulum (ER) to the 
Golgi and subsequently to the TGN.  As discussed in 
section 1.1, MMP-11 and MT3-MMP are activated by 
furin within the TGN (Kang et al., 2002; Pei and Weiss, 
1995; Santavicca et al., 1996).  Likewise, treatment of 
vaginal-cervical epithelial cells with estrogen stimulates 
intracellular activation of MMP-7 in the Golgi apparatus 
(Gorodeski, 2007).  Furthermore, resting neutrophils 
contain pro- and activated forms of MT6-MMP, which is 
distributed among specific granules, gelatinase B 
granules, secretory vesicles and the plasma membrane 
(Kang et al., 2001). It is at present unknown whether 
MMP-8/neutrophil collagenase and MMP-9/gelatinase B 
may be activated intracellularly by MT6-MMP in 
neutrophils.  However, the classical view is that these 
enzymes are rapidly activated after neutrophils 
degranulation, e.g. by HOCl (Peppin and Weiss, 1986; 
Weiss et al., 1985) (cf. section 1.2). Upon treatment with 
phorbol 12-myristate 13-acetate (PMA), microvascular 
endothelial cells accumulate activated forms of MMP-9.  
In addition, both pro- and activated forms of MMP-2 
were found in secretory vesicles of neuroblastoma and 
primary neurons and reactive astrocytes (Sbai et al., 
2010; Sbai et al., 2008).  In reactive astrocytes and 
melanoma cells, MMP-2 and MMP-9 were found in 
different vesicle populations aligned along 
microfilaments and/or microtubules (Sbai et al., 2010; 
Schnaeker et al., 2004).  In the context of the dogma of 
extracellular action of MMPs, the presence of 
intracellularly activated MMPs in the secretory pathway 
and in secretory vesicles was considered as a means for 
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rapid secretion of MMP activity in the extracellular 
milieu.  However, some MMP-2- and MMP-9-containing 
vesicles in neurons and melanoma cells also undergo 
retrograde transport, suggesting that these vesicles are not 
intended for secretion (Schnaeker et al., 2004; Sbai et al., 
2008).  In addition, since communication exists between 
the Golgi network and the endosomal pathway for the 
recycling of cargo proteins (Grant and Donaldson, 2009), 
it would be interesting to investigate whether proteins 
within the Golgi apparatus may be exchanged and taken 
up into the endosomal pathway, from where they may 
enter the cytosol by previously suggested mechanisms 
(cf. 3.2.1).  Alternatively, flip-flop mechanisms may 
orient vesicular MT-MMPs to the cytosolic space, as was 
suggested for endosomal escape.  
3.2.3 MMP activity associated with the 
cytoskeleton 
The intracellular matrix (ICM) consists of the actin 
cytoskeleton and the microtubular network. The ICM 
preserves the cellular shape, enables cell migration and 
intracellular transport and plays major roles in cell 
division.  MMP-2 cleaves the cytoskeletal proteins 
desmin and α-actinin and colocalizes with α-actinin in 
cardiomyocytes (Sung et al., 2007).  As previously 
mentioned, MMP-2- and MMP-9-containing vesicles 
are aligned with the cytoskeleton in neurons and 
reactive astrocytes, and both gelatinases are found in 
cytoskeletal fractions from these cells (Sbai et al., 
2010; Sbai et al., 2008).  Disruption of the actin 
cytoskeleton with cytochalasin D in astrocytes results 
in the partial recruitment of MMP-2 and gelatinolytic 
acitivity into actin aggregates, which further indicates a 
connection between gelatinases and the actin 
cytoskeleton (Ogier et al., 2006).  Both MT1-MMP 
and MT3-MMP are detected in cytoskeletal fractions 
of smooth muscle cells, where they cleave the 
cytoskeletal protein focal adhesion kinase (FAK) (vide 
infra) (Shofuda et al., 2004).  In addition, MT1-MMP 
is trafficked along the microtubule to the centrosomal 
compartment, where it induces malignant 
transformation by cleaving the integral centrosomal 
protein pericentrin (vide infra) (Golubkov et al., 2006; 
Golubkov et al., 2005b; Golubkov et al., 2005a).  
Moreover, cytoskeletal proteins constitute an important 
fraction of the intracellular degradomes of MMP-2, 
MMP-9 and MT1-MMP, as determined by various 
degradomics methods (cf. Table 3).  Hence, the 
functional analysis of the effect(s) of ICM cleavage by 
MMPs may lead to novel insights, some of which will 
be suggested throughout the manuscript. 
3.2.4 MMP activity in the sarcomere 
The cardiac myocyte is a specialized striated muscle cell 
that is composed of bundles of myofibrils that contain 
myofilaments.  The myofibrils have distinct, repeating 
units called sarcomeres, which represent the basic 
contractile units of the myocyte.  MMP-2 was localized 
to the sarcomere of cardiac myocytes by various methods 
including immunogold electron microscopy, confocal 
microscopy, substrate zymography analysis of highly 
purified thin myofilament preparations and 
coimmunoprecipitation with sarcomere proteins that are 
cleaved by MMP-2 during cardiac injury, causing 
myocardial dysfunction (vide infra) (Gao et al., 2003; 
Kandasamy et al., 2010; Sawicki et al., 2005; Wang et 
al., 2002a).  In addition, in dilated cardiomyopathy, both 
MMP-2 and MMP-9 are localized to the sarcomere, 
where they cleave myosin heavy chain (Rouet-Benzineb 
et al., 1999).  Under physiological circumstances, these 
MMP activities may be kept in check by sarcomeric 
TIMP-4 (Schulze et al., 2003). 
3.2.5 Mitochondrial MMP activity 
Mitochondria may be considered as the power plants of 
the cell and are crucial for numerous cellular processes, 
including apoptosis, signaling, and metabolic pathways 
involving lipids, amino acids and iron.  Both pro- and 
activated MMP-1 are associated with the mitochondrial 
membrane in glial Müller cells, Tenon’s capsule 
fibroblasts, corneal fibroblasts and retinal pigment 
epithelial cells (Limb et al., 2005).  Since the 
mitochondrial localization of MMP-1 is found in resting 
cells, it suggests a physiological role for MMP-1 in 
cellular homeostasis.  In addition, mitochondrial MMP-1 
confers resistance to apoptosis by uncharacterized 
mechanisms.  Both MMP-2 (Wang et al., 2002b; Kwan et 
al., 2004) and MMP-9 (Moshal et al., 2008) are detected 
in cardiac mitochondria during cardiac injury and 
increased levels of mitochondrial MMP-9 are associated 
with exacerbated mechanical dysfunction.   
3.2.6 MMP activity in the nucleus 
Surprisingly, many studies report nuclear localization 
of MMPs, including MMP-1,-2,-3,-9,-13,-26 and MT1-
MMP (cf. Table 4), and cleavage of nuclear matrix 
proteins (cf. Tables 3 and 5).  The nuclear matrix binds 
more than 200 nuclear proteins and supports their 
assembly into functional macromolecular complexes 
involved in important nuclear processes, such as 
transcription, RNA splicing and DNA replication (Zink et 
al., 2004).  The nuclear matrix is surrounded by a nuclear 
lamina and a double-membrane nuclear envelope.  
Hence, nuclear import and export mechanisms are needed 
for the movement of large macromolecules into and out 
of the nucleus (Quimby and Corbett, 2001).  As a 
consequence, to enter or exit the nucleus, MMPs need 
internal signals, termed nuclear localization signals 
(NLSs) or nuclear export signals (NESs). These signals 
are recognized by soluble receptors that mediate 
macromolecular transport through the nuclear pore 
complex.  Two types of human NLSs exist, i.e. classical 
basic Lys-rich and M9-type, which are recognized by 
importins/karyopherins-α and transportin 
(importin/karyopherin-β2), respectively.  Classical NESs 
are characterized by the presence of Leu residues and are 
recognized by the exportin CRM1 (Benmerah et al., 
2003; Quimby and Corbett, 2001).  
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Of interest, Si-Tayeb and coworkers found two 
activated forms of MMP-3 in the nucleus of 
hepatocellular carcinoma cells and myofibroblasts, 
whereas pro-MMP-3 was not found in the nucleus (Si-
Tayeb et al., 2006).  Using the bioinformatics software 
PSORT (Nakai and Horton, 1999), they detected a 
putative NLS (PKWRKTH) at position 107 to 113 in the 
catalytical domain, which was well conserved between 
the human, mouse and rat sequences of MMP-3.   
Nuclear entry was shown to be dependent on this NLS, as 
deletion of 2 amino acids led to a large decrease in 
nuclear localization.  Since pro-MMP-3 was not found in 
the nucleus, the NLS may be shielded by the propeptide, 
much like the catalytical cleft is protected in the latent 
pro-MMPs.  In contrast, pro-MMP-2 carries a putative 
NLS on its COOH-terminus that should be accessible 
without pro-peptide removal, thus allowing transfer of 
the full-length protein to the nucleus.  Nuclear 
translocation of MMP-3 was confirmed by Eguchi and 
colleagues, who showed that extracellular MMP-3 is 
taken up into chondrosarcoma cells and subsequently 
translocates to the nucleus where it induces transcription 
of the connective tissue growth factor (CTGF) gene (vide 
infra) (Eguchi et al., 2008).  Five additional NLSs were 
found, three in the pro-domain of MMP-3 and two in the 
hemopexin domain, that were all driving an enhanced 
green fluorescent protein (EGFP)-NLS construct to the 
nucleus.  In addition, MMP-3 was associated with a 
RAN-binding protein, which was involved in the nuclear 
import.  Hence, nuclear entry of MMP-3 is regulated by 
two independent pathways.  Loss of nuclear MMP-3 was 
detected 30 min after nuclear entry, suggesting 
degradation or nuclear export to the cytoplasm by a Leu-
rich NES sequence in the hemopexin domain.   
Besides MMP-2 and MMP-3, Si-Tayeb and 
colleagues detected putative NLSs in the sequences of 
MMP-1,-8,-10,-13,-19,-20,-23 and MT1-, MT3-, MT4- 
and MT5-MMP, which suggests that nuclear entry may 
be a feature of many MMPs.  MMPs that do not contain 
an NLS may enter the nucleus by binding to cargoes, 
such as RAN-binding proteins, other proteins with an 
NLS, various types of RNA and complexes of RNA plus 
proteins (ribonucleoproteins or RNPs) (Quimby and 
Corbett, 2001).  For example, MMP-9 may enter the 
nucleus bound to the nuclear protein Ku, an interaction 
that was detected at the cell surface (Monferran et al., 
2004).  In addition, some proteins without NLS but 
associated with clathrin-coated pits or caveolae are also 
able to shuttle in and out of the nucleus, albeit the precise 
mechanisms involved in these processes are poorly 
understood (Benmerah et al., 2003; Lee et al., 2004a).  
Such nuclear translocation via caveolae-mediated 
endocytosis was proposed for MT1-MMP in aggressive 
hepatocellular carcinoma cells (Ip et al., 2007). 
To avoid excessive proteolysis of nuclear proteins 
during cellular homeostasis, these nuclear MMPs may be 
under inhibition by TIMP-1 and TIMP-4, which are also 
present in the nucleus (cf. Table 4) (Zhao et al., 1998; 
Ritter et al., 1999; Zhang et al., 2002; Si-Tayeb et al., 
2006) 
In conclusion, a systematic investigation of the 
localization mechanisms and the presence of MMPs in 
the various subcellular compartments - under conditions 
of cellular stress and homeostasis - may provide more 
insight into the present fragmented image.  In addition, 
this may contribute to the elucidation of intracellular 
functions of MMPs, which may be of great importance 
when considering MMP inhibition therapy. 
3.3 Intracellular proteolysis by MMPs in 
physiology and pathology 
It has been clearly demonstrated in the previous chapters 
that MMPs may be activated intracellularly or enter cells 
and various cellular compartments after extracellular 
activation.  This leads to questions about the 
physiological and pathological implications of 
intracellular MMP activity.  Intracellular proteins, which 
are the subject of intracellular MMP proteolysis, will be 
discussed in the context of the physiological or 
pathological pathways affected by their cleavage.  We 
will review well-established, confirmed intracellular 
substrates, which are summarized in Table 5 with the 
(putative) location of their cleavages.  This table also 
includes the biological roles of the substrates, the studied 
MMPs, the identified cleavage sites, the context of the 
cleavage (in vitro, ex vivo or in vivo) and the (possible) 
effects of the cleavages on physiopathology.  Cleavage of 
substrates identified by degradomics (cf. Table 3) will be 
mentioned in the relevant sections. 
3.3.1 Intracellular proteolysis in innate 
immune defense 
The efficacy of innate host defense can be attributed 
to the ability of the immune system to recognize and 
neutralize microbial invaders quickly and efficiently.  In 
mammals, inflammatory leukocytes and affected 
epithelia synthesize and/or mobilize anti-microbial 
peptides that are capable of directly killing a variety of 
pathogens, i.e. cathelicidins and defensins.  The α- and β-
defensins comprise a family of cationic trisulfide peptides 
that kill bacteria by membrane disruption.  α-defensins 
were identified as antimicrobial proteins purified from 
extracts of cytoplasmic granules of polymorphonuclear 
(PMN) leukocytes.  Mice, however, lack leukocytic 
defensins.  Nevertheless, Paneth cells that populate the 
crypts of Lieberkühn throughout the mouse small 
intestine express many antimicrobial α-defensins called 
cryptdins (crypt defensins).  Cryptdin peptides, packaged 
in apically oriented granules of Paneth cells, are secreted 
into the crypt by degranulation that is both constitutive at 
a base-line level and inducible by infection.  Biosynthesis 
of prepro-α-defensins (~10 kDa) involves the rapid 
cleavage of the signal peptide producing pro-α-defensins 
(~8.5 kDa) that have little or no microbicidal acitivity in 
vitro.  Activation of defensin peptides requires 
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proteolytic removal of the NH2-terminal acidic pro-
region, yielding a mature peptide of ~3.5 kDa (Selsted 
and Ouellette, 2005).  
MMP-7 colocalizes with cryptdins (Crps) in mouse 
Paneth cells and mediates the processing and activation 
of various Crps in vitro (Wilson et al., 1999).  MMP-7 
cleaves pro-Crp-1, -6 and -15 at Ser43-Val44; Ser53-
Leu54 and Ser58-Leu59.  The latter cleavage generates 
the NH2-terminal consensus sequence in all related pro-
Crps (pro-Crp-1 to -16) except for pro-Crp-4 and -5, 
which do not show sequence identity for the above 
mentioned cleavage sites (Putsep et al., 2000).  However, 
they are cleaved at the same positions, i.e. Ser43-Ile44, 
Ala53-Leu54 and Ser58-Leu59 (Ayabe et al., 2002; 
Shirafuji et al., 2003).  When analyzing the processing 
intermediates of Crp4 (Crp444-92, Crp454-92 and Crp459-92), 
the most bactericidal of the known mouse α-defensins, 
Weeks et al. found that their in vitro antibacterial effects 
are very similar, contrasting with the lack of bactericidal 
and membrane-disruptive capacity of pro-Crp-420-92.  
Hence, cleavage by MMP-7 at Ser43-Ile44 is sufficient to 
activate bactericidal activity, and the amino acids 
between 20 and 43 of the proregion maintain the 
precursor in an inactive state, which may be important to 
prevent deleterious effects to the host cell during pro-α-
defensin synthesis, folding and packaging into granules 
(Weeks et al., 2006).  Why this processing occurs 
intracellularly is an enigma, but intragranular 
colocalization of bactericidal peptides and MMP-7 might 
enhance their cleavage, when compared to cleavage in 
the diluted extracellular milieu.  In addition, these and 
other observations (vide infra) do not exclude the 
possibility of additional MMP-7-mediated extracellular 
Crp activation. 
MMP-7 gene deletion ablates pro-Crp processing, 
resulting in accumulation of cryptdin precursors in 
Paneth cell granules and the absence of activated mature 
Crp peptides in the small intestine.  Since Crps constitute 
about 70% of the bactericidal activity released by Paneth 
cells (Ayabe et al., 2000), MMP-7 knockout mice 
without functional Crp peptides, have a functional defect 
in clearance of intestinal infections, and they succumb 
more rapidly and to lower doses of virulent Salmonella 
typhimurium compared with control mice (Wilson et al., 
1999).  Thus, defective pro-Crp activation is associated 
with a deficit in mucosal immunity and increased risk of 
systemic disease.   
Whereas murine leukocytes do not contain defensin 
peptides, in humans, α-defensins are primarily found in 
neutrophils (human neutrophil peptides 1-4 or HNP-1 to -
4) and small intestinal Paneth cells (human defensins 5 
and 6 or HD-5 and -6), the latter being activated by 
trypsin (Ghosh et al., 2002).  MMP-7 cleaves within the 
prodomain of pro-HNP-1, which does not produce the 
sequence of the mature peptide, but of a processing 
intermediate with antimicrobial activity (Wilson et al., 
2009).  However, since MMP-7 is not present in 
neutrophils, and the neutrophilic MMPs (MMP-8, MMP-
9 and MT6-MMP) are compartmentalized separately 
from α-defensins, proteolytic activation of pro-HNPs 
within maturing human neutrophil granules does not 
seem to be an MMP-dependent process. 
In the mouse, α-defensin genes duplicated and 
diversified further to give rise to the Defcr-rs gene 
subfamily that codes for numerous cysteine-rich 
sequence 4C (CRS4C) peptides that are unique to mice.  
Remarkably, preproregions of CRSC4 and Crp peptides 
are nearly identical but the mature CRSC4 peptides are 
cysteine-rich peptides very different from Crps (Ouellette 
and Lualdi, 1990).  Native CRSC4 peptides purified from 
mouse small intestine exist as disulfide-stabilized 
homodimers and heterodimers with antibacterial activity 
(Huttner and Ouellette, 1994).   As expected from the 
high sequence identity of the proregions, inactive pro-
CRSC4-1 (cryptdin-related protein 4C-1, defensin-related 
cryptdin-related sequence 2) was found to be converted 
to mature bactericidal CRSC4-1 by MMP-7-mediated in 
vitro proteolysis of the precursor proregion and at the 
same residue positions as determined for Crp activation, 
i.e. Ser43-Val44, Ala53-Leu54 and Ala58-Leu59.  The 
absence of processed CRSC4 peptides in MMP-7 
knockout mice demonstrates the in vivo activation of 
CRS4C by MMP-7 (Shanahan et al., 2010).   
Besides activation of antimicrobial peptides, it was 
recently discovered that MMPs may function as 
antimicrobial agents themselves.  A recent study showed 
that MMP-12 possesses antimicrobial activities that do 
not require the catalytical domain, but reside in the 
COOH-terminal hemopexin domain.  The hemopexin 
domain of MMP-12 inhibited the growth of various 
bacterial strains in vitro.  The origin of bactericidal 
activity was narrowed down to a unique four amino acid 
sequence of acidic amino acids flanked by basic residues 
(e.g. Lys348-Asp-Asp-Lys in human MMP-12) present 
on an exposed β loop of the protein.  This sequence is 
homologous in rabbit, rat, mouse and human MMP-12, 
but is not present in any other MMP.  MMP-12-deficient 
mice exhibited impaired bacterial clearance and increased 
mortality when challenged with both Gram-negative and 
Gram-positive bacteria at macrophage-rich portals of 
entry, such as the peritoneum and the lung.  After 
engulfment of bacteria by macrophages, intracellular 
stores of MMP-12 were mobilized to macrophage 
phagolysosomes, as determined by immunogold electron 
microscopy.  Once inside phagolysosomes, MMP-12 
adhered to bacterial cell walls and used its antimicrobial 
peptide to kill the bacteria by disruption of the cell 
membranes (Houghton et al., 2009).  Strictu sensu, in this 
case no evidence is provided for a host cell substrate 
conversion, but instead MMP-12 hemopexin domain 
binds to and kills micro-organisms by a non-catalytical 
function. 
 
In conclusion, both catalytical and non-catalytical 
actions of MMPs inside cells may contribute to the 
host’s innate immune defense against microorganisms. 
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3.3.2 Intracellular proteolysis in cancer 
Extracellular proteolysis by MMPs has conflicting 
effects on cancer cell differentiation, proliferation, escape 
from apoptosis and immune surveillance, migration and 
invasion, and tumor angiogenesis.  Depending on the 
substrates, as well as on the specific stage of cancer cell 
progression, the same MMP may exert a cancer-
promoting or -limiting function  (Egeblad and Werb, 
2002; Cauwe et al., 2007).  The stepwise progression 
from an early dysplastic lesion to full-blown metastatic 
malignancy is associated with increases in genomic 
instability (Vogelstein and Kinzler, 2004).  Chromosome 
instability, the inability to correctly segregate sister 
chromatids during mitosis (leading to an abnormal 
chromosome number termed aneuploidy), is thought to 
initiate and propagate malignant transformation 
(Schvartzman et al., 2010).  Dysruption of centrosome 
structure is an integral aspect of the origin of 
chromosomal instability in many cancers.  Centrosomes 
nucleate and organize microtubules and form spindle 
poles during mitosis.  In normal cells, the centrosome is 
usually composed of a pair of barrel-shaped structures, 
the centrioles, which are embedded in a lattice-like 
pericentriolar material (Zyss and Gergely, 2009).  As 
discussed before, cell surface-associated MT1-MMP is 
internalized by endocytosis, and microtubular trafficking 
causes the protease to accumulate in the centrosomal and 
pericentrosomal compartment (Remacle et al., 2003; 
Remacle et al., 2005).  MT1-MMP expression is 
associated with tumor progression and metastasis and is 
implicated both in the breaching of basement membranes 
by tumor cells and invasion of the ECM.  In addition, 
MT1-MMP activates soluble MMPs, cleaves adhesion 
and signaling receptors and acts as a tumor growth factor 
(Poincloux et al., 2009).  Besides these extracellular 
invasion-promoting functions, MT1-MMP was shown to 
have an intracellular oncogenic function by cleaving the 
integral centrosomal protein, pericentrin, at Gly672-
Leu673 and Gly1156-Leu1157 (Golubkov et al., 2005a; 
Golubkov et al., 2005b).  Pericentrin and pericentrin-2 
(pericentrin-B or kendrin) are derived from splice 
variants of the same gene and are known to be essential 
for normal centrosome function by the anchorage of the 
γ-tubulin ring complex - that initiates microtubule 
nucleation -  to the centrosome (Takahashi et al., 2002).  
Normal epithelial cells transfected with MT1-MMP 
acquired the ability to activate MMP-2, to cleave 
pericentrin and to invade a Matrigel matrix.  These events 
were associated with aberrations in chromosome 
segregation, up-regulation of gene expression of multiple 
oncogenic genes, aneuploidy and transformation of non-
malignant human mammary epithelial cells.  Indeed, 
MT1-MMP-expressing human epithelial cells were 
efficient at generating tumors in the orthotopic xenograft 
model in immunodeficient mice.  However, the tumors 
regressed because of insufficient host angiogenic 
response and inadequate neovascularization, also in line 
with the lack of upregulation of pro-angiogenic gene 
expression.  Both human and canine pericentrin peptides 
are cleaved by MT1-MMP in vitro, the latter at the 
Ser2068-Leu2069 peptide bond.  However, murine 
pericentrin is resistant to cleavage because of an Asp 
residue at the P1 position (cf. Figure 4) instead of Ser or 
Gly.  In addition, tumor biopsies showed proteolytic 
pericentrin fragments in association with high levels of 
activated MT1-MMP, whereas normal tissues contained 
intact pericentrin.  Hence, the intracellular proteolysis of 
pericentrin by MT1-MMP may have an important role in 
the generation of chromosome instability and malignant 
transformation (Golubkov et al., 2006; Golubkov et al., 
2005b; Golubkov et al., 2005a). 
Once tumor cells have acquired invasive capacities, 
polarized motility is governed by the organization of a 
leading edge in the direction of cell movement.   Cell 
motility requires molecular processes at the cell surface 
in which contacts between the invading tumor cell and 
the surrounding cells and stroma are repeatedly broken 
(anti-adhesion) and new contacts are established as the 
tumor cell moves forward (adhesion). Hence, the leading 
edge is stabilized by the formation of new focal 
adhesions or cell-ECM contact sites.  Besides its 
pericellular proteolytic functions, MT1-MMP also seems 
to affect tumor cell migration by perturbation of focal 
adhesions.  Indeed, in vascular smooth muscle cells, 
overexpression of MT1-MMP (and MT3-MMP) results 
in cell rounding, decreased adherence and increased 
migration (Shofuda et al., 2001).  These events were 
associated with a decreased number of focal contacts 
with integrin-mediated adhesion, whereas the cell surface 
expression of integrin subunits remained unchanged, 
excluding their cleavage by MT1-MMP.  However, MT1-
MMP overexpression resulted in the cleavage of the 125 
kDa focal adhesion kinase (FAK, pp125FAK, protein-
tyrosine kinase 2) into a 90 kDa NH2-terminal fragment 
(Shofuda et al., 2004).  FAK is a cytoplasmic protein-
tyrosine kinase recruited to and activated at focal 
adhesion sites and is especially important for the 
connection of ECM-integrin complexes with downstream 
signaling molecules and actin stress fibers (Tomar and 
Schlaepfer, 2009).  FAK cleavage was associated with 
partial dissociation of paxillin from the integrin-FAK 
complex and both events were inhibited by the 
metalloproteinase inhibitor BB94.  Paxillin is another 
important cytoskeletal and scaffolding protein recruited 
early to focal adhesions (Tomar and Schlaepfer, 2009).  
Loss of the FAK/paxillin interaction may be a major 
contributing factor in the reduced organization of focal 
adhesions and actin filaments, resulting in decreased 
integrin-mediated cell adhesion observed in cells 
overexpressing MT1-MMP.  Cleavage of FAK may be 
induced by MT1-MMP through an indirect mechanism, 
since calpains, caspases and granzyme B were also 
shown to proteolyse FAK (Carragher et al., 1999; Wen et 
al., 1997; Gervais et al., 1998).  However, as MT1-MMP 
was already mentioned to have an intracellular cleavage 
function in tumor cells, and both MT1-MMP and MT3-
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MMP were found in the cytoskeletal fraction of vascular 
smooth muscle cells (Shofuda et al., 2004), it is very 
likely that FAK is a direct intracellular target of MT1-
MMP.  Interestingly, viral Src kinase-transformed cells 
activate a FAK-dependent mechanism that attenuates 
endocytosis of MT1-MMP (cf. 3.2.1).  This in turn 
increases cell-surface expression of MT1-MMP and 
pericellular degradation of the ECM (Wu et al., 2005).  
Hence, intracellular cleavage of FAK by MT1-MMP may 
be a way to loosen focal adhesions, permitting the cell to 
detach for further migration, and at the same time it may 
enhance endocytosis of MT1-MMP at the rear end for 
recycling and relocalization at the leading edge.  In this 
context, a membrane flip-flop of MT1-MMP, as 
suggested in section 3.2.1, would allow MT1-MMP to 
cleave FAK and other cytoskeletal substrates at the focal 
adhesion (cf. Tables 3 and 5). 
Altogether, this may suggest a bimodal role for 
MT1-MMP in cancer progression. The early function 
of MT1-MMP takes place inside cells and promotes 
malignant transformation.  When the cells have 
acquired invasive capacity, MT1-MMP is delivered to 
the surface of invadipodia where it assists in the 
proteolysis of a path for the migrating cell.  After 
migration the intracellular cleavage of FAK may 
loosen focal adhesions at the rear end and recycle 
MT1-MMP to the novel invadipodia.  Hence, MT1-
MMP is not just a protease that supports tumor growth 
and metastasis, but it also functions as an oncogene 
that promotes chromosome instability and malignant 
transformation of normal cells at the early stages of the 
transition to malignancy (Golubkov and Strongin, 
2007).  Clinical trials with MMP inhibitors for the 
treatment of metastatic cancer have generally failed 
(Coussens et al., 2002).  Indeed, the beneficial effects 
of MT1-MMP inhibition in animal models of cancer 
may be explained in part by the absence of these 
oncogenic functions, which will not be the case for 
MMP inhibition in late-stage cancer trials. 
Besides its actions in the centrosomal compartment 
and at focal adhesions, activated MT1-MMP is also 
detected in the nuclei of hepatocellular carcinoma cells 
(cf. 3.2.6).  Of interest, cancer patients with nuclear 
MT1-MMP (and co-localized MMP-2) have a poor 
overall survival and large tumor size, whereas MT1-
MMP is not found in nuclei of the normal paralleled 
liver tissues and normal control livers (Ip et al., 2007).  
Since the protein composition of the nuclear matrix is 
altered in cancer cells (Zink et al., 2004), it is tempting 
to speculate that MT1-MMP, MMP-2 and other 
nuclear MMPs (cf. 3.2.6) may contribute to the 
degradation of nuclear matrix proteins.  Firm proof-of-
principle is not available but specific proteins in the 
nuclear matrix, e.g. fibronectin, are known 
extracellular substrates of MMPs. 
Another MMP that may affect cancer progression 
by its nuclear function is MMP-3.  As mentioned in 
section 3.2.6 and Table 4, activated MMP-3 was found 
in the nuclei of cultured chondrocytes, in normal and 
osteoarthritic chondrocytes (Eguchi et al., 2008), in the 
nuclei of dopaminergic neurons (Choi et al., 2008) and 
hepatocytes (Si-Tayeb et al., 2006).  In the latter two 
studies, nuclear MMP-3 was found to promote 
apoptosis, which will be discussed in 1.4.5.  In 
chondrocytes, nuclear MMP-3 interacts with the 
transcription enhancer dominant in chondrocytes 
(TRENDIC) in the connective tissue growth factor 
(CTGF) gene promoter and activates CTGF gene 
transcription.  Of interest, both the catalytical domain 
and the hemopexin domain can activate the CTGF 
promoter independently (Eguchi et al., 2008).  CTGF 
(hypertrophic chondrocyte-specific protein 24, insulin-
like growth factor-binding protein 8, CCN family 
member 2) is a member of the CCN family of secreted, 
matrix-associated proteins encoded by immediate early 
genes that play various roles in angiogenesis and tumor 
growth (Chu et al., 2008).  CCN stands for cysteine-
rich 61, connective tissue growth factor and 
nephroblastoma overexpressed.  CTGF is a 
multifunctional signaling modulator involved in a wide 
variety of biological and pathological processes such 
as angiogenesis, osteogenesis, renal disease, skin 
disorders and tumor development.  Hence, MMP-3-
induced transcription of CTGF in chondrocytes may be 
involved in matrix diseases, e.g. osteoarthritis and 
rheumatoid arthritis, and in fibrotic diseases, such as 
systemic sclerosis and atherosclerosis (Eguchi et al., 
2008).  CTGF regulates cancer cell migration, 
invasion, angiogenesis and anoikis.  Although CTGF 
expression is mostly associated with progression of 
many kinds of cancers, its role may vary considerably, 
depending on the tissue involved (Chu et al., 2008).  
CTGF in turn induces increased transcription of the 
MMP-1,-2,-3,-7,-9 and MT1-MMP genes, but reduces 
transcription of TIMP-1 and TIMP-2 (Kondo et al., 
2002; Chen et al., 2001a), which may then result in a 
positive feedback loop in angiogenesis and tumor 
progression.  In addition, CTGF is cleaved by MMP-
1,-2,-3,-7,-13 and MT1-MMP (Hashimoto et al., 2002; 
Butler et al., 2008; Dean et al., 2007; Dean and 
Overall, 2007), which may terminate the amplification 
loop.  
Angiogenesis is an important mechanism in tumor 
biology.  MMPs, and MMP-9 in particular, are 
involved in various aspects of the angiogenic switch 
(Hanahan and Weinberg, 2000) and in the angiogenic 
process (Ardi et al., 2007; Deryugina and Quigley, 
2010).  So far, most validated substrates, e.g. CTGF, 
are extracellular proteins.  A considerable amount of 
putative intracellular substrates of MMPs are linked to 
endothelial cell function (cf. Tables 3 and 5).  
However, the biological relevance of the cleavage of 
these intracellular proteins in the process of 
angiogenesis needs further exploration. 
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In contrast with these tumor-promoting functions of 
intracellular MMPs, MMP-26 may have antitumor 
properties inside breast cancer cells.  MMP-26 is 
characterized by an unorthodox, autolytic activation 
mechanism (cf. 1.1) and accumulates primarily inside 
cells, as only a small fraction of the enzyme is secreted 
into the extracellular milieu (Strongin, 2006).  In 
contrast to other MMPs, the promoter of the MMP-26 
gene includes the estrogen-response element (ERE). 
The estrogen-estrogen receptor (ER) complex 
stimulates the transcriptional activity of the MMP-26 
gene promoter in hormone-regulated carcinomas via 
binding of the ERE motif (Li et al., 2004).  
Interestingly, estrogen receptor β (ERβ, nuclear 
receptor subfamily 3 group A member 2) is susceptible 
to proteolysis by MMP-26, whereas ERα is resistant.  
MMP-26 targets the NH2-terminal region of ERβ 
coding for the divergent NH2-terminal A/B domain 
that is responsible for the ligand-independent 
transactivation function in vitro.  In breast carcinoma 
specimens, the ERα-dependent expression of MMP-26 
correlated inversely with the residual levels of intact 
ERβ in the cytoplasm, as determined by 
immunohistochemical analysis.  The levels of MMP-
26 are low in the normal mammary epithelium but are 
strongly upregulated in ductal carcinoma in situ 
(DCIS).  However, during further disease progression 
the expression of MMP-26 decreases again. In contrast 
with many tumor-promoting MMPs, the expression of 
MMP-26 in DCIS is correlated with a longer overall 
patient survival (Savinov et al., 2006). 
On the contrary, activation of pro-MMP-9 by 
MMP-26 promotes invasion of human prostate cancer 
cells (Zhao et al., 2003).  Activated forms of MMP-9 
were shown to accumulate in the cytosol of basal and 
phorbol PMA-stimulated human endothelial cells.  
Whereas MMP-9 was found complexed to TIMP-1 in 
the conditioned medium, it existed as a free enzyme in 
membrane-bound vesicles that were especially 
prominent at the invadipodia (as determined with 
immunogold electron microscopy).  In contrast, TIMP-
1 was spread more diffusely throughout the cytoplasm, 
occasionally present in small vesicles but never in the 
MMP-9-containing vesicles (Nguyen et al., 1998).  
Both MMP-3, which was also detected in the 
cytoplasm, and self-activated MMP-26 may act as 
activators for the intracellular pro-MMP-9 (cf. 1.1).  
Storage of intracellularly activated MMP-9, ready for 
rapid release, may facilitate invasion and migration of 
cancer cells.  
Finally, MMP-1 was found to be strongly 
associated with mitochondrial membranes (cf. 3.2.5) 
and nuclei and accumulated within cells during the 
mitotic phase of the cell cycle.  The intracellular 
association of MMP-1 to mitochondria and nuclei 
conferred resistance to apoptosis (vide infra), which 
may be a mechanism for tumor cells to escape from 
apoptosis (Limb et al., 2005). 
3.3.3 Intracellular proteolysis in cardiac 
disease 
Heart failure is a common cause of morbidity and 
mortality with a high incidence in developed countries. 
Approximately every 25 seconds, an American will 
have a cardiac event, and approximately every minute, 
someone will die of one (Lloyd-Jones et al., 2010). 
Following cardiovascular stress, a cascade of 
compensatory structural events occurs within the 
myocardium and contributes to eventual left 
ventricular dysfunction and the manifestation of heart 
failure syndrome. MMPs have been extensively 
studied in various cardiac pathologies such as 
ischemia-reperfusion (I/R), dilated cardiomyopathy 
(DCM) and myocardial infarct (MI) (Janssens and 
Lijnen, 2006; Spinale, 2007; Brauer, 2006; Creemers et 
al., 2001). Myocardial ischemia either with or without 
reperfusion induces ROS and pro-inflammatory 
cytokines. These reactive molecules are 
cardiodepressant through impairment of Ca2+ 
homeostasis. ROS can induce intracellular Ca2+ 
overload during oxidative stress.  In addition, ROS 
directly injure the cell membrane and disturb the 
integrity of proteins, lipids and DNA, causing cell 
death (Hori and Nishida, 2009).  However, low 
concentrations of specific ROS, such as peroxynitrite, 
may directly activate the zymogen forms of MMPs, as 
detailed in 1.2.  In addition, MMPs may be activated 
by caspases after myocardial infarction (cf. 1.1). 
During the last decade, Schulz and colleagues have 
accumulated a considerable amount of evidence on the 
intracellular localization and acute actions of MMPs, 
particularly MMP-2, in the heart.  In contrast with 
most researchers, who have focused on the long term 
proteolytic effects of MMPs on ECM remodeling, they 
showed that MMP-2 contributes to acute cardiac 
mechanical dysfunction before the development of 
changes in the collagen matrix (Chow et al., 2007b; 
Kandasamy et al., 2010; Ali and Schulz, 2009; Schulz, 
2007).  Indeed, already after 20 minutes of global no-
flow ischemia in the rat, a marked increase in pro-
MMP-2 was observed in the coronary effluent that 
peaked within the first minute of reperfusion.  The 
levels of pro-MMP-2 correlated positively with the 
duration of ischemia and negatively with the recovery 
of mechanical function.  Contractile dysfunction 
associated with the induced I/R improved with a 
neutralizing MMP-2 antibody and with general MMP 
inhibitors (doxycycline and 1,10-phenantroline (O-
phen)) (Cheung et al., 2000). 
Heart failure is characterized by a general decline in 
pump function caused by a decline in contractile 
properties of the cardiac myocytes. Myocardial 
contraction is initiated upon the release of Ca2+ into the 
cytosol from the sarcoplasmic reticulum following 
membrane depolarization.  Thin filament activation 
and relaxation dynamics have emerged as a pivotal 
regulatory system tuning myofilament function to the 
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beat-to-beat regulation of cardiac output.  Perturbation 
of thin filament dynamics is now recognized as an 
important cellular mechanism causing reduced cardiac 
pump function in a variety of cardiac diseases 
(Kobayashi et al., 2008).  I/R injury in the heart is 
associated with degradation or loss of myofilament 
regulatory proteins as well as structural and 
cytoskeletal proteins (Hein et al., 1995; Matsumura et 
al., 1996).   
 
 
 
 
Figure 5. Intracellular proteolysis by MMPs in cardiac disease.  MMPs may cause direct contractile dysfunction by the 
proteolysis of major sarcomeric proteins such as troponin I (TnI), myosin light chain (MLC) and myosin heavy chain (MHC).  
Intracardiomyocyte proteolysis by MMPs in cardiac injury also results in loss of cytoskeletal proteins, including α-actinin and 
desmin, and its chaperone, αB-crystallin (αB-crys).  Proteolysis of connexin-43 (Cx43) leads to adverse electrical changes, 
probably by perturbation of the Cx43/zona occludens-1 (ZO-1) interaction.  Under nitrosative stress, Cx43 translocates to the 
mitochondria, where its degradation leads to mitophagy and cell death, which may be ameliorated by cleavage of the N-methyl-
D-aspartate receptor-1 (NMDA-R1).  Proteolysis of glycogen synthase kinase-3β (GSK-3β) enhances its pro-apoptotic capacities 
and degradation of PARP in the nucleus also leads to enhanced apoptosis and cardiomyocyte death. 
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By immunogold electron microscopy, confocal 
microscopy, immunoprecipitation experiments and 
zymographic analysis of highly purified thin 
myofilament preparations, MMP-2 was localized to 
sarcomeres in close association with the thin 
myofilaments in hearts subjected to I/R (Wang et al., 
2002b).  The thin filament is composed of F-actin 
together with two tropomyosin strands, each binding a 
troponin (Tn) complex (Figure 5).  Tropomyosin and 
the Tn complex, composed of three subunits: troponin 
C (TnC) , I (TnI) and T (TnT), regulate the affinity of 
F-actin towards myosin.  In resting conditions (absence 
of Ca2+), TnI inhibits myosin cross-bridge formation to 
actin, and concomitant generation of myocardial force, 
via interactions with TnT and tropomyosin (Kobayashi 
et al., 2008). Activated MMP-2 was found to co-
localize with TnI (troponin I) and to rapidly degrade 
TnI in vitro.  Inhibition of MMP-2 activity with 
doxycycline and O-phen prevented I/R-induced TnI 
degradation and improved the recovery of the 
mechanical function of isolated rat hearts.  
Importantly, no significant myocardial necrosis was 
observed, as TnI and its degradation products were not 
found in the coronary effluent, an additional proof of 
the intracellular localization of MMP-2 action (Wang 
et al., 2002b).  This was confirmed in another model of 
myocardial contractile failure, in which the pro-
inflammatory cytokines tumor necrosis factor-α (TNF-
α), interleukin-1β (IL-1β) and interferon-γ (IFN-γ) 
depressed myocardial contractile function by 
enhancing peroxynitrite production.  MMP-2 activity 
was increased before the decline in myocardial 
mechanical function and this was followed by 
decreased levels of TnI in the cytokine-treated hearts, 
which was prevented by a neutralizing anti-MMP-2 
antibody (Gao et al., 2003).  However, these 
neutralization experiments imply that the anti-MMP-2 
antibody enters the intracellular milieu, for example by 
endocytosis, or that the binding and neutralization of 
MMP-2 occurs extracellularly and impedes the entry of 
MMP-2 in the myocyte. 
Using 2D-PAGE, Schulz and colleagues found that 
myosin light chain (MLC-1) was degraded in hearts 
subjected to I/R injury and that this proteolytic process 
was inhibited with MMP inhibitors (Doxycycline and 
O-phen).  Activated forms of MMP-2 were found in rat 
heart preparations of thick myofilaments, and by 
immunogold microscopy analysis, MMP-2 was 
localized in the sarcomere in a pattern consistent with 
the known distribution of MLC-1 (cf. Figure 5).  In 
addition, purified MLC-1 was susceptible to MMP-2 
(but not MMP-9) proteolysis in vitro (Sawicki et al., 
2005).  Of interest, a different localization of the two 
gelatinases, MMP-2 and MMP-9, was observed in 
hearts of patients with dilated cardiomyopathy (DCM) 
compared to control hearts.  In DCM hearts the 
gelatinases were localized exclusively within the 
cardiomyocytes in close association with the 
sarcomeric structure, whereas localization was mainly 
around the myocytes in control hearts.  MMP-9, and to 
a lesser extent, MMP-2, cleaved purified myosin heavy 
chain (MHC) in vitro (cf. Figure 5) (Rouet-Benzineb et 
al., 1999).  Hence, MMPs may cleave both regulatory 
and structural elements that generate myocardial force, 
leading to mechanical dysfunction and heart failure.   
This phenomenon may be enhanced by an 
imbalance between MMPs and TIMPs during cardiac 
injury.  Indeed, during I/R in isolated rat hearts, TIMP-
4 - the most abundant TIMP in the heart - was also 
rapidly released in the coronary effluent, as shown by 
reverse zymography and Western blot analysis.  By 
immunogold microscopy analysis a close association 
of TIMP-4 with sarcomeres was demonstrated in 
aerobically perfused rat hearts, whereas this pattern of 
positive staining was reduced in I/R hearts.  Although 
both MMP-2 and TIMP-4 were released into the 
extracellular milieu during reperfusion, a net 
proteolytic balance in hearts exposed to I/R was shown 
by in situ zymography of heart sections.  These data 
suggest that TIMP-4 plays an important homeostatic 
role in the normal myocardium and that its release 
from the cardiomyocytes contributes to myocardial I/R 
injury (Schulze et al., 2003).  Likewise, all TIMPs 
were downregulated in DCM hearts, especially TIMP-
1 (Rouet-Benzineb et al., 1999), further pointing to the 
participation of MMP/TIMP imbalances in cardiac 
diseases. 
As mentioned before, I/R injury is also associated 
with the degradation of cytoskeletal proteins such as α-
actinin, desmin and spectrin (Matsumura et al., 1996).  
This may constitute an additional intracellular function 
of MMP-2, as α-actinin and desmin (but not spectrin) 
were found to be in vitro substrates of MMP-2 (cf. 
Figure 5). α-actinin (α-actinin cytoskeletal isoform, 
non-muscle α-actinin-1, F-actin cross-linking protein) 
is an actin-binding protein. It forms an anti-parallel 
rodshaped dimer with one actin-binding domain at 
each end of the rod and bundles actin filaments in 
multiple cytoskeletal frameworks. Besides binding to 
actin filaments, α-actinin associates with a number of 
cytoskeletal and signaling molecules, for instance, 
cytoplasmic domains of transmembrane receptors and 
ion channels.  Thus, α-actinin exerts major structural 
and regulatory roles in cytoskeletal organization and 
muscle contraction (Sjoblom et al., 2008).  Desmin is 
the main intermediate filament protein expressed in 
cardiac, skeletal, and smooth muscle cells. It interacts 
with other proteins to form a continuous cytoskeletal 
network that maintains a spatial relationship between 
the contractile apparatus and other structural elements 
of the cell, thus providing maintenance of cellular 
integrity, force transmission, and mechanochemical 
signaling.  Mutations in desmin and in αB-crystallin 
(αB-crys), a chaperone for desmin and another MMP 
substrate (vide infra), lead to desminopathy, a 
myofibrillar myopathy (Goldfarb and Dalakas, 2009).  
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Peroxynitrite infusion into isolated rat hearts caused a 
decline in mechanical function and activation of MMP-
2 with concomitant loss of intact α-actinin (but not 
desmin), which was prevented by an MMP inhibitor 
(PD-166793) or the peroxynitrite scavenger reduced 
glutathione (GSH).  In addition, MMP-2 was found to 
co-localize with α-actinin in cardiomyocytes.  Hence, 
these results suggest yet another contribution of MMP-
2 to cardiac dysfunction by mediating cytoskeletal 
disorganization (Sung et al., 2007). 
In the heart, electrical stimulation readily spreads 
via direct cell-to-cell communication mediated by low 
resistance gap junction channels composed of proteins 
termed connexins, such that all myocytes contract in an 
ultra-fast wave at each beat.  Hence, connexin channels 
ensure propagation of molecular and electrical signals 
and are crucial in myocardial synchronization and 
heart function (Tribulova et al., 2008).  Induction of 
myocardial infarct (MI) in MMP-7 knockout mice 
resulted in increased early survival and favorable 
alterations in electrical conduction patterns compared 
with wildtype mice.  In wildtype mice, slower 
conduction velocity correlated with a 53% reduction in 
the gap junction protein connexin-43 (Cx43, gap 
junction 43 kDa heart protein, gap junction α-1 
protein), which is the predominant connexin isoform in 
atrial as well as ventricular tissues.  Because 
myocardial conduction patterns were altered, along 
with changes in gap junction proteins, the contributing 
factor for differences in survival was likely an 
alteration in electrical conduction due to MMP-7 
genetic deletion.  Surface plasmon resonance 
experiments revealed that MMP-7 binds to Cx43, and 
further in vitro analyses determined that MMP-7 
cleaves Cx43 in the cytoplasmic COOH-terminal tail 
(cf. Figure 5).  Infusion of MMP-7 induced Cx43 
degradation and resulted in arrhythmias and heart 
block in vivo (Lindsey et al., 2006).  COOH-terminal 
truncation of Cx43 will abolish interaction with other 
proteins, such as zona occludens-1 (ZO-1), which was 
reported to have striking effects on gap junction size 
and distribution (Hunter et al., 2005) and may 
contribute to the negative influence of MMP-7 on 
electrical conduction.  Of interest, ZO-1 is an MMP-9 
substrate (vide infra), which suggests that both MMPs 
may synergize in the perturbation of the Cx43/ZO-1 
interaction, leading to adverse electrical changes and 
decreased survival after MI. 
The mitochondria constitute yet another subcellular 
location wherefrom MMPs may disturb cardiac 
contractility.  Both MMP-2 (Wang et al., 2002b; Kwan 
et al., 2004) and MMP-9 (Moshal et al., 2008) are 
found in cardiac mitochondria.  Elevated levels of 
blood homocysteine (HCY) (termed 
hyperhomocysteinemia) induced expression of MMP-9 
in the mitochondrial compartment and induced 
mitochondrial permeability transition and contractile 
dysfunction, which was reversed by various 
compounds, including an inhibitor of the 
cardiomyocyte N-methyl-D-aspartate receptor-1 
(NMDA-R1) (MK-801), a general MMP inhibitor 
(GM6001) and cyclosporine A. The intramitochondrial 
nitrosative stress induced by HCY in cardiomyocytes 
was associated with an increased translocation of Cx43 
to the mitochondria and degradation of Cx43, and led 
to ‘mitophagy’ (mitochondrial autophagy) and cell 
death.  This suggests that MMP-9 or another MMP 
may degrade Cx43 in the mitochondria and cause 
contractile dysfunction in hyperhomocysteinemia.  
These effects were ameliorated by cardiac-specific 
deletion of NMDA-R1 (Tyagi et al., 2010).  
Interestingly, MMP-7 cleaves neuronal NMDA-R1 in 
the extracellular ligand-binding domain and this 
impairs NMDA-stimulated Ca2+ flux (Szklarczyk et 
al., 2008).  Hence, extracellular action of MMP-7 may 
be cardioprotective, whereas intracardiomyocyte 
cleavage of Cx43 by MMP-7 may cause heart failure, 
complicating the use of MMP inhibitors in cardiac 
disease. 
In conditions of stress, cardiomyocytes mount an 
adaptive response that attempts to normalize 
ventricular wall stress and maintain cardiac output.  
Prolonged stress overwhelms this protective response 
and leads to cardiomyocyte apoptosis and heart failure.   
Glycogen synthase kinase-3β (GSK-3β) is a 
multifunctional Ser/Thr kinase that plays important 
roles in necrosis and apoptosis of cardiomyocytes.  A 
major mechanism of cell necrosis is the opening of the 
mitochondrial permeability transition pore (mPTP). 
The threshold for mPTP opening is elevated by 
phosphorylation of GSK-3β at Ser9, which reduces 
activity of this kinase.  In addition, inhibition of GSK-
3β suppresses ATP hydrolysis by reducing ATP 
transport from the cytosol to the mitochondria.  This 
prevents both ATP depletion and accumulation of 
inorganic phosphate, two factors promoting mPTP 
opening.  Although the role of GSK-3β in apoptosis of 
cardiomyocytes has not been fully clarified, evidence 
to date supports its significant contribution to apoptosis 
induced by I/R, hypoxia/re-oxygenation, β-
adrenoreceptor activation and pressure overload 
(Miura and Miki, 2009).  GSK-3β was cleaved upon 
incubation with MMP-2 and this proteolytic cleavage 
of GSK-3β increased its activity.  H2O2 challenge of 
H9c2 cardiomyoblasts increased the activity and level 
of MMP-2, reduced the level of GSK-3β and increased 
GSK-3β kinase activity.  Both effects on GSK-3β were 
reduced by MMP inhibitors (GM6001 and ONO-
4187).  In addition, MMP-2 pull-down assays from 
H9c2 cell lysates showed the binding of MMP-2 with 
GSK-3β (Kandasamy and Schulz, 2009).  Since 
inhibition of GSK-3β is cardioprotective for many 
reasons (Miura and Miki, 2009), augmentation of its 
activity may be an additional way of MMP-2 to 
contribute to cardiac injury resulting from enhanced 
oxidative stress.  Interestingly, MMP-2 cleaves another 
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molecule that causes ATP depletion during oxidative 
stress, i.e. nuclear poly(ADP-ribose)polymerase 
(PARP, NAD+ ADP-ribosyltransferase 1, poly(ADP-
ribose) synthetase 1).  PARP is a DNA repair enzyme.  
It is activated by DNA strand breaks, which may be 
caused by oxidative stress (Ahmad et al., 2009).  Both 
MMP-2 and MMP-9 were found in nuclear extracts of 
cardiomyocytes and hepatocytes (cf. Figure 5). MMP-2 
was immunoprecipitated from nuclear extracts of heart 
cells with anti-PARP antibody and degraded PARP in 
vitro (Kwan et al., 2004).  Inhibitors of PARP have 
been shown to have a protective effect in cardiac injury 
(Pacher et al., 2005).  Mild damage to DNA activates 
the DNA repair machinery.  In contrast, once excessive 
oxidative and nitrosative stress-induced DNA damage 
occurs, as in various forms of myocardial reperfusion 
injury and heart failure, overactivated PARP initiates 
an energy-consuming cycle by transferring ADP-ribose 
units from NAD+ to nuclear proteins, resulting in rapid 
depletion of the intracellular NAD+ and ATP pools, 
slowing the rate of glycolysis and mitochondrial 
oxidative phosphorylation (the generation of ATP), 
and eventually leading to cellular dysfunction and 
death.  In addition, PARP also regulates the expression 
of a variety of pro-inflammatory mediators, which 
might facilitate the progression to heart failure.  Hence, 
Schulz and colleagues suggest that nuclear MMP-2 
may play a protective role during oxidative stress by 
proteolytic removal of the activated PARP overload 
(Schulz, 2007).  This means that besides contrasting 
extracellular vs. intracellular functions (cf. MMP-7, 
vide supra), MMPs may also have opposed roles 
depending on their subcellular location.  
In conclusion, MMP activities are detected in all 
subcellular compartments of the cardiomyocyte (cf. 
Figure 5) and generally contribute to dysfunction of the 
contractile apparatus and adverse electrical conduction 
after cardiac injury.  Therapeutic intervention by MMP 
inhibition thus seems promising. However, as some 
subcellular MMP functions may be cardioprotective, 
adverse effects may be inevitable without the use of 
subcellular compartment-specific inhibitors.  
 
3.3.4 Intracellular proteolysis in acute and 
chronic neurodegenerative diseases 
Within seconds to minutes after the loss of blood 
flow to a region of the brain, the ischemic cascade is 
rapidly initiated and comprises a series of successive 
biochemical events.  Hypoperfusion of a brain area 
leads to oxidative damage and excitotoxicity, which is 
the process by which neurons are damaged and killed 
via the overactivation of receptors for the excitatory 
neurotransmitter glutamate, such as the N-methyl-D-
aspartate receptor-1 (NMDA-R1) and the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPA-R) receptor. Oxidative stress and 
excitotoxicity in turn cause microvascular injury, 
blood-brain barrier (BBB) dysfunction and post-
ischemic inflammation, ultimately resulting in cell 
death of neurons, glia and endothelial cells.  These 
events exacerbate the initial injury and may lead to 
permanent cerebral damage, the extent of which is 
dependent on the degree and duration of ischemia 
(Lakhan et al., 2009; Lee et al., 2004b).  The 
extracellular participation of MMPs in cerebral 
ischemia has been well documented.  MMPs cause the 
increase in permeability of the BBB by attacking the 
endothelial cell tight junctions (TJs) and the basal 
lamina’s, i.e. the subendothelial and the parenchymal 
basement membranes (Agrawal et al., 2006), resulting 
in the final common pathway downstream of acute 
neuroinflammatory damage. When acute hypoxia–
ischemia initiates the cellular damage, MMPs target 
the matrix proteins around blood vessels and brain 
cells, resulting in cytotoxic and vasogenic edema, 
hemorrhagic transformation, and apoptosis of neurons 
and oligodendrocytes (Candelario-Jalil et al., 2009; 
Rosenberg, 2009; Cauwe et al., 2007). 
The BBB is a diffusion barrier, consisting of an 
interdependent network of cells designed to segregate 
the central nervous system (CNS) from the systemic 
circulation. One of the primary functions of the BBB is 
the strict regulation of paracellular permeability, which 
is mediated by the endothelial tight junctions (TJs) of 
the capillary that limit paracellular movement of 
solutes, ions, and water.  The preservation of the TJs is 
governed by three essential transmembrane proteins: 
claudins, occludin, and junction adhesion molecules 
(cf. Figure 6).  The cytoplasmic regions of these 
transmembrane proteins are attached to intracellular 
scaffolding proteins, such as zona occludens-1,-2 and -
3 and cingulin, which in turn are anchored to the actin 
cytoskeleton.  Treatment of brain endothelial cells with 
activated MMP-9 resulted in an increased frequency of 
discontinuities in the immunohistological staining of 
zona occludens-1 (ZO-1, tight junction protein 1) and a 
consistent decrease in the intensity of ZO-1 expression 
(Harkness et al., 2000).  ZO-1 was degraded in vivo 
during transient and permanent focal ischemia and this 
was attenuated with MMP inhibitors (BB-94 and KB-
R7785) (Jiang et al., 2001b; Asahi et al., 2000; Bauer 
et al., 2010b) and in MMP-9 knockout mice, with 
concomitant reduction of BBB disruption and infarct 
size (Asahi et al., 2001).  Degradation of ZO-1 was 
also observed after treatment of rat brain endothelial 
cells with activated MMP-13 (Lu et al., 2009).  
However, since ZO-1 is a cytoplasmic protein, 
degradation must occur intracellularly by cytoplasmic 
proteases. Indeed, cerebral ischemia and hypoxia 
increased both MMP-9 expression and activation in 
brain endothelial cells (Bauer et al., 2010a; Asahi et 
al., 2000), suggesting that endogenous intracellular 
MMP-9 cleaves ZO-1.  However, hypoxic conditioned 
medium of astrocytes (with upregulated levels of 
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MMP-2, -9 and -13) also induced ZO-1 cleavage in 
brain endothelial cells, which was reversed with 
neutralizing antibodies against MMP-9 and MMP-13.  
Hence, alternative explanations are that extracellular 
MMPs trigger ZO-1 cleavage indirectly, or that MMPs 
are internalized, for example by endocytic mechanisms 
as discussed in 3.2.1. 
The aberrant, excessive activity of extracellular 
MMPs contributes directly to neuronal cell death in 
multiple ways, including modulation of anoikis (Gu et 
al., 2002) and calpain activity (Copin et al., 2005).  Of 
interest, S-nitrosylated MMP-9 (cf. 1.2) may not only 
induce neuronal apoptosis by anoikis, but possibly also 
by the cleavage of actin. Indeed, increased pro- and 
activated MMP-9 levels in ischemic brains were 
associated with slightly decreased levels of actin (Gu et 
al., 2002), and cleavage of actin and other cytoskeletal 
proteins is pro-apoptotic (vide infra).  In addition, 
MMPs may also contribute to neuronal apoptosis by an 
intranuclear function.  Indeed, various studies show 
early upregulation of gelatinolytic activity in the 
nucleus after an ischemic insult (Gasche et al., 2001; 
Amantea et al., 2008; Gu et al., 2005; Yang et al., 
2007).  The MMPs identified in the nucleus were 
MMP-2, MMP-9, MMP-13 and MT1-MMP (cf. Figure 
6) (Yang et al., 2010; Cuadrado et al., 2009). In 
addition, furin was found co-localized with MT1-MMP 
and MMP-2 in ischemic cell nuclei, which may trigger 
the MMP activation cascade (cf. 1.1).  MMP inhibition 
(CH6631) reduced cerebral infarction as well as 
cerebral ischemia-induced apoptosis, as evidenced by 
reduced DNA fragmentation and cytochrome c release 
and increased intact PARP (Copin et al., 2005).  
Purified PARP was cleaved in vitro by MMP-2 and 
MMP-9, and by less defined gelatinase preparations 
and total nuclear extracts from ischemic brains.  In 
addition, this cleavage was inhibited by an MMP-2/-9 
inhibitor.  PARP activity was significantly reduced in 
ischemic brains compared with those treated with 
BB1101.  Activated PARP recruits X-ray cross-
complementary factor 1 (DNA repair protein XRCC1) 
which is also cleaved by MMP-2 and MMP-9 in vitro, 
as well as by gelatinase preparations and total nuclear 
extracts.  Nuclear gelatinolytic activity co-localized 
with PARP and XRCC1 staining in ischemic brains 
and their in vivo degradation during ischemia was 
reduced by the MMP inhibitor BB1101.  In addition, 
accumulation of oxidative DNA damage was also 
reduced by BB1101 (Yang et al., 2010).  As discussed 
above (cf. 3.3.3), PARP is activated by DNA strand 
breaks caused by oxidative stress.  XRCC1 is a 
substrate of PARP and is recruited by PARP to sites of 
DNA damage.  XRCC1 functions as a scaffold protein 
able to coordinate and facilitate the steps of various 
DNA repair pathways by interacting with major DNA 
repair enzymes (Horton et al., 2008).  In response to 
cellular damage by oxygen radicals or excitotoxicity, a 
rapid and strong activation of PARP occurs in neurons 
and excessive PARP activation has been implicated in 
cerebral ischemia (Skaper, 2003).  Hence, Yang and 
colleagues suggest that in mild damage of early stage 
I/R injury, proteolysis of PARP1 and XRCC1 may 
contribute to oxidative DNA damage and neuronal 
apoptosis by impairing their protective action in the 
DNA repair pathway.  However, in later disease stages, 
intranuclear MMP activity may contribute to recovery 
by clearing the burden of over-activated PARP1 that 
causes neuronal necrosis (Yang et al., 2010).  Hence, 
the beneficial effects of MMP inhibitors in the early 
stages would need to be balanced with later 
interference in recovery.  This scheme also implies 
specific time windows for the treatment of brain 
ischemia with MMP inhibitors (Hu et al., 2007). 
Intracellular proteolysis during brain inflammation 
not only affects neuronal survival but may also 
adversely influence synaptic function.  Application of 
recombinant MMP-7 to cultured rat neurons induced 
long-lasting inhibition of vesicular recycling as well as 
reduced local abundance of vesicular and active zone 
proteins within synaptic terminals.  Chronic 
application of MMP-7 resulted in synaptic atrophy, 
including smaller terminals and fewer synaptic vesicles 
(Szklarczyk et al., 2007a).  On the one hand, this effect 
may be explained by extracellular proteolysis of ECM, 
adhesion molecules and receptors such as NMDAR-1 
(Szklarczyk et al., 2008).  On the other hand, MMP-7 
was evidenced to proteolyse the presynaptic protein 
synaptosomal-associated protein of 25 kDa (SNAP-25) 
(cf. Figure 6).  SNAP-25 is a cytosolic soluble N-
sensitive factor attachment protein receptor (SNARE) 
complex protein that participates in the regulation of 
synaptic vesicle exocytosis (Matteoli et al., 2009).  
MMP-7 generates a long-lasting (7 days) 15 kDa 
SNAP-25 fragment by cleavage at the Ala128-Ile129 
peptide bond (Szklarczyk et al., 2007b).  MMP-7-
mediated proteolysis of SNAP-25 was inhibited by 
inhibitors of clathrin-dependent endocytosis (cf. 3.2.1).  
MMP-7 may thus share a particular function with 
clostridial toxins, which enter neuronal cells via 
receptor-mediated endocytosis and cleave SNARE 
proteins, generating long-lasting fragments and 
perturbing neurotransmitter exocytosis (Bajohrs et al., 
2004).  Hence, exogenous MMP-7 is able to access and 
cleave an intraneuronal substrate and may impair 
neurotransmission during brain inflammation. 
Besides their roles in neuronal apoptosis after acute 
cerebral I/R injury, intranuclear MMPs may also affect 
chronic neurodegenerative diseases such as 
Parkinson’s disease (PD).  PD results from 
neurodegeneration of dopaminergic neurons in the 
substantia nigra, which is associated with activation of 
microglia and accumulation of aggregated α-synuclein 
in specific brain stem, spinal cord, and cortical regions 
(Lees et al., 2009). Recent studies have implicated 
MMPs in the death of dopaminergic neurons in this 
disease. 
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Figure 6. Intracellular proteolysis by MMPs in acute and chronic neurodegeneration.  In acute cerebral ischemia, MMPs 
contribute to blood brain barrier disruption by the extracellular degradation of claudin and occludin, and by the intracellular 
proteolysis of zona occludens-1 (ZO-1).  Furthermore, activated MMP-2 and MMP-9 in the nucleus may cleave poly (ADP-
ribose) polymerase (PARP) and X-ray cross-complementary factor 1 (XRCC1), which causes apoptosis and neuronal cell death 
early after ischemia as it impairs DNA repair after oxidative DNA damage.  However, in later disease stages the clearance of the 
overactivated PARP overload may contribute to recovery.  MMP-2 may be activated by MT1-MMP, which in turn may be 
activated by furin, since all three proteases were found to colocalize in the nuclei of ischemic neurons.  In presynaptic terminals, 
proteolysis of synaptosomal-associated protein of 25 kDa (SNAP-25) may perturb synaptic vesicle exocytosis during 
neuroinflammation.  Intracellular proteolysis by MMPs also has pathogenic effects in chronic neurodegenerative diseases, such 
as Parkinson’s disease.  MMPs cleave α-synuclein and increase its aggregation, which may lead to enhanced accumulation of 
toxic Lewy bodies.  By degrading protective chaperones (e.g. heat shock proteins) and anti-oxidant molecules (e.g. DJ-1), 
MMPs also contribute indirectly to toxic protein precipitation and aggregation.  Finally, MMPs may also perturb the clearance of 
misfolded proteins by inactivating many proteins of the ubiquitin-proteasomal system (UPS) and lysosomal proteins. 
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In vitro, apoptotic dopaminergic neurons under 
cellular stress released activated MMP-3, but not the 
pro-form, which acted as a microglia activating 
molecule.  Both released activated MMP-3 and the 
catalytical domain of MMP-3 led to the production of 
superoxide and microglial inflammatory cytokines 
such as TNF-α, which in turn exacerbated neuronal 
apoptosis and necrosis.  In the N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-injected animal 
model of PD, neuronal degeneration, microglial 
activation, and superoxide generation were largely 
attenuated in MMP-3 knockout mice (Kim et al., 2005; 
Kim et al., 2007).  An activated form of MMP-3 was 
generated inside stressed dopaminergic cells by a 
serine protease different from furin (cf. 1.1).  This 
intracellular activated form of MMP-3 (but not the 
extracellular MMP-3) was found to participate in 
apoptotic signaling, upstream of caspase-3.  Hence, 
these results suggest that MMP-3 catalytic activity 
seems to play different synergistic roles in 
dopaminergic neuron degeneration, both intracellularly 
by promoting neuronal apoptosis and extracellularly by 
triggering neuroinflammation (Choi et al., 2008). 
In PD, dopaminergic neurons of the substantia 
nigra show toxic intracellular filamentous inclusions 
termed Lewy bodies, which consist mainly of an 
abnormal, post-translationally modified, and 
aggregated form of α-synuclein (α-syn, non-Aβ 
component of AD amyloid, non-A4 component of 
amyloid precursor, NACP) (cf. Figure 6). α-syn is a 
cytoplasmic (presynaptic) protein that normally 
regulates neurotransmitter release, possibly via 
interaction with lipid domains on secretory vesicles 
(Sulzer, 2010).  Of interest, MMP-3 and MMP-9, but 
not MMP-2, were found to co-localize with α-syn in 
Lewy bodies (Personal communications from Johannes 
Levin and Stefan Lorenzl, University of Munich, 
Germany and from Yoon-Seong Kim, Weill Cornell 
Medical College, New York).  Moreover, 
dopaminergic neuroblastoma cells under oxidative 
stress showed an upregulation of intracellular and 
secreted activated forms of MMP-3 and cleavage of α-
syn, which was inhibited by an MMP inhibitor (MMP 
inhibitor II).  Purified α-synuclein is cleaved by MMP-
3 most efficiently, but also by MT1-MMP, MMP-2, 
MMP-1 and MMP-9 (ordered by decreasing 
efficiency) (Sung et al., 2005).  Many non-overlapping 
cleavage sites were found for the cleavage of α-syn by 
MMP-3, -1 and -9 (cf. Table 3) (Levin et al., 2009).  
The tested MMPs cleaved preferentially in the COOH-
terminal part of α-syn in and around the non-Aβ 
component of Alzheimer plaques (NAC) domain.  The 
NAC domain is a hydrophobic region that is highly 
prone to aggregation.  Indeed, limited proteolysis by 
MMP-1 and MMP-3, but not by MMP-9, increased α-
syn aggregation.  In addition, α-syn fragments 
produced by MMP-3 facilitated aggregation of intact 
α-syn and had a more toxic effect on cell viability.  
However, high MMP concentrations, which resulted in 
pronounced degradation of α-syn, blocked subsequent 
aggregation.  Hence, it seems that, under oxidative 
stress, MMPs, especially MMP-3, may regulate α-syn 
aggregation and toxicity in dopaminergic neurons, 
thereby affecting onset and progression of 
neurodegeneration in PD.  In addition, MMP-3 was 
suggested to cleave protein DJ-1 (DJ-1, oncogene DJ1, 
Parkinson disease protein 7) (personal communication 
from Yoon-Seong Kim), and various degradomics 
screens identified DJ-1 as an in vitro substrate of 
MMP-1,-2,-8,-9 and MT1-MMP (cf. Table 2) (Dean et 
al., 2007; Dean and Overall, 2007; Butler et al., 2008).  
DJ-1 is an important redox-reactive signaling 
intermediate controlling oxidative stress after ischemia, 
upon neuroinflammation, and during age-related 
neurodegenerative processes such as PD (Kahle et al., 
2009).  In conclusion, inhibition of these pathogenic 
actions of MMP(-3) may have a neuroprotective effect, 
as was already shown in vitro and in vivo with 
doxycycline in the MPTP animal model of PD (Cho et 
al., 2009). 
Besides causing direct aggregation of substrates by 
proteolysis, MMPs may also contribute indirectly to 
protein aggregation in neurodegenerative diseases such 
as PD by the inactivation of protective proteins such as 
chaperones, proteins from the ubiquitin- proteasomal 
system (UPS) and proteins that function in lysosomal 
degradation.  Indeed, heat shock proteins (HSPs) play a 
substantive role in PD pathology and chaperone 
therapy was recently proposed as a novel treatment 
strategy (Bandopadhyay and de, 2010; Luo and Le, 
2010).  Indeed, extensive localization of several HSPs 
with α-syn in Lewy bodies has been demonstrated, 
including the (candidate) MMP substrates HSP27, 
HSP70 and HSP90.  HSPs inhibit α-syn toxicity and 
aggregation.  This was shown for another small HSP, 
αB-crystallin, which has protective functions in the 
heart (cf. 3.3.3) and in multiple sclerosis brain (cf. 
4.2.1) and is also an MMP substrate.  In addition, heat 
shock cognate protein 70 (HSC70) and HSP90 
facilitate the transfer of α-syn from the cytosol to the 
lysosomes for degradation (Bandopadhyay and de, 
2010).  Furthermore, failure of the UPS system has 
recently emerged as an additional pathogenic factor 
that underlies development of familial and sporadic PD 
(McNaught et al., 2001).  Hence, inactivation of UPS 
proteins by MMPs may contribute to the neurotoxic 
protein accumulation and aggregation observed when 
the UPS system fails.  Finally, additional defects in 
protein clearance may be caused by MMP-mediated 
degradation of lysosomal proteins (cf. Table 3).  In 
conclusion, inhibition of MMPs in PD may not only 
avoid α-syn truncation and aggregation, but may also 
preserve chaperone function, and maintain effective 
protein degradation and clearance.  
Neuronal survival requires continuous lysosomal 
turnover of cellular constituents delivered by 
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autophagy and endocytosis.  Hence, the lysosomal 
system is a convergence point for a surprising number 
of genetic mutations that cause neurodegenerative 
diseases (Nixon et al., 2008).  Of interest, various 
MMP (candidate) substrates are lysosomal proteins 
that contain mutations in neurodegenerative disorders, 
including cathepsins D and E, Niemann-Pick, type C2 
(NPC2), proganulin and triose phosphate isomerase (cf. 
Table 5).  Intracellular modification of these proteins 
by MMPs may constitute an unexplored pathogenic 
factor contributing to neurodegeneration in these rare 
monogenetic diseases.  Likewise, other proteins with 
mutations causing storage diseases are (potential) 
targets of MMPs, such as enolase-β, aldolase A, β-
glucuronidase, iduronate-2-sulfatase, and filamin C.  
This is certainly an unexpected but interesting link that 
needs further clinical research. 
 
3.3.5 Intracellular proteolysis and cataract 
The human lens is suspended in a complex 
environment.  The front side is constantly rinsed by the 
aqueous fluid, while the gel-like vitreous acts as a 
shock breaker.  The lens is composed of three main 
types of proteins, α-, β- and γ-crystallins.  Crystallins 
focus light on the retina by maintaining the necessary 
refractive characteristics and transparancy of the lens.  
Besides this structural role, crystallins may also 
function as chaperones and suppress the aggregation of 
proteins denatured by oxidation, heat, and other 
stressors.   Crystallins are constantly subjected to 
changes such as oxidation, deamidation, truncation, 
glycation, and methylation that accumulate with time. 
Such age-related modifications affect crystallin 
structure and function. With time, the modified 
crystallins aggregate, causing the lens to increasingly 
scatter light instead of focusing light on the retina, and 
causing the lens to gradually lose its transparency and 
become opaque. This age-related lens opacity, or 
cataract, is the major cause of blindness worldwide.  
Calpains have been implicated in the proteolytic 
modification of crystallins but their role in human 
cataractogenesis is yet to be established, primarily 
because of the presence of a calpain inhibitor in the 
lens at a several fold higher concentration than calpain 
itself (Sharma and Santhoshkumar, 2009).  Ex vivo 
incubation of mouse lenses with recombinant activated 
MMP-9 was shown to cause opacification of the lens 
within 15 min (Descamps et al., 2005).  2D-PAGE 
analysis of extracts from these lenses showed the 
disappearance of intact βB1-crystallin (βB1-crys) and 
the appearance of a βB1-crys fragment, as well as a 
minor βB3-crys fragment.  Truncation of βB1-crys by 
MMP-9 was confirmed in vitro in crude eye extracts 
and the scissile bond was identified at Ala47-Lys48 by 
Edman degradation.  In vitro degradation of eye 
extracts also identified a fragment of γC-crys.  
However, as this fragment was not found in the ex vivo 
opacificated lenses, it is not likely to be an in vivo 
target of MMP-9 in murine cataract.  Injection into the 
vitreous chamber of activated MMP-9 or the mouse 
CXC chemokine, granulocyte chemotactic protein-2 
(GCP-2), to attract neutrophils as an endogenous 
source of MMP-9, resulted in βB1-crys degradation in 
vivo, whereas such degradation was not observed in the 
lenses of MMP-9 knockout mice.  Ex vivo 
development of cataract in the presence of activated 
MMP-9 was accompanied by enzymatic loosening of 
the lens capsule, which is an uninterrupted basement 
membrane enclosing the lens (Descamps et al., 2005).  
Since the lens capsule is composed of the same 
molecules as most basement membranes (Danysh and 
Duncan, 2009), it is not surprising that MMP-9 or 
other MMPs may penetrate it and subsequently enter 
the lens fiber cells by an undefined mechanism.  Of 
interest, αB-crys, a more prominent crystallin in the 
eye, is also cleaved by MMP-9 and other MMPs (vide 
infra) (Starckx et al., 2003; Shiryaev et al., 2009).  
Although extensive αB-crys fragmentation was 
observed in human aged lenses (Sharma and 
Santhoshkumar, 2009), it was not shown to be an 
MMP target in the above-mentioned mouse study.  
However, this may be accounted for by interspecies 
differences and the animal model used, and does not 
exclude αB-crys as an (MMP) target in human cataract. 
In conclusion, lens crystallins were among the first 
intracellular MMP substrates discovered by in vivo 
studies with knockout mice and with direct 
pathological implications in cataract development. 
3.3.6 Intracellular proteolysis and apoptosis 
Extracellular MMPs may affect cellular apoptosis in 
multiple ways with both pro- and anti-apoptotic 
outcomes (Mannello et al., 2005).  Many effects of 
intracellular proteolysis by MMPs on cell death have 
been described in previous sections, such as the anti-
apoptotic effect of mitochondrial MMP-1 (cf. 3.3.2) 
(Limb et al., 2005) and cleavage of GSK-3β by MMP-
2, which enhances its pro-apoptotic and other 
pathogenic activities in the heart (Kandasamy and 
Schulz, 2009).  Intranuclear activities of MMP-9 and 
MMP-2 after cerebral ischemia may inactivate the 
nuclear matrix proteins PARP-1 and XRCC1, causing 
apoptosis and necrosis early after ischemia, but 
protecting neuronal cells from death at later stages in 
the evolution of ischemic lesions (Yang et al., 2010).  
Activated MMP-3 inside stressed dopaminergic 
neurons contributes to pro-apoptotic signaling 
upstream of caspase-3 (Choi et al., 2008).  The active 
form of MMP-3 (but not the pro-form) was already 
mentioned to be efficiently transported to the nucleus 
by means of a nuclear localization signal (cf. 3.2.6).  
Cell populations expressing a nuclear activated form of 
MMP-3 (by transfection) contained higher percentages 
of apoptotic cells than the control populations 
transfected with pro-MMP-3 (remaining cytosolic), as 
D I S C U S S I O N   P A R T   1  
205 | P a g e  
determined by immunofluorescent staining for 
activated caspase-3.  This induction of apoptosis was 
dependent on the catalytic activity of MMP-3, as 
transfection of an inactive mutant or treatment with the 
broad spectrum MMP inhibitor GM6001 significantly 
reduced the apoptotic index.  Hence, nuclear MMP-3 
induces apoptosis by its proteolytic activity (Si-Tayeb 
et al., 2006).  In completely different settings, cigarette 
smoke-induced apoptosis was associated with 
gelatinolytic activity in the nucleus, increased pro- and 
activated MMP-2 levels in nuclear and cytosolic 
fractions and early PARP-1 fragmentation before the 
time point of caspase-3 activation, again suggesting a 
role for MMP-2 activity in nuclear matrix proteolysis 
during apoptosis (Ruta et al., 2009).  Of interest, 
MMP-2 expression and activation were reduced by 
inhibitors of two major apoptotic pathways in 
endothelial cells, caspase- and p38 mitogen-activated 
protein kinase (MAPK)-induced apoptosis, i.e. the pan 
caspase inhibitor Z-VAD and the p38 inhibitor 
SB203580.  Curiously, Z-VAD increased, whereas 
SB203580 decreased MT1-MMP expression and 
activity.  These results would suggest that alteration of 
MMP-2 activity is rather effect than cause in the 
apoptotic cascade.  However, addition of pro- and 
activated MMP-2 to endothelial cell cultures showed a 
dose-dependent induction of apoptosis.  Elevation of 
p38 and its phosphorylation were observed following 
the addition of active MMP-2, pointing to a positive 
regulatory loop for MMP-2 in the p38 MAPK 
apoptotic pathway.  However, neither pro-MMP-2 nor 
activated MMP-2 influenced the levels of active 
caspase-3, suggesting that MMP-2 is downstream of 
caspases (Shapiro et al., 2010).  Indeed, a recent study 
by Yarbrough et al. showed increased MMP activity 
after treatment of heart homogenates with active 
caspase-3 and generation of activated forms of MMP-2 
by an active caspase cocktail, suggesting direct 
proteolytic activation of MMPs by active caspases (as 
discussed in 1.1) (Yarbrough et al., 2010).   
If one analyzes critically the apoptotic cascade by 
evaluation of intracellular substrates, rather than by 
scrutinizing the enzymes, it becomes factual 
knowledge that most of the well-defined intracellular 
MMP substrates (cf. Table 5) are also cleaved by pro-
apoptotic proteases such as calpains, caspases and 
granzymes, as summarized in Table 6.  Strikingly, as 
can be deduced from Table 6, cleavage of these 
proteins by MMPs or (other) apoptotic proteases seems 
to have a general pro-apoptotic effect (Figure 7). In 
addition, from degradomics substrate analysis (Table 
3), it is clear that other important apoptosis regulators 
may be modulated by MMPs.  These regulators include 
BH3-interacting domain death antagonist (BID), 
apoptosis-linked-gene-2-interacting-protein X (ALIX 
or programmed cell death protein 6) and cytochrome c.  
Granzyme A induces apoptosis by multiple cleavages, 
including the cleavage of histones, a process that opens 
up chromatin to DNases, and proteolysis of high 
mobility group B2 (HMGB2), which liberates the 
DNase activity of nucleoside diphosphate kinase A 
(Lieberman and Fan, 2003).  Both, histones and 
HMGB2, are high-confidence candidate substrates of 
MMPs (cf. Table 3).   
As mentioned in chapter 2, MMPs seem to degrade 
a whole array of intracellular matrix (ICM) proteins.  
Cleavage and reorganization of cytoskeletal proteins is 
essential in apoptosis progression as it ensures the 
systematic dismantling of the dying cell and probably 
contributes to the early cell rounding and retraction, 
and partly to apoptotic membrane blebbing 
(Ndozangue-Touriguine et al., 2008; Taylor et al., 
2008).  Indeed, MMPs degrade many focal adhesion 
proteins, including FAK, α-actinin and the filamins (cf. 
Tables 3 and 5 and Figure 7).  MMPs may also 
participate in the degradation of the actin meshwork 
surrounding the nuclear lamina, which disrupts the 
attachment between the actin cytoskeleton and the 
nuclear envelope, tearing the nucleus apart during 
apoptosis.  Of interest, apoptosis in ischemic brains 
was associated with increased levels of pro- and S-
nitrosylated active MMP-9 and decreased levels of 
actin (cf. 3.3.4) (Gu et al., 2002).  In addition, and 
again similarly to caspases, MMPs seem to target 
many proteins that are involved in essential 
housekeeping functions in the cell, such as regulation 
of transcription and translation, protein biosynthesis 
and carbohydrate metabolism (cf. Table 3).  This is in 
line with the early shutdown of transcription and 
translation observed during apoptosis and may shut off 
the life-support systems of the cell (Taylor et al., 
2008).  Furthermore, Tables 3 and 6 show that MMPs 
also target many heat shock proteins and other 
molecular chaperones, which are known to have 
multiple anti-apoptotic effects (Beere, 2004; Lanneau 
et al., 2008).  In conclusion, MMPs have many 
substrates in common with pro-apoptotic proteases and 
most MMP effects on substrates are pro-apoptotic (cf. 
Figure 7).  The observation that exceptions to this rule 
exist, strengthens the fact that by such proteolysis a 
regulatory role is played in the apoptotic process, and 
this is in line with the well-known duality of pro- and 
anti-apoptotic roles of MMPs (Mannello et al., 2005). 
Both, the calpains and caspases, are families of 
cysteine proteases that have important roles in the 
initiation, regulation and execution of cell death 
(Harwood et al., 2005).  For these enzymes it is 
generally accepted that they act intracellularly.  Of 
interest, Schulz and coworkers discovered that the 
general calpain inhibitor calpastatin inhibits MMP-2 in 
vitro.  Since much of the evidence for calpain 
degradation of substrates is based on the use of calpain 
inhibitors, calpains may have been incorrectly 
identified as the proteases responsible for some 
intracellular proteolytic activities (Kandasamy et al., 
2010).   
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Table 6.  Cleavage of intracellular MMP substrates by pro-apoptotic proteases and effect of substrate cleavage on the 
apoptotic pathway 
Substrate*  MMP  Calpain   Caspase  granzyme   Effect of cleavage  References 
INTERCELLULAR JUNCTION PROTEINS 
Cx43 MMP-7 ND ND ND pro-apoptotic (Giardina et al., 2007) 
ZO-1 MMP-9 ND caspase X ND pro-apoptotic (Bojarski et al., 2004) 
CYTOSKELETAL PROTEINS 
α-actinin MMP-2 calpain X capase-3 NC pro-apoptotic 
(Selliah et al., 1996; Communal et al., 
2002; Nakamura et al., 1993; Triplett and 
Pavalko, 2006) 
CAP1 MMP-9          MMP-2,-8,-13 ND ND ND anti-apoptotic (Wang et al., 2008) 
Desmin MMP-2 calpain 1    calpain 2 caspase-6 ND pro-apoptotic 
(Whipple and Koohmaraie, 1991; Chen et 
al., 2003; Papp et al., 2000) 
FAK MT1-MMP     MT3-MMP 
calpain 1    
calpain 2 
caspase-3,-7   
capase-6,-8 granzyme B pro-apoptotic 
(Carragher et al., 1999; Wen et al., 1997; 
Gervais et al., 1998; Cance and 
Golubovskaya, 2008) 
Gelsolin MMP-1,-2,-3,-7,-9 calpain X caspase-3 ND pro-apoptotic 
(Fujita et al., 1999; Geng et al., 1998; 
Kothakota et al., 1997; Wolf et al., 1999) 
Pericentrin MT1-MMP NC NC NC pro-apoptotic (Zimmerman et al., 2004) 
SARCOMERIC PROTEINS 
MLC-1 MMP-2 calpain 3 caspase-3 granzyme A pro-apoptotic (Cohen et al., 2006; Moretti et al., 2002; Nakamura et al., 1993) 
MHC MMP-2          MMP-9 calpain 2 caspase X granzyme A pro-apoptotic 
(Nakamura et al., 1993; Gerner et al., 
2000; Azarian et al., 1993) 
TnI MMP-2 calpain 1    calpain 2 NC ND pro-apoptotic 
(Gao et al., 1997; Ruetten et al., 2001; Di 
Lisa et al., 1995) 
MOLECULAR CHAPERONES 
αB-crys MMP-9 calpain 2 ND ND pro-apoptotic (Kelley et al., 1993; Kamradt et al., 2001) 
βB1-crys MMP-9 calpain2 CSS2 ND ND ND (Ma et al., 2004; David et al., 1993) 
βB3-crys MMP-9 calpain 2 ND ND ND (David et al., 1993) 
γC-crys MMP-9 calpain 2    calpain 3 ND ND ND (Baruch et al., 2001; Tang et al., 2007) 
PRESYNAPTIC PROTEINS 
α-syn MMP-1,-2,-3,-9    MT1-MMP 
calpain 1    
calpain 2 ND ND anti-apoptotic 
(Mishizen-Eberz et al., 2003; Kim et al., 
2004) 
SNAP-25 MMP-7 calpain 2 ND ND ND (Ando et al., 2005) 
NUCLEAR MATRIX PROTEINS 
PARP-1 MMP-2 calpain 1 capase-1,-3 granzyme A   granzyme B pro-apoptotic 
(Buki et al., 1997; Tewari et al., 1995; Gu 
et al., 1995; Froelich et al., 1996; Zhu et 
al., 2009) 
XRCC1 MMP-2         MMP-9 ND ND ND pro-apoptotic (Yang et al., 2010) 
ANTIBACTERIAL PEPTIDES 
pro-Crps MMP-7 ND ND ND ND / 
pro-CRS4C MMP-7 ND ND ND ND / 
SIGNALING PROTEINS 
ER-β MMP-26 ND ND ND anti-apoptotic (Lazennec, 2006) 
GSK-3β MMP-2 calpain 1 ND ND pro-apoptotic (Goni-Oliver et al., 2007) 
*The meaning of the acronyms can be found in Table 5.   
   NC, not cleaved; ND, not defined. 
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Figure 7. Intracellular proteolysis by MMPs in apoptosis.  Cleavage of intracellular substrates by MMPs has many pro-
apoptotic effects (+), but may also inhibit apoptotic pathways (-).  Degradation of cytoskeletal proteins (e.g. focal adhesion 
kinase (FAK), α-actinin, actin and the filamins) contributes to the systematic dismantling of the dying cell, as well as to the 
disruption of the actin meshwork surrounding the nuclear lamina.  Inactivation of housekeeping proteins such as the enzymes 
that regulate transcription and translation, carbohydrate metabolism and protein biosynthesis, may shut off life-support systems 
of the cell.  Cleavage of heat shock proteins might abolish their multiple anti-apopototic functions.  Truncation of the pro-
apoptotic protein BH3-interacting death domain antagonist (Bid) may contribute to the intrinsic apoptotic pathway, in contrast 
with cytochrome c degradation.  Translocation and degradation of connexin-43 (Cx43) in the mitochondria leads to mitophagy 
and cell death.  Cleavage of glycogen synthase kinase-3β (GSK-3β) enhances its pro-apoptotic capacities.  Inactivation of poly 
(ADP-ribose) polymerase (PARP) and X-ray cross-complementary factor 1 (XRCC1) causes apoptosis early after ischemia.  
Cleavage of histones may open up the chromatin to DNases and proteolysis of high mobility group B2 (HMGB2) liberates 
DNase activity.  Degradation of the calpain inhibitor calpastatin may stimulate apoptosis, whereas inactivation of the pro-
apoptotic proteases calpain 2 and various cathepsins may have anti-apoptotic effects.  Translocation of CAP1 to the 
mitochondria is pro-apoptotic and its degradation may result in defective apoptosis.   The presence of activated MMP-3 in the 
nucleus is pro-apoptotic, whereas mitochondrial MMP-1 confers resistance to apoptosis.  Apaf-1, apoptotic protease activating 
factor-1; FADD, Fas-associated death domain-containing protein; tBid, truncated Bid. 
Calpains are believed to be activated by an initial insult 
via a rise of intracellular Ca2+ from the ER, the 
mitochondria or an influx of extracellular Ca2+, as 
caused for example by oxidative stress (Harwood et al., 
2005).  Since MMPs are also Ca2+-dependent enzymes 
(Tallant et al., 2010) and may be activated by oxidative 
stress (cf. 1.2), they are indeed very likely to perform 
claimed calpain functions.  Likewise, because caspase 
activity requires a free sulfhydryl group in the catalytic 
site, many caspase inhibitors target this part of the 
enzyme.  MMPs possess an essential cysteine with a 
sulfhydryl group in the latent proform that is also a key 
regulator of enzyme activity.  This suggests that 
caspase inhibitors may activate MMPs by interacting 
with the latency-confering Cys in the propeptide (Van 
Wart and Birkedal-Hansen, 1990). 
In addition to the cleavage of common substrates in 
the apoptotic pathway, granzyme B directly activates 
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pro-caspases, whereas granzyme A induces caspase-
independent cell death (Vandenabeele et al., 2005).  
The parallellisms between MMPs and granzymes are 
striking, as they both are extracellular proteases that 
can be transported into the cell, for example by 
endocytic mechanisms (cf. 3.2.1).  Conversely, 
whereas granzymes are mostly known for their 
intracellular substrates and their extracellular functions 
only start to gain appreciation (Boivin et al., 2009), the 
reverse is true for MMPs.  Calpains may activate or 
inactivate pro-caspases, whereas caspase 3 cleaves the 
general calpain inhibitor calpastatin.  Thus caspase, 
calpain and granzyme cascades are tightly interrelated 
(Demon et al., 2009; Harwood et al., 2005). Of 
interest, calpain 2 and calpastatin were identified as 
MMP candidate substrates, as well as various 
cathepsins (cf. Table 3), which translocate from the 
lysosomal lumen in response to apoptotic stimuli and 
trigger apoptosis (Turk and Turk, 2009). 
Besides the apparent overlap in (pro-)apoptotic 
substrate cleavage (cf. Figure 7), and inhibitor profiles, 
other elements hint for a participation of MMPs in the 
apoptotic cascade and the cross-talk with (pro-
)apoptotic proteases.  Nitrosative stress, which 
promotes apoptosis by activation of mitochondrial 
apoptotic pathways, inhibits caspases by S-
nitrosylation (Kim et al., 2002), whereas MMPs were 
shown to be activated by S-nitrosylation and 
consequently induced apoptosis (cf. 1.2) (Gu et al., 
2002).  Hence, under specific conditions, such as 
oxidative and nitrosative stress, MMPs may indeed 
exert some caspase functions.  In support of this, early 
activation of MMPs in response to oxidative stress and 
cleavage of the apoptotic caspase-3 substrate PARP-1 
preceded caspase-3 activation in various studies (Yang 
et al., 2010; Ruta et al., 2009).  As already mentioned, 
in stressed dopaminergic neurons, intracellular 
activated MMP-3 was shown to be a pro-apoptotic 
signaling molecule upstream of caspase-3 (but not by 
direct cleavage of MMP-3) (Choi et al., 2008), 
whereas MMP-2 was found to be an apoptotic effector 
molecule downstream from caspase-3 in spontaneous 
apoptosis of endothelial cells (Shapiro et al., 2010; 
Yarbrough et al., 2010).  Conversely, mitochondrial 
MMP-1 was shown to confer resistance to apoptosis 
(Limb et al., 2005).   
Additional data enhance the links between MMPs 
and apoptotic substrate conversions. Like calpastatins 
inhibit calpains, the tissue inhibitors of 
metalloproteinase (TIMPs) are natural MMP inhibitors 
(Brew and Nagase, 2010).  TIMPs have been shown to 
inhibit (TIMP-1 and TIMP-2) or stimulate (TIMP-2 
and TIMP-3) apoptosis and were also detected 
intracellularly (cf. Table 4).  These findings suggest 
that the intracellular functions of TIMPs may 
contribute to the regulation of apoptosis by inhibiting 
MMP function or by other independent mechanisms. 
As a consequence, the extracellular effects of MMPs, 
for instance the cleavage of cytokines (e.g. pro-TNF-
α) and cytokine receptors (Cauwe et al., 2007), may 
work synergistically with intracellular substrate 
cleavages in the regulation of apoptosis. 
Common (pro-)apoptotic substrates and inhibitor 
profiles, MMP activation and action in early apoptotic 
phases, and cross-talk with pro-apoptotic proteases all 
point to MMPs as executioners of a novel form of 
caspase-independent cell death.  Caspases traditionally 
held the predominant role as prime mediators of 
apoptotic execution. However, recent evidence has 
accumulated that non-caspases, including calpains, 
cathepsins, granzymes and the proteasome have roles 
in mediating and promoting cell death (Vandenabeele 
et al., 2005).  Since modulation of apoptosis seems to 
be a leitmotiv in the intracellular functions of MMPs, 
they may soon be considered as the next addition to the 
growing list of apoptotic proteases.  Further research 
into the influences of intracellular MMPs on both 
caspase-dependent and caspase-independent apoptosis 
may unveil new modes to prevent pathological cell 
death, or conversely, to induce apoptosis in cancer 
cells and pathological autoreactive cells. 
4 INTRACELLULAR MMP SUBSTRATES 
DEGRADED OUTSIDE CELLS 
It is increasingly recognized that a subset of proteins 
owns both intracellular and extracellular functions 
(Butler and Overall, 2009a). This phenomenon is 
denominated ‘protein multifunctionality’ and a 
classical example is the identity of the intracellular 
phosphomannose receptor with the extracellular 
receptor of insulin-like growth factor II (Morgan et al., 
1987).  These functions may be very diverse and even 
affect physiopathology in opposite ways.  For example, 
the upregulation of intracellular heat shock protein 70 
(HSP70) is mostly cytoprotective and induces anti-
apoptotic mechanisms in cells, whereas increased 
levels of extracellular HSP70 are generally 
immunostimulatory and augment the synthesis of co-
stimulatory molecules and pro-inflammatory cytokine 
and chemokines (Asea, 2007).  These multifunctional 
proteins may travel between intracellular and 
extracellular compartments in non-conventional ways.  
Alternatively, the intracellular protein pool may leak 
from the cell after necrotic loss of membrane integrity.  
Here, we discuss the specific circumstances in which 
intracellular proteins may be accessed and modulated 
by extracellular MMPs.  Indeed, many of the 
intracellular (candidate) substrates in Table 3 and 
Table 5 have also been found extracellularly.  Hence, 
quite opposite to the previous chapter, in which it is 
described how MMPs enter cells and specific 
subcellular compartments to cleave intracellular 
proteins, this chapter deals with intracellular proteins 
that exit the cell and are proteolysed by MMPs in the 
extracellular milieu. 
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4.1 Extracellular  localization mechanisms 
of intracellular MMP substrates 
4.1.1 Non-classical secretion of intracellular 
MMP substrates 
The classical secretion of soluble proteins requires 
transportation into and through the endoplasmic 
reticulum (ER) and the Golgi apparatus. Signal 
peptides target proteins for translocation into the ER 
lumen. However, most intracellular proteins do not 
possess a signal sequence for secretion but leave the 
cell by ER-Golgi independent secretion pathways.  
Although the details of the unconventional secretory 
mechanisms remain elusive for most of these proteins, 
four main pathways have emerged as potential means 
of non-classical cell exit, i.e. direct membrane 
translocation, secretory lysosomes, multivesicular body 
(MVB)-derived exosomes and membrane vesicle 
secretion (Nickel and Seedorf, 2008; Nickel and 
Rabouille, 2009; Prudovsky et al., 2008).  Examples of 
intracellular MMP (candidate) substrates secreted by 
one of these four mechanisms are given in Table 7. 
A first mechanism consists of direct translocation 
across the plasma membrane, for example by direct 
interaction of membrane lipids and spontaneous 
penetration of the lipid bilayer, as proposed for 
galectin-3 (Lukyanov et al., 2005).  Alternatively, 
translocation may require the cooperation of a 
molecular apparatus of integral and peripheral 
membrane proteins (e.g. galectin-1) (Schafer et al., 
2004; Delacour et al., 2009).  The endolysosomal 
pathway is a second pathway for unconventional 
secretion and involves the sequestration of soluble, 
cytoplasmic proteins into endolysosomes.  These 
secretory lysosomes have characteristics of both 
lysosomes and secretory granules.  The mechanisms by 
which cytoplasmic proteins may enter the lumen of the 
secretory lysosomes have not been fully elucidated yet, 
but may involve the highly conserved ABC cassette 
transport proteins, which can pump large and small 
molecules across membranes.  A second trigger, 
extracellular ATP, is proposed to promote the fusion of 
secretory lysosomes with the cell membrane, which 
releases their content into the extracellular milieu 
(Nickel and Rabouille, 2009; Mambula et al., 2007).  
Of interest, pro- and activated MMP-9 forms were 
identified in secretory lysosomes of reactive astrocytes 
(cf. 3.2.2) (Sbai et al., 2010), suggesting that 
proteolysis may already occur before or during 
secretion. 
A third pathway is the secretion by exosomes 
derived from multivesicular bodies (MVBs).  Exosomes 
are 40-100 nm vesicles, which originate from the 
inward budding of MVBs to form intraluminal vesicles 
with concomitant engulfment of cytosolic components.  
Although MVBs primarily deliver cytoplasmic 
proteins for degradation by fusion with lysosomes, 
they can also release internal vesicles or exosomes into 
the extracellular space following their fusion with the 
plasma membrane (Simpson et al., 2008; Thery et al., 
2009).  As can be deduced from Table 7, many MMP 
(candidate) substrates have been found in exosomes.  
Of interest, both pro- and functionally active MT1-
MMP forms are present in exosomes and are ideally 
situated to cleave intracellular proteins upon secretion 
(Hakulinen et al., 2008).  Finally, a fourth mechanism 
for non-classical release of proteins is the secretion of 
membrane vesicles.  In contrast with the endosomal 
origin of exosomes, these ‘shedding vesicles’ are 
generated by direct budding from the plasma 
membrane.  According to their characteristics (size, 
density, appearance, sedimentation, lipid composition, 
protein markers) and cell type of origin, they have been 
termed ectosomes, shedding vesicles, shedding bodies, 
microparticles, membrane particles, exovesicles and 
microvesicles, without much consensus in terminology 
throughout the literature (Cocucci et al., 2009; Nickel 
and Rabouille, 2009).  Here, we will not differentiate 
between various subtypes and use the general term 
‘membrane vesicles’. Upon release, both exosomes and 
membrane vesicles circulate in the extracellular space 
adjacent to the site of discharge, where they can 
rupture and release the enclosed proteins.  However, 
some of these vesicles travel considerable distances by 
diffusion within tissues and appear in biological fluids 
such as blood and even urine.  In addition, recent data 
have emerged showing that they can fuse with other 
cells as a means of direct intercellular communication, 
which may play important roles in infections and 
immune functions, coagulation and tumor progression 
(Thery et al., 2009; Cocucci et al., 2009).   
4.1.2 Exposure of intracellular substrates to 
extracellular MMPs by various forms of cell 
death 
Apoptosis is characterized by a cascade of 
structural remodeling steps, which contribute to the 
progression towards cell death, but also prepare the 
cell for removal by phagocytes, preventing unwanted 
immune responses.  Apoptotic cells initially become 
rounded and retract from neighboring cells, which is 
accompanied by a period of dynamic plasma 
membrane blebbing and culminates into the shedding 
of apoptotic bodies and small apoptotic blebs (Taylor 
et al., 2008).  Of interest, intracellular proteins undergo 
a striking redistribution during apoptosis and become 
concentrated in and on the surface of apoptotic blebs.  
Small blebs contain molecules associated with the ER 
and the membrane skeleton, whereas apopotic bodies 
are enriched with nuclear proteins (Rosen and 
Casciola-Rosen, 1999; Casciola-Rosen et al., 1994).  
Whereas the shedding of apopotic bodies and blebs 
seems to be a means of safely breaking the cell apart 
into more manageable pieces for phagocytosis, the 
meaning of the intracellular protein translocation onto 
the cell surface is less evident. However, since both 
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calreticulin and annexin I trigger ligation and 
engulfment by phagocytes (Arur et al., 2003; Gardai et 
al., 2005), the surface localization of these intracellular 
proteins may constitute ‘eat-me signals’ for 
phagocytosis.  In this way, various MMP (candidate) 
substrates are exposed for degradation by extracellular 
MMPs (cf. Table 7) (Schiller et al., 2008; Casciola-
Rosen et al., 1994; Rosen and Casciola-Rosen, 1999) 
and will be discussed in the connected pathological 
context in section 4.2. 
In the absence of phagocytes, or when necrotic cells 
outnumber the phagocytes, apoptotic cells are not 
cleared in time and progress to secondary necrosis.  
Necrotic cell death results in the discharge of the 
intracellular content into the extracellular milieu, and 
will allow for the full intracellular protein pool to come 
in contact with extracellular MMPs. In principle, this 
may be caused by any condition that destroys the 
cellular integrity, by physical stresses, such as heat, 
cold, positive or negative pressure and irradiation at 
various wavelengths.  Chemical insults such as pH and 
toxins, biochemical activation of various classes of 
enzymes (e.g. lipases), porines (e.g. complement) and 
membrane channels, and finally infections with 
cytopathogenic viruses and other micro-organisms, all 
contribute to the live scenario of MMPs acting on 
intracellular substrates. Furthermore, some intracellular 
proteins are released from necrotic cells before the loss 
of membrane integrity. These specific damage-
associated molecular patterns (DAMPs) or ‘alarmins’ 
are released from primary and secondary necrotic cells, 
but not from apoptotic cells.  Hence, they function as 
endogenous adjuvants and activate the innate and 
adaptive immune system, signaling the ‘danger’ of 
immunogenic cell death and tissue damage (Kono and 
Rock, 2008; Bianchi, 2007).  Various proteins have 
been proposed to function as alarmins, many of which 
were identified as MMP (candidate) substrates (cf. 
Table 7) (Kono and Rock, 2008; Yang et al., 2009; 
Bianchi, 2007).  Modulation of these pro-inflammatory 
molecules may account for some of the multiple 
immunomodulatory roles of MMPs (Cauwe et al., 
2007; Manicone and McGuire, 2008).  Indeed, 
hyperactivation by MMP-mediated cleavage would 
strongly enhance inflammation, whereas an 
inactivating proteolytic effect may be required for the 
termination of the pro-inflammatory effect, much alike 
the thrombin-mediated cleavage and dampening of 
HMGB1 activity (Ito et al., 2008). 
Although apoptosis and necrosis seemed to be the 
two fates of choice for a dying cell, it has recently 
become clear that some phagocytic cells also succumb 
via the formation of extracellular chromatin structures, 
which were first identified in neutrophils and were 
termed neutrophil extracellular traps or NETs 
(Brinkmann et al., 2004).  Upon activation by pro-
inflammatory stimuli (IL-8, lipopolysaccharide (LPS), 
bacteria, fungi, activated platelets), neutrophils start a 
program that leads to the formation of NETs and to 
their death, termed NETosis.  This involves gradual 
disintegration of the nuclear membranes and loss of 
granule integrity, with subsequent filling of the cell 
with nuclear material, mixed with cytoplasmic and 
granule contents.  Hence, these NETs consist of 
bundled chromatin fibers (DNA and histones), 
decorated with (antimicrobial) granular and 
cytoplasmic proteins.  NETs capture and kill microbes 
such as bacteria, fungi and parasites using these 
antimicrobial proteins as well as bactericidal histones 
(Brinkmann and Zychlinsky, 2007; Papayannopoulos 
and Zychlinsky, 2009). Indeed, histones and histone-
derived fragments were shown to have a variety of 
antimicrobial functions, including bacterial cell 
membrane permeabilization, penetration into the 
membrane, and binding and neutralizion of bacterial 
LPS toxicity.  Of interest, a portion of these histone 
fragments have been shown to be produced from 
precursor histones via specific cleavage by endogenous 
proteases (Kawasaki and Iwamuro, 2008).  Since 
histones were identified as MMP-2 candidate 
substrates (cf. Table 3), and endogenous or exogenous 
ROS are required for NET formation and may activate 
MMPs (cf. section 1.2), MMPs may very well be the 
activators of histone microbicidal activity, 
intracellularly before the NETs are released, or 
extracellularly after NET expulsion.  This would 
indeed be very similar to the respective intracellular 
and extracellular activation of murine and human α-
defensins, as discussed in section 3.3.1.  MMP-9, 
which is present in tertiary neutrophil granules, was 
also found on these NETs (Brinkmann et al., 2004), 
and is thus ideally positioned to participate in 
proteolytic defensin and histone activation.  A recent 
proteomic study identified 24 different NET-associated 
proteins, a surprisingly restricted set, since the 
chromatin comes in contact with the full cytoplasmic 
contents during NETosis and the cell membrane 
ruptures during NET release (Urban et al., 2009).  
Interestingly, half of these NET proteins are MMP 
(candidate) substrates (cf. Table 7), again pointing to 
the potential modification of NET activities by MMPs.  
NETosis is restricted to neutrophils, but the formation 
of different kinds of extracellular traps (ETs) was also 
observed in other granulocyte cell types, such as mast 
cells and eosinophils (von Kockritz-Blickwede and 
Nizet, 2009). 
 
In conclusion, whereas MMPs may cleave various 
substrates within cells, it is clear that they can also 
access many intracellular proteins in the extracellular 
milieu.  Since many of the proteins that leave cells by 
unconventional ways are molecules with multiple 
functions, that differ according to their location in the 
extracellular vs. intracellular milieu, the modulation of 
these substrates by MMPs adds an additional layer of 
complexity to MMP inhibition in pathology.  Indeed, 
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inhibition of potential detrimental effects of MMPs on 
these bimodal substrates will require milieu-specific 
inhibitors that do not enter the compartment where 
substrate cleavage is beneficial. 
 
 
 
 
 
Table 7. Extracellular localization mechanisms of intracellular MMP substrates 
NON-CLASSICAL SECRETION 
MECHANISMS CELLULAR EXIT DURING CELL DEATH 
DIRECT TRANSMEMBRANE TRANSLOCATION APOPTOTIC BLEBS/BODIES 
Galectin-1 (Schafer et al., 2004) Annexin I (Arur et al., 2003) 
Galectin-3 (Lukyanov et al., 2005) La (Casciola-Rosen et al., 1994) 
LYSOSOMAL SECRETION Calreticulin (Rosen and Casciola-Rosen, 1999) 
Cathepsin D (Mambula et al., 2007) Histone H2A (Schiller et al., 2008) 
HMGB1 (Gardella et al., 2002) Histone H2B (Schiller et al., 2008) 
HSP70 (Mambula et al., 2007) Histone H4 (Schiller et al., 2008) 
EXOSOME-MEDIATED SECRETION Jo-1 (Rosen and Casciola-Rosen, 1999) 
Actin-β/γ (Thery et al., 2001) PARP (Rosen and Casciola-Rosen, 1999) 
α-Actinin-4 (Simpson et al., 2008) Vimentin (Boilard et al., 2003) 
Alix (Thery et al., 2001) ALARMINS 
Annexin I (Thery et al., 2001) α-defensins (Yang et al., 2009) 
Carbonic anhy-
drase II (Simpson et al., 2008) Annexin I (Bianchi, 2007) 
Cofilin-1 (Thery et al., 2001) Galectin-1 (Cambi and Figdor, 2009) 
Cyclophilin A (Yu et al., 2006) Galectin-3 (Cambi and Figdor, 2009) 
EF 1-α1 (Yu et al., 2006; Thery et al., 2001) HDGF (Bianchi, 2007) 
EF2 (Thery et al., 2009) HMGB1 (Bianchi and Manfredi, 2007) 
Enolase-α (Yu et al., 2006) HSP70 (Bianchi, 2007; Kono and Rock, 2008) 
Ezrin (Thery et al., 2009; Simpson et al., 2008) HSP90 (Bianchi, 2007; Kono and Rock, 2008) 
Ferritin light chain (Thery et al., 2001) Nucleolin (Bianchi, 2007) 
GAPDH (Thery et al., 2009; Simpson et al., 2008) NETOSIS 
Galectin-3 (Thery et al., 2001)  Actin-β/γ (Brinkmann et al., 2004; Urban et al., 2009) 
Histone H2A (Thery et al., 2001) α-Actinin-1 (Urban et al., 2009) 
Histone H2B (Thery et al., 2001) α-Actinin-4 (Urban et al., 2009) 
Histone H4 (Thery et al., 2001) α-defensins (Urban et al., 2009) 
HSC70 (Thery et al., 2009; Simpson et al., 2008) Annexin I (Brinkmann et al., 2004) 
HSP70 (Thery et al., 2009) Cytochrome c (Brinkmann et al., 2004) 
HSP90 (Thery et al., 2001; Yu et al., 2006) Enolase-α (Urban et al., 2009) 
Malate 
dehydrogenase (Simpson et al., 2008) Histone H2A (Brinkmann et al., 2004) 
Moesin (Thery et al., 2009; Simpson et al., 2008) Histone H2B (Brinkmann et al., 2004) 
Myosin (Thery et al., 2009; Simpson et al., 2008) Histone H4 (Brinkmann et al., 2004) 
Peroxiredoxin-1 (Thery et al., 2001) Myosin (Urban et al., 2009) 
PGK1 (Yu et al., 2006) Tubulin-α (Brinkmann et al., 2004) 
PGM1 (Simpson et al., 2008) 
Profilin-1 (Thery et al., 2001) 
Rab GDI-β (Simpson et al., 2008) 
Rho GDI-α/β  (Thery et al., 2009; Simpson et al., 2008) 
Tubulin-α/β (Thery et al., 2001) 
14-3-3 proteins (Thery et al., 2001; Simpson et al., 2008) 
SECRETION BY VESICLE SHEDDING 
Annexin I (Simpson et al., 2008) 
Galectin-1 (Cooper and Barondes, 1990; Harrison and Wilson, 1992)   
Galectin-3 (Simpson et al., 2008; Mehul and Hughes, 1997)   
Histones (Simpson et al., 2008) 
HSP27 (Simpson et al., 2008) 
HSP70 (Simpson et al., 2008) 
HSP90 (Simpson et al., 2008) 
The meaning of the acronyms can be found in Table 3 and 5.
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4.2 Extracellular  proteolysis  of 
intracellular  substrates  in  physiology  and 
pathology 
 
4.2.1 Extracellular proteolysis of intracellular 
autoantigens in organ-specific autoimmune 
diseases: multiple sclerosis 
Multiple sclerosis (MS) is a chronic neurological 
disorder of the CNS, characterized by the breakdown 
of the BBB, perivascular infiltration of inflammatory 
cells, leading to the formation of the so-called 
‘vascular cuffs’, and multiple regions of focal myelin 
and neuronal loss (lesions or plaques).  MMPs may 
contribute to these pathogenic events by increasing the 
permeability of the BBB, enhancing demyelination by 
the degradation of myelin (glyco) proteins, e.g. myelin 
basic protein (MBP).  By the generation of antigenic 
peptides, and by the facilitation of infiltration and 
migration of immune cells through the ECM and the 
basal membrane (Cuzner and Opdenakker, 1999; 
Opdenakker and Van Damme, 1994; Rosenberg, 2009; 
Agrawal et al., 2006; Opdenakker et al., 2003). While 
attempting to identify the components of the myelin 
sheath that provoke the autoimmune reaction in MS, 
van Noort and colleagues isolated αB-crystallin (αB-
crys) as a prominent target in myelin from MS brains, 
but not in healthy brain myelin (van Noort et al., 
1995).  In addition, αB-crys is the most abundant gene 
transcript present in early active MS lesions, whereas 
such transcripts are absent in normal brain tissue 
(Chabas et al., 2001).  MMP-9 cleaves αB-crys at 
multiple sites in vitro (cf. Table 8) and released various 
immunodominant and cryptic epitopes of αB-crys.   
Whereas both intact αB-crys and the immunodominant 
peptide 1-16 stimulated T-cell proliferation in vitro, 
neither intracerebral injection of the MMP-9-generated 
fragments nor injection of intact αB-crys triggered 
immediate neuroinflammation in an unprimed host in 
vivo (Starckx et al., 2003).  Besides being a major MS 
autoantigen, αB-crys was discovered to possess 
neuroprotective and anti-apoptotic functions in the 
brain.  αB-crys knockout mice are more susceptible to 
development of experimental autoimmune 
encephalomyelitis (EAE), a murine MS model, and 
administration of recombinant αB-crys ameliorated 
EAE symptoms (Ousman et al., 2007).  Hence, 
degradation of αB-crys by MMP-9 may be pathogenic 
by the ablation of these protective functions (Starckx et 
al., 2003).  This is supported by the finding that young 
gelatinase B-deficient mice are resistant to EAE 
development (Dubois et al., 1999).  The loss of 
protection at a more advanced age may be explained 
by the fact that various MMPs proteolyse αB-crys at 
multiple scissile bonds (cf. Table 8) (Shiryaev et al., 
2009) and may compensate for the absence of MMP-9-
mediated αB-crys destruction.   
 
 
Table 8.  Overview of the cleavage sites of various MMPs in αB-crystallin 
Cleavage sites*  MMP­9†  MMP­2  MMP­8  MMP­10  MMP­12  MT1­
MMP 
MT2­
MMP 
MT3­
MMP 
MT4­
MMP 
MT5­
MMP 
MT6­
MMP 
His7-Pro8 √ √ √ 
Pro16-Phe17 √ 
Arg22-Leu23 √ √ √ 
Pro46-Phe47 √ √ √ √ √ √ √ √ √ √ 
Tyr48-Leu49 √ √ √ √ √ 
Ser53-Phe54 √ √ √ √ √ 
Phe54-Leu55 √ √ √ √ √ √ √ √ √ √ √ 
Trp60-Phe61 √ √ √ √ √ √ √ 
Glu67-Met68 √ √ √ √ √ √ √ 
His83-Phe84 √ 
Glu88-Leu89 √ √ √ √ √ √ 
Asp96-Val97 √ 
Phe113-Ile114 √ √ √ √ √ √ √ 
Lys121-Tyr122 √ √ √ √ √ √ 
Pro130-Leu131 √ √ √ √ 
Tyr132-Ile133 √ √ √ √ √ √ √ √ √ √ 
Lys150-Gln151 √ √ √ √ √ √ √ √ √ 
*The cleavage sites are compiled from (Shiryaev et al., 2009) and (Starckx et al., 2003). 
†MMP-9 also partially processes the following peptide bonds: Met1-Asp2; Asp2-Ile3; Ala4-Ile5; Asp25-Gln26; Glu30-His31;  Leu32-Leu33; 
Ser35-Asp36; Thr40-Ser41; Thr42-Ser43; Phe47-Tyr48; Arg69-Leu70; Asn78-Leu79; Glu99-Val100; Val100-His101; Gly102-Lys103; 
Gly112-Phe113; Tyr122- Arg123; Ser136-Leu137; Pro160-Ile161;Val169-Tyr170 (Starckx et al., 2003). 
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4.2.2 Extracellular proteolysis of intracellular 
autoantigens in systemic autoimmune diseases: 
SLE 
Systemic lupus erythematosus (SLE) is a prototypic 
systemic autoimmune disease characterized by the 
production of high titers of autoantibodies directed 
against ubiquitous intracellular, and mostly nuclear, 
autoantigens. The diverse symptoms of SLE range from 
rash and arthritis through anemia and thrombocytopenia 
to serositis, nephritis, seizures, and psychosis.  
Pathogenic autoantibodies and circulating immune 
complexes are the primary cause of tissue damage in 
patients with SLE (Rahman and Isenberg, 2008).  More 
than 100 different autoantibodies have been found in SLE 
patients, and these arise from the dysregulation of all of 
the key components of the immune system (Sherer et al., 
2004).  Apoptotic cells have been increasingly accepted 
to have initiating and propagating effects in SLE (Munoz 
et al., 2005).  Indeed, lymphocytes of SLE patients show 
accelereated apoptotis rates (Emlen et al., 1994; Denny et 
al., 2006).  In addition, in SLE, phagocytes have 
decreased phagocytic activities, which results in a 
defective clearance of apoptotic cells (Ren et al., 2003; 
Gaipl et al., 2005).  Hence, the overload of apoptotic 
cells progresses to secondary necrosis and intracellular 
proteins become accessible to post-translational 
modifications (Dieker and Muller, 2009), for example by 
proteases (cf. 4.1.2). Altered intracellular autoantigens 
and danger signals released from necrotic cells create a 
pro-inflammatory environment in which dendritic cells 
engulfing apoptotic cells may become activated instead 
of tolerogenic (Savill et al., 2002; Viorritto et al., 2007).  
These activated ‘immunogenic’ dendritic cells may in 
turn activate autoreactive T and B cells, leading to the 
production of autoantibodies and formation of pathogenic 
immune complexes.  Infection or environmental 
exposures may raise the apoptotic burden to initiate 
autoimmune disease and cause relapses.  Furthermore, 
apoptotic cells cluster intracellular and nuclear proteins 
on the surface of apoptotic blebs and apoptotic bodies (cf. 
4.1.2), many of which are major SLE autoantigens.   
Hence, the question was raised whether MMPs may 
modify these systemic autoantigens exposed on the 
apoptotic cell surface, as well as the overload of SLE 
autoantigens released during (secondary) necrosis.  To 
investigate this, a system of dying monocytic leukemia 
cells was used with MMP-9 as a model protease.  This 
‘one-dimensional degradomics system’ identified 
adenylyl cyclase-associated protein-1 or CAP1 as novel 
and highly efficient substrate of MMP-9 during cellular 
necrosis (Cauwe et al., 2008).  Indeed, cleavage of CAP1 
was more efficient than the cleavage of gelatin, the 
physiological MMP-9 substrate.  In addition, CAP1 was 
also degraded by other MMPs (cf. Table 5), but at 
physiological concentrations, MMP-9 was the only 
(tested) MMP that caused its degradation.  CAP1 is a 
cytoskeletal protein involved in the promotion of actin 
filament turnover (Bertling et al., 2004; Moriyama and 
Yahara, 2002)  and it was identified as an autoantigen in 
SLE (Frampton et al., 2000) and rheumatoid arthritis 
(Kinloch et al., 2005).  Moreover, intact CAP1 was 
identified in the urines of patients with systemic 
autoimmune diseases such as SLE, vasculitis and 
Sjögren’s syndrome, as well as in healthy control urines.  
Whereas healthy control urines did not contain activated 
MMP-9, urine samples of patients with clinical 
parameters suggesting renal failure showed increased 
levels of pro-MMP-2 and pro-MMP-9, and the 
appearance of activated forms of both gelatinases, as 
evidenced by substrate zymography.  Of interest, in some 
patient urines, an inverse relation was observed between 
the levels of intact CAP1 and activated forms of MMP-2 
and MMP-9, and one urine sample of an SLE patient 
contained CAP1 fragments.  These findings, together 
with the high turnover rate of CAP1 by MMP-9, suggest 
that this cleavage may occur in vivo (Cauwe et al., 2008).  
In a recent study, a pro-apoptotic role is described for 
CAP1.  Upon apoptosis induction by various stimuli, 
CAP1 translocates rapidly to the outer mitochondrial 
membrane even before caspase activation.  CAP1-
knockdown cells are resistant to apoptosis inducers, 
showing that the mitochondrial translocation of CAP1 is 
proapoptotic, possibly by shuttling apoptosis-inducing 
actin to the mitochondria (Wang et al., 2008).  MMP-9 
was found in mitochondria (cf. 3.2.5 and 3.3.3) and its 
efficient cleavage of CAP1 may result in defective 
apoptosis, pushing the cell death program towards 
immunogenic necrosis.  Alternatively, CAP1 may be 
cleaved by MMP-1, which was found to confer resistance 
to apoptosis when associated with mitochondrial 
membranes (cf. sections 3.2.5 and 3.3.6 and Figure 7) 
(Limb et al., 2005). 
By developing and applying a two-dimensional 
degradomics (2DD) approach to THP-1 cytosol (cf. 
chapter 2), the intracellular degradome of MMP-9 was 
further expanded and this demonstrated that about two 
thirds of the identified (candidate) substrates are 
autoantigens described in one or multiple autoimmune 
conditions, and in cancer (e.g. annexin I, nucleolin, 
citrate synthase, cyclophilin A, HMGB1/2, α-enolase, 
histidyl-tRNA synthetase, HSP27, HSP90, 
phosphoglycerate kinase 1) (Cauwe et al., 2009).  
From Tables 3 and 5, it is clear that cleavage of 
systemic autoantigens may be a general MMP 
function, and that cleavage by MMPs is predictive of 
autoantigen status, as was described for the caspases 
and granzyme B (Rosen and Casciola-Rosen, 1999).  
Indeed, on top of the above-mentioned autoantigens 
targeted by MMP-9, MMPs (may) cleave many nucleic 
acid-associated autoantigens such as histones, hnRNPs, 
La, PARP-1, SmD3, nucleophosmin and cytoplasmic 
autoantigens including various elongation factors, 
cytoskeletal proteins, calpastatin, cathepsins G (Sherer 
et al., 2004; Hoffmann et al., 2009; Cauwe et al., 
2009). 
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Proteolysis of systemic autoantigens by caspases and 
granzymes was proposed to be immunogenic by the 
release of normally ‘hidden’ cryptic epitopes (Rosen and 
Casciola-Rosen, 1999).  However, Granzyme B may both 
release and destroy immunodominant epitopes (Darrah 
and Rosen, 2010).  In addition, a study with granzyme B-
deficient mice showed that granzyme B is not required 
for the development of pristane-induced SLE and may 
even have a protective effect, as the granzyme B-
deficient mice showed increased mortality after pristane 
treatment (Graham et al., 2005).  This suggests that 
autoantigen cleavage does not necessarily lead to the 
stimulation of autoimmunity.  As cleavage by MMPs is 
also predictive for autoantigen status, a similar question 
remains.  Will proteolysis by MMPs lead to the release of 
tolerance-breaking neo-epitopes or will degradation by 
MMPs disrupt immunodominant epitopes and contribute 
to the silent removal of (abundant) intracellular proteins 
after necrosis and tissue injury? 
In addition, the complex consequences of systemic 
autoantigen cleavage by MMPs may not be restricted to 
the alteration of the substrate’s immunogenicity.  Indeed, 
by cleavage of calreticulin and annexin I at the surface of 
apopotic cells, MMPs may abolish recognition by 
phagocytes in SLE (cf. 4.1.2), contribute to the clearance 
deficiency and further tip the balance to immunogenic 
secondary necrosis.  Alternatively, ingestion of apoptotic 
cells has been suggested to be tolerogenic in the absence, 
and immunogenic in the presence of danger signals, 
respectively (Viorritto et al., 2007; Savill et al., 2002).  
Hence, if MMPs degrade and inactivate danger signals, 
as discussed for the above-mentioned alarmins (cf. 4.1.2), 
they may promote tolerance and dampening of 
inflammation.    
In conclusion, further examination of the effects of 
proteolysis by MMPs on the immunogenicity and 
function of systemic autoantigens may yield interesting 
insights into the etiology and relapsing-remitting 
mechanisms of complex systemic autoimmune diseases. 
4.2.3 Extracellular proteolysis of intracellular 
autoantigens in acute necrotic conditions 
Fulminant hepatic necrosis, septic shock, ischemic 
conditions, acute respiratory distress syndrome (ARDS), 
tumor lysis syndrome, pre-eclampsia during pregnancy, 
hemolysis due to malaria, severe traumatic and burn 
injuries, are all acute conditions accompanied by massive 
cellular necrosis and tissue injury. These conditions 
depend on a rapid ‘cleaning’ system to remove the 
overload of toxic and immunogenic proteins released 
from the cells, in order to prevent inflammation and 
secondary injury.  Indeed, when cells die, monomeric and 
filamentous actins are released into the extracellular 
space and reach the systemic circulation.  In the plasma, 
where the ionic strength, pH and temperature promote 
polymerization, actin monomers can form long filaments 
together with coagulation factor Va, which triggers 
disseminated intravascular coagulation, if not rapidly 
resolved.  Functional organ decompensation leads to a 
condition resembling multiple organ dysfunction 
syndrome (MODS).  In addition, the high viscosity of 
actin filaments, the inhibitory effect of actin on 
fibrinolysis, and the fact that actin binds adenine 
nucleotides that activate purinergic receptors are all 
mechanisms that may lead to secondary tissue injury 
(Bucki et al., 2008).  However, to avoid these toxic 
effects of extracellular actin, a complex actin-scavenging 
system exists in the vascular compartment.  This system 
involves 2 proteins: plasma gelsolin that releases 
monomers from the toxic filaments, and Gc-globulin, 
which complexes the freed monomers.  Both actin-
gelsolin and actin-Gc-globulin complexes are 
subsequently cleared by the liver phagocytes much more 
efficiently than the free proteins (half-lives of 30 min. vs. 
1-2 days, respectively).  Nevertheless, excessive release 
of cellular actins or decreased activity of the actin-
scavenger system causes severe pathological conditions 
such as MODS, hepatic necrosis, ARDS, septic shock, 
and complications of pregnancy (Haddad et al., 1990; 
Lee and Galbraith, 1992; Dahl, 2005; Meier et al., 2006).   
Gelsolin exists in an intracellular and a secreted 
isoform.  Both isoforms are derived from a single gene 
by alternative transcriptional initiation sites and mRNA 
processing, which removes the signal sequence and 
NH2-terminus to generate cytoplasmic gelsolin.  The 
term ‘gelsolin’ refers to its ability to convert 
filamentous actin (F-actin) from a ‘gel’ to a ‘solvent’ 
state by rapid shortening of the filaments 
(Kwiatkowski et al., 1988).  Plasma gelsolin not only 
binds actin, but also scavenges a variety of potentially 
inflammatory moieties such as platelet-activating 
factor, lysophosphatidic acid, sphingosine-1-phosphate 
and bacterial cell wall constituents.  In this way, 
gelsolin can modulate the exuberance of the host 
response to sepsis, malaria, burns, trauma, and other 
acute clinical conditions.  The lower the levels of 
plasma gelsolin, the less favorable the prognosis of 
acute illness becomes   (DiNubile, 2008; Bucki et al., 
2008).  Plasma gelsolin was identified by 2D-PAGE as 
a MT1-MMP substrate in plasma (Hwang et al., 2004).  
In addition to MT1-MMP, gelsolin is cut into several 
fragments by various MMPs.  MMP-3 cleaves gelsolin 
most efficiently, followed by MMP-2, MMP-1, MT1-
MMP and MMP-9.  MMP-3 cleaves gelsolin at 
Asn416-Val417, Ser51-Met52, and Ala435-Gln436, 
which results in considerable loss of its 
depolymerizing activity (Hwang et al., 2004; Park et 
al., 2006).  This suggests that MMPs may weaken the 
extracellular actin-scavenging system by cleaving 
gelsolin and enhancing primary and secondary injury 
in pathological conditions induced by extracellular 
actin.   
However, MMPs may also have a beneficial effect 
after massive necrosis.  Indeed, by cleaving actin, they 
diminish primary and secondary effects of actin 
toxicity.  By degradation of many essential 
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actin/tubulin-binding proteins such as ezrin, moesin, 
CAP1, Arp2/3 complex subunits, IQGAP1, profilin, 
stathmin, tubulin (cf. Tables 3 and 5), they may inhibit 
polymerization and branching of the cytoskeleton in 
the extracellular space and prevent the previously 
mentioned consequences of massive necrosis (Cauwe 
et al., 2009). Hence, cleavage of cytoskeleton-
associated proteins after necrosis may have both 
positive and negative outcomes.  The extracellular 
clearance may be part of a physiological process that 
clears proteins released by occasional necrosis in the 
tissues.  In steady-state conditions, MMP activity in the 
circulation is kept in check by the general inhibitor α2-
macroglobulin.  Hence, gelsolin will not be cleaved 
and may exert its actin-scavenging role.  However, in 
acute inflammation, activated MMPs are found in the 
circulation, where they may inactivate gelsolin with the 
ensuing pathological consequences.  In addition, the 
outcome may depend on the MMP in charge.  Since 
MMP-9 is less efficient at gelsolin cleavage, it may 
have mostly beneficial effects by clearing abundant 
cytoskeletal proteins and by the very efficient 
degradation of CAP1 (vide supra).  However, MMP-3 
may be mostly pathogenic by weakening the gelsolin 
scavenging capacity.  Since MMP inhibitors were 
proposed as an interesting line of therapy in acute 
inflammatory conditions (Hu et al., 2007), determining 
the balance of pathogenic and beneficial effects of 
MMPs after massive necrosis may be of critical 
importance.  Indeed, an ideal time-window and 
duration of inhibition will limit or even prevent toxic 
side effects (Hu et al., 2007). 
4.2.4 Extracellular proteolysis of 
intracellular autoantigens in amyloid diseases 
Protein conformational diseases are diverse 
disorders characterized by abnormal unfolding, 
followed by aggregation and progressive accumulation 
of a disease-associated (glyco)protein.  Another 
common feature of these protein conformational 
diseases is that they are mostly late-onset illneses 
(Surguchev and Surguchov, 2010).  The pro-
aggregating roles of MMPs in two protein 
conformational diseases with mostly intracellular 
accumulation of protein aggregates, namely 
Parkinson’s disease (cf. 3.3.4) and cataract (cf. 3.3.5), 
were already discussed.  Here, we discuss the 
aggregation of gelsolin, which leads to familial 
amyloidosis of Finnish type (FAF).  FAF is a late-onset 
autosomal dominant disease, which leads to 
progressive peripheral neuropathy that involves the 
cranial nerves and especially the facial nerve.  These 
symptoms are caused by deposition of amyloid in the 
perineurium, vascular walls, cornea and skin  
(Luttmann et al., 2010).  FAF patients possess mutated 
plasma gelsolin (D187Y/N), which is aberrantly 
processed by at least two successive proteolytic events 
to generate amyloidogenic peptides.  D187Y/N 
mutations abolish Ca2+ binding in domain 2, 
destabilizing and rendering the domain accessible to 
aberrant proteolysis by an α-gelsolinase, that was 
identified as furin (Chen et al., 2001b).  Cleavage of 
mutated gelsolin by furin at Arg172-Ala173 occurs as 
it transits through the Golgi apparatus and yields a 
secreted 68 kDa COOH-terminal fragment (C68) that 
contains the amyloidogenic region at is NH2-terminus.  
C68 is the substrate for a second protease, β-
gelsolinase, whose activity yields major 8 kDa and 
minor 5 kDa amyloidogenic fragments.  Incubation of 
C68 with lysates of the human fibrosarcoma-derived 
cell lin HT1080 (but not with HT1080 culture medium) 
resulted in cleavage of C68 into the amyloidogenic 8 
kDa and 5 kDa peptides, and this was inhibited by the 
general MMP inhibitor GM6001 and TIMP-2, but not 
by TIMP-1.  These results suggest that the β-
gelsolinase is an MT-MMP.  Indeed MT1-MMP 
cleaves C68 in vitro at Ala242-Met243, generating the 
8 kDa fragment, which is converted into the 5 kDa 
upon additional incubation with MT1-MMP  (Page et 
al., 2005).  Other MMPs also cleave C68 in vitro (cf. 
4.2.3), i.e. MMP-3, -7, -9, but not MMP-2, indicating 
that multiple MMPs may contribute to 
amyloidogenesis.  ECM components, such as 
glycosaminoglycans accelerate amyloidogenesis at 
neutral pH, suggesting that gelsolin is cleaved and 
forms fibrils in the neutral environment of the ECM 
(Annabi et al., 2001).  However, since 
amyloidogenesis is optimal at low pH (Ratnaswamy et 
al., 1999) and MMPs may be activated intracellularly, 
intracellular β-gelsolinase activity by MMPs can not be 
excluded. 
MMPs were also shown to be involved in fibril 
formation (and degradation) in AA amyloidosis, 
caused by aggregation of the acute-phase protein 
serum amyloid A (SAA) (Stix et al., 2001) and in the 
most prevalent amyloid disease, Alzheimer’s disease, 
caused by amyloid β (Aβ) deposition in the brain.  Of 
interest, gelsolin inhibits the fibril formation of Aβ and 
destabilizes preformed Aβ fibrils (Ray et al., 2000).  In 
addition, cytoplasmic gelsolin reduces Aβ burden in a 
mouse model of Alzheimer’s disease and prevents Aβ-
induced apoptotic mitochondrial changes (Antequera et 
al., 2009). Hence, cleavage of the anti-amyloidogenic 
gelsolin may have pathogenic effects in both FAF, 
Alzheimer’s disease, and in acute necrotic conditions 
(cf. 4.2.3). 
In conclusion, the clarification of the roles played 
by MMPs in these and other amyloid diseases and 
protein conformational disorders, may result in novel 
therapeutic strategies. 
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CONCLUSION 
Matrix metalloproteinase substrate identification 
has evolved from extracellur matrix molecules to 
secreted and membrane-bound molecules.  All these 
substrates imply the extracellular action of MMPs.  
Here, we review that intracellular localization of 
MMPs may not be an artifact by mislocalizations.  
Activated MMPs are found in many subcellular 
compartments where they cleave intracellular proteins 
or even exhibit non-proteolytic functions acting as 
transcription factor (Eguchi et al., 2008) or 
antimicrobial agent (Houghton et al., 2009).  Indeed, 
most MMPs are modular entities that often share 
protein domains with members of sister enzyme 
families, including the ‘a disintegrin and 
metalloproteinase (ADAM)-family’ and the ‘a 
disintegrin and metalloproteinase with 
thrombospondin-like motif (ADAMTS)’ enzymes. 
Therefore, it is not surprising that biological functions 
of specific MMPs depend on protein domains different 
from the catalytic site. A recent prominent example of 
such MMP multifunctionality is the anti-apoptotic 
activity of the hemopexin domain, discovered for 
human MMP-2 and MMP-9 (Redondo-Munoz et al., 
2010) and the non-catalytical unwinding of collagen by 
collagenases and aggrecanases (Nagase and Fushimi, 
2008) .  
Searching for common denominators in the 
intracellular actions of MMPs, we came across various 
interrelated pathophysiological settings, such as 
cancer, cellular stress, apoptosis, degenerative and 
protein conformational diseases.  Indeed, under cellular 
stress, MMPs may be activated by ROS and RNS, and 
exert pathological actions such as the cleavage of heat 
shock proteins and other chaperones that are 
upregulated to avoid stress-induced protein 
precipitation and that rescue a stressed cell from 
apoptosis.  Hence, cleavage of chaperones is pro-
apoptotic and will lead to protein aggregation and cell 
death, as observed in protein conformational diseases, 
such as cataract, Parkinson’s disease and amyloid 
disorders.  Proteolysis by MMPs even causes direct 
aggregation and precipitation of amyloidogenic 
proteins, suggesting that MMP inhibition in such 
protein conformational diseases may have double 
benefits.  Extended cell death leads to degeneration, for 
example after ischemia/reperfusion injury in heart and 
brain.  Many observed intracellular cleavages have 
turned out to have pro-apoptotic effects.  However, 
dual roles in the apoptotic cascade are to be expected.  
Understanding the roles that MMPs may play in the 
decision making process as to whether a cell should 
live or die, may shed new light on the targeting of 
cancer cells and autoreactive cells in autoimmunity, 
and the prevention of cell death in degenerative 
diseases.  As a result, an additional reason why MMPs 
are produced as inactive zymogens seems to be to 
avoid intracellular damage in healthy cells, whereas 
stressed cells have various ways to activate the MMPs, 
such as proteolysis by caspases and oxidative stress.  
However, as MMP activity is regulated by subtle 
concentration changes of ROS and RNS, as well as by 
phosphorylation, it cannot be excluded that MMPs also 
function as intracellular signaling molecules in cellular 
homeostasis, by proteolytic or non-proteolytic actions. 
It will presumably take a while before we 
understand the complexities of subcellular enzyme 
substrate ecosystems in e.g. inflammation, at the tumor 
cell invasion front or in a developing organism. Along 
similar lines of complexities, by degradomics and 
reverse-degradomics approaches, attempts are made to 
understand the complex protease web (Overall and 
Kleifeld, 2006; Kruger et al., 2010). Similar to the 
Human Genome (HUGO) Project, the elucidation of 
degradomes, the establishment of the protease web and 
the exact and the complete remodeling of any protein 
as a substrate of proteases and peptidases are 
technically doable. Whether the full insights will lead 
to new treatments, remains an unanswered question. 
However, the definition of a critical activation 
cleavage within a cascade or a network will remain a 
valuable approach for the development of novel 
therapies.   
Nevertheless, therapeutic MMP inhibition is still 
far from home. The well-acknowledged complexities 
are the extended redundancy within the MMP family 
for a specific proteolytic action, with another MMP 
compensating for the inhibited one.  The extensive lists 
of substrates discovered for every single MMP imply 
that pathogenic substrates will accumulate when 
inhibiting cleavage of physiological ones. In addition, 
the same MMP may have a pathological effect in an 
early disease state and a protective function in the final 
stages.  Hence, inhibitors should not only be MMP-
specific, but also time- and substrate-specific.  With 
the discovery of intracellular MMP functions, an 
additional dimension is added to tissue ecosystems, 
since MMPs inside or outside cells may have different 
and even opposite effects on a particular disease 
outcome.  Hence and ideally, an effective MMP 
inhibitor should also be specific for the specific 
subcellular locations where the particular MMP action 
is pathogenic. 
In conclusion, what we presently know about 
intracellular MMP functions and cleavages of 
intracellular substrates may only be the tip of the 
iceberg.  Further characterization of intracellular 
substrates in physiology and pathology is amongst the 
challenges in current MMP research. 
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DISCUSSION PART 2.  NOVEL FUNCTIONS OF GELATINASE B/MMP‐9 IN THE 
SUPPRESSION OF LYMPHOPROLIFERATION AND SYSTEMIC AUTOIMMUNITY 
Inbred mice that spontaneously develop a disease similar to human SLE, such as New Zealand, 
MRL and BXSB mice, represent invaluable tools for the genetic dissection of susceptibility to SLE 
and for the elucidation of immunological abnormalities.  Common characteristics of these mice 
include a generalized B cell hyperreactivity leading to hypergammaglobulinemia, early IgM to IgG 
switching, production of autoantibodies against a wide variety of self antigens, formation of 
immune complexes (ICs) and multiple histopathological manifestations, of which 
glomerulonephritis is the most prominent [76].  During the present doctoral research we chose to 
investigate the influence of MMP-9 on the homozygous lpr mutation in the apoptosis-inducing 
receptor Fas.  The trimeric transmembrane receptor Fas (CD95, Apo-1) is constitutively expressed 
by different cell types, including T cells.  In contrast, the expression of Fas ligand (FasL, CD95L, 
CD178) is tightly regulated and limited to immune privileged sites and activated immune cells, such 
as T cells after repeated T cell receptor (TCR) stimulation at the end of the immune response. Fas 
engagement by FasL leads to the recruitment of Fas-associated death domain-containing protein 
(FADD) and activation of effector caspases that cleave essential cellular proteins and DNA, leading 
to apoptosis [77].  On the autoimmune MRL background (MRLlpr/lpr), the lpr mutation in the Fas 
gene causes IC-mediated glomerulonephritis, arthritis, vasculitis, pneumonitis and sialoadenitis, 
which is very similar to the autoimmune symptoms caused by the generalized lymphoproliferative 
disease (gld) mutation in the FasL gene [78].  Because of the C57Bl/6 background (B6) of the 
MMP-9 knockout mice [67], B6lpr/lpr with the lpr mutation on a B6 background were used to avoid 
lengthy backcrossings from the MRL to the C57Bl/6 background (cf. Chapter 4). Whereas 
MRLlpr/lpr mice develop massive nonmalignant lymphoproliferation and extensive autoimmune 
tissue injury, in B6lpr/lpr mice the lupus-like syndrome is delayed and subdued [78].   
Double negative (DN) T cells 
In healthy persons and normal mice, DN T cells represent only 1% to 5% of peripheral lymphocytes 
and have regulatory functions. These ‘regulatory DN T cells’ are able to suppress the activity of 
CD8+ and CD4+ T cells in an antigen-specific manner by direct Fas/FasL-mediated killing [48].  
Little, if any, defects in thymic negative selection are observed in the absence of a functional Fas 
pathway, ruling out defective T cell development as a major cause of lymphoproliferation [79].  
Several genetic deficiencies lead to T cell lymphoproliferation, as was described for CTLA-4 
deficient mice [80] and the Treg-deficient scurfy mice [81], but only the lymphoproliferation 
induced by impairment of the Fas pathway (by homozygous lpr or gld mutations or other Fas 
mutations in patients with autoimmune lymphoproliferative syndrome (ALPS)) is dominated by DN 
T cells [78,82].  This was recently clarified by the finding that in the periphery, DN T cells die at 
exceptionally high rates by Fas-mediated apoptosis. Hence, in the absence of functional Fas, they 
progressively accumulate in peripheral lymphoid organs causing lymphadenopathy and 
splenomegaly [83].  The origin of DN T cells, however, remains controversial [48,79].  On the one 
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hand, DN T cells were suggested to develop from thymically derived CD8+ T cells as upon 
activation in vitro, a fraction of CD8+ T cells downregulates CD8 and acquires a pro-inflammatory 
cytokine production capacity [84].  On the other hand, CD8-deficient mice have fully functional 
regulatory DN T cells and these were suggested to mature extrathymically in organs such as bone 
marrow, appendix, or liver.  In addition, DN T cells were found in the nasal-associated lymphoid 
tissue of normal and athymic nude mice [48]. Furthermore, it is not clear how these regulatory DN 
T cells switch from a suppressive to a pro-inflammatory phenotype in mice and patients with SLE, 
where the expanded DN T cell population provides help to autoreactive B cells, secretes pro-
inflammatory cytokines and induces nephritis [46,49-51]. 
MMP‐9 effects on leukocyte homeostasis 
As detailed in Chapter 4, the presence of MMP-9 in B6lpr/lpr mice attenuates and delays the 
accumulation of DN T cells, the production of autoantibodies and the extent and severity of 
autoimmune tissue injury.  Since MMP-9 controls dendritic cell stimulatory and alloreactive T cell 
responses [71,72], the question was raised whether MMP-9 may attenuate lpr-induced 
lymphoproliferation.  Hence, future experiments will investigate whether MMP-9 deficieny 
enhances (DN) T and B cell proliferation in vivo.  Alternatively, or on top of enhanced proliferation, 
lack of MMP-9 may result in an additional apoptosis defect, as was described in zymosan peritonitis 
[85] and as suggested by many pro-apoptotic cleavages of intracellular substrates (cf. Discussion 
Part I). Analysis of lymphocyte apoptosis in B6lpr/lpr.MMP-9-/- and B6lpr/lpr.MMP-9+/+ mice will shed 
light on MMP-9-mediated regulation of apoptosis in systemic autoimmunity.  Finally, since MMP-9 
modulates cytokines and chemokines [61,62], as well as many membrane-associated molecules (cf. 
Chapter 1), it may be interesting to test whether cytokines such as BAFF and IL-10, and their 
respective receptors BAFF-R and IL-10R, may be modulated by MMP-9.  In addition, MMP-9 
mediates ectodomain cleavage of RAGE [86].  Since soluble RAGE was shown to inhibit activation 
of autoreactive B cells by chromatin ICs [87], measurement of soluble RAGE in B6lpr/lpr mice with 
or without MMP-9 deficiency may reveal in vivo proteolysis and the concomitant effects of RAGE 
shedding on systemic autoimmunity. 
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Figure 1. Degradation of SLE autoantigens by MMP-9 in vitro.  The autoantigens (100 µg/mL) were incubated for 
5h (and/or 20h for Ro-60 and La) in the absence (tF, -) or presence (+) of various concentrations of activated MMP-9 
(200 nM to 1.6 nM, decreasing from lane 3 to 6) and analysed by SDS-PAGE. Control incubations included incubation 
with activated MMP-9 (200 nM) supplemented with the metalloprotease inhibitor EDTA (20 mM) and incubation with 
the catalytical domain of MMP-3 (cd-MMP-3, 2 nM), used to activate MMP-9.  In addition, the highest concentration 
of MMP-9 was also incubated separately as a control for non-substrate fragment bands (lane 9).  Visualization of the 
intact substrates (arrows) before incubation is shown under t0.  Fragments generated by MMP-9 are indicated with 
asterisks (*). Apparent molecular masses are shown next to the gels in kDa.  Rib. Protein P0, ribosomal protein P0; 
CENP-B, centromere protein B; U1snRNP, U1 small nuclear ribonucleoprotein. 
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MMP‐9 and systemic autoantigen cleavage 
MMP-9 may also control lymphoproliferation and autoantibody production by the proteolysis 
of systemic autoantigens.   In systemic autoimmunity, most autoantibodies are directed to nucleic 
acid-binding proteins that are part of large intranuclear complexes such as nucleosomes, 
centromeres, small nuclear (sn) and nucleolar (sno) ribonucleoproteins (RNPs) or heterogenous 
nuclear (hn) RNPs, whereas other autoantibodies target particles that are temporarily located in the 
cytoplasm such as Ro RNPs, tRNA synthetase complexes and ribosomes.  For example, the 
U1snRNP complex is a major component of the spliceosome and consists of multiple proteins, 
including the seven Sm core proteins (B and its splice variant B’, D1, D2, D3, E, F, G) and the 
U1snRNP-specific proteins (U1snRNP 70 kDa, U1snRNP A and U1snRNP C) [9].  Many SLE 
autoantigens were found to be (candidate) substrates of MMP-9 by one-dimensional (cf. Chapter 2) 
and multidimensional (cf. Chapter 3) degradomics approaches. In addition, MMP-9 also cleaves 
major SLE autoantigens, such as the diagnostic Sm antigen B/B’, Ro-52 (Sjögren’s syndrome 
antigen A or SSA), ribosomal protein P0 (cf. Chapter 4), Sm antigen D3 (cf. Chapter 3) and La 
antigen (SSB) (Figure 1). Anti-Ro and anti-La antibodies are used for diagnosis in the absence of 
anti-double stranded(ds) DNA antibodies and have a high sensitivity and specificity for subacute 
cutaneous lupus (SCLE) and neonatal lupus erythematosus (NLE) [88].  Additional components of 
the Ro/La RNP complexes are nucleolin and calreticulin, which are also cleaved by MMP-9 (cf. 
Chapter 3) and other MMPs (cf. Discussion Part 1), respectively. The presence of anti-ribosomal 
protein P antibodies is associated with lupus cerebritis and psychosis [88]. Centromere protein B 
(CENP-B) is the immunodominant antigen of anti-centromere antibodies, which have a lower 
frequency in SLE but are often connected to the development of Raynaud’s phenomenon and 
pulmonary hypertension [9].  
Although some autoantigens were cleaved by MMP-9 with low efficiency (e.g. Ro-60 and 
U1snRNP 70 kDa), most autoantigens were cleaved fast and extensively (Figure 1).  For example, 
digestion of CENP-B and Ku (p70/p80) resulted in a ladder pattern, much alike the degradation of 
CAP1 (cf. Chapter 2); actin and tubulin (cf. Chapter 3); and U1snRNP A and ribosomal protein P0 
(cf. Chapter 4).  In addition, up till now, we did not find an autoantigen that was not cleaved at all.  
Hence, cleavage of intracellular proteins by MMP-9 may be considered as predictive for their 
autoantigen status, as was suggested for caspases and granzyme B (cf. Discussion Part 1) [53]. 
 
 
 
 
 
 
 
D I S C U S S I O N   P A R T   2  
 
237 | P a g e  
 
MMP‐9 and clearance of immunodominant epitopes 
  Many autoantibodies targeted at MMP-9 substrates have a high prevalence in SLE and are 
correlated with disease activity [8,9]. Hence, regarding the extent of SLE autoantigen cleavage, it 
was tempting to speculate that destruction of immunodominant epitopes for T and B cells 
contributes to the protective effects of MMP-9 in lpr-induced systemic autoimmunity. These cryptic 
epitopes are normally hidden inside cells, but when released into the extracellular milieu, their 
elimination by proteolysis may be crucial to maintain tolerance after (extensive) cell death.  In 
B6lpr/lpr mice, the accumulated DN T cells will eventually undergo secondary necrosis and provide a 
continous pool of autoimmune stimuli, which may be supplemented with necrotic material from 
autoimmune tissue lesions.  Therefore, the absence of MMP-9-mediated proteolysis may result in 
an additional clearance deficiency, which accelerates the onset of systemic autoimmunity and 
promotes its propagation (cf. Introduction).   
In a first attempt to corroborate this, we analyzed autoantibody responses against two abundant 
intracellular MMP-9 substrates, actin and tubulin (cf. Chapter 4).  Anti-actin and anti-tubulin IgG 
titers were indeed higher in B6lpr/lpr.MMP-9-/- mice compared with B6lpr/lpr.MMP-9+/+ mice, but this 
may be a general consequence of enhanced systemic autoimmunity and epitope spreading to 
multiple autoantigens. A more controlled approach to verify the effect of MMP-9-mediated 
proteolysis on B cell epitopes was to compare recognition of intact or cleaved autoantigens by 
autoantibodies from SLE mice and patients using competitive ELISA (cf. Chapter 4).  In this way, it 
became clear that proteolysis of the autoantigens ribosomal protein P0 and U1snRNP A by MMP-9 
strongly disturbed autoantibody binding, confirming a destruction of B cell epitopes by MMP-9 in 
these autoantigens.  Future experiments with multiple autoantigenic substrates of MMP-9 (and non-
substrates) may reveal if clearance of B cell epitopes is a general effect of MMP-9-mediated 
proteolysis.  Using plasma samples from B6lpr/lpr.MMP-9-/- mice and B6lpr/lpr.MMP-9+/+ mice, the 
relative effects or proteolysis on conformational vs. linear B cell epitopes may be assessed by a 
comparison of Western Blot analysis (for linear epitopes) and immunoprecipitation followed by 
Western blot analysis (for conformational epitopes).  To analyze the elimination (or formation) of 
autoreactive T cell epitopes, leukocytes of B6lpr/lpr mice and SLE patients may be stimulated to 
proliferate with intact and degraded autoantigens. 
However, since cell death results in the release of the entire cellular proteome, the total 
immunogenic or tolerogenic effect of proteolysis on the immune system is the sum of the 
destruction and generation of immunodominant epitopes within each individual cellular antigen 
(and by the complete pool of available proteases). To investigate whether proteolysis by MMP-9 
decreases or enhances the immunogenicity of the total intracellular protein pool, mice were 
immunized twice with THP-1 cytosol in complete Freund’s adjuvant (CFA) (Figure 2).  Lymph 
node T cell proliferation was compared after stimulation with MMP-9-cleaved vs. intact THP-1 
cytosol.  Interestingly, a significantly lower T cell proliferation was observed after stimulation with 
cleaved vs. intact intracellular proteins in the presence of antigen-presenting cells.  This suggests 
that the net proteolytic effect of MMP-9 results in the elimination of immunodominant T cell 
epitopes. To confirm this in vivo, mice will be immunized with intact or cleaved cytosol.  
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Assessment of T and B cell proliferation in vivo and comparison of autoantibody titers may be 
another way of evaluating the effects of proteolysis on cellular and humoral autoimmune responses.  
Many of the cleaved SLE autoantigens are shared by other systemic autoimmune diseases, for 
example Ro/La in Sjögren’s syndrome, U1snRNP in mixed connective tissue disease, CENP-B in 
systemic sclerosis, Jo-1 in polymyositis/dermatomyositis and Ku (p70/p80) in a variety of 
connective tissue disorders [88].  In addition, autoantigenic substrates are shared by multiple MMPs 
(cf. Discussion Part 1), suggesting that clearance of systemic autoantigens may be a common 
function of MMPs. 
Finally, as clearance deficiencies only trigger systemic autoimmunity on a susceptible 
background [27], it would be interesting to investigate whether the lack of MMP-9 is permissive for 
tolerance breaking after induction of extensive necrosis, which may be mimicked by applying a 
burn injury model to MMP-9 knockout and C57Bl/6 wildtype mice [42].  
 
 
Figure 2. MMP-9-mediated proteolysis decreases general T cell responses to intracellular autoantigens.  (A) 
NMRI mice were immunized subcutaneously with THP-1 cytosol (1 mg) in complete Freund’s adjuvant (CFA) and 
boosted on day 7 with THP-1 cytosol in CFA (1 mg).  (B) Lymph node cells were isolated on day 10 and (C) stimulated 
to proliferate with THP-1 cytosol that was previously incubated in the absence (– control) or presence (+ MMP-9) of 
activated MMP-9 (100 nM) for 4.5h and 24h, and with THP-1 cytosol that was not incubated (t0).  Cytosol cleavage 
was verified by SDS-PAGE analysis.  (D) Proliferation was assessed by measuring incorporated 3H-thymidine (after 
18h).  *, P < 0.05, Mann-Whitney U  test (n=6). CAP1, adenylyl cyclase-associated protein-1. 
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MMP‐9 in the circulation of SLE patients 
In accordance with the exacerbation of lpr-induced systemic autoimmunity in the absence of 
MMP-9, various studies report lower MMP-9 levels in the circulation of SLE patients compared 
with healthy controls and in SLE patients with active disease compared with inactive disease (Table 
1).  However, other studies report no differences or increased levels of MMP-9 in SLE patients.  
These controversial results may be partly explained by the heterogeneity of the SLE patient 
population, with damage to different organ systems, and with both relapsing patients with active 
disease and patients in remission with inactive disease.   
Table 1. Serum MMP-9 levels/activities in SLE patients compared with healthy controls. 
Study Method1 Conclusions SLE vs. control2 
Faber-Elmann  
et al., 2002 [89] 
Gel zymo, 
activity 
assay  
Increased serum MMP-9 activities in SLE patients vs. healthy 
controls.  MMP-9 levels only correlated with SLE activity index in 
male patients. 
↑ 
Makowski and 
Ramsby, 2003 [90] Gel zymo 
Inverse correlation of serum MMP-9 levels with anti-dsDNA 
antibody titers. ↓ 
Ainiala et al., 2004 [91] ELISA 
No significant difference in serum MMP-9 levels in SLE patients 
and controls and no correlation with SLE activity index.  
Significantly elevated serum MMP-9 levels in  
NPSLE patients vs. non-NPSLE patients. 
↔ 
Liu et al., 2004 [92] ELISA 
Decreased MMP-9 serum levels in SLE patients vs. healthy 
controls, in patients with active disease vs. inactive disease and in 
patients with renal damage vs. without renal damage. 
↓ 
Robak et al., 2006 [93] Activity assay 
Decreased total and activated MMP-9 serum levels in SLE patients 
vs. healthy controls and in patients with active disease vs. inactive 
disease.  No correlation with SLE activity index. 
↓ 
Chang et al., 2008 [94] Gel zymo, ELISA Increased serum MMP-9 levels in SLE patients vs. healthy controls ↑ 
Rho et al., 2008 [95] ELISA No significant difference in serum MMP-9 levels in SLE patients and controls. ↔ 
Hou and Zhang, 2008 
[96] ELISA 
Decreased MMP-9 serum levels in SLE patients vs. healthy 
controls. No correlation of MMP-9 levels with SLE activity index. ↓ 
Jiang et al., 2009  [97] ELISA 
No significant differences in MMP-9 and MMP-9/TIMP-1 ratios 
between non-nephritic SLE patients and healthy controls.  
Increased serum MMP-9 levels and MMP-9/TIMP-1 ratios in 
nephritic SLE patients vs. non-nephritic SLE patients and healthy 
controls.  Negative correlation between serum MMP-9/TIMP-1 
ratios and anti-dsDNA antibody titers. 
↔ 
Lesiak et al., 2010 [98] ELISA 
Increased MMP-9 and TIMP-1 levels in SLE patients vs. healthy 
controls.  Decreased MMP-9 and increased TIMP-1 levels after 
hydroxychloroquine treatment. 
↑ 
1Methods used voor the measurement of MMP-9 levels or activities: Activity assay based on affinity capture and 
cleavage of a quenched fluorescent peptide; Gel zymo, gel zymography or substrate zymography; ELISA, enzyme-
linked immunosorbent assay. 
2Comparison of MMP-9 levels in SLE patients vs. healthy controls: ↑, increased  in SLE vs. control; ↔, no differences 
between SLE and control; ↓decreased  levels in SLE vs. control. 
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In addition, higher MMP-9 levels may be a consequence of higher production in chronically 
inflamed organs, which is underscored by higher MMP-9 levels in patients with neuropsychiatric 
SLE (NPSLE) [91] and lupus nephritis [97].  However, in the case of lupus nephritis, decreased 
MMP-9 levels in nephritic vs. non-nephritic patients have also been reported, whereas we found 
increased levels of pro- and activated MMP-9 in the urines of patients with indications of renal 
failure (cf. Chapter 2).  The main complication with these studies is the fact that MMP-9 levels have 
been measured in serum instead of in plasma. Serum is not an ideal source for the analytical 
determination of circulating MMP-9 levels as during coagulation/fibrinolysis activated platelets and 
leukocytes, such as degranulating neutrophils, will result in artefactually high MMP-9 levels, which 
is even more pronounced for serum samples collected in tubes with clot activators [99].  Since 
peripheral blood mononuclear cells (PBMCs) from SLE patients were found to secrete higher 
MMP-9 levels in vitro than PBMCs from control patients [96,100], which probably reflects their 
increased activation status, secretion during clotting will readily contribute to the higher serum 
levels reported in several SLE studies.  During the present doctoral research, fresh frozen plasma 
samples from patients with rheumatic diseases such as SLE, Sjögren’s syndrome, vasculitis, 
systemic sclerosis and polymyositis were collected by immediate centrifugation and freezing on dry 
ice, followed by storage at -70°C.  Preliminary data show decreased plasma MMP-9/MMP-2 in 
systemic autoimmune patients compared with healthy controls, but this needs to be confirmed with 
more healthy control samples in order to reach final conclusions.  In addition, MMP-9/TIMP-1 
ratios should be determined in order to evaluate the potential in vivo activity of MMP-9.  Hence, 
MMP-9 levels may be decreased in SLE patients before the appearance of clinical symptoms and 
during onset and amplification stages, contributing to clearance deficiencies in SLE.  However, 
autoimmune organ damage may lead to enhanced production of MMP-9 in inflamed tissues, where 
it might contribute to clearance of intracellular contents released by necrotic lesions.  In accordance 
with this hypothesis, increased MMP-9 activities were detected only in later stages of experimental 
SLE, when clinical manifestations were already observed [101]. 
Conclusion 
The net protective effect exerted by MMP-9 in lpr-induced systemic autoimmunity may be based on 
multiple mechanisms, as summarized in Figure 3. Further elucidation of the individual mechanisms 
that contribute to the exacerbation of lpr-induced systemic autoimmunity in the absence of MMP-9 
may have clinical significance.  Indeed, since systemic autoantigen cleavage is a common feature of 
MMPs, the chronic use of general or broad-spectrum MMP inhibitors should not be recommended 
as it may trigger or exacerbate systemic autoimmunity in a susceptible host. 
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Discussion Figure 3.  Protective roles of MMP-9 in the etiopathogenesis of SLE.  MMP-9 may promote apoptosis 
by extracellular or intracellular cleavages (cf. Discussion Part 1). MMP-9 degrades many intracellular proteins and 
systemic autoantigens, and this may contribute to the immunogenic clearance of secondary necrotic cell-derived 
material (SNEC) by destruction of immunodominant epitopes for T and B cells (cf. Chapters 2 and 3).  MMP-9 may 
contribute to leukocyte homeostasis by dampening (double negative) T cell proliferation (cf. Chapter 4).  After 
upregulation by tissue injury and inflammation, MMP-9 may contribute to the removal of immunogenic necrotic cell-
derived material (NEC) and immune complexes.  In addition, MMP-9 degrades various danger signals or alarmins (cf. 
Chapter 3 and Discussion Part 1), such as HMGB1 and its receptor RAGE, possibly inactivating the proinflammatory 
danger signaling.  Finally, proteolysis by MMP-9 may generate low doses of self-peptides, which promote tolerance by 
the induction of regulatory T cells (Tregs) and anti-inflammatory cytokines that suppress pathogenic T and B cells. BCR, 
B cell receptor; FcγR, Fcγ receptor; IL-6, interleukin-6; IFN-α, interferon-α; MHC II, major histocompatibility complex  
Class II; TCR, T cell receptor; TLR7/9, Toll-like receptor 7/9; UVB, ultraviolet B. 
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Future perspectives 
The enhanced lymphadenopathy observed in B6lpr/lpr.MMP-9-/- vs. B6lpr/lpr.MMP-9+/+ mice may 
stem from increased cell proliferation or additional apoptotic defects in the absence of MMP-9.  
Incorporation of Edu (5-ethynyl-2′-deoxyuridine) will be combined with flow cytometry analysis to 
compare proliferation and apoptosis of different lymphocyte subsets in both groups of mice.  
Shedding and inactivation of proliferation-inducing membrane molecules by MMP-9 may be at the 
basis of a proliferation-suppressive effect.  Hence, proteolysis of such membrane-associated 
candidates will be assessed in B6lpr/lpr.MMP-9-/- vs. B6lpr/lpr.MMP-9+/+ mice.   
MMP-9 may also control lymphoproliferation and autoantibody production by the clearance of 
systemic autoantigen epitopes.   Indeed, MMP-9-mediated degradation of systemic autoantigens 
such as ribosomal protein P0 and U1snRNP A largely abolishes recognition by autoantibodies from 
B6lpr/lpr mice as well as from SLE patients, as demonstrated with competitive ELISA experiments.  
These experiments may be corroborated with data from immunoprecipitations of cleaved and intact 
autoantigens with plasma samples from SLE mice and patients.  In addition, to investigate if 
proteolysis has general epitope-degrading effects in multiple autoantigens, differentially labeled 
cleaved and uncleaved cytosol samples may be subjected to immunoprecipitation and further 
analyzed by 1-dimensional or 2-dimensional SDS-PAGE analysis.  The relative effects or 
proteolysis on conformational vs. linear B cell epitopes may be assessed by a comparison of 
Western Blot analysis (for linear epitopes) and immunoprecipitation followed by Western blot 
analysis (for conformational epitopes).  To analyze the elimination (or formation) of autoreactive T 
cell epitopes, leukocytes of B6lpr/lpr mice and SLE patients may be stimulated to proliferate with 
intact and degraded autoantigens both ex vivo and in vivo. 
In a more biochemical approach, the cleavage sites of MMP-9 in systemic autoantigens will be 
determined by Edman degradation and LC-MS/MS.  The identified cleavage sites may then be 
compared with known immunodominant epitopes of systemic autoantigens [9], in order to 
determine if these are released or destroyed by MMP-9-mediated proteolysis. 
Since proteolysis by MMP-9 abolishes autoantibody recognition of systemic autoantigens such 
as ribosomal protein P0 and U1snRNP A, immune complexes (ICs) containing these autoantigens 
will be isolated by gel filtration chromatography and incubated with MMP-9 to assess whether 
proteolysis may dissociate these complexes.  Alternatively, formation of ICs between isolated free 
autoantibodies and cleaved or intact autoantigens will be compared.  These ex vivo experiments 
may be complemented in vivo by injecting B6lpr/lpr.MMP-9-/- mice (having high autoantibody titers) 
with high doses of activated MMP-9 for one or two weeks, after which autoantibody and IC 
concentrations should be reassessed to evaluate the IC clearance potential of MMP-9 in vivo. 
Alternatively, B6.MMP-9-/- and B6 control mice will be immunized various times with cleaved 
or intact autoantigen (e.g. ribsomal protein P0) in CFA and the development of autoantibody titers 
will be compared.  Since in all of these experiments cleavage by MMP-9 occurs ex vivo, an 
experiment will also be included in which B6.MMP-9-/- and B6 control mice are immunized only 
with intact autoantigen or cytosol in order for the proteolysis of the autoantigen(s) to take place in 
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vivo.  Autoantibody titers, epitope spreading and SLE symptoms such as proteinuria will be 
assessed during various months.  In order to confirm in vivo cleavage of systemic autoantigens, one 
of the mentioned degradomics approaches (cf. Discussion Part 1) may be applied to organ extracts 
or plasma samples of B6lpr/lpr.MMP-9-/- vs. B6lpr/lpr.MMP-9+/+ mice, as well as immunized B6.MMP-
9-/- and B6 control mice. 
Finally, the application of a burn injury model to MMP-9 knockout and B6 wildtype mice may 
be a way of testing whether lack of MMP-9 may result in a clearance deficiency that results in the 
break of tolerance to intracellular antigens. 
Regarding the levels of MMP-9 in SLE patients and in patients with other rheumatic diseases, a 
group of control samples from healthy donors will be collected to compare the plasma and urinary 
MMP-9/MMP-2 levels and MMP-9/TIMP-1 ratios, and the correlations between various 
autoantibody titers, proteinuria and MMP-9 levels. 
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SUMMARY 
Matrix metalloproteinases (MMPs) constitute a family of 24 different neutral endopeptidases in 
human. These proteases intervene in physiological processes such as reproduction, development, 
immunity and tissue repair.  However, dysregulation of MMP activity has multiple pathogenic 
effects in cancer, inflammation, vascular diseases, neurodegenerative disorders and autoimmune 
diseases.  Gelatinase B/MMP-9 is secreted by a variety of immune and cancer cells, major 
producers being neutrophils and macrophages at sites of inflammation.  MMP-9 was previously 
shown to generate immunodominant T cell epitopes from myelin basic protein and αB-crystallin in 
multiple sclerosis, from collagen type II in rheumatoid arthritis, and from insulin in type I diabetes.  
This may explain the pathogenic effect of MMP-9 and why MMP-9-deficient mice are less 
susceptible to develop disease symptoms in these organ-specific autoimmune diseases. Hence, the 
question was raised whether MMP-9 may proteolyse systemic autoantigens and how this may affect 
the development of systemic autoimmunity. 
Whereas organ-specific autoimmune diseases target a limited number of autoantigens that are 
mostly confined to the affected organ, in systemic autoimmunity the autoantigen spectrum is 
generally very broad and mainly comprises ubiquitous intracellular proteins.   The prototypic 
autoimmune condition, systemic lupus erythematosus (SLE), is characterized by high titers of 
autoantibodies against more than a hundred different intracellular and intranuclear autoantigens. 
The formation and deposition of ICs causes inflammation and tissue injury throughout the body, 
affecting the skin, kidneys, joints, lungs, central nervous system and blood vessels.  In SLE, 
enhanced apoptosis may be triggered by genetic and environmental factors (e.g. viral infection, 
drugs, toxins). In addition, various mechanisms for the clearance of dying cells are impaired.  As a 
consequence, the overload of apoptotic cells progresses to secondary necrosis and intracellular 
proteins are released into the extracellular milieu, where they may be accessed by MMPs and other 
proteases. Therefore, a first rationale for the study of MMP-9 in systemic autoimmunity was to 
investigate whether MMP-9 might cleave SLE autoantigens. 
To define whether MMP-9 is able to proteolyze systemic autoantigens, we started an unbiased, 
systematic characterization of the intracellular substrate repertoire or ‘degradome’ of MMP-9 using 
a one-dimensional degradomics approach. To mimick the necrotic release of intracellular proteins 
in SLE, we used a model system consisting of dying human monocytic THP-1 cells, supplemented 
or not with activated MMP-9.  In this way, we identified adenylyl cyclase-associated protein-1 or 
CAP1 as a novel and highly efficient substrate of MMP-9. CAP1 is a cytoskeletal protein that was 
identified as an autoantigen in SLE and rheumatoid arthritis.  Moreover, we detected intact CAP1 in 
the urines of patients with systemic autoimmune diseases such as SLE, Sjögren’s syndrome and 
vasculitis, as well as in healthy control urines. Whereas no active MMP-9 was detected in urines of 
healthy controls, all urine samples of patients with clinical parameters of renal failure contained 
activated MMP-9.   In addition, in some patient urines, an inverse relation was observed between 
the levels of intact CAP1 and activated MMP-9, suggesting CAP1 degradation in vivo. 
S U M M A R Y  
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Identification of additional substrates by this one-dimensional degradomics approach was hampered 
by the complexity of the cellular protein pool.  In order to proceed to higher resolution 
identification of intracellular MMP-9 substrates, a second aim was to develop a straightforward and 
inexpensive multidimensional degradomics platform. This multidimensional degradomics 
technology reduces the sample complexity by first separating the proteins according to their net 
charge or isoelectric point using ion exchange chromatography, followed by a second dimension of 
separation by molecular weight on SDS-PAGE and by centrifugal filtration steps. Application of 
this multidimensional degradomics technology on THP-1 cytosol resulted in the isolation of 100-
200 MMP-9 candidate substrates, of which about 70 were identified by tandem mass spectrometry 
(MS/MS).  Of interest, about 2/3 of these candidate substrates were autoantigens described in one or 
multiple autoimmune conditions and in cancer.  In addition, about 40% of the substrates were 
intracellular matrix proteins, such as actin and tubulin.  These results showed that systemic 
autoantigen proteolysis might indeed be a function of MMP-9, but also suggested that proteolysis 
by MMP-9 may be required to clear the toxic and immunogenic burdens of intracellular (matrix) 
proteins and systemic autoantigens released after extensive necrosis. 
To address the in vivo role of MMP-9 in systemic autoimmunity, a third and long-term aim was to 
generate mice that lack MMP-9 and have the lpr (lymphoproliferative) loss-of-function mutation in 
the apoptosis-inducing receptor Fas.  C57Bl/6 mice without functional Fas (B6lpr/lpr mice) develop 
moderate lymphoproliferation and late-onset systemic autoimmunity with little immunopathology.  
However, the additional genetic knockout of MMP-9 in B6lpr/lpr mice resulted in greatly amplified 
and earlier onset lymphoproliferative disease with enhanced lymphadenopathy and splenomegaly, 
and significantly reduced survival compared with single Fas deficiency. In addition, the absence of 
MMP-9 in B6lpr/lpr mice resulted in increased autoantibody production against multiple autoantigens 
and more pronounced autoimmune tissue injury. Since ‘intact’ autoantigens seemed to be better 
stimuli for autoantibody production, suppression of lpr-induced systemic autoimmunity may be a 
consequence of MMP-9-mediated clearance of immunodominant T and B cell epitopes in 
autoantigenic substrates.  Hence, deficiency of MMP-9-mediated proteolysis may engender an 
additional clearance deficiency, which accelerates the onset of systemic autoimmunity and 
promotes its amplification. 
In conclusion, MMP-9 degrades a whole spectrum of intracellular (matrix) proteins and systemic 
autoantigens. Clearance of intracellular proteins may be of crucial importance to preserve immune 
tolerance after acute or chronic necrosis, as observed in SLE. Along this line, MMP-9 was 
identified as a protective factor in an in vivo model of systemic autoimmunity. Our preclinical 
studies have medical implications. Some recent studies suggest the use of MMP inhibitors for SLE 
and other systemic autoimmune disease.  Our studies indicate that MMP inhibition for the treatment 
of SLE needs to be studied with sufficient reservation as it may trigger or exacerbate systemic 
autoimmunity in a susceptible host.  
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SAMENVATTING 
Bij de mens omvat de familie van de matrix metalloproteïnasen (MMPs) 24 verschillende neutrale 
endopeptidasen. Deze proteasen komen tussen in fysiologische processen zoals reproductie, 
ontwikkeling, immuniteit en weefselherstel.  Ontregeling van MMP activiteit heeft echter 
pathogene effecten bij kanker, inflammatie, vasculaire ziekten, neurodegeneratieve aandoeningen 
en auto-immuunziekten.  Gelatinase B/MMP-9 wordt vooral gesecreteerd door macrofagen en 
neutrofiele granulocyten tijdens inflammatie, maar wordt ook geproduceerd door veel andere 
immuun- en kankercellen.  Proteolyse van auto-antigenen door MMP-9 genereert 
immunodominante restepitopen voor auto-reactieve T cellen. Dit werd reeds aangetoond voor de 
klieving van collageen type II in reumatoïde artritis, van ‘myelin basic protein’ en αB-crystalline in 
multiple sclerose, en van insuline in diabetes type I.  Bovendien bleken MMP-9-deficiënte muizen 
minder gevoelig voor het ontwikkelen van symptomen in diermodellen van deze orgaanspecifieke 
auto-immuunziekten.  Bijgevolg werd de vraag gesteld of MMP-9 ook systemische auto-antigenen 
kan klieven en hoe dit de ontwikkeling van systemische auto-immuniteit zou beïnvloeden. 
Orgaan-specifieke auto-immuniteit is meestal gericht tegen een beperkt aantal auto-antigenen die 
voorkomen in het aangetaste orgaan. Systemische auto-immuunziekten worden daarentegen 
gekenmerkt door een breed spectrum aan auto-antigenen, vooral bestaande uit veel voorkomende 
intracellulaire eiwitten. Systemische lupus erythematosus of SLE is het type-voorbeeld van een 
systemische auto-immuunziekte en wordt gekenmerkt door hoge titers van auto-antistoffen tegen 
meer dan 100 verschillende intracellulaire and intranucleaire auto-antigenen. De vorming en 
afzetting van immuuncomplexen veroorzaakt inflammatie en weefselschade over het hele lichaam 
en tast vooral huid, nieren, gewrichten, longen, centraal zenuwstelsel en bloedvaten aan.  In SLE 
veroorzaken genetische en omgevingsfactoren (bv. virale infecties, medicatie, toxines) een toename 
van apoptose of geprogrammeerde celdood. Bovendien zijn verschillende mechanismen voor het 
opruimen van apoptotische cellen verstoord.  Bijgevolg zal de overmaat aan apoptotische cellen 
leiden tot secundaire necrose en openbarsten.  Hierdoor worden intracellulaire eiwitten vrijgesteld 
in het extracellulair milieu, waar ze kunnen gemoduleerd worden door MMPs en andere proteasen, 
hetgeen een extra argument vormt voor de studie van MMP-9 in systemische auto-immuniteit. 
Om te bepalen of MMP-9 in staat is om systemische auto-antigenen te klieven, werd een 
systematische karakterisatie van het intracellulaire substraatrepertoire of ‘degradoom’ van MMP-9 
opgestart aan de hand van een 1-dimensionele ‘degradomics’ methode.  Om het necrotisch 
vrijstellen van intracellulaire eiwitten in SLE na te bootsen, werd een modelsysteem gebruikt van 
necrotische humane monocytische THP-1 cellen, met of zonder toevoeging van geactiveerd MMP-
9.  Op deze manier werd ‘adenylyl cyclase-associated protein-1’ of ‘CAP1’ geïdentificeerd als een 
nieuw en uitzonderlijk efficiënt substraat van MMP-9.  CAP1 is een cytoskeleteiwit en een auto-
antigeen in reumatoïde artritis en SLE.  Bovendien, detecteerden we intact CAP1 in urines van 
patiënten met systemische auto-imuunziekten zoals SLE, Sjögrens syndroom en vasculitis, en in 
urines van gezonde personen. Verder werden geactiveerde vormen van MMP-9 teruggevonden in 
urinestalen van patiënten met klinische parameters van nierfalen, terwijl in urines van personen 
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zonder nierziekte geen actief MMP-9 aanwezig was.  Bovendien, werd in sommige urines van 
patiënten een omgekeerde relatie teruggevonden tussen de niveaus van intact CAP1 en van 
geactiveerd MMP-9, hetgeen suggereert dat CAP1 in vivo wordt afgebroken. 
Identificatie van bijkomende substraten was door de complexiteit van het eiwitmengsel niet 
mogelijk met een 1-dimensionele aanpak. Om op grotere schaal intracellulaire MMP-9 substraten te 
kunnen identificeren, werd eenvoudige en goedkope multidimensionele degradomics technologie 
ontwikkeld. Deze multidimensionele methoden reduceren de complexiteit van het proteïnemengsel 
door de eiwitten eerst te scheiden volgens hun netto-lading of isoëlektrisch punt met behulp van 
ionenuitwisselingschromatografie en vervolgens in een tweede dimensie volgens moleculair 
gewicht met behulp van SDS-PAGE en centrifugale filtratie.  Toepassing van de multidimensionele 
degradomics technologie op THP-1 cytosol leidde tot de isolatie en visualisatie van  ongeveer 200 
kandidaatsubstraten waarvan een 70-tal geïdentificeerd werden m.b.v. tandem massaspectrometrie 
(MS/MS).  Ongeveer 2/3 van deze kandidaatsubstraten was reeds bekend als auto-antigeen in 
verschillende auto-immuunziekten en kankers.  Ook werden talrijke intracellulaire matrix eiwitten, 
zoals actine en tubuline, geïdentificeerd als nieuwe substraten van MMP-9. Deze resultaten toonden 
aan dat proteolyse van systemische auto-antigenen wel degelijk een functie van MMP-9 kan zijn.  
Bovendien leidden deze data tot de suggestie dat proteolyse door MMP-9 vereist zou kunnen zijn 
om de overmaat aan toxische, immunogene intracellulaire (matrix) eiwitten en systemische auto-
antigenen op te ruimen die worden vrijgesteld na extensieve necrose. 
Om de rol van MMP-9 in systemische auto-immuniteit in vivo te onderzoeken, werden muizen 
gegenereerd die genetisch deficiënt zijn in MMP-9 en met de inactiverende lpr (lymfoproliferatie) 
mutatie in de apoptose-inducerende receptor Fas. C57Bl/6 muizen zonder functionele Fas receptor 
(B6lpr/lpr muizen) ontwikkelen matige lymfoproliferatie en chronische systemische auto-immuniteit 
op latere leeftijd en met weinig immunopathologie.  De additionele genetische knockout van MMP-
9 in B6lpr/lpr muizen resulteerde echter in een versnelde en sterk toegenomen lymfoproliferatie met 
uitgesproken lymfadenopathie en splenomegalie, en significant gereduceerde overleving vergeleken 
met enkel deficiëntie van Fas.  Bovendien leidde het ontbreken van MMP-9 in B6lpr/lpr muizen tot 
een verhoogde productie van auto-antistoffen tegen multipele auto-antigenen en tot meer 
uitgesproken auto-immune weefselschade.  Vermits ‘intacte’ auto-antigenen betere stimuli bleken te 
zijn voor auto-antilichaamproductie, zou de onderdrukking van lpr-geïnduceerde systemische auto-
immuniteit een gevolg kunnen zijn van de opruiming van immunodominante T- en B-cel epitopen 
in auto-antigenische substraten.  Bijgevolg zou het ontbreken van MMP-9-gemedieerde proteolyse 
tot een bijkomend defect in opruiming kunnen leiden, hetgeen de ontwikkeling van systemische 
auto-immuniteit kan versnellen en bestaande auto-immuunreacties kan amplificeren. 
We kunnen dus besluiten dat MMP-9 een uitgebreid spectrum aan intracellulaire (matrix) proteïnen 
en systemische auto-antigenen kan klieven. Opruiming van intracellulaire eiwitten zou cruciaal 
kunnen zijn om immuuntolerantie te behouden na acute of chronische necrose, zoals voorkomend 
bij SLE. Bovendien werd MMP-9 geïdentificeerd als een beschermende factor in een in vivo model 
van systemische auto-immuniteit.  Deze pre-klinische studies hebben medische implicaties.  
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Verschillende studies stellen immers voor om MMP remmers te gebruiken in SLE en andere 
systemische auto-immuunziekten. Onze data suggereren echter dat men voorzichtig moet 
omspringen met de studie van MMP inhibitie bij SLE, aangezien hierdoor systemische auto-
immuunreacties kunnen ontstaan of geamplificeerd worden in patiënten met een ongunstige 
genetische achtergrond. 
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